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“Die organische Chemie kann einen jetzt ganz toll machen. Sie 
kommt mir wie ein Urwald der Tropenländer vor, voll der 
merkwürdigsten Dinge, ein ungeheures Dickicht, ohne Ausgang 
und Ende, in das man sich nicht hinein wagen mag.” 
Friedrich Wöhler (1835) 
 
 
 
 
 
 
 
 
 
 
 
 
 
“At this time organic chemistry can drive one completely crazy. It seems to me like a 
primeval tropical jungle, full of the most remarkable things, an amazing thicket, without 
escape or end, into which one would not dare to enter.”  
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Abstract 
 
The central core of a number of biologically active natural products and pharmaceuticals 
often contain an N-heterocycle. The development of new, efficient methodology for the 
synthesis of indole-based N-heterocycles (for example tetrahydro-β-carbolines, 
azepinoindoles and indoloazocines) was investigated during this research project. Two 
approaches were explored, employing either an intramolecular Heck reaction or 
intermolecular Heck reaction at the indole-2-position.  
Although the intramolecular Heck reaction proved unsuccessful, research into the 
intermolecular Heck reaction ultimately lead to the development of a domino Heck-aza-
Michael reaction for the preparation of a series of C1-substituted tetrahydro-β-carboline 
scaffolds. This domino Heck-aza-Michael methodology was then successfully applied to the 
synthesis of both tetrahydroisoquinoline and isoindoline heterocycles.  
A one-pot, three-component method incorporating a domino Heck–aza-Michael reaction 
was developed for the rapid synthesis of functionalised tetrahydroisoquinolines. Following 
the in situ generation of an acrylamide, a domino process involving intermolecular Heck 
reaction and subsequent intramolecular aza-Michael addition afforded 
tetrahydroisoquinolines bearing C1-acetamide functionality. 
Using chiral amine substrates, an asymmetric domino Heck-aza-Michael reaction was 
developed for the preparation of chiral 1,3-disubstituted N-heterocycles in good yields and 
with moderate to high diastereoselectivity. 
A range of the current methods available were then employed in the synthesis of indole-
based N-heterocyclic scaffolds, which were further derivatised as potential PPARγ agonists 
for the treatment of type 2 diabetes. 
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Plain English Summary 
 
The efficient preparation of molecules used for the treatment of a number of diseases is 
highly sought after by the pharmaceutical industry. This report details the development of a 
new, rapid and efficient method for the synthesis of the central core of a number of these 
pharmaceuticals. This new methodology allows for a reduction in the time, money, effort 
and minimises the generation of waste during the synthetic process. The preparation of a 
series of molecules for the treatment of type 2 diabetes is also described herein. 
 
 Chapter One 
Introduction  
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Thesis Overview 
 
The research presented in this thesis details efforts to develop new palladium-catalysed 
methodology to access N-heterocyclic scaffolds. A brief investigation into the further 
functionalisation of selected indole-based N-heterocycles as potential PPARγ agonists for 
the treatment of type 2 diabetes is also presented. 
The introductory chapter (Chapter One) presents a review of the current synthetic 
methodologies available to access indole-based N-heterocycles from tryptamine. Palladium 
chemistry at the indole-2-position and the Heck reaction in particular are discussed in detail 
in addition to a brief review of domino reactions and their many advantages. The design and 
synthesis of indole-based PPARγ agonists is introduced in this chapter and the project aims 
complete this chapter. 
Chapter Two details attempts to develop new methodology to access a range of indole-based 
scaffolds differing in both ring size and functionality introduced during N-heterocycle 
formation. The preparation of the new ring system employing an intramolecular Heck 
reaction subsequent to the tethering of the appropriate olefin from the N10-amine of 
tryptamine was investigated.  
To further expand the methodology for the synthesis of indole-based N-heterocycles, the 
intermolecular Heck reaction at the indole-2-position, followed by addition of the N10-amine 
of tryptamine was explored. The successful development of a domino Heck-aza-Michael 
reaction for the synthesis of C1-substituted tetrahydro-β-carbolines is described in Chapter 
Three. 
In addition to the synthesis of tetrahydro-β-carbolines, the extension of the domino Heck-
aza-Michael process for the synthesis of a number of other N-heterocycles is presented in 
Chapter Four. The development of both a multicomponent and an asymmetric variant of this 
domino Heck-aza-Michael methodology are also described. 
Chapter Five discusses the recent use of indole-based compounds as PPARγ agonists for the 
treatment of type-2-diabetes. Our contribution to this burgeoning field focused on a number 
of indole-based N-heterocyclic scaffolds, readily accessed from tryptamine. The selection of 
several of these scaffolds and further functionalisation as PPARγ agonists is presented. 
Chapter Six provides the concluding remarks for this research project and presents some 
ideas for the future work. Also included in this thesis are experimental details for all of the 
reactions carried out during this research project (Chapter Seven), as well as a copy of the 
publications resulting from the work contained within this thesis in Appendix One. 
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1.1 Chapter Overview 
 
Indole-based N-heterocycles are ubiquitous and many exhibit interesting biological activity.1 
There are several different forms of these heterocyclic scaffolds present in nature, differing 
in both ring size and functionality and these are introduced in the following chapter. This 
chapter also evaluates a number of the synthetic strategies currently available to access 
indole-based N-heterocycles from tryptamine. 
Although the indole moiety is itself an N-heterocycle, the terminology “N-heterocycle” as 
used in the remainder of this document refers to the C-N heterocycle attached to the indole 
scaffold at the indole-2- and indole-3-position (Figure 1.1). Where reference is made to the 
N10-amine of tryptamine (2), it refers to the amine tethered to the indole scaffold at the 
indole-3-position (Figure 1.1) 
 
Figure 1.1 A graphical depiction of the terms used frequently within this thesis 
 
This introductory chapter details previous approaches to the application of palladium 
chemistry at the indole-2-position, palladium-mediated domino reactions and provides a 
comprehensive review of the Heck reaction including catalytic considerations. 
This chapter also briefly introduces the synthesis of indole-based PPARγ agonists. Previous 
research by the Pfeffer group identified indole-based PPARγ agonists possessing a modest 
level of insulin-sensitising activity.2-3 Attention turned to the indole-scaffold in an attempt to 
increase the insulin-sensitising activity of these potential PPARγ agonists by varying the size 
and functionality contained within the indole-based N-heterocycle.  
1.2 Indole Alkaloids 
 
The importance of heterocycles is evident due to their wide use in chemical, biological and 
industrial settings. Heterocycles form the central core of numerous biologically active 
natural products and pharmaceutical agents, and many are applied in other settings as 
herbicides and corrosion inhibitors.1 Currently, over one half of the 20 million or more 
chemical compounds registered contain heterocyclic systems.1 
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The benzo[b]pyrrole heterocycle (known trivially as indole) is one of the most commonly 
observed heterocycles. The indole moiety is present in a large number of natural products, 
many of which exhibit interesting biological activity,4-7 for example reserpine (3 - Figure 
1.2), introduced in the 1950’s as one of the first drugs to treat diseases of the central nervous 
system.8 The natural incorporation of an indole group into the biologically important amino 
acid tryptophan is further evidence of its implicit relevance to life. 
 
Figure 1.2 The indole scaffold as found in the natural products reserpine8 
 
The indole scaffold has been successfully employed in numerous pharmaceutical agents, for 
example HIV-1 reverse transcriptase inhibitors (Rescriptor 4, Figure 1.3) and new 
antimigraine drugs (Zomig 5, Figure 1.3). This indole functionality has also been utilised in 
other areas of chemistry, including polymer chemistry for the fabrication of micro pH 
sensors (indole polymer 6, Figure 1.3).9 
 
Figure 1.3 The indole heterocycle employed in a number of pharmaceutical agents and polymers 
 
1.2.1 The Synthesis of Indole-Based N-Heterocycles from Tryptamine 
 
The abundance of both serotonin and tryptophan derivatives in nature have inspired organic 
chemists to design and synthesise thousands of indole-containing pharmaceuticals.9 An 
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important subset of these indole alkaloids possess a third ring (more specifically a C-N 
heterocycle) fused at the indole-2 and indole-3 position (Figure 1.4). 
 
Figure 1.4 Indole-based natural products that contain additional C-N heterocycles of varying sizes 
 
The pyrrolo[2,3-b]indole skeleton (containing an additional 5-membered N-heterocycle) is 
found in a number of naturally occurring compounds10-11 (for example the insecticide 
okaramine C (7) - Figure 1.4).12 This pyrroloindole scaffold is central to several other 
biologically active natural products, showing potential as anticancer agents and potent 
vasodilators.13-17 
The tetrahydro-β-carboline (containing an additional 6-membered N-heterocycle) forms the 
central core of numerous pharmaceutical targets developed for the treatment of medical 
conditions including breast cancer, type-2-diabetes and bacterial infections.6, 18-21 This ring 
system is also prevalent in several more structurally complex natural products including the 
secologanin-type terpinoid indole alkaloid ajmalicine (8 - Figure 1.4) and the 
antihypertensive agent reserpine (3 - Figure 1.2).8, 18, 22-25 
The azepino[4,5-b]indole skeleton containing an additional 7-membered N-heterocycle has 
been identified in a number of recently isolated natural products including arboflorine (9 - 
Figure 1.4).26-27 The indoloazocine scaffold (which contains an additional 8-membered ring) 
is central to numerous natural products including the lundurines, okaramine N, and 
deoxyisoaustamide 10 (Figure 1.4).28-33 These indoloazocines have also been employed as 
useful intermediates in the synthesis of larger molecules.34 
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Due to their high level of biological activity, it is important that the aforementioned indole 
scaffolds can be rapidly accessed synthetically. The use of methodology that facilitates the 
installation of a variety of functional groups is also highly desirable in a medicinal chemistry 
setting, with a simple common starting point for the synthesis of such N-heterocyclic 
systems being advantageous. 
The synthesis of indole-based N-heterocycles within this research project was limited to 
those where the tricyclic scaffolds are accessible from tryptamine or similar tryptophan 
derivatives. Tryptamine (2) is a readily available source of the indole ring system and is 
commonly used as a starting material for the synthesis of indole-based N-heterocycles, as it 
already contains multiple sites for further functionalisation. 
Current methods to prepare tricyclic indole-based scaffolds from tryptamine include the 
Pictet-Spengler reaction, the Bischler-Napieralski reaction, and numerous transition-metal 
catalysed cyclisations. The following section describes these relevant synthetic approaches 
available for the synthesis of indole-based N-heterocycles. 
1.2.2 The Pictet-Spengler Reaction 
 
The Pictet-Spengler reaction is the most common method for the synthesis of tetrahydro-β-
carbolines (THβCs).35-36 This method involves the acid-catalysed reaction of an appropriate 
aryl-amine and a carbonyl compound (usually an aldehyde or ketone) to form a new C-N 
heterocycle.37 This reaction was originally developed by Pictet and Spengler in 1911 for the 
synthesis of tetrahydroisoquinolines from phenethylamine, however it was soon realised that 
this reaction also took place using tryptamine to form the tetrahydro-β-carboline scaffold in 
high yields (Scheme 1.1).38 
The Pictet-Spengler reaction includes the formation of a Schiff base 11 (imine) from the 
condensation of the amine and a carbonyl compound. The imine is then attacked by the 
indole-scaffold, promoted by the acid catalyst to form intermediate 13.39 Deprotonation of 
13 follows to form the tetrahydro-β-carboline scaffold 14 (Scheme 1.1).  
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Scheme 1.1 The acid-catalysed Pictet-Spengler reaction for the synthesis of tetrahydro-β-carbolines 
 
This reaction performs well for the synthesis of 6-membered N-heterocycles using simple 
acid catalysts (for example trifluoroacetic acid). To expand the scope of this reaction 
sequence, several modifications to the Pictet-Spengler reaction have been developed in 
recent years include the synthesis of oxygen containing heterocyclic systems,40-42 the use of 
non-acid catalysts43-46 and modified aldehyde reagents, 22-23, 25, 47 microwave-assisted 
synthesis48-50 and asymmetric variants.51-54 
The Pictet-Spengler reaction has been employed to great effect in the total synthesis of 
natural products as well as in the preparation of a number of potential pharmaceutical 
agents.55-56 Tetrahydro-β-carbolines synthesised using the Pictet-Spengler reaction (for 
example THβC 15) have also been employed as useful intermediates in the synthesis of 
natural products and medicinal chemistry targets containing larger indole-based N-
heterocycles (for example indoloazocine 16 - Scheme 1.2).33, 57-61 
 
Scheme 1.2 The synthesis of an indoloazocine from a tetrahydro-β-carboline intermediate 
 
The Pictet-Spengler reaction allows for the synthesis of 6-membered N-heterocycles with 
the possibility of introducing a wide variety of functional groups at the C1-position of the 
newly formed tetrahydro-β-carboline, depending on the availability and stability of the 
carbonyl compounds required. 
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1.2.3 The Bischler-Napieralski Reaction 
 
An alternative method to access tetrahydro-β-carboline scaffolds is the Bischler-Napieralski 
reaction. As in the case of the Pictet-Spengler reaction, this methodology was first 
developed for the synthesis of isoquinolines, but in this instance involves the 
cyclodehydration of an amide to form the new 6-membered N-heterocycle (Scheme 1.3).37, 62 
 
Scheme 1.3 The formation of an indole-based N-heterocyclic system through the Bischler-Napieralski 
reaction 
 
This reaction follows a very similar mechanism to the Pictet-Spengler reaction, through 
formation of intermediate 18 following reaction of an amide 17 with a dehydrating agent 
(POCl3, P2O5, PPA, TFAA, Tf2O or similar),63 which is then attacked by the electron-rich 
indole scaffold. Deprotonation of 19 leads to formation of the new C1-substituted 6-
membered N-heterocycle 20 (Scheme 1.3).64 
The imine of the resultant product 20 can be readily reduced (asymmetrically if required)65-67 
to form the secondary amine, which can then be functionalised for the preparation of 
potential pharmaceutical agents,68 or as the key step in the total synthesis of natural 
products.69-73 
In comparison to the Pictet-Spengler and Bischler-Napieralski reactions developed over 100 
years ago, efficient methodology to access 5-, 7-, and 8-membered rings attached to the 
indole scaffold have only been developed in recent years. A number of these methods are 
described in the following section. 
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1.2.4 Acid-Catalysed Cyclisations 
 
Acid-catalysed methodology (either a Brønsted-Lowry or Lewis acid) to access 6-, 7-, and 
8-membered indole-based N-heterocycles has been recently developed, often for the 
synthesis of intermediates as part of larger total syntheses. 
The synthesis of 1,1-disubstituted tetrahydro-β-carbolines 23 from 2-methylaziridines 22 
was reported recently by Mumford et al.74 This methodology allowed access to a range of 
ether substituted THβCs from tryptamine 21, in moderate to excellent yields using a Lewis 
acid catalysed electrophilic cyclisation (Scheme 1.4). An asymmetric version of this reaction 
using α-methyl tryptamine was also reported.74 
 
Scheme 1.4 The synthesis of disubstituted tetrahydro-β-carbolines from 2-methylaziridines 
 
The use of traditional acid-catalysis has also been employed in the formation of 
functionalised azepinoindoles. The synthesis of 5-phenylhexahydroazepino[4,5-b]indoles 25 
from tryptamines as potential neuroleptic agents was reported by Elliot et al. using a 
phosphoric acid mediated alkylation (Scheme 1.5).75 
 
 
Scheme 1.5 Acid-medicated cyclisation to form the azepinoindole scaffold 
 
The formation of the azepinoindolone 27 was recently published by Miranda et al. (Scheme 
1.6) which, following functionalisation of the indole-2-position, involved an acid-mediated 
lactamisation reaction.76 This particular reaction sequence allowed the introduction of 
various alkyl and ester substituents onto the azepinoindole scaffold.76 
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Scheme 1.6 Acid-mediated lactamisation to form the functionalised azepinoindolone scaffold 
 
A fascinating example of an azepinoindole synthesis through a Pictet-Spengler type 
cyclisation was reported by the group of Giger which involved the formation of a 
diazabicyclo[3.2.2]nonedione intermediate 29, which was subsequently reduced using a 
borane-THF solution to afford azepinoindole 30 (Scheme 1.7).77 
 
Scheme 1.7 A Pictet-Spengler type cyclisation followed by reductive fragmentation of a 
diazabicyclo[3.2.2]nonedione intermediate leads to the formation of the azepinoindole scaffold 
 
Recent advances in the chemistry of lanthanides have lead to the development of an epoxide 
ring opening cyclisation sequence catalysed by ytterbium(III) triflate (Scheme 1.8).78 The 
functionalised indoloazocines (32 and 33) were produced in good yield and excellent ee, 
providing an efficient route for the total synthesis of two natural products from tryptamine. 
 
Scheme 1.8 Synthesis of functionalised indoloazocines using ytterbium-catalysis 
 
Although the acid-catalysed processes mentioned above provide access to a range of 
functionalised indole-based N-heterocycles, organometallic-catalysed processes are by far 
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the most efficient means for the synthesis of N-heterocyclic systems and are described in the 
following section. 
1.2.5 Transition-Metal Catalysed Cyclisations 
 
Transition metals are classified as metallic elements that have valence electrons in two shells 
instead of one. This electron configuration bestows the unique property to accept or donate 
electrons, allowing these metals to readily change oxidation states during a catalytic cycle. 
The more important and extensively studied transition metals in homogenous catalysis are 
found among the “late transition metals” which include ruthenium, palladium, nickel and 
platinum. The use of ligands to form transition metal complexes allows their catalytic 
properties to be fine-tuned. The many advantages of transition-metal catalysis has lead to its 
use in the development of many new synthetic transformations offering enhanced 
chemoselectivity, regioselectivity and perhaps most importantly enantioselectivity over 
conventional organic reactions.79 The following section describes the use of ruthenium, 
copper, gold, mercury and palladium catalysed cyclisation processes.* 
Copper-Catalysed Cyclisations 
 
Copper-catalysis has emerged as a cheap and efficient method for achieving the arylation (or 
vinylation) of O-, S- and N-nucleophiles. A number of copper-catalysed Ullmann type 
processes have recently been developed for the synthesis of N-heterocycles.82 The synthesis 
of pyrroloindoles from tryptamine or tryptophan has been studied extensively (often 
involving an oxidative cyclisation process), however a number of these methods result in 
decomposition of the aromaticity of the indole ring system.83-86 The development of a 
copper-catalysed C-N cross-coupling process for the synthesis of pyrroloindoles (for 
example 35 and 37), has provided access to these 5-membered indole-based N-heterocycles 
in good yield from tryptamine or tryptophan derivatives (Scheme 1.9), allowing the indole 
ring system to remain intact.13 
                                                        
* For a more comprehensive review of transition-metals and their use in organic chemistry refer to 
Transition Metals for Organic Synthesis (Beller, M.; Bolm, C., 2 ed. WlLEY-VCH Verlag GmbH: 
Weinheim, 2004.), Metal-Catalysed Cross-Coupling Reactions (de Meijere, A.; Diederich, F., 2 ed.; 
WILEY-VCH Verlag GmbH.: Weinheim, 2004)80 and The Organometallic Chemistry of the 
Transition Metals (Crabtree, R. H., John Wiley & Sons, Inc.: Hoboken, New Jersey, 2005.).81  
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Scheme 1.9 The copper-mediated synthesis of pyrroloindoles 
 
Mercury-Catalysed Cyclisations 
 
The synthesis of indoloazocine ring 39 from tryptamine using a mercury-catalysed 
cyclisation process was recently reported by Donets et al. (Scheme 1.10).87 
 
Scheme 1.10 The synthesis of indoloazocines using a mercury-catalysed process 
 
In this process a new 8-membered N-heterocycle is formed in excellent yield. In the early 
stages of this reaction it was proposed that mercury forms a complex with the alkyne 38, 
activating it for nucleophilic attack from the indole-2-position. Significantly, this mercury 
mediated process tolerates a range of simple alkyl substituents tethered to the alkyne. 
Gold-Catalysed Cyclisations 
 
The use of gold-catalysed processes in synthetic chemistry has rapidly increased over the 
past decade.88-92 A greater understanding of how gold can activate both alkynes and alkenes 
has resulted in the use of gold-catalysis to effect difficult transformations.93-98 To this end, 
Echvarren et al. in 2006 reported the gold-catalysed cyclisation of functionalised 
tryptamines (for example 40 and 43) to afford indole-based N-heterocyclic scaffolds (using 
either AuI or AuIII catalysts) where the newly formed ring differed in size from a 5- to an 8-
membered ring (Scheme 1.11).99-100 
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Scheme 1.11 Gold catalysed cyclisation to form indole-based heterocyclic scaffolds 
AuI = (Acetonitrile)[(2-biphenyl)di-tert-butylphosphine]gold(I) hexafluoroantimonate, DNBS = Dinitrobenzenesulfonyl 
 
The authors propose that the cationic gold(I) complex leads solely to the formation of the 
azepino[4,5-b]indole 42 (Scheme 1.11). When the same substrate was subject to the more 
electrophilic AuCl3 catalyst, formation of the indoloazocine scaffold 41 took place via an 8-
exo-dig process. In the presence of the tosyl-amine 43, which functioned as a leaving group, 
formation of the pyrroloindole tetracycle 44 occurred. This was proposed to be the result of 
(i) formation of the 8-membered ring, (ii) rearrangement to form a conjugated gold-carbene 
species, and (iii) readdition of the sulfonamide to form the tetracycle 44.99 
Ruthenium-Catalysed Cyclisations 
 
During their investigations into ring closing metathesis (RCM) for the synthesis of β-
carboline alkaloids, González-Gómez et al. reported the formation of an indoloazocine 
scaffold 46 and a 9-membered N,O-heterocycle 47 (Scheme 1.12).101 
 
Scheme 1.12 A ruthenium-catalysed cyclisation to form indole-based heterocyclic scaffolds 
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For the synthesis of the indoloazocine 46, formation of the THβC ammonium salt was 
facilitated by reaction of 45 with an excess of methyl iodide. Allylic rearrangement to form 
the new 8-membered N-heterocycle then took place in the presence of the Hoveyda–Grubbs 
ruthenium complex.102 A similar allylic rearrangement, this time following the synthesis of 
the N-oxide using m-CPBA, lead to formation of the 9-membered indole-based heterocycle 
47 (Scheme 1.12).101 
1.2.6 Palladium-Mediated Cyclisations 
 
The Nobel Prize for chemistry in 2010 was awarded to Richard Heck, Ei-ichi Negishi and 
Akira Suzuki for their contribution to the development of palladium-catalysed carbon-
carbon bond forming reactions. Palladium is unique as a catalyst as it is able to facilitate 
diverse synthetic transformations under mild reaction conditions, is tolerant to a range of 
functional groups, and is extremely atom economical.103-104 
The element palladium was first discovered in 1803 by the British chemist William Hyde 
Wollaston who named it after the asteroid Pallas, discovered a year earlier. Palladium is a 
silvery-white precious metal predominantly found in Russia, the USA and South Africa and 
has found use in a variety of applications including jewellery and electronics.103 Palladium 
was not employed in organic chemistry until the 20th century, following invention of the 
Wacker process (the palladium- and copper-catalysed oxidation of ethylene to 
acetaldehyde). Following mechanistic studies of this process by Tsuji et al. the modern era 
of organopalladium chemistry was born.105 
A number of  palladium(0) catalysed processes were developed during the 1970s to facilitate 
the formation of carbon-carbon bonds including the Negishi coupling with the alkyl zinc 
reagent and the Suzuki reaction using functionalised boronic acids and esters (Figure 1.5). 
106-108 80, 103, 109-119 
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Figure 1.5 Palladium-catalysed processes for the formation of new carbon-carbon bonds 
 
Palladium is located in group 8 of the periodic table and is classed as a late transition metal. 
This means that the d orbital of palladium in only partially filled, a property essential to its 
ability to both donate and accept electrons. The judicious choice of electron-rich or electron-
poor ligands can be employed to tailor the reactive nature of palladium to facilitate a range 
of synthetic transformations as required. Additional fundamental characteristics that make 
palladium-catalysis ideal for a range of cross-coupling reactions are detailed below.103, 105 
x Palladium is a second row transition metal of moderately large atomic size. The size of 
palladium appears to govern the stability and the general reactivity of palladium 
catalysts. The other complexes comprising of elements from the same periodic table 
group such as nickel are quite reactive but lack selectivity where on the other hand 
platinum derivatives are considered too stable. 
x Palladium favours the 0 and +2 oxidation states (although the +1, +3 and +4 oxidation 
states of palladium have also been observed). This important characteristic of palladium 
complexes means that palladium does not readily undergo radical or single-electron 
processes, minimising the occurrence of side reactions. 
x Palladium has a high affinity for non-polar π-compounds (such as alkenes and alkynes). 
The relatively high electronegativity of palladium also allows a carbon-palladium bond 
formed during the catalytic cycle and also this species remains unreactive towards other 
polar functional groups present. 
x A majority of the palladium-complexes available do not require the vigorous exclusion 
of air and/or moisture from the reaction. 
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Not limited to only carbon-carbon bond forming reactions, palladium complexes have 
recently been employed to catalyse many other synthetic transformations including 
hydrogenation, amination, amidation, cyanation, and carbonylation to name a few.120-130 Due 
to this ever growing number of synthetic transformations catalysed by palladium, many of 
the methods utilised for the construction and subsequent functionalisation of heterocycles 
employ palladium catalysts.9 Palladium-catalysis also facilitates a much greater level of 
chemo-, regio- and stereoselectivity in the formation of N-heterocycles than many other 
bond-forming processes available.9, 103, †  
A recent report by Vicente et al. described the formation of a tryptophan-based palladacycle 
49 following reaction of L-tryptophan methyl ester (48) with a stoichiometric amount of 
palladium acetate (Scheme 1.13).134-135 
 
Scheme 1.13 The synthesis of an L-tryptophan based palladacycle 
 
This intermediate was then able to be used in the halogenation of the indole-2-position, as 
well as the synthesis of a number of β-carboline analogues (for example 50 and 51) through 
the insertion of isocyanides or carbon monoxide into the Pd-C2 bond of the cyclopalladated 
complex 49 (Scheme 1.14).135 
 
Scheme 1.14 The synthesis of functionalised β-carbolines from a palladacycle intermediate 
 
                                                        
† A full review of palladium-catalysed heterocycle synthesis is beyond the scope of this report; 
however several excellent reports are available in the literature including Palladium in Heterocyclic 
Chemistry. A Guide for the Synthetic Chemist (Li, J. J.; Gribble, G. W. Elsevier Science Ltd., 2000).9, 
79, 131-133 
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Palladium has also been employed for the formation of the indoloazocine framework 53 as a 
key step in the total synthesis of (+)-austamide, (+)-deoxyisoaustamide and okaramine N 
(Scheme 1.15).28, 31 In the first two examples (Scheme 1.14 and 1.15) the use of a 
stoichiometric amount of palladium was needed to facilitate formation of the new N-
heterocycle. The preparation of indole-based N-heterocycles using only a catalytic amount 
of palladium is discussed in the following section. 
 
Scheme 1.15 A palladium-mediated key step in the total synthesis of natural products 
 
Stille-Coupling 
 
The palladium-catalysed Stille coupling of an indole-stannane to afford tryptamines 
functionalised at the indole-2-position was reported in 1993 by Palmisano and 
Santagostino.136 Initially, to further extend the scope of this reaction, several vinyl-bromides 
were tethered from the N10-amine of a tryptamine-tin derivative. Subsequent treatment with 
a catalytic amount of palladium(0) facilitated an intramolecular Stille cross-coupling 
reaction to afford the polycyclic ring systems (Scheme 1.16).136 
 
Scheme 1.16 The synthesis of indole-based N-heterocycles through a Stille cross-coupling 
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Domino Tsuji-Trost/Heck Reactions 
 
The synthesis of an azepino[4,5-b]indole 63 using a palladium-catalysed single step or 
domino Tsuji-Trost/Heck reaction was reported by Stewart et al. in 2009 (Scheme 1.17).137 
 
Scheme 1.17 The synthesis of azepino[4,5-b]indoles using a Tsuji-Trost/Heck reaction sequence 
 
This carefully controlled reaction sequence involved the initial functionalisation of the 
trifluoroacetate protected N10-amine of tryptamine 60 through palladation of allyl bromide 
61, known as the Tsuji-Trost reaction. Following installation of the olefin, an additional 
portion of base is added and the temperature increased to allow intramolecular Heck reaction 
at the indole-2-position to take place, forming the new 7-membered N-heterocycle 63 in 
good yield. As the Heck reaction at the indole-2-position appears to occur at a slower rate 
than that of other aryl halides, the use of palladium-catalysis for the first reaction in this 
domino sequence allows the allylation step to proceed much faster, allowing sufficient time 
for the intramolecular Heck reaction to take place.137 
1.3 The Heck Cross-Coupling Reaction 
 
The formation of N-heterocycles utilising both intramolecular and intermolecular Heck 
reactions was studied extensively during this project and as such a more detailed description 
of this reaction is warranted. The Heck reaction (or Mizoroki-Heck reaction) was first 
discovered independently by the groups of Heck138-144 and Moritani-Fujiwara145-146 in the late 
1960s; however these pioneering reactions required a stoichiometric amount of palladium. 
The development of a catalytic version of this reaction was first reported by Mizoroki (in 
1971)108, 147 and then refined by Heck (in 1972).107 The Heck-Mizoroki reaction traditionally 
takes place between an aryl (or vinyl) halide 64 and an alkene 65 in the presence of a 
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catalytic amount of palladium(0),103 and can be defined as a vinylic substitution reaction 
where the vinylic hydrogen is replaced by an aryl, benzyl or vinyl group (Scheme 1.18).103-
104  
 
Scheme 1.18 The Heck reaction is classified as a vinylic substitution reaction 
 
The gradual refinement of the Heck reaction over the past 40 years has lead to this powerful 
reaction finding a range of applications including in the total synthesis of natural products 
and pharmaceuticals, the preparation of hydrocarbons, and the synthesis of novel polymers 
and dyes.80, 104, 148-150 
1.3.1 The Catalytic Cycle 
 
The Heck reaction is based on a Pd(0)/Pd(II) catalytic cycle and the original cycle proposed 
by Heck is still generally accepted (although some parts of the mechanistic cycle are still not 
fully understood and alternative mechanisms have been proposed151). The Heck reaction 
involves four main processes, namely oxidative addition, migratory insertion, β-hydride 
elimination and reductive elimination (Scheme 1.19).80, 152  
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Scheme 1.19 The catalytic cycle of the Heck reaction104 
 
The first step of the sequence involves oxidative addition of the aryl-halide 68 to the 
coordinatively unsaturated palladium(0) complex 67 (which can either be a 14 or 12 electron 
species depending on the number of ligands attached). Following oxidative addition, the 
electrophilicity of this complex is greatly enhanced, and as such it readily coordinates an 
alkene 71. Migratory insertion of the σ-arylpalladium(II) complex 72 into the C=C double 
bond via a four membered transition state affords the σ-(β-aryl)alkylpalladium complex 73 
(Scheme 1.19). Internal rotation occurs such that a β-hydrogen is aligned syn-periplanar to 
the palladium (see 74), allowing β-hydride elimination to take place to afford the more 
thermodynamically stable (E)-alkene 76. Regeneration of the active Pd(0) catalyst 67 
through base-mediated reductive elimination completes the catalytic cycle (Scheme 1.19). A 
number of the key considerations of this cross-coupling process are discussed in more detail 
below. 
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Preactivation 
 
For the palladium to be catalytically active, it is required in its highly reactive Pd(0) state.152 
However, this Pd(0) species is unstable and must be prepared in situ, from either the more 
stable Pd(II) salts (e.g. Pd(OAc)2 or PdCl2) or the less stable Pd(0) complexes (e.g. Pd2dba3 
or Pd(PPh3)4). When the Pd(II) salts are employed, they are generally used in combination 
with phosphine ligands or other additives that reduce the Pd(II) to the Pd(0)L2 species 67.153-
158 There is also evidence to suggest that the base,159 alkene107 or even solvent160 may play a 
role in reducing the Pd(II) to the Pd(0), however when present, it is considered that the 
phosphine ligands are the most active and hence, the most likely to facilitate this reduction.  
To satisfy the 18-electron rule, the Pd(0) species typically coordinates to four ligands. Some 
recent reports propose that Pd(IV) may be involved in certain palladium-mediated 
transformations.161-163 There is also evidence to suggest that the formation of palladium 
nanoparticles occurs at higher temperatures and these nanoparticles may also play a role in 
facilitating the Heck reaction, especially under ligand free conditions.164-167 
Oxidative Addition 
 
During the oxidative addition step, the catalytically active Pd(0) species 67 is oxidised to 
Pd(II) 69 as it binds an aryl or vinyl group and a halide (or pseudohalide) leaving group. The 
rate of oxidative addition depends on the halide or pseudohalide present with the general 
order for reactivity being: diazonium salts > iodide > triflate > bromide > tosylate = 
chloride.80, 104 The oxidative addition process is often the rate determining step in the Heck 
reaction, especially in the case of aryl-bromide and aryl-chlorides. Ligands to stabilise and 
activate the Pd(0) complex are added to decrease the activation energy and therefore 
increase the rate of this oxidative addition step.104 Aryl-chlorides are typically the most 
sluggish coupling partners (due to the relative strength of the C-Cl bond).168-169 However, the 
recent development of an air-stable tri-tert-butyl phosphonium tetrafluoroborate salt by the 
group of Fu, where the active ligand is formed in situ during the reaction, has allowed aryl-
chlorides to be used as Heck substrates.170-171 
Migratory Insertion 
 
The migratory insertion process is the step of the catalytic cycle in which the new C-C bond 
is formed.148 Following oxidative addition, a ligand of the electrophilic Pd(II) complex 69 is 
replaced by the olefinic coupling partner 71.80, 103, 148, 172 The π-coordinated alkene 72 then 
rotates to the in-plane position resulting in a four membered ‘square-shaped’ transition state 
that allows syn-insertion to occur forming a new σ-bond in a concerted fashion. This 
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insertion is also rate-determining in the Heck-catalytic cycle. This syn-insertion is the key 
step that determines both the regiochemistry173-174 and stereochemistry175-176 of the Heck 
reaction, with steric and electronic properties of the coupling partners playing significant 
roles. The regioselectivity of the Heck reaction is discussed in more detail on the following 
page. 
β-Hydride Elimination 
 
The formation of the final olefinic product 76 is a result of the β-hydride elimination step of 
the catalytic cycle. As elimination can only occur in a syn-fashion, internal rotation of the 
new C-C bond formed takes place following the insertion of the olefin into the palladium(II) 
complex. This rotation allows the Pd(II)-halide complex to align syn to the β-hydrogen. The 
elimination of the Pd(II) species 77 to afford the olefin product is a reversible process, with 
the formation of the more thermodynamically stable trans isomer is favoured.80 However, if 
dissociation of the Pd(II)-hydride complex to the olefin is slow, re-addition to the double 
bond can occur, resulting in the formation of double bond regioisomers.177-178 
Reductive Elimination 
 
The final step in the Heck catalytic cycle is reductive elimination to regenerate the palladium 
complex to its active Pd(0) species. This process generally involves a base removing the HX 
from the palladium(II)-complex 77, producing the Pd(0)L2 species 67 that is required for the 
next catalytic cycle. The exact mechanism of the reduction of Pd(II) to Pd(0) remains 
unknown, however a recently published mechanism suggests a base-promoted elimination of 
Pd(II) to Pd(0) (Scheme 1.20, dotted line), proposed to be more energetically favoured than 
the traditional β-elimination pathway (Scheme 1.20, solid line).179  
 
Scheme 1.20 The base-promoted vs. the traditional elimination mechanism 
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Regioselectivity 
 
The regiochemical173-174 and stereochemical175-176 outcomes of the Heck reaction are defined 
during the migratory insertion step (Scheme 1.21). This regioselectivity is controlled by two 
major factors, namely the electronic and steric properties associated with the cross-coupling 
partners.103, 148  
 
Scheme 1.21 The two possible regiochemical outcomes of the Heck reaction 
 
The use of electron-deficient alkenes (for example butyl acrylate) is favoured both sterically 
and electronically and therefore only results in the terminal β-product 85 (Scheme 1.21). 
However, the use of electron-rich alkenes (for example heteroatom or alkyl substituted 
alkenes) under classical Heck conditions often results in a mixture of both internal 82 and 
terminal products 85 (Scheme 1.21).103 The regioselectivity of the Heck reaction with 
electron-rich alkenes can be guided by controlling the π-complex formation and insertion 
steps of the catalytic cycle.  
There are two slightly different mechanisms proposed for the Heck reaction (Scheme 1.22), 
depending on the leaving group present; the neutral pathway (if the leaving group is a tightly 
coordinating halide e.g. bromide) and the cationic pathway (if the leaving group is weakly 
coordinating such as a pseudohalide like triflate).104 
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Scheme 1.22 The Heck reaction with an electron-rich alkene can proceed via a neutral or cationic 
mechanism 
 
A number of reaction parameters can be manipulated so that one pathway is favoured. These 
include judicious choice of the aryl-halide substrate and reaction conditions, however if no 
precautions are taken the two pathways occur simultaneously, often resulting in a mixture of 
internal 88 (α-substituted) and terminal 89 (β-substituted) products. 
The neutral pathway predominates when an aryl- or vinyl-halide is used as the Heck 
substrate, which results in the formation of a neutral oxidative addition complex. When 
ligation of the olefin to the electrophilic palladium(II) complex takes place, immediately 
prior to migratory insertion, a phosphine ligand is substituted for the alkene, preferentially to 
the halide, maintaining the neutrality of the Pd(II) species 87 (Scheme 1.22). In order to 
favour the neutral pathway, monodentate neutral donor ligands are often employed as they 
coordinate more weakly to palladium than the bidentate ligands.148 
The regiochemistry of the Heck reaction proceeding via the neutral pathway is largely 
dependent on the steric properties of the related substrates. With electron-deficient olefins, 
insertion at the least substituted and most electron-deficient carbon takes place resulting in 
the terminal β-substituted product 89. For electron-rich alkenes, the electronic factors favour 
insertion at the carbon with the greatest electron density, which in the case of electron-rich 
terminal alkenes results in the formation of the internal α-substituted product 88. However, 
in these cases the steric factors favour insertion at the least substituted carbon, resulting in 
formation of the terminal β-substituted product 89. As such, a mixture of regioisomers is 
often observed from the reaction of an electron-rich alkene when the Heck reaction follows 
the neutral pathway.103-104, 180 The neutral pathway typically performs better for the electron-
deficient alkenes, where the regiochemistry is much more predictable. 
If the cationic pathway is followed, many of the regiochemical problems associated with 
electron-rich terminal alkenes under classic Heck conditions are overcome, as it provides 
access predominantly to the internal α-substituted Heck adduct 88 (Scheme 1.22). The 
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cationic pathway was originally proposed by Cabri (and independently by Hayashi181) in the 
early 1990’s, after the discovery that a bidentate phosphine ligand controlled regioselectivity 
in the arylation of vinyl ethers with aryl triflates.182-183 Dissociation of the weakly 
coordinating triflate anion, which readily occurs in polar solvents, leads to the formation of a 
cationic palladium-alkene π-complex 90.184 An alternative method to initiate a Pd-cationic 
pathway is through the use of silver185-186 or thallium salts.187-188 The general mechanism for 
the shift to this pathway is through the abstraction of a halide from the oxidative elimination 
product (ArPdL2X 69 – Scheme 1.22) to form the cationic palladium(II) species 90. This 
halide dissociation can also be promoted using metal scavengers (typically Ag and Tl), 
highly polar solvents and aryldiazonium tetrafluoroborate salts.189-191 
If the cationic pathway dominates electronic factors are favoured over steric factors in 
determining the regiochemical outcome of the Heck reaction. Following coordination of the 
alkene to the Pd(II) complex, the polarisation of the olefinic π-system is enhanced. This 
increase in polarisation facilitates insertion of the aryl group onto the α-carbon of the double 
bond, due to its associated charge density being less than that of the terminal carbon, 
resulting in formation of the 1,1-disubstituted product (Scheme 1.22).188 The role of steric 
properties in the cationic Heck-reaction, although not as important as electronic properties, 
cannot be ignored. As in the case of the neutral pathway, there appears to be a fine balance 
between both of these factors that plays a role in determining the regioselectivity of the 
Heck reaction. The cationic pathway typically performs better for electron-rich olefins than 
electron-poor alkenes due to an unfavourable interaction between the latter and the cationic 
Pd(II) complex, resulting in a slow rate of migratory insertion.180 
1.3.2 Reaction Conditions 
 
In addition to the mechanistic pathway, there are many other important factors that play a 
role in determining both the rate and outcome of the Heck reaction. A recent review by 
Beletskaya148 has highlighted the fact that even small variations in the conditions 
surrounding the Heck reaction can have considerable effects on the overall result. 
Selection of the halide in the Heck substrate is an important consideration. Oxidative 
addition of the Pd(0) to the aryl-halide or pseudohalide is a key rate determining step of the 
Heck catalytic cycle. For example, addition of Pd(0) to an aryl-iodide is much faster than 
that for an aryl-chloride. However, reductive elimination to regenerate the Pd(0) species 
occurs much faster for the corresponding Pd(II)-chloride complex than for the Pd(II)-iodide, 
so what is gained in one step of the catalytic cycle is often lost in another.104 The aryl-
iodides are typically much more expensive to prepare than the bromide and chloride 
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counterparts. The Heck reaction of the widely available aryl-chlorides often requires the use 
of bulky electron rich phosphine ligands.171 The development of several Heck reactions that 
employ C-H activation, where no halide or pseudohalide is required has also been reported 
in recent years.192-194 These findings have resulted in the reduction of cost and labour in the 
preparation of suitable Heck precursors, however the catalytic conditions facilitating the 
Heck reaction need to be highly reactive and selective to achieve the desired transformation.  
A wide range of palladium complexes are currently available as sources of Pd(0), including 
Pd2(dba)3 and those that require reduction such as palladacycles and N-heterocyclic carbene 
complexes. However, the first choice of a palladium source is often Pd(OAc)2 or Pd(PPh3)4 
because of their reduced cost and applicability in industry. It is difficult to predict how 
particular catalytic systems will perform in the Heck reaction, and as such, the screening of a 
range of Pd/Ligand combinations and additives is commonly reported.80 
The selection of a ligand can have a dramatic effect on both the selectivity and reactivity of 
the Heck reaction. Ligands play a role in all stages of the Heck catalytic cycle, including 
preactivation of the catalyst, oxidative addition and reductive elimination. In terms of 
regiochemistry, formation of the terminal β-substituted product is promoted in the presence 
of monodentate phosphine ligands (for example PPh3) and the internal α-substituted product 
can be favoured when using strongly chelating, bulky bidentate phosphine ligands.148, 180 
There are a plethora of ligands to choose from including monodentate phosphines (PPh3, 
Sphos, XPhos etc.), bidentate phosphines (dppf, BINAP etc.) and N-heterocyclic carbenes, 
many of which are commercially available.148, 195-197 Phosphine ligands are still the most 
commonly used as they stabilise the reactive intermediates through both electronic and steric 
effects.148 Phosphine ligands have the added advantage of both increasing the rate of 
dissociation and reducing the rate of readdition of the Pd(II)-hydride complex during the β-
hydride elimination phase of the catalytic cycle, limiting the formation of double-bond 
isomers and additional by-products.148, 198-199 Chiral ligands to impart stereochemistry during 
the catalytic cycle (for example BINAP and phosphinooxazolines) have also been employed 
to great effect in the Heck reaction.200-201 In these instances, the introduction of a new 
stereogenic centre is only observed through accompanying double bond migration. 
The role of the base in the Heck catalytic cycle is still not entirely understood. The main role 
of the base is to facilitate the reduction of the Pd(II)-halide complex to the catalytically 
active Pd(0).148, 202 The most commonly used bases in the Heck reaction are tertiary amines 
(NEt3 or Cy2NMe) or inorganic bases (K2CO3 or Cs2CO3).80 In some cases, evidence also 
exists that the base may play additional roles in the catalytic cycle, including the 
neutralisation of HBr203 and as a hydride source in the deoxygenation of triflates.151 182, 204 
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The choice of base used in the Heck reaction can have a significant effect on the product 
formed during the Heck reaction, as reported by Kang et al. where exchanging NEt3 with 
K2CO3 resulted in the formation of the conjugated diol 93 instead of the saturated ketone 92 
(Scheme 1.23).205 
 
Scheme 1.23 Changing base from NEt3 to K2CO3 resulted in formation of the diol 93 instead of the 
ketone 92 
 
Several different solvents have been employed in the Heck reaction, with DMF, MeCN, 1,4-
dioxane and THF proving to be the most useful as they are able to weakly coordinate with 
the palladium complex, increasing its stability.80 DMSO, benzene and toluene have also 
been used to great effect in controlling both the regioselectivity and stereoselectivity in a 
number of processes.103, 201 The importance of solvent choice in enantioselective palladium-
catalysed transformations was demonstrated by Sulikowski et al. where the use of THF 
afforded the indolizidine 96, however when the reaction was carried out in DMF, the desired 
asymmetric enamide 95 was the major product (Scheme 1.24).206 
 
Scheme 1.24 Changing solvent from THF to DMF resulted in formation of the enamide 95 instead of 
the indolizidine 96 
 
1.4 Palladium-Catalysed Domino Reactions 
 
Many of the transformations carried out in modern organic syntheses involve the use of 
reagents and solvents that are known to be flammable and/or toxic and can therefore 
negatively affect both human health and the environment.207 As such, it is highly desirable 
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that synthetic processes are developed that produce only the desired compound, in high 
yields, whilst minimising both reagent consumption and the subsequent generation of waste.  
Several of the methodologies investigated during this research project for the synthesis of N-
heterocycles were domino processes. Domino reactions have emerged as a powerful tool for 
the modern synthetic chemist, generating a high level of molecular complexity in one 
efficient step.208 Domino reactions are attractive to research laboratories because of their 
potential to minimise the use of solvents, reagents, time and energy.208 Moreover, in an 
industrial environment, a process that saves on labour costs is also considered advantageous. 
A domino reaction is defined as “the execution of two or more bond-forming 
transformations under identical reaction conditions, in which the latter transformations take 
place at the functionalities formed by the preceding transformation.”208-209  
One early example of a domino reaction was the acid-catalysed polycyclisation of the 
tertiary and allylic alcohol 97 in the presence of ethylene carbonate 98 (Scheme 1.25).210 
During this domino process, four new ring systems were formed, with each corresponding 
reaction taking place at the functional group introduced by the previous reaction in the 
sequence. The resulting cyclopentene 100 was then readily converted to the cyclohexanone 
in progesterone 101. 
 
Scheme 1.25 An early example of a domino reaction used in the synthesis of progesterone210 
 
As domino processes require two or more reactions to take place under the same conditions, 
the substrate must be controlled in such a way so that each individual reaction occurs in the 
desired order. This control can often be achieved through steric or electronic differentiation; 
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an elegant example of the latter was reported by Tietze et al. in the domino Tsuji-Trost/Heck 
reaction (Scheme 1.26).211 
 
Scheme 1.26 A palladium-mediated domino process displaying substrate control 
 
The introduction of the electron-donating methoxy group slowed down the rate of oxidative 
addition of the aryl-iodide and therefore the Heck reaction, allowing the Tsuji-Trost 
allylation to occur preferentially, significantly enhancing the yield of the overall domino 
process (Scheme 1.26). 
The range of single-step reactions involving palladium catalysis has grown to the extent 
where palladium-mediated reactions are commonplace in most synthetic laboratories. 
Consequently, the number of palladium-mediated domino reactions reported has also 
increased over the last decade.212-216 The more feasible domino reactions are those where all 
transformations occur under similar reaction conditions, for example, where each of the 
reaction steps is palladium-catalysed (Scheme 1.26).137, 209, 214, 217 Likewise, because of the 
reliance of base in many Pd-cross coupling reactions, domino reactions involving both a Pd-
catalysed and a base initiated synthetic step (for example Aldol condensation - Scheme 1.27 
- or aza-Michael addition) are also plausible.218-219 ‡ 
 
Scheme 1.27 A domino Heck/Aldol process where the first step is palladium-catalysed 
                                                        
‡ An comprehensive review of domino reactions can be found in Domino Reactions in Organic 
Synthesis (Tietze, L. F.; Brasche, G.; Gericke, K., 1 ed.; Wiley-VCH: Weinheim, 2006).209 
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The major focus of the research presented in this thesis was the development of new 
methodology (including domino reactions) for the synthesis of indole-based N-heterocycles 
from tryptamine. A second project, investigating the synthesis of indole-based PPARγ 
agonists for the treatment of type-2-diabetes, was also initiated. 
1.5 Indole-Based PPARγ Agonists 
 
In 2005, over 1.1 million people worldwide died from diabetes.220 However, this number is 
more likely closer to 3 million, as many deaths where diabetes was a predominant factor 
were attributed to heart disease or kidney failure.220 Currently, over 180 million people 
worldwide have been diagnosed with diabetes. Alarmingly, the number of sufferers is 
expected to more than double by the year 2030, as this chronic disease achieves epidemic 
status.220 
A large range of antidiabetic drugs are currently available, however there is still no ideal 
treatment or cure for type 2 diabetes.221 As such, there remains a great need for the 
development of new or improved treatments with much better safety profiles. This research 
project focused on the synthesis of new antidiabetic agents that act at the same biological 
target as the commercially available thiazolidinedione antidiabetic agents (the Peroxisome 
Proliferator-Activated Receptor γ or PPARγ), with the aim of developing safer 
pharmaceutical agents with limited side effects. 
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1.6 Project Aims 
 
New Palladium-Catalysed Methodology 
 
To complement existing methodology, it was envisaged that a new palladium-catalysed 
approach, involving either an intermolecular or intramolecular Heck reaction at the indole-2-
position, could be developed for the preparation of indole-based N-heterocycles from 
tryptamine. 
 
Scheme 1.28 Two alternative strategies identified for the formation of indole-based N-heterocycles 
 
Two approaches were initially considered for N-heterocycle synthesis, either by the tethering 
an olefin from the N10-amine of tryptamine followed by intramolecular Heck reaction 
(Scheme 1.28, Strategy A), or an initial cross-coupling at the indole-2-position followed by 
nucleophilic amine addition to form the new heterocycle (Scheme 1.28, Strategy B). At the 
time of design, only one palladium-catalysed cyclisation involving a Heck reaction at the 
indole-2-position to form an indole-based N-heterocyclic scaffold from tryptamine had been 
reported,137 and as such, further investigation into this approach was warranted.  
As palladium chemistry is well known at the indole-2-position,§ a Heck reaction was seen as 
a plausible key step in the formation of indole-based N-heterocycles. As numerous 
functionalised alkenes and alkynes are commercially available, this approach would allow 
access, from a common 2-haloindole precursor to a diverse range of indole-based 
heterocyclic scaffolds, differing in both ring size and the functionality introduced by the 
                                                        
§ The indole-2-position has been functionalised using a range of palladium-mediated transformations 
including the Kumada,222-224 Negishi,225-228 Suzuki,229-232 Stille,136, 233-234 Sonogashira,235-237 and Heck 
reaction.238-241 For a comprehensive review of palladium-catalysed reactions involving indoles refer to 
Chapter 3 of Palladium in Heterocyclic Chemistry. A Guide for the Synthetic Chemist (Li, J. J.; 
Gribble, G. W. Elsevier Science Ltd., 2000)9  
  Chapter 1 
- 32 - 
olefin (Scheme 1.29). A similar approach to a diverse series of benzofused sultams from α-
haloarylsulfonamides was recently been reported by Hanson et al.242  
 
Scheme 1.29 A novel palladium-catalysed approach to functionalised indole-based N-heterocycles 
 
Domino reactions are an efficient way to rapidly introduce molecular complexity, and as 
such a number of the methodologies investigated during this research project for the 
synthesis of indole-based N-heterocycles were domino processes. This includes domino 
reactions where both of the steps are palladium-catalysed (Tsuji-Trost/Heck domino 
reactions), in addition to domino processes where only one step is palladium-mediated (the 
Heck reaction) and the other step is base initiated (alkylation or aza-Michael addition). 
Indole-Based PPARγ Agonists 
 
The synthesis of PPARγ agonists from tryptamine employing selected indole-based N-
heterocyclic scaffolds was also investigated. Recent work within the Pfeffer group focused 
on the design and synthesis of indole-based PPARγ agonists from tryptamine.2-3 Two indole-
based compounds synthesised from tryptamine and substituted on both nitrogens exhibited a 
moderate insulin-sensitising effect (Figure 1.6), when compared to the commercially 
available treatment Rosiglitazone. These compounds were identified as lead compounds in 
the development of new potential PPARγ agonists for the treatment of type 2 diabetes 
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Figure 1.6 Two lead compounds that exhibited a moderate insulin-sensitising ability 
 
This medicinal chemistry project involves the synthesis of conformationally rigid analogues 
of flexible lead compounds previously investigated. This approach is often used in the 
determination of pharmacophoric conformation, as key functional groups are constrained in 
the one position.243 The potential pharmacophore can be locked into various configurations 
through the incorporation of cyclic or unsaturated functionality into the existing molecule.243 
As a range of methods are currently available for the synthesis of indole-based N-
heterocycles (see section 1.2), there are many possible variations in both the ring size and 
functionality introduced onto the indole scaffold during N-heterocycle formation. 
 
Scheme 1.30 The proposed modification to improve the biological activity of the PPARγ agonists 
 
A simple modification to the indole-based aromatic scaffold was proposed through the 
introduction of a second N-heterocyclic ring system (Scheme 1.30), whilst keeping the 
acidic head group and aromatic tail group relatively similar to those previously reported.2-3 
Furthermore, the introduction of key characteristics identified from naturally occurring 
PPARγ agonists may improve biological activity as well as the safety profile of the potential 
PPARγ agonists synthesised during this project. 
 
 
 Chapter Two 
Indole-Based N-Heterocycles: 
Intramolecular Heck Reactions 
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2.1 Chapter Overview 
 
To further exploit the intramolecular Heck reaction at the indole-2-position, a number of 
new methodologies to access indole-based N-heterocyclic scaffolds were investigated using 
single-step or domino processes. This approach involved the tethering of an appropriate 
olefin to the N10-amine of tryptamine followed by intramolecular Heck reaction at the 
indole-2-position to form the new N-heterocycle. Although a range of olefinic tethers were 
installed at the N10-position, the intramolecular Heck reaction to form the new heterocycle 
could not be completed, and as such at this point in time this approach to indole-based N-
heterocycles proved unsuccessful. 
2.2 The Synthesis of Indole-Based N-heterocycles: Intramolecular Heck Reactions 
 
The indole-2-position can be readily halogenated in high yields, using a range of 
methodologies.9, 13, 134, 137, 232, 244-248 These indole-2-halogenated precursors are amenable to 
further functionalisation using a range of synthetic transformations, in particular palladium-
mediated cross-coupling reactions. 
One plausible strategy for heterocycle formation was envisaged by first tethering a suitable 
group from the amine which could then undergo intramolecular cross-coupling reaction with 
the halogenated indole-2-position of tryptamine to form the new N-heterocycle (Scheme 
2.1). As a wide range of substituted alkenes suitable for tethering off the N10-amine are 
commercially available, the synthesis of numerous N-heterocycles of differing size and 
functionality was envisaged. 
 
Scheme 2.1 The intramolecular Heck reaction strategy the formation of indole-base N-heterocycles 
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Before an investigation into a number of these cyclisation pathways was undertaken, several 
parameters were considered. The type of halogen to be inserted at the indole-2-position 
required careful selection. Although aryl-chlorides have recently been shown to partake in 
the Heck cross coupling reaction,169, 249-250 they are often sluggish and require the use of 
more highly active and often very air-sensitive palladium-catalysts (the oxidative-addition 
step of the catalytic cycle is much slower than for aryl bromides and aryl iodides).170, 251 As 
the indole ring system is naturally very electron-rich, a greater degree of electrophilicity 
would be induced at this position through bromination or iodination, allowing the Heck 
reaction to proceed at a much faster rate. Iodination at the indole-2-position would be ideal 
for facilitating a rapid Heck reaction, however the conditions required to iodinate this 
position are harsh and expensive (traditionally employing metal-halogen exchange with 
lithium or mercury salts),13, 134 and do not always tolerate a number of the functional groups 
expected to be present during this investigation. Previous research has shown the Heck 
reaction is readily accomplished using 2-bromoindoles.137 As the synthesis of 2-
bromoindoles is readily achieved in high yields using mild reagents (NBS or pyridinium 
tribromide) 137, 232, 247, 252 2-bromoindole substrates were used throughout the remainder of 
this investigation. 
The size of the heterocycle ring formed and the functionality introduced during the 
cyclisation process could be controlled through careful selection of the N10-amine tether. As 
a base is required to complete the catalytic cycle of the intramolecular Heck reaction, the 
possibility of functionalising the N10-amine under the same basic conditions exists (for 
example alkylation or aza-Michael addition). As such, if the base and solvent required can 
be selectively chosen to facilitate both the amine functionalisation and the palladium-
mediated cross-coupling reactions, a domino process is possible. 
 
Scheme 2.2 A range of N-heterocycles were to be synthesised using the intramolecular Heck reaction 
 
For the intramolecular Heck reaction with alkenes following the neutral pathway, the 
possibility exists for the formation of regioisomers during heterocycle synthesis (for 
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example the formation of both a 7-membered ring with the double bond external to the ring 
and an 8-membered ring with the double bond internal to the new ring formed are 
possible).253-258 Furthermore, all possible products from the cyclisations proposed during this 
research project were favoured under Baldwin’s rules (5-7-exo-trig are favoured as are 6-7-
endo-trig, however the rules don’t cover the formation of 8-membered heterocycles). As 
such, the outcome of each cyclisation process depends solely on the regioselectivity of the 
palladium-catalysed cross-coupling reaction. It was considered that the cyclisations 
investigated during this study would lead predominantly to the exo-trig product 125, where 
the olefin lies external to the new N-heterocyclic ring as it is much less sterically demanding 
on the “square-like” palladium-alkene π-complex 123 formed during the intramolecular 
Heck reaction (Scheme 2.3). 
 
Scheme 2.3 The exo-trig cyclisation is favoured for the intramolecular Heck reaction as it is much 
less sterically demanding 
 
The following section details the investigation into the intramolecular Heck reaction in a 
number of both single-step and domino processes for the synthesis of 6, 7, and 8-membered 
indole-based N-heterocycles. The syntheses attempted are described in the following section 
and include a domino Tsuji-Trost/Heck reaction sequence, an aza-Michael/Heck domino 
process and single-step alkylation/Heck reactions. 
2.3 Domino Tsuji-Trost/Heck Reactions 
 
The synthesis of an azepino[4,5-b]indole 63 using a palladium-mediated single-step or 
domino Tsuji-Trost/Heck reaction sequence was recently reported by Stewart et al. (Scheme 
2.4. See also Section 1.2.6).137 
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Scheme 2.4 The synthesis of azepino[4,5-b]indoles using a Tsuji-Trost/Heck reaction sequence 
 
To date this domino Tsuji-Trost/Heck reaction sequence (Scheme 2.4) had only proved 
successful using the unsubstituted allyl bromide 61. The aim of this project was to further 
develop this methodology to allow access to substituted azepino[4,5-b]indoles. As such, it 
was envisaged that access to more highly functionalised indole scaffolds could be realised 
by applying a similar domino process to substituted allyl bromides (for example crotyl 
bromide, dimethylallyl bromide and methyl-4-bromocrotonate). 
The domino precursor for the first series of reactions (Table 2.1) was prepared in accordance 
to the method recently published by Stewart et al (Scheme 2.4).137 The 2-bromoindole 
domino precursor 60 was then subject to the previously identified domino conditions using 
crotyl bromide (Table 2.1, entry 1) or methyl-4-bromocrotonate (Table 2.1, entry 2).  
Table 2.1 Extension of the domino Tsuji-Trost/Heck reaction to access azepino[4,5-b]indoles 
 
Entry R Conditions  Yield (%) 
1 Me    (129) Pd(PPh3)4, NaH, Cs2CO3, Bu4nHSO4, PhMe/DMF Trace a 
2 CO2Me    (130) Pd(PPh3)4, NaH, Cs2CO3, Bu4nHSO4, PhMe/DMF NR 
 
c Trace is less than 10% yield as identified by NMR spectroscopy 
Reaction was performed by adding NaH (1.6 eq) to a solution containing the aryl-halide (1.0 eq.), Cs2CO3 (3.0 eq.), Bu4nHSO4 
(0.3 eq) in PhMe:DMF (4 mL, 9:1) in a sealed tube. After stirring for 10 min, Pd(PPh3)4 (10 mol%) and allyl bromide (2.0 eq) 
were added and the reaction mixture heated to 60 oC for 30 mins. After this time additional NaH (0.6 eq) was added and the 
reaction mixture heated to 100 oC for 16 h. 
 
Unfortunately, the use of the more highly functionalised allyl bromides using the previously 
identified domino conditions failed to furnish the desired azepino[4,5-b]indoles. A trace 
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amount of the azepinoindole 129 was identified following the reaction with crotyl bromide 
(Table 2.1, entry 1), identified through the absence of the resonance previously attributed to 
the amide proton in the 1H NMR spectrum as well as the presence of the resonances 
assigned to the additional aliphatic peaks. However, when the ally bromide methyl ester 
(entry 2) was trialled, the reaction completely failed. It was proposed that under these 
conditions, which use simple palladium-catalysts and relatively mild bases and non-polar 
solvents, the complexation of the palladium (oxidative addition) to the more highly 
substituted allyl bromides does not occur as readily as for allyl bromide. As such, the 
likelihood of side reactions occurring before allylation can take place is greatly increased.  
It was thus envisaged that a more nucleophilic amine would allow allylation to proceed more 
quickly, avoiding the possibility of side reactions. A substrate was prepared using the p-
toluenesulfonyl protecting group which is known to be more readily alkylated than the 
trifluoroacetate amine protecting group under mild basic conditions (Scheme 2.5).259-262 
 
Scheme 2.5 Preparation of the sulfonamide substrate 
 
The tosylation of the N10-amine of tryptamine (2) was achieved in quantitative yields, 
following literature protocol (Scheme 2.5).263-265 The presence of the desired sulfonamide 
131 was identified using NMR spectroscopy through the introduction of the resonance 
attributed to the methyl group (δ 2.32 ppm), the resonance attributed to the sulfonamide NH 
proton (δ 4.53 ppm), as well as a downfield shift and additional splitting patterns observed 
for the resonances attributed to the ethylene chain of tryptamine, following the reaction with 
the sulfonyl chloride.  
Initial attempts to brominate the indole-C2-position using N-bromosuccinimide (NBS) in 
CH2Cl2 as described by Jain et al.252 furnished the desired product 132 in a yield of 56%. 
However, a by-product resulting from the proposed bromination of the sulfonamide was also 
observed following analysis of the reaction mixture by NMR spectroscopy. The formation of 
similar complexes has been reported numerous times in the literature, in particular for the 
aminobromination of olefins.266-267 To overcome the formation of this by-product, 
pyridinium tribromide was employed to afford the 2-bromoindole sulfonamide 132 in 90% 
yield (Scheme 2.5). Following purification by column chromatography, the structure of 2-
bromoindole 132 was immediately confirmed by NMR spectrometry and mass spectrometry.  
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The indole-nitrogen served as a potential competitive nucleophile in the domino process, 
therefore the final step in the preparation of the domino precursor involved the protection of 
the indole nitrogen with a tert-butoxycarbonyl (Boc) group. The Boc group was installed 
under standard conditions, by reacting the 2-bromosulfonamide 132 with di-tert-
butoxycarbonyl dicarbonate in the presence of a catalytic amount of DMAP (Scheme 2.6).264  
 
Scheme 2.6 Indole protection of the 2-bromosulfonamide derivative 
 
Unfortunately, the Boc protection of the indole-nitrogen did not proceed as cleanly as 
desired due to the enhanced nucleophilicity of the sulfonamide. The desired mono-Boc 
compound 133 was isolated in an unoptimised yield of 48% with the 1H NMR spectrum 
revealing the presence of the resonance attributed to the tert-butyl group (δ 1.68 ppm), as 
well as the absence of the indole-NH resonance (approximately δ 8.30 ppm) and the 
downfield shift of the indole-C7-aromatic proton (indole-NH δ 7.33 ppm to indole-N-Boc δ 
8.00 ppm). The major by-product observed in this reaction was the di-Boc compound 134 
(isolated in 44% yield), formed by reaction of both the indole-nitrogen and the sulfonamide. 
Although this indole protection step did not provide the desired domino precursor in high 
yields, enough product was isolated to carry out preliminary investigations into the Tsuji-
Trost/Heck reaction using the tosyl 2-bromoindole substrate (a more detailed investigation 
into optimisation of this indole-nitrogen protection is discussed in Section 3.2.4). 
The more nucleophilic 2-bromosulfonamide domino precursor 133 was then subjected to the 
domino process using the same palladium catalyst (Pd(PPh3)4) that was previously shown to 
facilitate the Heck reaction at the indole-2-position (Table 2.2).137, 252 As the first step of this 
proposed domino sequence occurs in the presence of the palladium-catalyst and base and 
nucleophilic amine, both an SN2 alkylation and a Tsuji-Trost allylation are possible to install 
the necessary olefin. 
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Table 2.2 The domino Tsuji-Trost/Heck reaction using the 2-bromosulfonamide precursor  
 
Entry R Pd Catalyst Base Solvent Yield (%) 
1 Me    (135) Pd(PPh3)4 Na2CO3 PhMe NR 
2 H      (136) Pd(PPh3)4 K2CO3 PhMe NR 
 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), and base (3.0 eq.), PhMe (4 mL). After stirring for 
10 min, Pd(PPh3)4 (10 mol%) and allyl bromide (2.0 eq) were added and the reaction mixture heated to 120 oC for 16 h. 
 
Unfortunately, the use of the 2-bromosulfonamide substrate in this domino process for the 
formation of azepino[4,5-b]indoles, using both allyl bromide and crotyl bromide, proved 
unsuccessful. Following analysis of the crude reaction mixtures, only starting material was 
detected in the 1H NMR spectrum (Table 2.2).  
Attempts to further expand the scope of this domino Tsuji-Trost/Heck reaction using more 
highly substituted allyl bromides and alternative aryl-halide substrates were also 
unsuccessful. To further pursue the development of new methodology for the synthesis of 
indole-based N-heterocycles attention turned to the single step process involving (i) 
alkylation of the N10-amine followed by (ii) intramolecular Heck reaction at the indole-2-
position. 
2.4 Single Step Alkylation/Heck Reactions 
 
Azepino[4,5-b]indoles 
 
The successful application of a similar single-step methodology was reported in the 
aforementioned publication by Hanson et. al. for the synthesis of benzofused sultams 
containing both alkene and ester functionality external to the new ring formed (Scheme 
2.7).242  
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Scheme 2.7 The alkylation/Heck reaction sequence for the synthesis of benzofused sultam 
alkenylesters. 
 
Through reaction of the α-haloarylsulfonamide 137 with the ethyl-4-bromocrotonate 
(Scheme 2.7), an appropriate olefinic partner was installed which then undergoes 
intramolecular Heck reaction to form the new 6-membered heterocycle 139 in good yield (a 
favoured 6-exo-trig cyclisation). As such, it was envisaged that a similar approach could be 
applied to our 2-bromotryptamine system, using a range of functionalised allyl bromides 
(see Scheme 2.2) would provide access to azepino[4,5-b]indole scaffolds (a 7-exo-trig 
cyclisation). 
As the starting materials were readily available, initial investigations for this single step 
process were carried out using the trifluoroacetate 60 and tosyl 133 substrates discussed in 
the previous section (Section 2.3). Unfortunately, a high yielding, selective, N10-alkylation 
process for these substrates was not identified following the screening of a range of reaction 
conditions. It was therefore envisaged that a more acidic amide proton would allow selective 
functionalisation of the N10-amine. To achieve this selectivity, the more electron 
withdrawing 2-nitrobenzenesulfonyl (Ns or nosyl) protecting group was installed through 
reaction of tryptamine (2) with 2-nitrobenzenesulfonyl chloride (in 94% yield) following a 
similar protocol used to introduce the p-tosyl group previously (Scheme 2.8).265  
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Scheme 2.8 Preparation of the 2-nosylsulfonamide 
 
The desired increase in acidity of the sulfonamide proton from tosyl to the nosyl group was 
readily detected in the 1H NMR spectrum, from the downfield shift of the resonance 
attributed to the sulfonamide proton (Ts δ 4.45 ppm, Ns δ 5.32 ppm) due to the increased 
deshielding effect of the aryl-nitro group. Following protection of the N10-amine, the indole-
2-position was then brominated using pyridinium tribromide in 91% yield (Scheme 2.8), 
again confirmed by the absence of the indole-2-proton in the 1H NMR spectrum (δ 7.01 
ppm, doublet, indole-2-ArH), in addition to the upfield shift of the indole-C2 resonance in 
the 13C spectrum (δ 124.4 ppm to δ 109.3 ppm). 
The nosyl-2-bromotryptamine 141 was then subjected to alkylation conditions reported in 
the literature and following a simple work up procedure the desired allylamine product 142 
was isolated in an excellent yield of 93% (Scheme 2.9).261 The identity of this product was 
confirmed by means of NMR spectroscopy and mass spectrometry, with the characteristic 
splitting patterns of the allyl group readily observed in the 1H NMR spectrum. 
 
Scheme 2.9 Alkylation of the nosyl sulfonamide with allyl bromide 
 
With the installation of the N10-amine olefin tether proceeding in high yields, the requisite 
Heck cyclisation precursors were prepared through reaction of the 2-bromosulfonamide 
substrate with three different allyl bromides (crotyl bromide, dimethylallyl bromide and 
methyl-4-bromocrotonate) in excellent yields (Scheme 2.10). Following this, the indole-
nitrogen was protected with the tert-butoxycarboyl group (Boc group) in moderate yields to 
afford the fully functionalised Heck reaction precursors (146, 147 and 148). 
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Scheme 2.10 Preparation of the Heck cyclisation precursors 
 
With the requisite precursors for the formation of azepino[4,5-b]indole ring systems 
synthesised in good yields using a general procedure, attention now turned to the Heck 
cyclisation reaction. The intramolecular Heck reaction of the 2-bromoindole precursors was 
investigated by screening a range of palladium catalysts and bases for each of the substrates 
(Table 2.3). 
Table 2.3 Optimisation of the Heck reaction to form functionalised azepino[4,5-b]indoles 
 
Entry R1 R2 Product Pd Catalyst a Base  Solvent Yield (%) 
1 CO2Me H 149 Pd(PPh3)4 K2CO3 PhMe NR 
2 CO2Me H 149 Pd2(dba)3/P(tBu)3 Cy2NMe PhMe NR 
3 CO2Me H 149 Pd(OAc)2/PPh3 NEt3 PhMe NR 
4 Me H 150 Pd(PPh3)4 K2CO3 PhMe NR 
5 Me H 150 Pd2(dba)3.CHCl3 NEt3 PhMe NR 
6 Me H 150 Pd2(dba)3/P(tBu)3 Cy2NMe PhMe NR 
7 Me H 150 Pd(OAc)2/PPh3 NEt3 PhMe NR 
8 Me Me 151 Pd(PPh3)4 K2CO3 PhMe NR 
9 Me Me 151 Pd2(dba)3/P(tBu)3 Cy2NMe PhMe NR 
10 Me Me 151 Pd2(dba)3.CHCl3 NEt3 PhMe NR 
11 Me Me 151 Pd(OAc)2/PPh3 NEt3 PhMe NR 
 
a Palladium catalyst loading 10 mol%. (where applicable the Pd:Ligand ratio was 1:1). 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), palladium catalyst (10 mol%), and base (3.0 eq.) 
in PhMe (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
It was known that the Heck reaction at the indole-2-position can be achieved using 
Pd(PPh3)4 in reasonable yield in the presence of an inorganic base in toluene or dioxane, and 
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generally requires reasonable high temperatures to proceed. As such, to form the 
functionalised azepino[4,5-b]indole, initial trials were completed using Pd(PPh3)4, K2CO3, 
and toluene at 120 oC in a sealed tube (Table 2.3, entries 1, 4 and 8). Unfortunately, no trace 
of the desired product was detected following analysis of the crude reaction mixture by 
NMR spectroscopy and mass spectrometry. 
Formation of the new 7-membered heterocycle using the Heck reaction was then attempted 
using a range of palladium-catalysts including the highly reactive system pioneered by Fu.170 
Once again, following analysis of the crude reaction mixtures, no trace of the desired 
azepino[4,5-b]indole ring systems was identified (Table 2.3). 
The failure of these olefin tethers to cyclise at the indole-2-position and form the new 7-
membered heterocycles (149-151) was unexpected, as it is known that the Heck reaction 
does in fact take place at the indole-2-position with electron deficient alkenes (e.g. butyl 
acrylate). The formation of the 7-membered ring (preferentially to the 8-membered ring also 
possible during this process) has also proved favourable at this position.99-100, 137  
Mechanistically, oxidative addition of the palladium(0) species must occur at the 
halogenated indole-2-position, as highlighted in previous literature examples of a palladium-
mediated cross-coupling reactions at this position (see Section 1.2.6).137, 252 Following 
oxidative insertion, the palladium forms a complex with the olefin in order to bring it close 
enough to the indole-2-position for migratory insertion to occur (see Section 1.3 for a 
discussion on the catalytic cycle of the Heck reaction). From the failure of formation of the 
new N-heterocycle it was proposed that migratory insertion did not take place.  
For electron-deficient terminal alkenes (for example butyl acrylate) the σ-alkyl palladium(II) 
complex is formed α- to the carbonyl, allowing migratory insertion of the R group (the 
indole attached at the C2-position) to occur at the electron deficient end of the alkene (the β-
end). In contrast, if an electron-rich olefin is used, ligation of the olefin by the PdII species 
occurs at the β-position, resulting in formation of the α-substituted alkene.  
As the more highly substituted allyl bromides contain functionality at this β-position of the 
alkene, palladium-ligation and therefore migratory insertion would be expected to occur at a 
much slower rate. The failure of intramolecular Heck reaction is understandable for the case 
of the dimethylallyl tether as the β-position is disubstituted, however, the fact that the allyl 
ester and crotyl tethers also did not undergo Heck reaction is surprising (Table 2.3). 
A number of reasons were proposed for the failure of the intramolecular Heck reaction, with 
both the allyl ester and crotyl tethers. In terms of steric properties, the allyl group is much 
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more crowded in the presence of the 2-nitrobenzenesulfonyl group 152 than it was for the 
trifluoroacetate group 153 successfully employed in the Tsuji-Trost/Heck reaction sequence 
discussed earlier (Figure 2.1). Even though free rotation can occur through several of the 
bonds of this tether, the additional steric bulk may hinder the progress of the migratory 
insertion process. 
 
Figure 2.1 The olefin is more sterically hindered in the case of the nosyl sulfonamide when compared 
with that of the trifluoroacetamide successful in previous cases. 
 
When compared to the reported successful intramolecular Heck reaction of the allyl ester 
tether 154 for the synthesis of the benzofused sultams (see Scheme 2.6), the tether present in 
our 2-bromotryptamine derivative 155 also had a much higher degree of free rotation. The 
conjugation of the sultam system would presumably hold the olefinic tether in much closer 
proximity to the palladium-halide complex 154, allowing migratory insertion to occur more 
readily (Figure 2.2) 
 
Figure 2.2 Preorganisation in the sultam system means the olefin tether is in much closer proximity 
to the palladium-halide complex than for the 2-bromotryptamine substrate 
 
Similarly hampered intramolecular Heck reactions have been well reported in the literature, 
where the addition of even a small amount of flexibility in the molecule can significantly 
affect the success of the Heck reaction (Scheme 2.11).268 
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Scheme 2.11 Flattening of the ring by replacing the central methoxy group with a carbonyl group 
significantly enhanced the yield of the intramolecular Heck reaction268 
 
In conclusion, a combination of favourable steric and electronic properties in the Heck 
cross-coupling partners were crucial in the facilitation of the intramolecular Heck reaction to 
form the new N-heterocyclic ring. Unfortunately, in our case, the correct combination was 
not identified and development of new palladium-mediated methodology to access 7-
membered indole-based heterocycles was no longer pursued. 
Indoloazocines 
 
With the synthesis of azepino[4,5-b]indole ring systems unsuccessful using the single-step 
alkylation/Heck reaction sequence, the synthesis of indoloazocines using this strategy was 
also briefly investigated. A similar process for the formation of the 7-membered heterocycle 
161 was used by the group of Hanson for the synthesis of benzofused sultams (Scheme 
2.12).242 
 
Scheme 2.12 Synthesis of a benzofused sultam containing a 7-membered heterocycle 
 
In a similar fashion, to that discussed for the azepinoindoles, the σ-alkyl palladium(II) 
complex should form at the terminal end of the electron rich alkene, eventually resulting in 
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the formation of the 8-membered indole-based N-heterocyclic ring (the α-substituted product 
as observed in the synthesis of sultams – Scheme 2.12). 
Following a literature protocol for the functionalisation of sulfonamides using the 
Mitsunobu reaction,269-270 the nosyl-2-bromotryptamine 141 prepared for the previous study 
was reacted with 3-buten-1-ol 162 (Scheme 2.13). 
 
Scheme 2.13 Mitsunobu reaction to prepare the Heck precursor 
 
The highest yield obtained for this Mitsunobu process was 57%, but only when an excess of 
the azodicarboxylate and triphenylphosphine were used (increasing the chance of forming 
the activated alcohol species, prior to nucleophilic attack). The immediate success of this 
reaction was again confirmed by analysis of the 1H NMR spectrum which contained new 
resonances at δ 5.07 and 5.75 ppm attributed to the olefinic protons within 163. The absence 
of the proton resonance that could be assigned to the sulfonamide also confirmed isolation of 
the desired product. With the 2-bromoindole-alkene in hand, the indole nitrogen was Boc 
protected as previously (88% yield), and the fully functionalised precursor 164 was subject 
to Heck conditions to form the indoloazocine 165 (Table 2.4). 
Table 2.4 Optimisation of the intramolecular Heck reaction to form the indoloazocine. 
 
Entry Palladium Catalyst  Base Solvent Yield (%) 
1 Pd(PPh3)4 Na2CO3 PhMe NR 
2 Pd2(dba)3/P(tBu)3 Cy2NMe Dioxane NR 
3 Pd2(dba)3/P(tBu)3 Cy2NMe PhMe NR 
4 Pd2(dba)3/DavePhos Cy2NMe PhMe NR 
 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), palladium catalyst (10 mol%), and base (3.0 eq.) 
in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The Heck reaction between the indole-2-position and tethered alkene was first trialled using 
Pd(PPh3)4 and an inorganic base (Table 2.4, entry 1), as these were previously successful for 
Heck chemistry at the indole-2-position. However, once again, as in the case of the 
azepino[4,5-b]indole 7-membered ring system, formation of the 8-membered indoloazocine 
165 also failed. Screening of several additional catalytic systems did not furnish any of the 
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desired N-heterocycle. The failure of this approach is also proposed to be due to the 
palladium-alkene complex not forming as required to facilitate the migratory insertion step 
as discussed in the previous section.  
In summary, investigations were carried out into the development of a general palladium-
catalysed approach to functionalised 7- and 8-membered indole-based N-heterocycles using 
an intramolecular Heck cyclisation reaction at the indole-2-position. Attempts to synthesise 
more highly functionalised indole-based scaffolds than the current methods provide, using 
various alkene tethers off the N10-amine of tryptamine, proved unsuccessful. As such, this 
approach was no longer pursued for the synthesis of 7- and 8-membered N-heterocycles. 
2.5 Domino and Single Step Aza-Michael/Heck Reactions 
 
Attempts to improve on existing methodology and develop a new approach to functionalised 
azepino[4,5-b]indoles and indoloazocines to this point had proved unsuccessful. As such, 
our attention now turned to the synthesis of 6-membered indole-based N-heterocycles. 
The first approach proposed for the synthesis of C1-substituted tetrahydro-β-carbolines was 
through the use of a domino aza-Michael/Heck reaction sequence. This reaction sequence 
has been successfully employed by Hanson et al., for the formation of 5-membered 
heterocycles in the synthesis of benzofused sultams (Scheme 2.14). The domino reaction 
proceeds under mildly basic conditions for the aza-Michael addition of methyl propiolate, 
with the resultant alkene 167 undergoing cross-coupling with the aryl-iodide, facilitated by 
Jeffery conditions (phosphine-free, with the addition of TBACl) to afford the requisite 
heterocycle 168 in good yield over 2 steps.261 
 
Scheme 2.14 A domino aza-Michael/Heck reaction sequence for the synthesis of benzofused sultams 
 
In a similar fashion it was envisaged that a C1-substituted tetrahydro-β-carboline 172 could 
also be formed from reaction of an appropriately functionalised 2-bromotryptamine 169 and 
methyl propiolate 170 using a domino aza-Michael/Heck reaction (Scheme 2.15, a favoured 
6-exo-trig cyclisation). The formation of the 6-membered ring during this process should 
result, with migratory insertion of the indole-2-position occurring at the most electron-
deficient end of the alkene (the β-substituted product). 
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Scheme 2.15 The proposed domino aza-Michael/Heck reaction for the synthesis of β-carbolines 
 
In this system, an appropriate amine protecting group is required that allows aza-Michael 
addition to proceed rapidly, prior to Heck reaction. As the sulfonamide protecting groups 
used previously in this investigation (both tosyl and nosyl) are known to be readily 
functionalised under mildly basic conditions,242, 260, 265, 270-271 they were considered ideal for 
this domino process. 
The first domino reaction was attempted with the tosyl-2-bromotryptamine substrate 133. 
The reaction was carried out with potassium carbonate and DMF to promote initial 
intermolecular aza-Michael addition to the alkyne, with Pd(PPh3)4 present to facilitate the 
subsequent cross-coupling reaction (Scheme 2.16). 
 
Scheme 2.16 Attempted aza-Michael/Heck domino reaction to form the 6-membered N-heterocycle 
 
Following a simple work up, analysis of the crude reaction mixture by NMR spectroscopy 
revealed a complex mixture of products. As the Heck reaction of similar alkenes is known at 
the indole-2-position, it was presumed that aza-Michael addition did not take place readily 
enough to allow sufficient time for Heck reaction to occur. As such, the nosyl-2-
bromotryptamine substrate 141, was then subjected to this domino process (Table 2.5). 
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Table 2.5 Optimisation of the domino aza-Michael/Heck reaction 
 
Entry Pd Catalyst  Base Additive Solvent Yield (%) 
1 Pd(PPh3)4 K2CO3 TBACl PhMe Trace a 
2 Pd2(dba)3/P(tBu)3 Cy2NMe TBACl Dioxane Trace a 
3 Pd(PPh3)4 Cy2NMe TBACl DMF NR 
 
a Trace is <10% as determined by 1H NMR 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), palladium catalyst (10 mol%), and base (3.0 eq.) 
additive (1.0 eq) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The domino process was attempted using a range of palladium catalysts, bases, solvents and 
additives (Table 2.5). The phase transfer agent TBACl was also added in an attempt to 
improve both the solubility of the reagents and the intermediates in Heck catalytic cycle. 
Following analysis of the crude reaction mixture by NMR spectroscopy, trace amounts of 
the desired product 174 were identified in two of the domino reactions (Table 2.5 entries 1 
and 2), however, attempts to purify this compound by column chromatography proved 
unsuccessful.  
As this domino process did not provide high yields of the newly formed 6-membered N-
heterocycle, the domino approach was abandoned and the aza-Michael/Heck reaction 
sequence investigated in a single step fashion using the nosyl-2-bromotryptamine substrate 
141. Following literature procedures, the aza-Michael addition step with methyl propiolate 
170 was investigated first (Table 2.6).272-273 
Table 2.6 Optimisation of the aza-Michael addition 
 
Entry Additive Base Solvent Temperature (oC) Yield (%) 
1 PPh3 (10 mol%) - CH2Cl2 25 (16 h.) NR a 
2 - Cy2NMe MeCN 0 (2 h.) 86% 
 
a The major product isolated from this reaction was due to aza-Michael addition of the indole-nitrogen to methyl propiolate 
 
The first method attempted for the aza-Michael addition employed a triphenylphosphine 
catalyst in CH2Cl2 as reported to facilitate aza-Michael addition of sulfonamides to 
propiolates in high yields with only formation of the (E)-isomer (Table 2.6, entry 1).273 
Attempts to functionalise the sulfonamide with methyl propiolate using these conditions lead 
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exclusively to the aza-Michael addition product from the indole-nitrogen, indicating this 
PPh3-catalysed process is selective for aryl amines over alkyl amines. 
A second literature procedure reported the aza-Michael addition of sulfonamides to methyl 
propiolate promoted by N-methylmorpholine at 0 oC for two hours in acetonitrile.272 As N-
methylmorpholine was not readily available in our laboratory, a similarly hindered amine 
base N,N-dicyclohexylmethylamine (Cy2NMe) was trialled instead (Table 2.6, entry 2). 
Following a simple work up the desired product 175 was isolated in 86% yield (as a 9:1 
mixture of (E):(Z) isomers as determined by 1H NMR spectroscopy). The absence of a 
resonance that could be attributed to a sulfonamide proton was evident. Additionally, the 
presence of the olefinic proton resonances (δ 5.52 and 8.10 ppm) confirmed that aza-
Michael addition to the sulfonamide was successful. Following isolation of the desired 
alkenyl-ester 175, the indole nitrogen was protected as the N-Boc derivative 176 in a good 
yield of 66%. With the 2-bromotryptamine-alkenyl ester in hand, the intramolecular Heck 
reaction to form the new 6-membered N-heterocycle was trialled (Table 2.7). 
Table 2.7 Optimisation of the Heck reaction for formation of the 6-membered N-heterocycle 
 
Entry Palladium Catalyst a Base Solvent Temperature (oC) Yield (%) 
1 Pd(PPh3)4 K2CO3 PhMe 120 (16 h.) Trace b 
2 Pd2(dba)3/P(tBu)3 Cy2NMe PhMe 120 (16 h.) Trace b 
3 Pd2(dba)3/P(tBu)3 Cy2NMe Dioxane 120 (16 h.) NR 
 
a Palladium catalyst loading 10 mol%. Palladium and ligand used in a 1:1 ratio where applicable. 
b Trace is less than 10% as determined by 1H NMR. 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), palladium catalyst (10 mol%), and base (3.0 eq.) 
in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
Following a simple work-up, analysis of the crude reaction mixtures by NMR spectroscopy 
and mass spectrometry revealed the presence of the desired product. However, separation of 
this product was not achieved, due to a number of co-eluting by-products. Analysis of the 1H 
NMR spectrum indicated that both the (E) and (Z) geometrical isomers of the 6-membered 
heterocycle were present, as well as the 7-membered ring from Heck reaction at the α-end of 
the alkene. 
Despite the initial starting material containing a mixture of isomers, addition of the 
palladium complex to the double bond during the reaction process, followed by internal 
rotation and β-hydride elimination, should lead exclusively to the more thermodynamically 
stable product where the indole-2-position lies trans to the methyl ester (as depicted in, 
Table 2.7). However, as each of the steps in the Heck catalytic cycle are potentially 
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reversible,274 if dissociation of the olefin to the Pd(II)-hydride complex is relatively slow, 
addition of the Pd back into the double bond can occur, leading to the formation of double 
bond isomers.177-178 
The electronic properties of the alkene tether were also considered to hinder the progress of 
this reaction. Under classical conditions, migratory insertion occurs at the most electron-
deficient end of the terminal alkene. However, as the alkene was disubstituted (both 
sulfonamide and ester functionality), formation of the σ-alkyl palladium(II) complex may 
occur at either side of the alkene, leading to formation of the 6- or 7-membered heterocycle.  
2.6 Conclusion 
 
This chapter detailed the attempts to develop new methodology for the synthesis of 
functionalised indole-based N-heterocycles further exploiting the intramolecular Heck 
reaction at the indole-2-position. This investigation focussed on the initial tethering of an 
appropriate olefin from the N10-amine of tryptamine, followed by an intramolecular Heck 
reaction to form new 6,7 or 8-membered ring systems. 
Installation of the olefin tether (using substituted allyl bromides and propiolates) to the N10-
amine was completed in high yields, however the intramolecular Heck reaction at the indole-
2-position to form the new N-heterocycle was unsuccessful for each system, with a trace 
amount of the desired product detected, at best. 
 Chapter Three 
Indole-Based N-Heterocycles: 
Intermolecular Heck Reactions 
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3.1 Chapter Overview 
 
Following the unsuccessful investigations into the construction of indole-based N-
heterocycles using the intramolecular Heck reaction, attention turned to the intermolecular 
Heck cross-coupling reaction at the indole-2-position. The following chapter describes the 
development a domino Heck-aza-Michael reaction for the synthesis of C1-substituted 
tetrahydro-β-carbolines. Investigations into the optimisation and scope of the domino Heck-
aza-Michael process using a variety of commercially available acrylate starting materials are 
discussed in detail. 
3.2 Domino Heck-aza-Michael Reactions 
 
Due to their biological relevance (see Chapter One),6, 18-25 it is important that tetrahydro-β-
carbolines (THβCs) can be easily prepared and contain multiple functional groups for further 
synthetic manipulation. Traditionally, C1-substituted THβCs are accessed through the acid-
catalysed Pictet-Spengler reaction between tryptamine and an appropriate aldehyde.35-36 
Alternatively, a four step process involving a Bischler-Napieralski reaction to afford the 
dihydro-β-carboline, and subsequent reduction, is effective in producing specific THβCs.65 
Unfortunately, using these methods specific C1-substituted tetrahydro-β-carbolines are not 
always readily accessible due to the instability of a number of substituted aldehydes, and the 
requisite reaction conditions required to effect these types of cyclisations (for example the 
acid-catalyst in the case of the Pictet-Spengler reaction, and POCl3, as well as high 
temperatures in the Bischler-Napieralski reaction). 
One specific example of the limitations of these traditional methods is when access to 
acetate substituted β-carbolines is required. As synthesis of the requisite β-formyl ester 
reagent for the Pictet-Spengler reaction is difficult and the reagent is relatively unstable (it 
can only be handled at low temperatures, typically -78 oC),275 limits are placed on their use 
in certain types of syntheses. Efforts to overcome the limitations have focused on a modified 
Pictet-Spengler reaction to access the equivalent tetrahydro-β-carboline (179 and 181) using 
alkynoates22, 276 or perhydro-1,3-heterocycles25 (instead of the β-formyl ester - Scheme 3.1).  
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Scheme 3.1 Current syntheses of specific 1-substituted THβCs. 
 
Even with these modified approaches, access to a range of functionalities at the tetrahydro-
β-carboline C1-position is limited, as the range of commercially available alkynoates are few 
and the conditions required to prepare the perhydro-1,3-heterocycle starting materials are not 
trivial. As such, an alternative synthesis to this specific THβC scaffold was sought that 
would allow access to a series of β-carbolines, where the functionality introduced at the C1-
position could be readily varied. A domino Heck-aza-Michael reaction of tryptamine 169 
(Scheme 3.2), was foreseen as an efficient method for introducing molecular diversity at C1 
of the THβC scaffold 183.  
 
Scheme 3.2 The proposed domino Heck-aza-Michael process to access functionalised tetrahydro-β-
carbolines 
 
Previous research determined that a Heck reaction between 2-bromotryptamine and electron 
deficient terminal alkenes takes place using a catalytic amount of Pd(PPh3)4 in toluene in the 
presence of K2CO3. As the Heck reaction regenerates the olefin functionality following syn-
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elimination, and is reliably efficient with electron deficient terminal alkenes, the potential 
exists for a second nucleophilic addition reaction, in this case, a 1,4-Michael addition, 
depending on the nature of the tethered amine and if it reacts before or after the Heck 
reaction (an intra vs. intermolecular aza-Michael reaction). 
As both the Heck reaction148-149 and aza-Michael additions261, 277-278 are known to proceed 
under mildly basic conditions, a domino Heck-aza-Michael reaction to access the THβC 
scaffold appeared plausible. In this proposed reaction, a new C-C and C-N bond would be 
created in sequence, at the same carbon atom. Using cheap and readily available acrylates 
under mild conditions, an orthogonally protected THβC scaffold containing multiple sites 
for further functionalisation would be produced. Unlike propiolates, a wide range of suitable 
acrylates (such as butyl acrylate, acrolein, acrylonitrile and acrylic acid) are cheap and 
commercially available, allowing C1 functionality of the new N-heterocycle to be 
customised via appropriate alkene selection. 
Domino Heck-Michael methodology for the formation of heterocycles has not been widely 
reported.218, 279-281 Early examples of this methodology included the synthesis of 
pthalimidines281 and tetrahydronapthalenes.218 Unfortunately these methods suffered from 
low yields, long reaction times and limited substrate scope. More recently in 2005, the 
synthesis of isoindolinones 185 using a domino Heck-aza-Michael reaction was reported by 
the group of Wahab Khan (Scheme 3.3).280 Although this reaction sequence allowed for the 
synthesis of a series of isoindolinones where the amide substituent could be readily varied, 
attempts to use electron deficient alkenes other than acrylates (for example acrylonitrile and 
acrolein) failed.280 
 
Scheme 3.3 The synthesis of isoindolinones using a domino Heck-aza-Michael reaction 
 
A rhodium-catalysed olefination-aza-Michael process was recently reported for the synthesis 
of similar isoindolinone systems  (Scheme 3.4).282 Following C-H activation, the rhodium-
catalysed cross-coupling of the electron deficient terminal alkene occurs, installing the 
conjugated Michael acceptor. A 1,4-addition of the benzamide then takes place to form the 
new N-heterocycle 187 in good yields. This process proved successful when using acrylates, 
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ethyl vinyl ketone and acrylonitrile, allowing access to a greater range of C1-substituted 
isoindolinones than the aforementioned domino Heck-aza-Michael process.280 
 
Scheme 3.4 The rhodium-catalysed olefination/aza-Michael domino process for the synthesis of 
functionalised isoindolinones282 
 
The synthesis of tetrahydroisoquinolines employing a domino Heck-aza-Michael process 
was published in 2004 by Ferraccioli et al.283 The first step in this multicomponent reaction 
was the ortho-alkylation of an aryl iodide 188 with bromoethylcarbamate 189 to form the 
corresponding phenethylamine 190 (Scheme 3.5) through a C-H activation process 
involving norbornene. 
 
Scheme 3.5 A three-component process for the synthesis of tetrahydroisoquinolines employing a 
domino Heck-aza-Michael reaction 
 
The Heck reaction between the aryl-iodide 190 and tert-butylacrylate afforded the 
conjugated Michael acceptor 191. Finally, formation of the N-heterocycle through 1,4-
addition of the carbamate furnishes the new ring system 192 in an excellent yield of 68% for 
the three step process. Using the bromopropylcarbamate substrate, this reaction sequence 
was also successfully applied to the synthesis of C1-substituted tetrahydro-2-
benzazepines.283 
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A palladium(II) mediated domino C-H olefination/aza-Michael addition was developed for 
the synthesis of the tetrahydroisoquinoline ketone derivatives 194 and 195 (Scheme 3.6). 
This process tolerated the presence of electron-withdrawing substituents on the aromatic 
ring, however when methyl acrylate was employed, only the Heck adduct was isolated.284 
 
Scheme 3.6 A tandem C-H alkenylation/aza-Michael addition reaction sequence for the synthesis of 
the tetrahydroisoquinoline ketone 
 
A recent report by Hanson et al. detailed the application of a domino Heck-aza-Michael 
process to the synthesis of a series of unique benzofused sultams (Scheme 3.7).279 In this 
case, the initial cross-coupling took place under Jeffery’s phosphine-free conditions,285-287 
with the subsequent aza-Michael addition of the sulfonamide forming the new N-heterocycle 
197 in exceptional yields over a two-step process. 
 
Scheme 3.7 A domino Heck-aza-Michael reaction to access benzofused sultams279 
 
Once again, this methodology allowed variation of the sulfonamide substituent, and proved 
successful for several acrylates including methyl vinyl ketone and acrylic acid. However, 
attempts by this same group to expand the scope of this domino Heck-aza-Michael 
methodology to substrates where the sulfonyl group lay external to the new heterocycle 
failed (Scheme 3.8).279 
 
Scheme 3.8 Attempts by the group of Hanson to expand the scope of the domino Heck-aza-Michael 
reaction to include other heterocyclic systems proved unsuccessful279 
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Despite the ‘mixed success’, the development of a domino Heck-aza-Michael reaction for 
the synthesis of tetrahydro-β-carbolines using a range of electron deficient terminal alkenes 
was seen as an efficient way of introducing functionality during the formation of the 
tetrahydro-β-carboline scaffold. The following section describes our preliminary 
investigations into such a system using a single-step process and the eventual development 
of a domino Heck-aza-Michael reaction for the synthesis of C1-substituted tetrahydro-β-
carbolines. 
3.2.1 Initial Investigations 
 
When assessing this Heck-aza-Michael reaction sequence retrosynthetically (Figure 3.1), a 
number of parameters were identified that required consideration for the development of the 
domino process.  
 
Figure 3.1 Retrosynthetic analysis of the domino Heck-aza-Michael reaction for the synthesis of C1-
substituted THβCs 
 
The first consideration was the primary amine of tryptamine (2). As this amine is very 
nucleophilic, it required protection before bromination of the indole-2-position could be 
attempted. A suitable protecting group was therefore required to prevent this amine from 
interfering with bromination of the indole-2-postion. However, as this amine was also 
required to take part in the 1,4-addition process following the Heck reaction, the protecting 
group needed to allow the N10-amine to retain a certain degree of nucleophilicity. In 
addition, this nucleophilicity had to be suitably tuned so that aza-Michael addition of the 
alkene did not occur prior to Heck reaction. 
The second consideration for this domino process was the intermolecular Heck reaction. 
Suitable catalytic conditions were required that would facilitate a swift Heck reaction to 
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rapidly consume the alkene, negating the possibility of intermolecular aza-Michael addition. 
In addition to the palladium catalyst, a base and solvent also needed to be identified that 
were universal to rapid Heck reaction and aza-Michael addition. The Heck reaction between 
aryl-halides and electron-deficient terminal alkenes results in cross-coupling to the β-
position of the alkene.104 Aza-Michael addition at the same β-position of the attached alkene 
can result in only formation of the 6-membered N-heterocycle 202. 
The third consideration was the indole-nitrogen. Following halogenation of the indole-2-
position, the nucleophilicity of this amine is enhanced.288 Therefore, protection of this 
indole-nitrogen may be required so that either complexation with the palladium-catalyst 
and/or 1,4-addition to the conjugated alkene from this amine did not take place. Protection 
of this nitrogen with an electron withdrawing group would have the added advantage of 
increasing the electrophilicity at the indole-2-position, increasing the rate of oxidative 
addition of the palladium, and hence the rate of the early stages of the Heck reaction. It was 
also envisaged that through protection of the indole-nitrogen, electron density would be 
withdrawn from the β-carbon of the Michael acceptor installed during the first step of the 
domino process, promoting conjugate addition under mildly basic conditions.  
As the Heck reaction was known to occur at the indole-2-position using tert-
butoxycarbonyl-2-bromotryptamine  and the trifluoroacetamide-2-bromotryptamine 60, 
these systems were investigated first.2, 137 
Tert-butoxycarbonyl Protected Tryptamine 
 
The first system examined was tert-butoxycarbonyl (Boc) protected 2-bromotryptamine 206. 
The requisite functionalised tryptamine was prepared by Boc-protection at the N10-amine, 
followed by bromination of the indole-2-position using pyridinium tribromide.2 This 
substrate was then subjected to the previously identified conditions for the intermolecular 
Heck reaction with butyl acrylate (Scheme 3.9). 
  
Scheme 3.9 The Heck reaction between Boc-2-bromotryptamine and butyl acrylate 
 
This reaction lead exclusively to the formation of the Heck adduct 207, with none of the 
domino product 208 identified via initial analysis of the crude reaction mixture by 1H NMR 
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spectroscopy. Isolation of the Heck adduct (63% yield) was readily confirmed by the 
presence of the olefinic resonances in the 1H NMR spectrum at δ 6.20 and 7.74 ppm. 
Although the N10-amine was sufficiently protected to allow Heck reaction to occur, the 
carbamate was not nucleophilic enough to undergo aza-Michael addition. As such, the Boc 
protecting group was not considered ideal for the domino process. However, further 
investigations into this system were carried out in a single-step fashion following isolation 
of the Heck adduct (Scheme 2.35).  
Following deprotection of the Boc group from amine 207 (20% TFA in CH2Cl2), the indole 
ester 209 was subject to conditions known to promote Michael addition, 242, 277-278, 280-281, 289-
293 i.e. potassium carbonate in refluxing THF for 16 hours. After this time, the solvent was 
removed and analysis of the crude product was performed by 1H NMR spectroscopy. 
Surprisingly, under these reaction conditions none of the desired β-carboline 210 was 
observed. Using the recovered starting material, formation of the N-heterocycle was then 
attempted using a stronger base and more polar solvent combination. To this end, the 
tryptamine ester 209 was stirred with sodium methoxide in methanol at room temperature 
overnight (Scheme 3.10).294 
 
Scheme 3.10 Following Boc deprotection aza-Michael addition occurred to form the THβC.  
 
Following workup, analysis of the crude mixture by 1H NMR spectroscopy revealed that the 
aza-Michael addition to form the 6-membered N-heterocycle had been successful, though in 
a low yield. Formation of the tetrahydro-β-carboline 210 was readily observed in the 1H 
NMR spectrum by the new resonance at δ 4.48 ppm (triplet) assigned to the proton at the 
C1-position where the two new bonds were formed. In the presence of methanol, 
transesterification from the butyl ester to the methyl ester also occurred.  
Although several steps were required to prepare the C1-substituted THβC scaffold 210 using 
the N-Boc tryptamine 206, this positive result proved that a Heck-aza-Michael reaction 
sequence for the formation of a new 6-membered heterocycle using tryptamine was 
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plausible. As such, subsequent tuning of the nucleophilicity of the N10-amine was 
undertaken. 
Trifluoroacetate Protected Tryptamine 
 
The next N10-amine protecting group investigated for this domino process was 
trifluoroacetate. The pKa of the trifluoroacetamide (typically 17.2 in DMSO)295 is much less 
than that of the tert-butyl carbamate (typically 24.2 in DMSO)295, and from the previous 
domino Heck-aza-Michael processes investigated it is known that functionalised amides are 
able to undergo aza-Michael addition subsequent to the intermolecular Heck reaction to 
form the new N-heterocycle (see Schemes 3.3-3.4). As such, it was expected that the 
trifluoroacetate amine protecting group was well suited to the domino process.  
The preparation of the requisite starting material has previously been completed, thus the 
Heck precursor was readily available. The domino Heck-aza-Michael process with 
trifluoroacetate-2-bromotryptamine 60 and butyl acrylate (1.2 equivalents) was attempted 
using the previously identified conditions for the Heck reaction (Pd(PPh3)4, and K2CO3 in 
toluene at 120 oC) (Scheme 3.11). 
 
Scheme 3.11 Attempted domino Heck-aza-Michael process with the trifluoroacetate-2-
bromotryptamine lead only to formation of the Heck adduct 
 
Once again, formation of the desired THβC 212 was not observed, however the Heck adduct 
211 was isolated in an unoptimised yield of 58%. Intramolecular aza-Michael addition of the 
isolated conjugated ester to form the THβC 212 was then attempted by stirring the Heck 
adduct 211 with 1.5 equivalents of NaH in THF at room temperature overnight. 
Unfortunately, cyclisation to form the desired THβC scaffold did not occur. However, the 
mildly basic conditions often used to promote aza-Michael addition can also be employed in 
the cleavage of the trifluoroacetamide protecting group.264, 296-297 Therefore, a one-pot 
deprotection and subsequent aza-Michael addition was attempted using K2CO3 in 
methanol/H2O (Scheme 3.12). 
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Scheme 3.12 One-pot trifluoroacetate-deprotection and subsequent aza-Michael addition 
 
Following purification by column chromatography the desired C1-substituted THβC 213 
was isolated in a yield of 57%. The presence of the THβC scaffold was confirmed by a 
resonance at δ 5.06 ppm in the 1H NMR spectrum assigned to the C1-proton, the presence of 
a resonance at δ 3.75 ppm assigned to the methyl group as well as the downfield shift and 
the additional splitting patterns induced by the ring strain on the tryptamine ethylene CH2 
proton resonances following cyclisation. Transesterification from the butyl to methyl ester 
was again observed.  
When the trifluoroacetate protecting group was used, the desired tetrahydro-β-carboline 213 
was synthesised in fewer steps in comparison with the Boc-protecting group reaction 
sequence (Scheme 3.10). Unfortunately, both approaches required deprotection of the N10-
amine prior to aza-Michael addition and as such, a more efficient domino process was 
sought. The conditions necessary to promote aza-Michael addition to this point also required 
optimisation so that transesterification did not take place. 
Sulfonyl Protected Tryptamine 
 
Alkyl-sulfonamides have been shown to be readily functionalised using a range of methods 
including allylation, Mitsunobu reactions and more importantly aza-Michael addition.259-262 
Due to its ready availability, the p-toluenesulfonyl (tosyl) protecting group for the N10-amine 
of tryptamine was investigated first. 
To investigate the likelihood of a domino process occurring with the sulfonamide system, 2-
bromosulfonamide 133 and butyl acrylate (1.2 equivalents) were subjected to the conditions 
previously identified for Heck reaction at the indole-2-position (Scheme 3.13).  
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Scheme 3.13 The domino Heck-aza-Michael reaction with the tosyl-2-bromotryptamine 
 
The first reaction attempted with this tosyl-2-bromosulfonamide 133 afforded the domino 
Heck-aza-Michael adduct 214 as the major product in a yield of 44%. This domino product 
was readily detected in the 1H NMR spectrum with the presence of a new resonance at δ 
6.12 ppm assigned to the C1-proton (Figure 3.2). The absence of the resonance assigned to 
the sulfonamide, in addition to the resonances assigned to the butyl ester protons confirmed 
the identity of the desired tetrahydro-β-carboline 214 (Figure 3.2). 
 
Figure 3.2 The 1H NMR spectrum of the tetrahydro-β-carboline butyl ester 
 
This promising result confirmed that the use of a sulfonyl protecting group was suited for 
aza-Michael addition to occur, under mildly basic conditions and without the need for 
deprotection of the N10-amine. The isolation of the desired THβC also established that both 
the Heck and aza-Michael reactions would proceed under the same mildly basic conditions 
(Pd(PPh3)4, K2CO3, PhMe). With the knowledge that a domino Heck-aza-Michael process 
was possible, our attention now turned to increasing the yields of each step in the reaction 
sequence to afford the desired N-heterocycle in synthetically useful amounts. 
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As protection of the indole nitrogen was proceeding with less than satisfactory yields (< 
50%, Scheme 2.6) the domino Heck-aza-Michael reaction was attempted with the indole 
unprotected using the previously identified domino conditions (Scheme 3.14). 
 
Scheme 3.14 The domino Heck-aza-Michael reaction with the indole-nitrogen unprotected 
 
The domino process, this time with the indole nitrogen unprotected, once again proved 
successful affording the C1-substituted tetrahydro-β-carboline 215 as the major product in a 
modest yield of 30% (Scheme 3.14).  
To further improve the yield of this domino process, without protection of the indole-
nitrogen, three features of were identified for optimisation; namely, the Heck reaction 
conditions, the nucleophilicity of the sulfonamide, and the degree of electron deficiency of 
the Michael acceptor. 
3.2.2 Optimisation of the Intermolecular Heck Reaction 
 
The initial step of this domino process, the Heck reaction with N10-tosyl-2-bromotryptamine 
132 where the indole-nitrogen remained unfunctionalised, was optimised first. An ideal 
palladium catalyst was required that was active in the presence of a mild base and relatively 
non-polar solvent so that intermolecular aza-Michael addition did not occur prior to the 
Heck reaction. A range of catalysts, mild bases and solvents were trialled in the attempt to 
couple the tosyl-2-bromotryptamine 132 with butyl acrylate (Table 3.1). 
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Table 3.1 Optimisation of the catalytic conditions for the intermolecular Heck reaction at the indole-
2-position. 
 
Entry Palladium Catalyst (10 mol%) Base Solvent Yield (%) 
1 Pd(OAc)2/PPh3 a NEt3 Toluene 22 
2 Pd2(dba)3/P(tBu)3 a NEt3 Toluene 43 
3 Pd2(dba)3/P(tBu)3 a Cy2NMe Toluene 65 
4 Pd(PPh3)4 NEt3 Toluene 39 
5 Pd(PPh3)4 Na2CO3 Toluene 99 
6 Pd(PPh3)4 K2CO3 DMF Trace b 
7 Pd(PPh3)4 K2CO3 MeCN Trace b 
8 Pd(PPh3)4 K2CO3 Dioxane 32 
9 Pd(PPh3)4 CH3CO2Na Toluene 75 
 
a  Catalyst and ligand used in a 1:1 ratio. 
b Trace is < 10% as determined by 1H NMR. 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), acrylate (1.2 eq), palladium catalyst (10 mol%), 
and base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The results from this investigation were consistent with previous reports of the Heck 
reaction at the indole-2-position,137, 252 with Pd(PPh3)4 (10 mol%) generating the highest 
yields (entries 5 and 9, Table 3.1). An interesting phenomenon was observed when looking 
at the carbonate counter-ions; the use of Na2CO3 produced only the Heck adduct 216 (Table 
3.1, entry 5), whereas K2CO3 facilitated the formation of the desired tetrahydro-β-carboline 
215 (Scheme 3.14). Unfortunately, the highly reactive catalytic system pioneered by Fu, 
afforded only a moderate amount of the Heck product (Table 3.1, entry 3).170 As Pd(PPh3)4 
produced the highest yield of the Heck adduct 216, this catalyst was used for the remainder 
of this study.  
With the indole nitrogen unprotected, the Heck reaction was occurring in very high yields, 
ruling out this step as the cause for the overall low yield observed in the domino process 
(Scheme 3.14). From this study, it was identified that the aza-Michael addition step to form 
the new N-heterocycle must be limiting and as such was investigated next. 
3.2.3 Optimisation of aza-Michael addition 
 
Initial investigations involved identifying the conditions required to promote aza-Michael 
addition in a single-step fashion. The Heck adduct 216 was treated with a range of bases, 
solvents and additives known to promote aza-Michael addition at varying temperatures 
(Table 3.2).242, 277-278, 280-281, 289-293, 298 
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Table 3.2 Attempts to promote aza-Michael addition in a single step fashion 
 
Entry Base Solvent Additive Temperature (oC) % Conversion a 
1 K2CO3 Toluene - 110 0 
2 K2CO3 DMF - 110 0 
3 K2CO3 Methanol/H2O - 60 0 
4 K2CO3 H2O - 100 0 
5 KOtBu Toluene - 25 0 
6 DBU Toluene - 25 0 
7 NEt3 Toluene - 110 0 
8 NEt3 DMF - 120 0 
9 Na2CO3 DMF - 100 0 
10 - Toluene TBACl 100 0 
11 K2CO3 Toluene Pd(PPh3)4 100 0 
12 K2CO3 Toluene Pd(OAc)2 110 0 
 
a As determined by 1H NMR Spectroscopy. 
Reaction was performed in a sealed tube containing Heck adduct 216 (1.0 eq.), base (3.0 eq.)  and additive in solvent (4 mL). 
The reaction mixture was then heated to temperature for 16 h. 
 
Unfortunately, aza-Michael addition to form the desired THβC 215 was not achieved in a 
single step reaction sequence from the Heck adduct 216 (Table 3.2). Initial trials involved 
the use of potassium carbonate in various solvents at elevated temperatures (Table 3.2, 
entries 1-4). Analysis of each crude mixture through 1H NMR spectroscopic analysis 
revealed no trace of the desired aza-Michael product. A range of bases were then trialled in 
either toluene or DMF (Table 3.2, entries 5-9). The use of amine bases (DBU and NEt3) and 
a stronger tert-butoxide base (KOtBu) failed to promote aza-Michael, with not even a trace 
of the desired product detected in any of the 1H NMR spectra. The role of tetra-n-
butylammonium chloride (TBACl) was also investigated as it had been used as an additive 
in previous reports of domino Heck-aza-Michael reactions.279 The Heck adduct was stirred 
with TBACl in toluene at 100 oC (Table 3.2, entry 10), but as in previous cases, analysis by 
NMR spectroscopy revealed only starting material. 
As the aza-Michael addition was observed in the preliminary domino process previously 
investigated (Scheme 3.14), but not promoted in a single step fashion, it was considered that 
the palladium catalyst could be playing a role in facilitating aza-Michael addition (through 
an aminopalladation pathway either with Pd0 or PdII).299 This was investigated by stirring the 
Heck adduct with Pd(PPh3)4 or Pd(OAc)2 and K2CO3 in toluene again at elevated 
temperatures (Table 3.2, entries 11-12). Once more, these reactions did not produce the aza-
Michael product 215. 
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The failure of a range of bases, solvents and additives to induce aza-Michael addition to 
form the THβC scaffold in a single-step fashion was unexpected. In the continued attempts 
to increase the yields of this domino process above 30% (Scheme 3.14), without protection 
of the indole-nitrogen, attention turned to the optimisation of the base and solvent employed 
in the domino Heck-aza-Michael reaction. With the Heck reaction optimised, and single step 
aza-Michael cyclisation of the Heck adduct unsuccessful, optimisation of this domino 
process by its very nature would optimise the aza-Michael process. To investigate this 
parameter of the domino reaction, 2-bromoindole 132, in the presence of butyl acrylate and 
Pd(PPh3)4, was reacted with a range of bases, solvents and additives (Table 3.3). 
Table 3.3 Optimisation of the domino Heck-aza-Michael process 
 
Entry Base Solvent Additive Yield (%) 
1 K2CO3 Toluene - 30 
2 Na2CO3 Toluene - Trace 
3 Cs2CO3 Toluene - 0 
4 CH3CO2Na Toluene - 0 
5 NEt3 Toluene - Trace 
6 DBU Toluene - Trace 
7 KOtBu Toluene - 0 
8 K2CO3 MeCN - Trace 
9 K2CO3 DMF - Trace 
10 K2CO3 Dioxane - 0 
11 K2CO3 Toluene/DMF (9:1) - 0 
12 K2CO3 Toluene TBACl (1 eq.) Trace 
13 Na2CO3 Toluene TBACl (1 eq.) Trace 
14 Na2CO3 Toluene TBACl a (1 eq.) 17 
15 Na2CO3 Toluene TBACl a (3 eq.) Trace 
 
a Additive added after stirring for 12 hrs and stirring continued for 4 hrs. 
Trace is <10% as determined by 1H NMR 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), acrylate (1.2 eq), palladium catalyst (10 
mol%),additive (1.0 eq) and base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
Both inorganic and organic bases of varying strength were trialled in the domino process, 
using Pd(PPh3)4 and butyl acrylate in toluene (Table 3.3, entries 1-7). The best results 
obtained were using potassium carbonate (Table 3.3, entry 1), as in the initial combination 
used (Scheme 3.14). A variety of more polar solvents were used in an attempt to improve the 
domino process (Table 3.3, entries 8-11). Unfortunately these did not enhance formation of 
the β-carboline scaffold 215 using the domino process, and intermolecular aza-Michael 
reaction was observed at either the sulfonamide or indole-nitrogen. 
The use of the additive tetra-n-butylammonium chloride (TBACl) was also investigated. The 
TBACl can play several roles: as a source of Cl- improving the Heck catalytic cycle 
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(increasing the rate of reductive elimination following halogen exchange and catalyst 
regeneration),104 as a phase transfer agent improving solubility of the inorganic base and 
intermediates in the catalytic cycle, and also as a base promoting aza-Michael addition of the 
sulfonamide.279 This reaction was carried out where in one-pot, the TBACl was added after 
16 hours (to allow sufficient time for Heck reaction to take place), and stirring continued at 
120 oC for an additional 4 hours. Although this approach proved slightly more effective than 
when polar solvents or stronger bases were used, the desired THβC scaffold 215 was still 
only isolated in a low yield of 17% (Table 3.3, entry 14). 
Unfortunately, the use of varying combinations of bases, solvents and additives, failed to 
improve the overall yield of the domino process from the initial 30% (Scheme 3.14). 
Predominantly, the use of stronger bases and more polar solvents resulted in aza-Michael 
addition occurring at the sulfonamide or indole nitrogen before the Heck reaction had taken 
place at the indole-2-position. This often resulted in a complex mixture of inseparable 
compounds (including the desired compound 215 and several by-products - Scheme 3.15).  
 
Scheme 3.15 The desired product and by-products formed during the domino process 
 
To minimise side reactions, the domino Heck-aza-Michael process for this N-sulfonyl-2-
bromotryptamine system was confined to the use of mild bases and relatively non-polar 
solvents, allowing sufficient time for the Heck reaction to take place before aza-Michael 
addition occurred. 
To this point it had been identified that the p-tosyl-2-bromotryptamine substrate 132 
underwent a domino Heck-aza-Michael reaction to form the new N-heterocycle 215 in 30% 
yield (Scheme 3.14). However, it was considered that the nucleophilicity of this sulfonamide 
may not be ideal for this cyclisation step. In a further attempt to increase the yields of the 
domino process, with the indole-nitrogen remaining unprotected, alternative sulfonyl 
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protecting groups were also trialled (in order to tune the nucleophilicity of the sulfonamide 
proton at the N10-position of tryptamine). The 2-bromotryptamine substrates were prepared 
as before, by reacting tryptamine with the appropriate sulfonyl chloride, followed by 
bromination of the indole-2-position using pyridinium tribromide. These substrates were 
then subjected to the previously identified domino conditions (Table 3.4). 
Table 3.4 The role of the sulfonyl protecting group amine for the N10-amine 
 
 
Entry R Major Product Conversion (%) 
1 p-toluenesulfonyl Heck-aza-Michael (215) 30 
2 benzenesulfonyl Heck-aza-Michael (219) 36 
3 2-nitrobenzenesulfonyl Heck (220) 50 
 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), acrylate (1.2 eq), palladium catalyst (10 mol%), 
and base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
Alternative sulfonyl groups for the N10-amine of tryptamine did not significantly increase the 
yield of the domino Heck-aza-Michael process. The use of 2-nitrobenzenesulfonamide 
(Table 3.4, entry 3) increased the acidity of the sulfonamide proton (as observed by the 
downfield shift of the resonance attributed to the amide in the 1H NMR spectrum when 
compared to that of the p-tosyl sulfonamide), however it only resulted in formation of the 
Heck adduct 220 in 50% yield; no aza-Michael addition was observed. The benzenesulfonyl 
group (Table 3.4, entry 2) performed similarly to the p-toluenesulfonyl group (Table 3.4, 
entry 1) in terms of yields for the domino process; however, it proved more difficult to 
handle in terms of solubility and purification following bromination. For this reason, along 
with a useful spectroscopic ‘handle’ provided by the methyl group present, the p-
toluenesulfonyl group was used for the remainder of this investigation. 
Thus far, several approaches to increasing the yield of the domino Heck-aza-Michael 
process without protecting the indole-nitrogen had proved unsuccessful. With the N10-amine 
protecting group, palladium catalyst, base and solvent all investigated for the optimisation of 
the domino process, the only avenue left to pursue was the protection of the indole-nitrogen. 
3.2.4 The Role of the Indole Protecting Group 
 
The indole moiety is known to be extremely electron rich, and this has been exploited in a 
number of the cyclisations discussed in Chapter One. As such, it was considered that the 
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indole ring system may be donating electron density into the β-position of the Michael 
acceptor following Heck reaction, deactivating this carbon for the required 1,4-addition. It 
was therefore envisaged that aza-Michael addition could be improved by drawing electron 
density away from this Michael acceptor through protection of the indole nitrogen (Figure 
3.5). It was also proposed that protection of the indole-nitrogen would also increase the 
electrophilic nature of the initial aryl-halide, increasing the rate of the Heck reaction by 
speeding up the oxidative addition step.  
A molecular model of the Heck adduct 216 with the indole-nitrogen unprotected was 
compared to one in which the indole-nitrogen was protected with the tert-butoxycarbonyl 
(Boc) group 221 (Figure 3.3). It was clear, even at this simple level of theory,** that the 
electrophilic nature of the Michael acceptor could be enhanced through the protection of the 
indole-nitrogen (with a Boc group in this case). With the indole-nitrogen unprotected the 
Michael acceptor appears to be quite electron-rich (Figure 3.4 – red region). However, 
following protection, the β-position of the Michael acceptor becomes much more electron-
deficient (Figure 3.3 – blue region).  
 
 
Figure 3.3 The electrophilicity of the Michael acceptor could be increased through 
 protection of the indole nitrogen  
(Red = electron-rich, Blue = electron-deficient) 
 
 
                                                        
** Molecular modelling was performed using Discovery Studio 2.1 (Accelrys). It uses the DelPhi to 
calculate the spatial distribution of electrostatic potential and the potential on atoms. It uses a two-
dielectric implicit solvent model and a finite difference method to solve the Poisson-Boltzmann 
equation. The structure geometry was minimised with CHARMm. 159 iterations were carried out. 
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The first domino process trialled with the indole-protected domino precursor 133 produced 
the desired THβC 214 in an unoptimised yield of 44%, indicating that indole protection had 
the potential to significantly increase the yield for the domino process (Scheme 3.13). It was 
proposed that the greater the electron withdrawing effect of the indole protecting group 
would enhance 1,4-addition via electrophilic enhancement of the Michael acceptor. 
Unfortunately, initial attempts to protect the indole nitrogen by reaction with Boc2O had 
afforded the desired mono-protected compound 133 in a moderate yield of 48% (Scheme 
2.6). The installation of the indole protecting group in good yield was now crucial to the 
overall synthesis of the desired tetrahydro-β-carboline from tryptamine. To further 
investigate the protection of the indole-nitrogen of the tosyl-2-bromotryptamine, a number 
of parameters were evaluated including the protecting group itself, the base, solvent, and the 
reaction temperature (Table 3.5). 
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Table 3.5 Optimisation of the protection of tosyl-2-bromotryptamine indole-nitrogen  
 
Entry Reagent Base (Equivalents) Solvent Temp (oC) R Yield (%) 
1 Boc2O DMAP (0.05) THF 40 Boc (133) 48 
2 Boc2O DMAP (0.10) THF 60 Boc (133) 47 
3 Boc2O DMAP (0.10) Dioxane 100 Boc (133) 33 
4 Boc2O DMAP (0.10) MeCN 60 Boc (133) 50 
5 Boc2O DMAP (0.05) MeCN 60 Boc (133) 44 
6 Boc2O DMAP (0.05) DCM 30 Boc (133) 56 
7 Boc2O DMAP (0.05) DCM 40 Boc (133) 50 
8 Boc2O DMAP (0.10) DCM 40 Boc (133) 50 
9 Boc2O DMAP (0.10) DMF 50 Boc (133) 35 
10 Boc2O DMAP/NEt3 DCM 40 Boc (133) 45 
11 Boc2O - THF 60 Boc (133) 0 
12 Boc2O NEt3 Dioxane 25 Boc (133) 0 
13 Boc2O NaH (2) THF 25 Boc (133) 0 
14 Boc2O KOtBu (1.5) THF 25 Boc (133) 55 
15 Boc2O KOtBu (2) THF 25 Boc (133) 43 
16 Boc2O NaHCO3 (3) DMF 25 Boc (133) 0 
17 Boc2O Na2CO3 (3) DMF 25 Boc (133) 52 
18 Boc2O K2CO3 (3) DMF 40 Boc (133) 47 
19 Boc2O K2CO3 (3) MeCN 50 Boc (133) 36 
20 Bn Bromide NaH (2) DMF 25 Bn (222) 35 
21 Bn Bromide NaH (3) THF 25 Bn (222) 39 
22 Ns Chloride DMAP (0.2)/ DIPEA(1.5) DCM 25 Ns (223) 30 
23 Ts Chloride DMAP (0.2)/ DIPEA (1.2) DCM 25 Ts (224) 32 
24 Ac Chloride NaH (2) THF 25 Ac (225) Trace 
25 Bz Chloride Na2CO3 (2) DMF 25 Bz (226) 0 
26 Bz Chloride K2CO3 (2) DMF 25 Bz (226) 0 
27 Bz Chloride KOtBu (2) DMF 25 Bz (226) Trace 
28 Bz Chloride NaH (2) DMF 25 Bz (226) Trace 
29 Bz Chloride NaH (4) DMF 25 Bz (226) 0 
30 Bz Chloride DMAP (0.2)/ DIPEA (1.2) DCM 25 Bz (226) Trace 
31 Benzyl Chloroformate NaH (3.5) DMF 25 Cbz (227) Trace 
32 DNBz Chloride DMAP (0.2)/NEt3 CH2Cl2 25 
DNBz 
(228) 0 
 
Trace is <10% as determined by 1H NMR 
 
The tert-butoxycarbonyl (or Boc) protecting group was the most extensively investigated 
(Table 3.5, entries 1-19), with reactions carried out where the base, catalyst, solvent and 
reaction temperature were varied. The success of this reaction process was determined by 
analysis of the crude product by NMR spectroscopy with the 1H NMR spectrum revealing 
the absence of the resonance typically attributed to the indole-nitrogen proton (δ 8.30 ppm), 
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the downfield shift of the indole-C7-aromatic proton resonance and the addition of the 
proton resonances due to the new functional group installed. 
Despite the range of conditions trialled, the desired tert-butoxycarbonylindole 133 was at 
best isolated in yield of 56% (Table 3.5, entry 6). The major by-product from this reaction 
was the aforementioned di-Boc indole 134. The best yields for this reaction were obtained 
using a catalytic amount of DMAP (0.05 equivalents) in DCM at 30 oC. A range of 
alternative protecting groups were investigated through reaction with the appropriate 
sulfonyl chlorides, acid chlorides, alkyl halides and chloroformates. The indole nitrogen was 
successfully protected using the benzyl, 2-nitrobenzenesulfonyl and p-toluenesulfonyl 
protecting groups (Table 3.5, entries 20-23), in yields ranging from 32-39%.13, 300-302 Further 
attempts to protect the indole amine using acetyl chloride, benzoyl chloride, benzyl 
chloroformate and 3,5-dinitrobenzoyl chloride also failed, as these groups showed a much 
greater affinity for the sulfonamide over the indole nitrogen.13, 302-308 
During attempts to selectively protect the indole nitrogen using acetyl chloride (Table 3.5, 
entry 24), it was observed that stirring 2-bromoindole 132 with one equivalent of sodium 
hydride followed by the addition of acetyl chloride, lead almost exclusively to the acetylated 
sulfonamide 229 (Scheme 3.16). 
 
Scheme 3.16 Selective protection of the sulfonamide over the indole nitrogen 
 
The selective deprotection of an acetyl group in the presence of an indole-Boc group has 
been reported to occur in the presence of one equivalent of hydrazine monohydrate.309 In an 
attempt to further exploit this selectivity, an alternative approach to the protection of the 
indole nitrogen was investigated. This approach involved the initial protection of 
sulfonamide with the acetyl group, followed by functionalisation of the indole nitrogen as 
required, and subsequent removal of the acetyl protecting group.  
To carry out this investigation, acetyl protection of the p-toluenesulfonamide to afford the 
disubstituted-sulfonamide 229 was followed by reaction with Boc2O under standard 
conditions to afford the fully functionalised 2-bromoindole 230 in 66% yield over 2 steps 
(Scheme 3.17). The Boc-acetyl substrate was then treated with one equivalent of hydrazine-
monohydrate in THF at room temperature for 3 hours. 
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Scheme 3.17 An alternative approach for preparation of the domino precursor 
 
Following a simple work up, the desired tosyl-2-bromotryptamine 133 was isolated in 74% 
yield. Unfortunately, the overall yield for this three-step process (48%) was no better than 
that achieved using standard Boc protection conditions (56%, Table 3.5, entry 6). Although 
this approach showed promise for improving the overall yield of the synthesis of the domino 
precursor, it was no longer pursued at this point. The introduction of additional steps in the 
pathway to access the domino precursor was not ideal, as the purification and isolation of the 
corresponding intermediates negated the positive effects of the domino process. 
As some of the di-Boc-2-bromotryptamine 134 was on hand from previous investigations 
(Scheme 2.6), the selective deprotection of the Boc group from the sulfonamide using 
hydrazine monohydrate was also briefly investigated. The di-Boc-2-bromotryptamine 134 
was subjected to the same conditions that had previously proved successful in acetyl 
cleavage (Scheme 3.18). 
 
Scheme 3.18 Attempted selective deprotection of the Boc-sulfonamide 
 
Analysis of the crude reaction mixture by NMR spectroscopy revealed that both of the Boc 
groups remained intact. A further survey of the literature revealed that selective deprotection 
of secondary amine-Boc group in the presence of an indole-Boc group could be achieved 
using low concentrations of TFA in CH2Cl2.310-311 As such, the di-Boc-2-bromotryptamine 
134 was treated with increasing concentrations of TFA in CH2Cl2 and the reactions were 
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monitored over several hours. After 16 hours, the reaction mixtures were analysed by 1H 
NMR spectroscopy with the results shown in Table 3.6. 
Table 3.6 Attempted selective Boc deprotection of the N10-sulfonamide 
 
Entry % TFA in CH2Cl2 Major Product a 
1 1% 134, 133 (trace) 
2 2% 134: 133 (2:1) 
3 3% 134: 133: 132 (mixture) 
4 4% 132 
5 5% 132 
 
a As determined by 1H NMR spectroscopy 
 
The attempts to selectively cleave the Boc group from the sulfonamide failed, as at 
concentrations of TFA sufficient to cleave the sulfonamide Boc group (>2% TFA in 
CH2Cl2), the indole-Boc group was also removed. This approach to selective deprotection of 
the sulfonamide was therefore no longer pursued.  
An alternative strategy to selectively protecting the indole nitrogen was devised involving 
the use of copper salts. A report by Jisha et al. in 2009 detailed the selective recognition of 
Cu2+ ions using Dansyl-Naphthalimide dyads as fluorescent hosts (Figure 3.4).312 
 
Figure 3.4 Selective recognition of copper(II) ions by Dansyl-Naphthalimide dyads 
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A number of other reports also described the isolation of compounds with sulfonamide 
moieties complexed to copper(II) ions.313-317 Applying this theory to our system, selective 
protection of the indole nitrogen seemed plausible given that the copper(II) ion could 
exclusively complex to the sulfonamide. The copper could then be readily removed during 
workup, affording the desired 2-bromoindole domino precursor 133.††  
As Cu2+ can associate with four ligands, there were two different ways this complexation 
could occur, either in a 1:2 copper:sulfonamide complex 232 (Figure 3.5 A) or in a 1:1:1 
copper:sulfonamide:ligand complex 233 (Figure 3.5 B – Where the ligand is N,N-
tetramethylethylenediamine (TMEDA)). 
 
Figure 3.5 The possible 1:2 copper-sulfonamide complex (A) or the 1:1:1 TMEDA-copper-
sulfonamide complex (B) 
 
The reaction was carried out by stirring the copper(II) salt (and ligand where applicable) 
with the sulfonamide. After a few hours, allowing time for the copper-sulfonamide complex 
to form, a base was added to the reaction mixture followed by the Boc2O to protect the 
indole nitrogen. This reaction was carried out a number of times using a range of Cu2+ 
sources, bases, solvents, and also ligands (Table 3.7). 
 
 
 
 
                                                        
†† A similar strategy has been employed using boron and copper chelates for the selective protection 
of the side chain of specific amino acid residues.318-321 
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Table 3.7 Protection of the indole nitrogen using copper(II) to protect the sulfonamide. 
 
Entry Copper Source  Ligand Base (Eq.) Solvent Yield (%) 
1 CuBr2  - DMAP (0.2) THF 0 
2 CuBr2  - KOtBu (1.5) MeCN 0 
3 CuSO4 - K2CO3 (2.0) DMF Trace 
4 CuSO4 - K2CO3 (2.0) DMF 0 
5 CuSO4 TMEDA  KOtBu (1.0) THF 39 
6 CuSO4 TMEDA  KOtBu (2.0) THF 43 
7 CuSO4 TMEDA KOtBu (1.5) THF 58 
 
Trace is <10% as determined by 1H NMR  TMEDA = N,N-Tetramethylethylenediamine 
Reaction performed by stirring 2-bromotryptamine (1.0 eq), the copper salt (1.0 eq), and ligand (1.0 eq) for 1 h. The base was 
added, and after 30 mins, Boc2O (1.1 eq) was added and the reaction mixture stirred at room temperature for 16 h. 
 
Following a workup involving several washes of the reaction mixture with a saturated 
aqueous solution of ammonium chloride to remove the copper(II), analysis of the crude 
product was carried out by NMR spectroscopy and, where applicable, the mono-Boc indole 
133 was isolated by column chromatography. The use of copper salts to temporarily protect 
the sulfonamide allowed selective protection of the indole-nitrogen, strongly suggesting that 
the copper(II) was playing a role, but did not significantly increase the reaction yield. The 
highest yield obtained for the protection step using copper sulfate, TMEDA, and potassium 
tert-butoxide (Table 3.7, entry 7, 58%) was not considerably greater than the use of DMAP 
in DCM employed previously (Table 3.5, entry 6, 56%). Without confirming the formation 
of the copper:sulfonamide complex through a crystal structure or by other means, it was not 
possible to know if the copper (II) was in fact complexing to the sulfonamide moiety, and 
hence this approach to selectively protecting the indole nitrogen was no longer pursued. 
In conclusion, with the indole-2-position brominated, the p-toluenesulfonamide and the 
indole-nitrogen have very similar properties and selective functionalisation of the indole 
nitrogen could not be accomplished. Resigned to the fact that indole protection would 
proceed at less than 60% yield, attention now turned to optimising the domino Heck-aza-
Michael process. 
Optimisation of the Domino Heck-aza-Michael Reaction 
 
With the indole nitrogen protected, the increased electrophilicity (due to the EWG now 
present on the indole nitrogen) about the conjugated 1,4-system, following the Heck 
reaction, should allow for aza-Michael addition to proceed much more readily than in 
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previous cases. The domino process was optimised using varying combinations of bases and 
additives with Pd(PPh3)4 and butyl acrylate remaining consistent throughout (Table 3.8). 
Table 3.8 Optimisation of the domino Heck-aza-Michael process with the indole-nitrogen protected. 
 
Entry R Palladium Catalyst  Base  Solvent Additive Yield (%) 
1 Boc Pd(PPh3)4 K2CO3 Toluene - 83 
2 Boc Pd(PPh3)4 Na2CO3 Toluene - 27 
3 Boc Pd(PPh3)4 Na2CO3 Toluene TBACl a 86 
4 Boc Pd(PPh3)4 Na2CO3 Toluene NaH a 0 
5 Boc Pd(PPh3)4 Na2CO3 Toluene TBAF a 0 
6 Boc Pd(PPh3)4 K2CO3 Toluene b - 0 
7 Ts Pd(PPh3)4 K2CO3 Toluene - 54 
8 Ts Pd(PPh3)4 K2CO3 Toluene TBACl c 0 
9 Bn Pd(PPh3)4 K2CO3 Toluene - 54 
 
a Added after 16 hrs. Stirring continued at 120 oC for further 4 hrs. 
b Reaction performed in microwave at 120 oC, 200W for 90 mins. 
c Added to initial reaction mixture 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), acrylate (1.2 eq), palladium catalyst (10 mol%), 
additive (1.0 eq) and base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The use of the Boc-protected indole-nitrogen (Table 3.8, entry 1) dramatically improved the 
domino Heck-aza-Michael process and the THβC 214 was produced in an excellent yield of 
83% using Pd(PPh3)4 and K2CO3 in toluene. Given that these conditions had previously 
worked the best with the indole nitrogen unprotected (Scheme 3.14, 30%), this result 
confirmed the original hypothesis (Figure 3.4) that protection of the indole-nitrogen had the 
capacity to significantly enhance the yields of this domino process by increasing 
electrophilicity of the Michael acceptor following the initial Heck reaction. 
To confirm the role this indole-protecting group was playing, benzyl and tosyl protecting 
groups on the indole-nitrogen were also trialled. The domino process performed reasonably 
well for the benzyl and tosyl protected 2-bromoindoles (Table 3.8, entries 7 and 9, both 
54%). From these results it was apparent that a protecting group on the indole-nitrogen 
enhanced the intramolecular 1,4-conjugate addition required for the domino Heck-aza-
Michael process. 
It was also determined that a one-pot system (Table 3.8, entry 3) could be employed to 
access the THβC 214 using butyl acrylate. In this case, the use of Na2CO3 and Pd(PPh3)4, 
resulted in the Heck adduct undergoing partial aza-Michael addition (up to approximately 
30% - Table 3.8, entry 2). After this time, one equivalent of TBACl was added and further 
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reaction at 120 oC for four hours furnished the tetrahydro-β-carboline in an exceptional yield 
of 86% for the two-step process. 
In further reactions, tosyl-2-bromotryptamine 133 was subjected to the previously identified 
domino conditions, this time however instead of the conventional heating method, 
microwave irradiation was used (Table 3.8, entry 6). The use of microwave heating in 
organic synthesis has been shown to reduce reaction times, whilst increasing yields and 
product purity through the elimination of side reactions often observed when longer 
conventional heating methods are employed.322-324 Following a simple workup, analysis of 
the crude reaction mixture by NMR spectroscopy revealed that the major product from this 
microwave reaction was in fact the Heck adduct, with only a trace amount of the desired 
tetrahydro-β-carboline detected in the 1H NMR spectrum. 
3.2.5 The Scope of the Domino Heck-aza-Michael Methodology 
 
The domino Heck-aza-Michael reaction with butyl acrylate (Table 3.8) proved successful in 
producing the resultant butyl ester tetrahydro-β-carboline 214 in reproducible yields of 
≥80%. To establish the versatility of this methodology, the domino process was repeated 
using a range of suitable alkenes possessing a 1,4-conjugated Michael acceptor (Table 3.9).  
Table 3.9 The synthesis of C1-substituted THβCs using the domino Heck-aza-Michael process. 
 
Entry Alkene Product a Yield (%) 
1 butyl acrylate 
 
83 
2 methyl acrylate 
 
79 
3 2-hydroxyethylacrylate 
 
64 
4 acrolein 
 
64 
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Entry Alkene Product a Yield (%) 
5 acrylamide 
 
80 b 
6 acrylonitrile 
 
67 
7 3-buten-2-one 
 
78 
8 acrylic acid 
 
NR 
9 cinnamaldehyde 
 
NR 
10 2-cyclopenten-1-one 
 
NR 
11 butyl methacrylate 
 
NR 
 
a products isolated as a racemic mixture 
b Partial Boc deprotection during synthesis resulted in an inseparable mixture of the indole protected and indole unprotected 
THβC.  
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), alkene (1.2 eq), palladium catalyst (10 mol%), and 
base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The two-step domino process performed well for a number of terminal alkenes with isolated 
yields ranging from 64-83% (Table 3.9, entries 1-7). The methodology provided access to a 
series of structurally diverse THβC scaffolds, containing a variety of functional groups 
readily available for further functionalisation, including esters 214, 236, 237 (Table 3.9, 
entries 1-3), aldehyde 238 (Table 3.9, entry 4), nitrile 240 (Table 3.9, entry 6) amide 239 
(Table 3.9, entry 5), and ketone 241 (Table 3.9, entry 7). The unreactive nature of the acrylic 
acid (Table 3.9, entry 8) may be explained by the poor solubility of the corresponding 
carboxylate ion. The one-pot procedure (using Na2CO3 and TBACl) developed for the 
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synthesis of the butyl ester derivative (Table 3.9, entry 3) was also trialled using a range of 
alkenes, however; for reasons unknown the only other example that proved successful under 
these conditions was when methyl acrylate was used as a reagent (81%, Table 3.9, entry 2).  
The domino process was next trialled with a number of more highly substituted alkenes in 
an attempt to introduce a greater level of molecular complexity into the newly formed 
tetrahydro-β-carboline scaffold. Unfortunately, no trace of the desired domino product was 
observed following the attempts with cinnamaldehyde, cyclopenten-2-one and butyl 
methacrylate (Table 3.9, entries 9-11).  
The Heck reaction with these more highly substituted alkenes is not as trivial as the terminal 
alkenes successfully employed previously largely due to steric effects. During the Heck 
catalytic cycle, migratory insertion of the substituted alkene into the palladium-complex 
following oxidative addition does not occur as readily as for the unsubstituted terminal 
alkenes, and often requires the use of more active palladium-complexes (for example 
Pd2(dba)3/P(tBu)3).104, 325-328 An additional disadvantage of the Heck reaction using 
disubstituted alkenes is the lack of regioselectivity during the formation of the double bond 
product. This low regioselectivity can be explained by a lack of selectivity during the β-
hydride elimination step of the Heck catalytic cycle. Additionally, as each of the steps of this 
catalytic cycle are reversible, readdition of the H-Pd-Br complex to the double bond (before 
being reduced back to the Pd(0) species by the base present) can result in β-hydride 
elimination to different hydrogen atoms resulting in various double bond isomers being 
formed.104, 327 
In conclusion, a domino Heck-aza-Michael process, using a number of electron deficient 
alkenes for the synthesis of a series C1-substituted THβC scaffolds was successfully 
developed. It was determined that the p-toluenesulfonyl protecting group was ideal for the 
N10-amine, as it did not interfere with bromination of the indole-2-position, and also allowed 
Heck reaction to take place before aza-Michael addition occurred. It was also found that 
protection of the indole-nitrogen with a Boc group was essential for obtaining synthetically 
useful yields of the THβCs from this domino process. 
This new methodology complements existing methods for the synthesis of tetrahydro-β-
carbolines and provides an alternative strategy when access to specific C1-substituted 
THβCs are required.  
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3.3 Conclusion 
 
Investigation into the synthesis of indole-based N-heterocycles employing an intermolecular 
Heck reaction at the indole-2-position lead to the development of an extremely efficient 
domino Heck-aza-Michael reaction that furnished C1-substituted tetrahydro-β-carbolines in 
four steps from tryptamine. Through judicious choice of the N10-amine protecting group, it 
was possible to exclusively access either the Heck adduct or the domino THβC adduct.  
This novel methodology, employing cheap and readily available starting materials under 
mild conditions, afforded a series of functionalised N-heterocycles highly amenable to larger 
total syntheses. This domino Heck-aza-Michael reaction paves the way for the development 
and application of many more domino reactions of this type. The synthesis of a series of C1-
substituted tetrahydro-β-carbolines using a domino Heck-aza-Michael reaction resulted in a 
recent publication (see Appendix One).329 
Additional investigations into this domino Heck-aza-Michael reaction and attempts to apply 
this process to the synthesis of additional N-heterocycles are described in the following 
chapter (Chapter Four). 
 Chapter Four 
Extension of the Domino 
Heck-aza-Michael Methodology 
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4.1 Chapter Overview 
 
Following the successful development of a domino Heck-aza-Michael process for the 
synthesis of C1-substituted tetrahydro-β-carbolines (Chapter Three), several additional 
ortho-halogenated aryl amines were identified as suitable substrates for this domino process. 
This chapter details the development of domino Heck-aza-Michael methodology for the 
synthesis of a number of N-heterocyclic systems (Figure 4.1). Further extensions of this 
domino process, to include a multicomponent version and an asymmetric variant, are also 
discussed. 
4.2 Domino Heck-aza-Michael Reactions: A General Approach to N-Heterocycles 
 
In theory, any aryl- or vinyl-halide containing an ortho-tethered primary amine group is a 
potential substrate 246 for this domino reaction; provided the N-heterocyclic ring formed is 
of suitable size (i.e. cyclisation of a 2-bromoaniline to produce a 4-membered ring would not 
be favoured). As such, 2-bromobenzylamine, 2-bromophenethylamine, in addition to 
appropriately substituted benzofuran and benzothiophene scaffolds were identified as ideal 
candidates for further investigation into domino Heck-aza-Michael reactions (Figure 4.1). 
 
Figure 4.1 A generic domino process potentially applicable to the synthesis of other  
functionalised N-heterocycles 
 
The key considerations for this domino process, as determined during the THβC synthesis, 
were the need for a relatively fast Heck reaction, whilst controlling the nucleophilicity of the 
tethered amine through careful selection of the protecting group, base and solvent. Other 
factors that needed to be taken into account included the size of the N-heterocyclic ring 
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being formed, the differing reactivity of each aryl halide, and the variation of the 
nucleophilic nature of phenethylamines as compared to benzylamines. The following 
sections describe attempts to prepare a range of additional N-heterocyclic ring systems 
utilising the domino Heck-aza-Michael reaction. 
4.2.1 Domino Heck-aza-Michael Reactions: Benzofurans 
 
Following the success of the domino Heck-aza-Michael process for the synthesis of the 
indole-based N-heterocycles 249, it was envisaged that tetrahydro-β-carboline analogues 250 
where the indole nitrogen is replaced with an oxygen (i.e. benzofuran based N-heterocycles) 
could be prepared using a similar strategy. The requisite 2-bromobenzofuran domino 
precursor 254 containing both the tethered sulfonamide and the ortho-halogenated aromatic 
scaffold is shown below (Scheme 4.1) 
 
Scheme 4.1 The proposed synthesis of benzofuran based N-heterocycles using domino Heck-aza-
Michael reactions 
 
The benzofuran scaffold is found in a number of natural products (Frondosin B, Figure 
4.2),330-335 and medicinal chemistry targets, for example BNC105 which was developed as a 
vascular disruption agent for the treatment of tumours (Figure 4.2).336-341 Benzofuran 
analogues of the tetrahydro-β-carboline have also shown potential for the treatment of 
diabetes (Figure 4.2, benzofuran 257), asthma, hypertension (Figure 4.2, benzofuran 258), 
and depression.342-343  
 
Figure 4.2 The benzofuran scaffold is found in natural products and medicinal chemistry agents 
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Methodology to access the O-analogue of the tetrahydro-β-carbolines is limited, and these 
approaches are often based around the acid catalysed Pictet-Spengler reaction.41, 344-347 Both 
bromination348-351 and the Heck reaction at the benzofuran-2-position have been reported 
using a variety of conditions,9, 352-356 and as such, the domino Heck-aza-Michael reaction to 
form the O-analogue of tetrahydro-β-carbolines was envisaged as a plausible route to 
benzofuran-based N-heterocycles. The benzo[b]furan analogue of tryptamine is not readily 
available and had to be prepared. To achieved this, a multistep synthesis from 2-
hydroxyacetophenone was devised, as outlined below (Scheme 4.2). 
 
Scheme 4.2 The retrosynthesis of the tosyl-2-bromobenzofuran domino precursor 
 
The first stages of the conceived retrosynthetic analysis involved the synthesis of 3-
coumarone from 2-hydroxyacetophenone 260 through bromination of the methyl group, 
followed by cyclisation (facilitated by nucleophilic attack from the alcohol).357 A 
Wadsworth-Horner-Emmons reaction between benzofuranone and an appropriate 
phosphonate would allow installation of the ethyl acetate and double-bond migration should 
produce the benzo[b]furan scaffold 259 (Scheme 4.2).358 Reduction of the ester with LiAlH4 
to form the corresponding alcohol would follow. A similar approach taken to access the 
tryptamine analogue in the aforementioned O-analogue Pictet-Spengler publication41 
involved activation of the alcohol through reaction with trifluoromethansulfonic anhydride 
and subsequent nucleophilic displacement by 4-methoxypyridine to afford the substituted 
tryptamine O-analogue. As access to trifluoromethanesulfonic anhydride was limited, we 
proposed a modified approach to prepare the domino precursor, through reaction of the 
alcohol with p-toluenesulfonyl chloride followed by displacement with p-
toluenesulfonamide to afford the O-analogue of the tosyl-tryptamine. Subsequent 
bromination of the benzofuran-2-position would provide access to the requisite domino 
precursor 254. The following section describes the synthesis of the tosyl-2-bromobenzofuran 
254 following the approach outlined above. 
The first step in this reaction sequence involved the synthesis of 3-coumarone (261) from 2-
hydroxyacetophenone (259) (Scheme 4.3). The α-bromination of the methyl group was 
achieved using copper(II) bromide in a refluxing mixture of ethyl acetate and chloroform, 
according to literature protocol.359-360 The successful bromination of the methyl ketone was 
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readily determined by 1H NMR spectroscopy (and confirmed by mass spectrometry), with an 
upfield shift in the resonance attributed to the hydroxyl group of the phenol (-OH, δ 12.24 
ppm to δ 11.72 ppm) and the downfield shift of the resonances assigned to the methyl proton 
following bromination (-CH3 δ 2.61 ppm, to -CH2Br δ 4.44 ppm). 
 
Scheme 4.3 The synthesis of 3-coumarone from 2-hydroxyacetophenone 
 
Initial attempts to cyclise the bromoacetophenone were made using sodium acetate in 
DMF,361 with limited success. It was eventually determined that cyclisation in the presence 
of triethylamine and acetonitrile, afforded 3-coumarone (261) in 87% yield over 2 steps 
(Scheme 4.3). Cyclisation to form the new 5-membered ring was confirmed by NMR 
spectroscopy, with the absence of the resonance previously attributed to the alcohol proton, 
and the slight downfield shift of the CH2 proton resonance (-CH2Br δ 4.44 ppm, -CH2-O- δ 
4.61 ppm). 
The next step in the sequence was the Wadsworth-Horner-Emmons (W-H-E) reaction to 
install the ethyl acetate functionality, and subsequent internalisation of the double-bond to 
form the benzofuran aromatic ring (Scheme 4.4).  
 
Scheme 4.4 Synthesis of the benzofuran ester from 3-coumarone 
 
A similar reaction pathway employing a nitrile phosphorane followed by reduction of the 
nitrile to afford the primary amine, has been reported as an efficient means to access 
tryptamine analogues.357 However, as the approach using the ester phosphorane is more cost 
effective, it was used instead. The reaction was carried out by refluxing 3-coumarone (261) 
with 1.5 equivalents of (carbethoxymethylene)triphenylphosphorane in toluene for 16 hours 
(Scheme 4.4). Following purification by column chromatography the ethyl ester benzofuran 
259 was isolated in 77% yield. The identity of this product was confirmed by absence of the 
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CH2 resonance of the C2-position once the benzofuran ring system was formed (now an 
aromatic-CH, δ 7.63 ppm, singlet), and the addition of the ethyl acetate proton resonances. 
The ester 259 was reduced to the corresponding alcohol 262 with lithium aluminium hydride 
(Scheme 4.5, 90% yield). The alcohol product 262 was readily detected in the 1H NMR 
spectrum by the absence of the ethyl ester proton resonances and the addition of both a CH2 
and an OH proton resonance. Following this, the alcohol 262 was converted to the sulfonate 
through reaction with p-toluenesulfonyl chloride and the activated alcohol (-OTs) displaced 
by p-toluenesulfonamide under basic conditions to afford benzofuran 263 (in 56% yield over 
2 steps, Scheme 4.5). 362 The correct identity of the sulfonamide-benzofuran was confirmed 
by NMR spectroscopy and mass spectrometry. 
 
Scheme 4.5 Synthesis of the benzofuran-sulfonamide from the benzofuran-acetate 
 
With the tosyl benzofuran 263 in hand, attention turned to the C2-bromination of the 
benzo[b]furan to complete the synthesis of the domino precursor 254. A number of methods 
are reported,350, 352-353 however, in our hands, this bromination was accomplished (Scheme 
4.6) using N-bromosuccinimide in a solution of chloroform/acetonitrile (95% yield).350 The 
identity of this product was confirmed by NMR spectroscopy with the absence of the 
benzo[b]furan-C2-aromatic proton resonance and the upfield shift of the C2 resonance in the 
13C NMR spectrum following bromination (-CH δ 142.3 ppm to –CBr δ 128.1 ppm). 
 
Scheme 4.6 Bromination of the benzo[b]furan-2-position 
 
The synthesis of the novel domino precursor 254 was achieved in 32% yield over 7 steps 
from 2-hydroxyacetophenone (260), and it was subsequently used as a substrate in the 
domino Heck-aza-Michael reaction for the synthesis of functionalised benzofuran-based N-
heterocycles. A range of palladium catalysts, base, and solvents were trialled in the presence 
of butyl acrylate, and following a simple work up, the crude reaction mixture was analysed 
by 1H NMR to initially determine the success of the reaction (Table 4.1). 
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Table 4.1 Domino Heck-aza-Michael reaction to access benzofuran-based N-heterocycles 
 
Entry Palladium Catalyst a Base Solvent Major Product b 
1 Pd(PPh3)4 K2CO3 PhMe 266 c 
2 Pd(PPh3)4 Na2CO3 PhMe Heck adduct 265 (61%)d 
3 Pd(OAc)2/PPh3 K2CO3 PhMe 266 c 
4 Pd(OAc)2/SPhos K2CO3 PhMe 266 c 
5 Pd2(dba)3/P(tBu)3 K2CO3 PhMe 266 c 
6 Pd(OAc)2/SPhos NEt3 DMF 266 c 
7 Pd(OAc)2/XPhos NEt3 DMF 266 c 
8 Pd(PPh3)4 NEt3 DMF 266 c 
 
a Palladium catalyst loading 10 mol%, where applicable palladium:ligand ratio used was 1:1 
b As determined by 1H NMR spectroscopy 
c Trace of the domino adduct detected in the 1H NMR spectrum 
d Isolated yield 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), butyl acrylate (1.2 eq), palladium catalyst (10 
mol%), and base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The first attempt (Table 4.1, entry 1) was made using Pd(PPh3)4 and K2CO3 in toluene, the 
conditions previously found optimal for the domino reaction in the synthesis of tetrahydro-β-
carbolines (see Chapter Three). Unfortunately, the major product identified from this 
reaction mixture was produced from intermolecular Michael addition, followed by Heck 
reaction (as indicated by two sets of butyl ester proton resonances and the alkene proton 
resonances). The result from this first reaction indicated that under these catalytic 
conditions, intermolecular aza-Michael addition takes place prior to Heck reaction. In an 
attempt to slow down the rate of aza-Michael addition, Na2CO3 was used as base instead of 
K2CO3, in the presence of Pd(PPh3)4 (Table 4.1, entry 2). The major product from this 
attempt was the Heck adduct 265, isolated in a yield of 61%. This result confirms that 
Pd(PPh3)4 does in fact promote the Heck reaction at the benzofuran-2-position, however the 
conditions are not sufficient to promote intramolecular aza-Michael addition.  
Further attempts focussed on increasing the rate of the Heck reaction (instead of slowing 
down the aza-Michael addition) so that a rapid concentration of the Heck adduct was 
produced prior to aza-Michael addition. These reaction trials (Table 4.1, entries 3-5) were 
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carried out using more active palladium catalysts in the presence of K2CO3 and toluene. 
Once again, however, the major product identified from these reaction mixtures was due to 
intermolecular 1,4-addition taking place prior to the Heck reaction. The more active catalytic 
conditions did not significantly increase the rate of the Heck reaction at the benzofuran-2-
position. 
Three additional reactions were trialled using DMF and triethylamine (Table 4.1, entries 6-
8), with palladium catalysts known to promote Heck reaction at the benzofuran-2-
position.353 Again, the major product identified in each of these cases was the aza-
Michael/Heck adduct 266.  
The high yielding synthesis of benzo[b]furan-based N-heterocycles was not successfully 
completed. In a number of cases, a trace amount of the desired product 264 was detected in 
the 1H NMR spectrum of the crude reaction mixture. Although the Heck reaction was 
completed in some instances, it was not occurring at a fast enough rate, and as such, 
intermolecular aza-Michael addition was taking place prior to completion of the Heck 
reaction. Attempts to slow down the rate of aza-Michael addition (Table 4.1, entries 2, 6-8) 
by altering the base and solvent employed proved unsuccessful, as did attempts to increase 
the rate of the Heck reaction using palladium catalysts known to be more active (Table 4.1, 
entries 3-7).80, 148 
It was proposed that iodination of the benzo[b]furan-2-position would facilitate a faster 
Heck reaction, increasing the chance of the domino process taking place. The literature 
procedures currently available to iodinate this position require the use of reagents that do not 
tolerate a number of the functional groups present (for example the use of n-BuLi to 
facilitate lithium-iodine exchange is not ideal in the presence of an ester, alcohol or amide 
during preparation of the domino precursor), and an efficient route to iodinate this 
benzofuran-2-position was not identified. Also proposed was the use of an alternative N10-
amine protecting group which would not undergo aza-Michael addition as readily as the p-
toluenesulfonamide (for example the 2-nitrobenzenesulfonyl or trifluoroacetyl protecting 
groups), however this approach was not investigated. 
These results highlight how subtle electronic differences in the aryl-halide substrate can play 
a significant role in determining the success of N-heterocycle formation. For the tetrahydro-
β-carboline synthesis, the yield of the domino process was significantly enhanced through 
the protection of the indole-nitrogen, drawing electron density away from both the aryl-
halide and β-position of the Michael acceptor. Unfortunately, the electron rich benzofuran 
system cannot be optimised using a similar approach. Additional electron withdrawing 
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groups (e.g. NO2 or CF3) could be introduced onto the aromatic scaffold during 
benzo[b]furan synthesis to further modulate electronic properties. 
4.2.2 Domino Heck-aza-Michael Reactions: Benzothiophenes 
 
In a similar approach to that just discussed, it was envisaged that the synthesis of 
benzothiophene analogues of tetrahydro-β-carbolines 251 could be accessed using domino 
Heck-aza-Michael reactions (Scheme 4.7). 
 
Scheme 4.7 The proposed synthesis of benzothiophene-based N-heterocycles using  
domino Heck-aza-Michael reactions. 
 
The benzothiophene analogues of the tetrahydro-β-carbolines have been employed in a 
number of medicinal chemistry projects, for example as antagonists of the H3 histamine 
receptor (Figure 4.3, benzothiophene 268) as well as inhibitors of the histone deacetylase 
(HDAC) enzyme (Figure 4.3, benzothiophene 269).363-364 
 
Figure 4.3 Benzothiophene-based N-heterocycles have been developed to treat a range of medical 
conditions 
 
Although the benzothiophene scaffold has been extensively studied, methodology to access 
the S-analogue of the tetrahydro-β-carbolines is limited.344, 365-366 As both bromination349, 367-
369 and the Heck reaction at the benzothiophene-2-position have been reported,9, 370-371 a 
domino Heck-aza-Michael reaction was seen as an efficient way to access benzofuran-based 
N-heterocycles, introducing molecular diversity at the C1-position of the newly formed 
heterocyclic scaffold. 
Once again the benzothiophene analogue of tryptamine was not readily available, and a 
similar approach to that used for the synthesis of the benzofuran domino precursor 267 was 
employed from thiophenol following literature procedures.372-373 The first step in the 
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synthesis of the benzothiophene domino precursor involved the alkylation of thiophenol 
(270) with ethyl-4-chloroacetoacetate under basic conditions to afford the thiophenol 
ketoester 271 in 95% yield (Scheme 4.8).374  
 
Scheme 4.8 Synthesis of the benzothiophene ester from thiophenol 
 
Cyclodehydration of keto ester 271 in the presence of polyphosphoric acid and phosphorous 
pentoxide afforded the benzothiophene ester 272 (Scheme 4.8, 81% yield).373 The successful 
cyclisation to form the benzothiophene ring system was confirmed by NMR spectroscopy, 
with the absence of the corresponding CH2 resonance in the 1H NMR spectrum and the 
addition of the C2-aromatic proton resonance (δ 7.36 ppm).The ester 272 was then reduced 
to the corresponding alcohol 273 (Scheme 4.9) upon treatment with LiAlH4 (88%). This 
result was readily detected through analysis of the 1H NMR spectrum with the addition of 
the proton resonances assigned to the CH2 and OH functionality. In similar fashion to the 
reaction sequence used to prepare the benzo[b]furan domino precursor, the alcohol was 
reacted with p-toluenesulfonyl chloride to form an appropriate leaving group, which was 
then displaced by p-toluenesulfonamide in a moderate yield over 2 steps (33%) to afford 
benzothiophene 274 (Scheme 4.9). 
 
Scheme 4.9 Synthesis of the benzothiophene sulfonamide from the benzothiophene ester 
 
With the requisite sulfonamide 274 accessed in 5 steps from thiophenol (270), attention 
turned to the chemoselective bromination of the benzothiophene-2-position. Several 
attempts to brominate this benzothiophene-2-position were carried out using a number of the 
standard procedures employed previously during this research project (pyridinium 
tribromide, NBS, Br2).367 
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Scheme 4.10 Bromination of the benzothiophene-2-position 
 
Unfortunately, the highest yield obtained for the bromination of the benzothiophene-2-
position was 27%, using NBS in CH2Cl2 (Scheme 4.10). The major by-product identified 
from this reaction was once again the bromo-sulfonamide complex, discussed previously in 
Chapter 2 (section 2.3.1).266-267 Further attempts were made to brominate the 
benzothiophene-2-position earlier in the reaction sequence for the synthesis of the domino 
precursor (using the ester, alcohol and sulfonate derivatives). However, these bromination 
attempts also failed to produce the desired 2-bromobenzothiophene 275 and an efficient, 
high yielding synthesis of the domino precursor from thiophenol (270) was not identified.  
One attempt at the domino Heck-aza-Michael reaction for the synthesis of benzothiophene-
based N-heterocycles was carried out using the small amount of domino precursor 275 
isolated following the bromination using NBS (Scheme 4.10). The domino reaction was 
performed using the catalytic conditions that produced the highest yields of the analogous 
tetrahydro-β-carboline (Scheme 4.11). 
 
Scheme 4.11 Attempted domino Heck-aza-Michael reaction for the synthesis of benzothiophene-
based N-heterocycles 
 
Following analysis of the crude reaction mixture, the major products identified from this 
attempted domino reaction was the intermolecular aza-Michael product along with the 
desired product 276 (inseparable by column chromatography). The presence of the 
benzothiophene-based N-heterocycle (<30% conversion by 1H NMR spectroscopy) was 
identified by the C1-proton resonance at δ 5.69 ppm of the 1H NMR spectrum and also mass 
spectrometry ([M + H]+ 458.2). This result confirmed that the domino reaction was indeed a 
plausible pathway to access benzothiophene-based N-heterocycles 251, however a much 
more efficient synthesis of the domino precursor is required before further optimisation of 
this reaction sequence can be carried out. 
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4.2.3 Domino Heck-aza-Michael Reactions: Tetrahydroisoquinolines 
 
In our continuing attempts to expand the scope of this domino Heck-aza-Michael 
methodology, tetrahydroisoquinolines 252 were the next N-heterocyclic scaffold to be 
investigated. The tetrahydroisoquinoline scaffold forms the central part of a number of 
naturally occurring alkaloids,375-381 such as the antitumor natural product quinocarcinol 277 
(Figure 4.4).380-381 A number of potential pharmaceuticals have also been formed around this 
tetrahydroisoquinoline core.310, 382  
 
Figure 4.4 The tetrahydroisoquinoline antitumour natural product quinocarcinol 
 
Tetrahydroisoquinolines have traditionally been prepared from phenethylamine based 
starting materials using the Pictet-Spengler reaction,35-36, 383-385 or the related Bischler-
Napieralski methodology.66, 384, 386-389 Alternatives to these aforementioned reactions are 
limited; the Ferracioli synthesis involving a sequential palladium-catalysed ortho-
alkylation/vinylation combined with aza-Michael addition being one of the most recent 
(Scheme 3.5).283 
The synthesis of tetrahydroisoquinolines using a four step reaction sequence, through initial 
intermolecular Heck reaction, amine deprotection, aza-Michael addition and then amine 
reprotection has been reported.277  To complement and further investigate the scope of these 
existing methodologies, the development of the domino Heck-aza-Michael reaction, using 
cheap and readily available acrylates for the efficient synthesis of a series of substituted 
tetrahydroisoquinolines 252 was investigated. As in the case of the THβCs, the tosyl (Ts) 
protecting group was employed to control amine nucleophilicity through the sulfonamide.329 
The domino substrate 279 was prepared by reacting 2-bromophenethylamine (278) with 
tosyl chloride in 86% yield (Scheme 4.12).  
 
Scheme 4.12 The preparation of the tosyl-2-bromophenethylamine domino precursor 
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Using this substrate, a series of trial reactions were carried out to determine if a domino 
Heck-aza-Michael process was feasible. These reactions were initially performed by treating 
aryl bromide 279 with butyl acrylate, a palladium catalyst, base and solvent in a pressure 
vessel and heating to 120 oC for 16 hours. Identification of the products was initially 
performed by means of 1H NMR spectroscopy of the crude reaction mixture (Table 4.2). 
Table 4.2 Optimisation of the domino process for tetrahydroisoquinoline formation  
 
Entry Palladium Catalyst a Base Solvent Major Product b 
1 Pd(PPh3)4 K2CO3 PhMe 282 
2 Pd(PPh3)4 Na2CO3 PhMe Heck adduct 281 
3 Pd2(dba)3/P(tBu)3 Cy2NMe PhMe Heck adduct 281 
4 Pd(OAc)2/PPh3 NEt3 PhMe Heck adduct 281 
5 Pd(OAc)2/PPh3 NEt3 DMF Heck adduct 281 
6 Pd2(dba)3.CHCl3 K2CO3 PhMe NR 
7 Pd(OAc)2/PPh3 K2CO3 PhMe Domino adduct 280 (80) d 
8 Pd2(dba)3/DavePhos K2CO3 PhMe Domino adduct 280 (79) d 
9 Herrmann-Beller palladacycle e Cy2NMe DMF/MeCN/H2O 
c Domino adduct 280 (67) d 
 
a Catalyst loading was 10 mol%, where applicable palladium catalyst and ligand used in a 1:1 molar ratio  
b As determined by 1H NMR analysis of crude reaction mixture. For immediate identification of product ratios in the 1H NMR 
spectra δ: H = 5.46; H = 4.60, H = 7.84, H = 6.28 ppm  
c DMF/MeCN/H2O (5:5:1)  
d Isolated Yield  
e Herrmann-Beller catalyst is [trans-Di-(μ-acetato)-bis[ortho-(di-ortho-tolylphosphino)benzyl]-dipalladium (II)]. 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), butyl acrylate (1.2 eq), palladium catalyst (10 
mol%), and base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
In the first attempt, the optimum conditions identified for the synthesis of THβCs (Pd(PPh3)4, 
K2CO3, PhMe, Table 4.2, entry 1), produced adduct 282 exclusively i.e. aza-Michael 
reaction favoured but Heck reaction slow. A number of alternative Pd-catalysts (Pd(PPh3)4, 
Pd2(dba)3/P(tBu)3 and Pd(OAc)2/PPh3) combined with a range of bases (Table 4.2, entries 2-
4) were subsequently trialled, however, only the Heck adduct 281 was produced. It was 
apparent that whilst the Heck reaction was proceeding, the base used in each of these trials 
(Na2CO3, Cy2NMe and NEt3, Table 4.2, entries 2, 3 and 4 respectively) was not strong 
enough to induce either intra- or intermolecular aza-Michael addition as only traces of these 
products were observed. From the previous work into THECs it was known that the aza-
Michael process was sensitive to subtle variations in the base used, and again changing the 
base (e.g. from K2CO3 to Na2CO3 Table 4.2, entries 1 and 2) either facilitated or reduced the 
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likelihood of the aza-Michael reaction. Of the bases trialled to this point (Table 4.2, entries 
1-6), only K2CO3 was successful in promoting aza-Michael reaction (albeit 
intermolecularly). 
To ensure rapid formation of the Heck intermediate 281, the highly reactive and electron 
rich Pd2(dba)3/DavePhos catalyst system (developed by Buchwald and Hartwig) was used in 
combination with K2CO3.390 This catalytic system furnished the desired 
tetrahydroisoquinoline 280 in 80% yield (Entry 8, Table 4.2). Following further trials, other 
catalytic systems (Entries 7 and 9, Table 4.2) also resulted in clean conversion of the domino 
precursor to tetrahydroisoquinoline 280. These additional successes indicate that judicious 
choice of base and solvent is crucial for promoting the desired aza-Michael cyclisation 
(compare entries 4 and 8, Table 4.2). In assessing each of these procedures the 
Pd(OAc)2/PPh3 and K2CO3 in toluene catalytic system was deemed the most attractive due 
to its availability and relatively low cost.391  
The identity of the tetrahydroisoquinoline butyl ester 280 was confirmed using mass 
spectrometry and NMR spectroscopy. The characteristic peaks in the 1H NMR spectrum 
(Figure 4.5) included the C1-proton resonance (δ 5.46 ppm) and the resonances assigned to 
the butyl ester. 
 
Figure 4.5 The 1H NMR spectrum of the tetrahydroisoquinoline n-butyl ester 
 
A range of acrylates were then subjected to this domino process to afford a series of C1-
substituted tetrahydroisoquinolines (Table 4.3). 
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Table 4.3 The formation of C1-substituted tetrahydroisoquinolines 
 
Entry Alkene R Yield (%) a 
1  butyl acrylate  CO2nBu (280) 80  
2  methyl acrylate  CO2Me (283) 83  
3  2-hydroxyethyl acrylate  CO2(CH2)2OH (284) 76  
4  acrylonitrile  CN (285) 82  
5  3-buten-2-one  COCH3 (286) 79  
6  acrylamide  CONH2 (287) Trace b 
7  acrolein  CHO (288) NR c 
8  acrylic acid  CO2H (289) NR c 
 
a Products isolated as a racemic mixture 
b Trace = less than 10% as determined by 1H NMR  
c NR = No reaction 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), alkene (1.2 eq), palladium catalyst (10 mol%), and 
base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The resulting products contained a range of functionalities including esters 280, 283 and 
284, ketone 286 and nitrile 285 (Table 4.3, Entries 1-5). Unfortunately, reactions attempted 
with both acrolein and acrylic acid did not furnish the desired tetrahydroisoquinolines, even 
though the reaction with acrolein had been successfully employed in the THβC domino 
Heck-aza-Michael reaction.329 
4.2.4 Domino Heck-aza-Michael Reactions: Isoindolines 
 
Domino Heck-aza-Michael processes had now been developed for the synthesis of six 
membered N-heterocyclic scaffolds in the form of C1-substituted tetrahydro-β-carbolines 
249 and tetrahydroisoquinolines 252. The next heterocyclic scaffold to be investigated was 
the isoindolines 253, to ascertain if the scope of this methodology could be extended to 
include five membered N-heterocycles. 
Although not as prevalent in natural products, the isoindoline scaffold has been employed in 
a number of potential pharmaceutical agents, including isoindoline 290 (Figure 4.6), 
synthesised as a ligand for the melanocortin subtype-4 receptor (MC4R).293, 310, 382, 392-393 
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Figure 4.6 An isoindoline synthesised as a ligand for the MC4 receptor 
 
Isoindolines substituted at the C1-position have been accessed using a radical cyclisation of 
N-benzylenaminone esters.394 More recently, 1,3-disubstituted isoindolines have been 
synthesised using Brønsted acid catalysed 1,2-addition followed by aza-Michael addition.395 
The synthesis of isoindolines using a four step reaction sequence, through initial Heck 
reaction, amine deprotection, aza-Michael addition and then amine reprotection has also 
been reported.293  To complement these existing methodologies, the development of a 
domino Heck-aza-Michael reaction, using cheap and readily available acrylates, for the 
efficient synthesis of a series of substituted isoindolines was investigated. An appropriately 
substituted benzylamine 199 was prepared in 99% yield as a precursor to C1-substituted 
isoindolines (Scheme 4.13).  
 
Scheme 4.13 The preparation of the tosyl-2-bromobenzylamine domino precursor 
 
As with both the THβCs and the tetrahydroisoquinolines, a range of conditions were 
evaluated in the preparation of the desired isoindoline (Table 3.4). The bromosulfonamide 
199, butyl acrylate, a palladium catalyst, base, and solvent were combined in a pressure 
vessel and heated to 120 oC for 16 hours. Following a simple work up, the major product 
was identified by means of 1H NMR spectroscopy (Table 4.4).  
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Table 4.4 Optimisation of the domino process for isoindoline formation  
 
Entry Palladium Catalyst a Base Solvent Major Product b 
1  Pd(PPh3)4  K2CO3  PhMe  Mixture  
2  Pd(PPh3)4 Na2CO3  PhMe  Mixture  
3  Pd(PPh3)4 Cs2CO3  PhMe  NR c 
4  Pd(PPh3)4 K2CO3 DMF  NR c 
5  Pd2(dba)3/P(tBu)3  Cy2NMe  PhMe  293/292 
6  Pd2(dba)3.CHCl3  NEt3  DMF  NR c 
7  Pd(OAc)2/PPh3  K2CO3  PhMe  NR c 
8  Pd(OAc)2/PPh3  NEt3  PhMe  Isoindoline 292 (74) d 
9  Pd(OAc)2/PPh3  NEt3  DMF  Isoindoline 292 (77) d 
10  Pd2(dba)3/DavePhos  Cy2NMe  DMF  Isoindoline 292 (79) d 
11  Pd2(dba)3/XPhos  Cy2NMe  DMF  Isoindoline 292 (62) d 
12  Pd2(dba)3/SPhos  Cy2NMe DMF  Isoindoline 292 (48) d 
13  Herrmann-Beller palladacycle e Cy2NMe  DMF:MeCN:H2O 
f Isoindoline 292 (54) d 
 
a Palladium and ligand used in a 1:1 molar ratio  
b As determined by 1H NMR analysis of crude reaction mixture. For immediate identification of product ratios in the 1H NMR 
spectra δ: H = 5.28; H = 5.10, H = 7.62, H = 6.38 ppm  
c NR = No reaction  
d Isolated yield   
e Herrmann-Beller catalyst is [trans-Di-(μ-acetato)-bis[ortho-(di-ortho-tolylphosphino)benzyl]-dipalladium (II)]. 
f DMF/MeCN/H2O (5:5:1)  
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), butyl acrylate (1.2 eq), palladium catalyst (10 
mol%), and base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The first trial with tetrakis(triphenylphosphine) palladium (Pd(PPh3)4) afforded mixtures of 
the three predicted products (entry 1, Table 4.4). Repeating the reaction with Pd(PPh3)4 but 
changing the base and solvent (entries 2-4, Table 4.4) also proved unsuccessful. The highly 
active catalytic system of Pd2(dba)3/P(tBu)3 minimised the formation of the aza-Michael-
Heck product 294, however, complete conversion of the Heck adduct 293 to the desired 
isoindoline 292 did not occur (entry 5, Table 4.4).170 A high yield of the desired isoindoline 
292 was observed when Pd(OAc)2/PPh3 and triethylamine were used in either toluene or 
DMF (entries 8 and 9, Table 4.4). The use of other highly active Pd-catalysts also proved 
successful when combined with an amine base in DMF. Again, it was apparent that a 
suitable base (in this case an organic base rather than an inorganic base) was crucial to 
effecting the desired cyclisation following Heck reaction. 
Even though the Pd2dba3/DavePhos catalytic system (entry 10, Table 4.4) provided the 
isoindoline 292 in the highest yield, it was not significantly greater than that obtained when 
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the Pd(OAc)2/PPh3 system was used (entry 9, Table 4.4). This latter system was 
subsequently used for the remainder of this investigation due to its low cost and availability.  
The identity of the isoindoline butyl ester 292 was confirmed using mass spectrometry and 
NMR spectroscopy. The characteristic peaks in the 1H NMR spectrum (Figure 4.7) included 
the C1-proton resonance (δ 5.27 ppm), the downfield shift and additional splitting patterns 
of the C3-proton resonances (δ 4.73 and 4.50 ppm), and the resonances assigned to the butyl 
ester protons. 
 
Figure 4.7 The 1H NMR spectrum of the isoindoline n-butyl ester 
 
This optimised domino process was then used with a range of acrylates to afford a series of 
C1-substituted isoindolines (Table 4.5).  
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Table 4.5 The formation of C1-substituted isoindolines 
 
Entry Alkene R Yield (%) a 
1 butyl acrylate CO2nBu (292) 77 
2 methyl acrylate CO2Me (295) Unknown b 
3 2-hydroxyethyl acrylate CO2(CH2)2OH (296) 84 
4 acrylamide CONH2 (297) 71 
5 acrylonitrile CN (298) 68 
6 acrylic acid CO2H (299) 85 
7 3-buten-2-one COCH3 (300) 86 
8 acrolein CHO (301) NR c 
 
a products isolated as a racemic mixture 
b This domino process also performed well using methyl acrylate, however the isoindoline product could not be separated from 
the remaining starting material by column chromatography. 
c NR = No reaction 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), alkene (1.2 eq), palladium catalyst (10 mol%), and 
base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The series of products synthesised contain a range of functionalities including a carboxylic 
acid 299, esters 292 and 296, ketone 300, amide 297 and nitrile 298. This time the use of 
acrylic acid resulted in the formation of the isoindoline acetic acid 299, presumably due to 
the increased solubility of the resulting carboxylate ion in the triethylamine/DMF solvent 
system. 
To further illustrate the power of this domino Heck-aza-Michael methodology, a comparison 
for the synthesis of the carboxylic acid isoindoline follows (Scheme 4.14). In a recent 
publication the preparation of the Boc-isoindoline acid 302 was completed in 6 steps from 2-
bromobenzylamine hydrochloride 291 as part of a larger synthesis of dipeptides as ligands 
for the melanocortin subtype-4 receptor (Figure 4.5).293 
 
Scheme 4.14 Comparison of methodology to access the isoindoline carboxylic acid derivative 
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Employing the newly developed domino Heck-aza-Michael methodology it was possible to 
access a similar tosyl-isoindoline acid 299 from 2-bromobenzylamine hydrochloride 291 in 
84% yield over 2 steps. This allows for a much more efficient synthesis of substituted N-
heterocycles without the need for lengthy and costly purification of intermediates, saving 
time, money and the subsequent generation of waste. 
4.2.5 Summary 
 
Following the successful development of a domino Heck-aza-Michael reaction for the 
synthesis of the tetrahydro-β-carbolines,329 the scope of this new methodology was expanded 
to include the tetrahydroisoquinoline and isoindoline N-heterocyclic scaffolds. 
Unfortunately, attempts to also apply this methodology to the synthesis of both the O- and S-
analogues of the tetrahydro-β-carbolines were not high yielding and more optimisation is 
required. For the benzofuran derivatives, the conditions trialled were not sufficient in 
producing the Heck adduct prior to intermolecular aza-Michael addition. While the domino 
reaction with the benzothiophene derivative appeared promising, an efficient synthesis of the 
domino precursor was not achieved. 
The key considerations of the domino Heck-aza-Michael methodology were identified as (i) 
the relatively quick formation of the Heck adduct (controlled through appropriate selection 
of Pd catalyst) and (ii) the nucleophilicity of the tethered amine (mediated through careful 
selection of the protecting group, base and solvent).   
In determining the appropriate conditions for the Heck reaction, a palladium catalyst was 
required that facilitated a fast, high-yielding reaction between the aryl halide and the alkene, 
in the presence of a mild base and relatively non-polar solvent. It is important the acrylate is 
consumed rapidly by the Heck process so that intermolecular aza-Michael reaction does not 
take place. For the Heck reaction at the indole-2-position, Pd(PPh3)4 afforded the highest 
yields. In the case of the benzyl- and phenethylamine aryl halides, the use of Pd(OAc)2/PPh3 
proved optimal. 
Most importantly, an appropriate base is required; one that is able to sufficiently promote 
aza-Michael reaction, but not to the extent that it occurs before a high concentration of the 
Heck adduct is realised. Indeed, the outcome of reactions that were repeated, varying only 
the base used, ranged from rapid intermolecular Michael reaction prior to the Heck reaction 
through to the desired domino Heck-aza-Michael process. For the synthesis of both the 
THβCs and tetrahydroisoquinolines, K2CO3 was required for a rapid cyclisation, however, in 
the case of the isoindolines, the new N-heterocycle formed in the presence of a milder amine 
base (either NEt3 or Cy2NMe). 
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From the outset it was envisaged that reaction progress would be limited by (i) size of the N-
heterocycle being formed and (ii) steric properties associated with the Heck reaction and 
subsequent Michael addition. If the steric bulk of a proximal sulfonamide (benzylamine vs. 
phenethylamine) was a critical factor, initial Heck reaction would be faster for formation of 
THβCs 249 and tetrahydroisoquinolines 252 over isoindoline 253. Furthermore, for the 5 
membered isoindoline series, a strained transition state in the Michael addition step may also 
hinder the progress of the domino reaction. Nevertheless, as little difference in the overall 
yields were observed for each of the domino processes studied herein, the role of ring size 
and steric properties appears to be minor.  
In summary, a general approach to N-heterocycles using  high yielding domino Heck-aza-
Michael reactions to access C1-substituted tetrahydro-β-carbolines, tetrahydroisoquinolines 
and isoindolines have been successfully developed. These reactions employed mild 
conditions, readily available palladium catalysts and acrylates. The mild conditions 
described suggest this domino process may be applied to more complex substrates and 
possibly in key transformations in total syntheses. As indicated, the use of other highly 
active palladium catalysts may benefit the scope of this process and its functional group 
tolerance. 
The expansion of the scope of these domino Heck-aza-Michael reactions to include 
tetrahydroisoquinolines and isoindolines resulted in a recent publication (see Appendix 
One).396 
4.3 Multicomponent Domino Heck-aza-Michael Reactions 
 
Of the domino Heck-aza-Michael reactions reported to date, including those investigated 
during this work, the alkene employed has been restricted to commercially available electron 
deficient terminal alkenes.279-281, 283, 329 Therefore, it was envisaged that the scope of this 
domino Heck-aza-Michael methodology could be greatly improved if much more highly 
functionalised terminal alkenes were amenable to this process. Additionally, if the 
functionalised alkene was able to be synthesised in the same reaction from suitable starting 
materials prior to the domino reaction (for example acryloyl chloride (304) and an amine 
305 – Scheme 4.15), a one-pot, three-component approach for the synthesis of more highly 
functionalised heterocycles 306 would then be possible. 
  Chapter 4 
- 106 - 
 
Scheme 4.15 A three-component domino reaction approach to various N-heterocyclic amides 
 
One pot, multicomponent processes, like domino reactions, are an efficient means of 
completing multiple synthetic steps without the need for purification of intermediates. 
Three-component domino Heck-aza-Michael reactions to date have involved variations in 
the domino precursor, that is, the first step of the multicomponent reaction was the 
preparation of the aryl-halide (Scheme 4.16).279, 283, 397 In the reaction sequence developed by 
the group of Hanson, both alkyl and aryl amines that were employed in the initial coupling 
step with the sulfonyl chloride 307 proved successful. 
 
Scheme 4.16 A multicomponent domino Heck-aza-Michael reaction sequence where the aryl-halide 
is readily varied. 
 
However, the electron deficient terminal alkene employed in these three-component domino 
reactions was limited to commercially available ester, carboxylic acid and ketone 
derivatives. The in situ generation of the functionalised alkene employed in domino Heck-
aza-Michael processes has not been successfully developed.279 
It was envisaged that by coupling acryloyl chloride (304) with a primary or secondary 
amine, a vast array of acrylamides would be produced, suitable for the domino Heck-aza-
Michael reaction. If indeed acrylamide formation occurred under the same mildly basic 
conditions required for both the Heck and aza-Michael steps in this domino process, a 
sequential one-pot three-component domino Heck-aza-Michael reaction for the synthesis of 
amide substituted N-heterocycles was plausible. 
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Tetrahydro-β-carbolines 
 
The first system investigated for the multicomponent domino Heck-aza-Michael process was 
the tetrahydro-β-carbolines. The requisite domino precursor was prepared in three steps from 
tryptamine as previously described (see Chapter Three). Initial investigations employed 
acryloyl chloride and benzylamine to afford the N-benzylacrylamide needed for the Heck 
reaction. The first reaction was carried out by adding acryloyl chloride (304) to a solution 
containing benzylamine (308) and K2CO3 in toluene. After stirring for one hour to allow 
sufficient time for acrylamide formation, the tosyl-2-bromotryptamine 133 and Pd(PPh3)4 
were added and the reaction mixture was heated to 120 oC for 16 hours (Scheme 4.17). 
 
Scheme 4.17 Attempted multicomponent synthesis of tetrahydro-β-carbolines 
 
Following a simple work up, analysis of the crude reaction mixture revealed that the major 
product from this reaction was in fact the Heck adduct 309 (isolated in 80% yield). A trace 
amount of the desired domino adduct 310 was observed in the 1H NMR spectrum, but could 
not be separated from the other compounds present in the reaction mixture. As the Heck 
reaction was taking place in a good yield, it was known that acrylamide formation was 
successful. However, acrylamides are not as electron-deficient as acrylates, and following 
Heck reaction, aza-Michael addition did not occur. It was proposed that the electronic 
properties of the indole system were too unpredictable and as such, a simpler scaffold was 
investigated. 
Isoindolines 
 
The next system to be investigated in regards to the multicomponent approach to 
functionalised N-heterocycles was the isoindolines. In a similar fashion to that previously 
described for the tetrahydro-β-carbolines, the initial investigations were carried out using 
acryloyl chloride (304), benzylamine (308) and the 2-bromobenzylamine domino precursor 
199, under the conditions previously successful for the synthesis of isoindolines (Scheme 
4.18). 
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Scheme 4.18 Attempted multicomponent synthesis of isoindolines 
 
In this case, again only the Heck adduct was identified following analysis of the crude 
reaction mixture. The presence of the amide in the conjugated Michael acceptor, instead of 
the more electron-withdrawing ester alkenes, meant that aza-Michael addition did not 
proceed to form the desired isoindoline 311. For previous cases employing the ester 
acrylates, the domino Heck-aza-Michael process occurred in excellent yields. However, as 
the acrylamides are typically not as inductively electron withdrawn as the esters, aza-
Michael addition does not take place. These initial results once again confirmed how subtle 
electronic differences this time in the alkene used in the domino process can play a role in 
determining the success of N-heterocycle formation. 
Tetrahydroisoquinolines 
 
With the multicomponent approach to both the tetrahydro-β-carbolines and isoindolines 
proving unsuccessful, attention turned to the tetrahydroisoquinolines. The use of acrylamide 
for the previous domino Heck-aza-Michael reaction with this system was unsuccessful. 
Therefore, it was proposed that a multicomponent domino process would provide access to 
C1-acetamide tetrahydroisoquinolines similar to those used as potential pharmaceutical 
agents (Figure 4.8).293, 398-402 
 
Figure 4.8 C1-acetamide tetrahydroisoquinoline medicinal chemistry agents  
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Benzylamine was again chosen as the amine substrate. This trial reaction involved the 
addition of acryloyl chloride (304) to a solution containing benzylamine (308), and 
potassium carbonate in toluene. After stirring at room temperature for one hour, the 2-
bromophenethylsulfonamide 279 and Pd(OAc)2/PPh3 were added, and the resultant mixture 
heated to 120 oC for 16 hours (Scheme 4.19). A simple work up followed by flash 
chromatography afforded the desired tetrahydroisoquinoline 314 in an excellent yield of 
97%. 
 
Scheme 4.19 Three-component synthesis of functionalised tetrahydroisoquinoline 
 
Following this initial success, a range of amines were subsequently used in this three-
component domino Heck-aza-Michael reaction including alkyl primary amines (Table 4.6, 
entries 1-11), aryl amines (Table 4.6, entries 12-15), acyclic secondary amines (Table 4.6, 
entries 16-19), cyclic secondary amines (Table 4.6, entries 20-25), and amino acids (Table 
4.6, entries 26-30). 
The first attempt with tryptamine (2) only resulted in trace amounts of the desired 
tetrahydroisoquinoline 315. This lack of reactivity appeared to be due to the insolubility of 
either the initial amine or corresponding acrylamide in toluene. To overcome this, a few 
drops of DMF were added to the reaction mixture following the addition of the amine. This 
approach quickly proved successful, with the second attempt using tryptamine affording 
tetrahydroisoquinoline 315 in 92% yield (entry 2, Table 4.6). During the elaboration of the 
series of C1-amide substituted tetrahydroisoquinolines, a number of other amines also 
required the addition of DMF to improve their reaction mixture solubility. 
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Table 4.6. Formation of functionalised tetrahydroisoquinolines using a three-component domino 
Heck-aza-Michael reaction  
 
Entry Amine R Yield (%) 
1 benzylamine 
 
97 
2 tryptamine a 
 
92 
3 n-heptylamine 
 
89 
4 propylamine 
 
42 
5 cyclohexylamine 
 
77 
6 tert-butylamine 
 
93 
7 2-nitrobenzylamine hydrochloride a 
 
32 b 
8 tyramine 
 
0 c 
9 4-(2-aminoethyl) morpholine 
 
0 d 
10 2-(2-aminoethyl) pyridine 
 
NR 
11 4-methoxy phenethylamine 
 
0 c 
    
    
    
    
  Chapter 4 
- 111 - 
Entry Amine R Isolated Yield (%) 
12 aniline 
 
83 
13 p-anisidine 
 
79 
14 2-aminopyrazine a 
 
28 
15 2-(amino)-4- (p-tolyl)-thiazole 
 
NR 
16 diethylamine 
 
57 
17 N-methyl phenethylamine 
 
0 e 
18 diisopropylamine 
 
NR 
19 N,N-dicyclohexylamine 
 
NR 
20 piperidine 
 
88 
21 morpholine 
 
78 
22 THβC 
 
NR 
23 2,2,6,6-tetramethylpiperidine 
 
NR 
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Entry Amine R Isolated Yield (%) 
24 indole 
 
NR 
25 pyrrole 
 
NR 
26 glycine methyl ester hydrochloride a 
 
72 
27 L-tryptophan benzyl ester hydrochloride a 
 
96 f 
28 L-alanine methyl ester hydrochloride a 
 
54 f 
29 L-valine methyl ester hydrochloride 
 
73 g 
30 L-proline methyl ester hydrochloride 
 
0 f 
 
a A few drops of DMF were added to aid in amine solubility in the reaction mixture 
b In situ deprotection of the 2-nitrobenzyl group occurred during reaction and the product isolated was the 
tetrahydroisoquinoline acetamide in 32% yield.  
c The Heck adduct was isolated  
d Crude NMR indicated the product had formed in excellent yield but desired product was not isolated following column 
chromatography.  
e The product formed from this reaction contains a di-substituted amide in which the two substituents are not equivalent which 
resulted in an inseparable mixture of regioisomers.  
f The diastereomeric ratio was determined to be 1:1.  
g The diastereomeric ratio in this case was 3:7 (determined by chiral HPLC). 
Reaction was performed by the addition of acryloyl chloride (1.2 eq) to a sealed tube containing the amine (1.2 eq), base (3.0 
eq.) and solvent (4 mL). After stirring for 1 hr. the aryl-halide (1.0 eq.), and palladium catalyst (10 mol%) were added and the 
reaction mixture heated to 120 oC for 16 h. 
 
The one-pot, three-component domino Heck-aza-Michael process proved to be quite 
general, with high yields (up to 97%) of the C1-acetamide tetrahydroisoquinolines observed 
when alkyl amines, aryl amines, secondary amines and amino acids were used. The only 
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limiting factor in this process appeared to be solubility of the amine and corresponding 
acrylamide, rectified by the use of DMF as a co-solvent 
For the domino process employing 2-nitrobenzylamine hydrochloride (Table 4.6, entry 7), 
the in situ deprotection of the 2-nitrobenzyl group to afford tetrahydroisoquinoline 320 was 
observed. The 2-nitrobenzyl group has been reported to be photolytically cleaved in polar 
solvents (typically 254-365nm).403-405 As this reaction was carried out in toluene in a dark 
fume hood, deprotection of the 2-nitrobenzyl group under our reaction conditions was 
unexpected. In this instance, the basic conditions and high temperatures employed in this 
reaction sequence proved adequate in cleaving the 2-nitrobenzyl group. 
Multicomponent reactions using a chiral amino acid precursor (Table 4.6, entries 27-30) 
were carried out to identify whether a stereoselective variant of this one-pot process was 
achievable. The introduction of a stereogenic centre at the C1-position of the newly formed 
tetrahydroisoquinoline was determined by both 1H and 13C NMR spectroscopy. 
Unfortunately, when L-tryptophan and L-alanine were used, a 1:1 mixture of diastereomers 
were produced. As such, in these cases the presence of a stereocentre in the acrylamide 
moiety had no significant induction effects on stereochemistry at the C1-position. However, 
in the case of the L-valine derivative 342 (Table 4.6, entry 29), the product was present as a 
3:7 mixture of diastereomers. In this case, the L-valine moiety contained in the acrylamide 
induced some diastereo-discrimination (40% de) at the C1-position of the newly formed 
tetrahydroisoquinoline (the asymmetric domino Heck-aza-Michael reaction was further 
pursued in Section 4.4.2). 
It was also envisaged that this domino process could be applied to the synthesis of esters, 
thioesters and anhydrides (Scheme 4.20). However, initial investigations into the formation 
of the necessary alkene revealed that these processes were not as facile as acrylamide 
formation. Due to time constraints this avenue of investigation was not pursued. 
 
Scheme 4.20 This multicomponent process in the synthesis of ester, thioester and anhydride tethered 
tetrahydroisoquinolines 
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In summary, a domino Heck-aza-Michael process was developed where in one-pot, the 
electron deficient alkene generated from reaction between acryloyl chloride and an amine, 
underwent domino Heck-aza-Michael reaction to afford a series of C1-acetamide 
tetrahydroisoquinolines. This is the first example of a domino Heck-aza-Michael reaction 
that allows the electron deficient terminal alkene to be readily varied in a one-pot process. 
This multicomponent domino reaction proved to be quite general, using a range of primary 
and secondary amines to afford functionalised tetrahydroisoquinolines, in moderate to 
excellent yields (28-97%).  This one pot process, when employed in a medicinal chemistry 
or combinatorial setting would facilitate the rapid generation of compound libraries. 
4.4 Asymmetric Domino Heck-aza-Michael Reactions 
 
Chirality is a very important concept in chemistry, and a majority of the biological 
molecules found in nature occur as a single enantiomer. This property of molecules has also 
proven important in a medicinal chemistry setting, where many receptors discriminate 
between molecules to a degree where only one enantiomer induces activity. Approximately 
70% of all pharmaceuticals currently available are enantiopure. The chirality of 
pharmaceuticals offers a number of advantages for example the administration of 
enantiomerically pure drugs is often through a decreased dosage to the racemic mixture, 
lowering the load on metabolism and an enhanced activity. Additionally, the use of chiral 
drugs results in increased specificity, which minimises the risk of side effects and possible 
cytotoxicity caused by the ‘wrong’ enantiomer. (for example the thalidomide tragedy may 
have been avoided if only the R-(+)-thalidomide was used, reportedly responsible for 
sedative effects whereas S-(-)-thalidomide and its derivatives were reported to be 
teratogenic).406 
As such, the stereoselective synthesis of molecules has become a major focus of modern 
organic chemistry. A number of techniques have emerged to access compounds as their 
single enantiomer for example asymmetric epoxidation, hydrogenation and alkylation.407-
413‡‡ However, the resolution of a mixture of enantiomers can often be the cheapest, most 
practical way of obtaining enantiomerically pure material, although as only one enantiomer 
is generally required, a large amount of waste is generated from this process. Alternatively, 
the use of relatively cheap chiral starting materials from the chiral pool or chiral catalysts 
(organocatalysts or metal-based catalysts) can also result in the synthesis of one major 
stereoisomer.415-416 
                                                        
‡‡ The Nobel Prize in Chemistry in 2001 was awarded to W. S. Knowles, R. Noyori and K. B. 
Sharpless for the development of chirally catalysed hydrogenation and oxidation reactions.414 
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In the current context, a majority of the biologically active natural products containing the 
N-heterocyclic scaffolds have a stereocentre at the C1-position (Figure 4.9). As such, it 
would be useful if the methodology used to synthesise these N-heterocyclic systems could 
be modified such that only one enantiomer was produced.  
 
Figure 4.9 Natural products containing a stereocentre at the C1-position of the N-heterocycle 
 
Thus far, the focus of this project has been on new methodology for the construction of N-
heterocyclic systems. With this accomplished, the next challenge lay in enforcing 
stereochemical bias during N-heterocycle formation. A number of synthetic strategies were 
envisaged for controlling the stereochemistry at the C1-position during the domino Heck-
aza-Michael process, including the use of chiral catalysis and chiral amines and alkenes 
(Figure 4.10). Each of these approaches in the pursuit of an asymmetric domino Heck-aza-
Michael reaction are discussed in detail in the following sections. 
 
Figure 4.10 Four possible approaches were considered in the development of a stereoselective 
domino Heck-aza-Michael reaction. 
 
4.4.1 Chiral Protecting Groups 
 
The first approach for introducing an asymmetric centre at C1-position of the newly formed 
N-heterocycle was through the use of a chiral protecting group. The theory behind this 
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approach is that following Heck reaction, the bulky chiral protecting group on the nitrogen 
undergoing 1,4-addition would permit aza-Michael addition to occur preferentially from 
only one side of the double bond.  
As sulfonyl protecting groups had performed best for the previous domino processes 
investigated, the (1R)-(-)-camphorsulfonyl group was chosen for this study. The sulfonic 
acid 346 was converted to the sulfonyl chloride 347 using thionyl chloride and then reacted 
with the amine 278 to afford the domino precursor 348 (Scheme 4.21).417 
 
Scheme 4.21 The preparation of the (1R)-(-)-camphorsulfonyl domino substrate 
 
With the requisite chiral precursor 348 in hand, the domino reaction was attempted using the 
same conditions previously identified for the formation of tetrahydroisoquinolines (Scheme 
4.22). 
 
Scheme 4.22 The asymmetric domino Heck-aza-Michael reaction using a chiral protecting group. 
 
Following a simple work up, analysis of the NMR spectrum revealed that heterocycle 
formation had in fact taken place, with the characteristic C1-proton resonance detected at δ 
5.40 ppm. The presence of two distinct C1-proton resonances in this region (Figure 4.11 - δ 
5.40-5.45) indicated that the reaction had resulted in the formation of two diastereomers (in 
a ratio of 1:3 – 50% de).  
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Figure 4.11 The presence of diastereomers (in a ratio of 1:3) was detected due to the two distinct C1-
proton resonances 
 
Attempts to separate the diastereomers and confirm which stereoisomer was the major one 
formed during the reaction proved unsuccessful, and a clean NMR spectrum of the major 
diastereomer was not obtained. However, mass spectrometry confirmed the desired product 
349 was present in the reaction mixture.  
A similar attempt was made using the chiral protecting group to access isoindolines in a 
stereoselective fashion. In this example, the 2-bromobenzylamine was treated with sulfonyl 
chloride 347 in a solution containing triethylamine and CH2Cl2 to prepare the domino 
precursor 350 in 83% yield. Following this, the domino reaction was attempted using the 
conditions previously identified for isoindoline formation (Scheme 4.23). 
 
Scheme 4.23 Attempted stereoselective synthesis of isoindolines using a chiral protecting group 
 
Unfortunately, analysis of the crude reaction mixture by NMR spectroscopy indicated no 
domino Heck-aza-Michael reaction had occurred. These results once again confirm how 
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subtle electronic differences, this time in the sulfonamide moiety (when compared to the 
tosyl derivative) involved in the domino process can play a role in determining the success 
of N-heterocycle formation. 
4.4.2 Chiral Alkenes 
 
Conjugated Michael acceptors containing chiral auxiliaries have been successfully employed 
in asymmetric synthesis, and facilitate the introduction of a stereocentre during 1,4-addition 
by an achiral amine (For example Scheme 4.24).298, 415, 418-422 
 
Scheme 4.24 Asymmetric aza-Michael addition in the presence of a chiral acrylamide421 
 
During the multicomponent synthesis of functionalised tetrahydroisoquinolines (see section 
4.3) it was observed that the valine acrylamide lead to a 3:7 mixture of diastereomers (40% 
de) following the domino Heck-aza-Michael process (Scheme 4.25). 
 
Scheme 4.25 The multicomponent asymmetric synthesis of tetrahydroisoquinolines 
 
It was envisaged that chiral alkenes could induce an even greater degree of stereoselectivity 
during the domino Heck-aza-Michael process. To this end, (R)-(-)-pantolactone acrylate 357 
and (1S,2R,5S)-(+)-menthol acrylate 359 were prepared through reaction of acryloyl chloride 
(304) with the corresponding alcohol (Scheme 4.26).423-424 
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Scheme 4.26 The preparation of chiral acrylates 
 
With the chiral acrylates in hand, the 2-bromophenethylamine substrate 297 was subject to 
the previously identified domino conditions for the synthesis of tetrahydroisoquinolines. It 
was proposed that the chiral auxiliary now present would induce aza-Michael addition 
preferentially from one side of the double bond (Scheme 4.27). 
 
Scheme 4.27 Attempted stereoselective synthesis of tetrahydroisoquinolines using chiral alkenes 
 
The attempted stereoselective domino Heck-aza-Michael reaction using both the menthol 
and pantolactone acrylates did not result in the formation of the desired heterocycles. 
Attempts to induce a stereocentre at the C1-position of both the isoindoline and tetrahydro-
β-carboline ring systems, using these chiral alkenes also proved unsuccessful. 
As both the chiral protecting group and chiral alkene strategies had failed to provide a 
general and efficient stereoselective synthesis of the desired N-heterocyclic scaffolds, 
attention turned to the use of chiral amine starting materials. 
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4.4.3 Chiral Amines 
 
In recent years, chiral amines have been used to great effect in asymmetric synthesis, 
especially in the case of the stereoselective aza-Michael addition.395, 425-432 The most 
common amines used for these asymmetric aza-Michael additions contain a chiral carbon 
alpha to the amine. One example of this was recently published by Enders et al. (Scheme 
4.28). 
 
Scheme 4.28 The Enders stereoselective synthesis of tetrahydroisoquinolines426 
 
Formation of the imine from reaction of the methyl ketone with p-anisidine occurred first, 
followed by the enantioselective reductive amination in the presence of List’s TRIP catalyst 
(3,3’-bis(2,4,6-triisopropylphenyl)-1,1’-binaphthyl-2,2-diylhydrogenphosphate)433 and a 
biphenyl-substituted benzothiazole to afford the chiral amine 363. The 
tetrahydroisoquinoline 364 is then formed by asymmetric aza-Michael addition, furnishing 
the trans-isomer as the major product in excellent yield (in a diastereomeric ratio of 95:5). A 
similar process was also applied to the stereoselective synthesis of tetrahydro-β-carboline to 
great effect (85% yield, 94% ee, 95:5 d.r.).426 
In terms of asymmetric domino Heck-aza-Michael reactions, the stereoselective synthesis of 
tetrahydroisoquinolines using a three-component process was reported in 2007 by Ferracioli 
et al. (Scheme 4.29). 
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Scheme 4.29 The Ferracioli three-component process involving an asymmetric domino Heck-aza-
Michael reaction 
 
Following ortho-vinylation to install the amine tether, Heck reaction and subsequent 
asymmetric aza-Michael addition afforded the tetrahydroisoquinoline in 49% yield 
(diastereomeric ratio cis/trans 78:22). Of particular interest in this case is formation of the 
cis-isomer 367 as the major isomer during the reaction process, whereas for the 
aforementioned reductive amination/aza-Michael addition reaction sequence (Scheme 4.28), 
the trans-isomer 364 was the major product. Although this three-component reaction proves 
that an asymmetric domino Heck-aza-Michael reaction is possible using chiral amine 
substrates, the process suffers from low overall yields and only moderate diastereoselectivity 
(56% de).  
The introduction of a stereocentre at the 1-position of the N-heterocycles employing 
naturally occurring amino acids was investigated, with the hope of increasing both the 
reaction yield and diastereoselectivity compared to the Ferracioli asymmetric synthesis 
(Scheme 4.30). At this point it was unknown which diastereomer would be the major one 
formed during the reaction process, as both the Enders and Ferracioli synthesis (employing a 
similar asymmetric aza-Michael addition) reported the opposite major stereoisomer. 
 
Scheme 4.30 The proposed stereoselective domino Heck-aza-Michael reaction employing chiral 
amine substrates 
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Tetrahydro-β-carbolines 
 
The introduction of a stereocentre at the C1-position of the tetrahydro-β-carboline, using 
tryptophan with a protected carboxylic acid moiety, has been employed in the Pictet-
Spengler reaction.35, 246, 434-436 Through the use of L-tryptophan instead of tryptamine for the 
domino Heck-aza-Michael reaction, it was expected the stereocentre present would induce 
specific stereochemistry at the C1-position of the THβC formed.  
The N10-amine of L-tryptophan methyl ester hydrochloride (48) was protected with the tosyl 
group (88% yield), with subsequent bromination of the indole-2-position to afford the 2-
bromoindole in yield of 69%. The indole nitrogen was then protected with the Boc group in 
an excellent yield (87%) to afford the domino precursor 371 (Scheme 4.31). 
 
Scheme 4.31 Preparation of the domino substrate for the stereoselective synthesis of  
tetrahydro-β-carbolines from tryptophan (major isomer shown) 
 
The only product isolated from the reaction to protect the indole-nitrogen was the mono-
protected compound as desired. No side reaction at the sulfonamide was observed as in 
previous cases (Scheme 2.6), indicating that the sulfonamide of the tryptophan was not as 
nucleophilic as that of the protected tryptamine 132. This was quickly confirmed when 2-
bromotryptophan 371 was subject to the previously identified domino Heck-aza-Michael 
conditions. 
 
Scheme 4.32 Attempted asymmetric domino Heck-aza-Michael reaction 
 
Following a simple work up, analysis of the crude product reaction mixture indicated that 
only Heck reaction had occurred (identifiable by the alkene proton resonances present as 
well as the sulfonamide proton resonance still clearly visible in the 1H NMR spectrum), and 
no intramolecular aza-Michael adduct was observed. The methyl ester in close proximity to 
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the sulfonamide was inductively drawing electron density away from the sulfonamide, 
making it much less nucleophilic than in the case of tryptamine, preventing aza-Michael 
addition to form the new heterocycle.  
In an effort to tune the nucleophilicity of N10-amine of tryptophan,§§ a slight modification to 
the domino substrate was proposed. By reducing the ester to the corresponding alcohol, 
followed by conversion to the silyl-ether, the nucleophilicity of the amine should become 
similar to that of the tryptamine-sulfonamide 133, whilst preserving the requisite chirality 
(Scheme 4.33). In fact, the additional bulk of the tert-butyldimethylsilyl ether should further 
enhance the stereoselectivity of this domino process. 
 
Scheme 4.33 Modification of the domino precursor 
 
The methyl ester 371 was reduced to the corresponding alcohol, using sodium borohydride 
in a solution of THF/ethanol using literature protocol, without affecting the tosyl, bromo, or 
Boc groups.437 The success of this reaction was confirmed by the loss of the methyl ester 
proton resonance in the 1H NMR spectrum, as well as the addition of the CH2 and OH 
proton resonances. The alcohol was then converted to the silyl ether 373 through reaction 
with tert-butyldimethylsilyl chloride (TBDMS-Cl) in the presence of imidazole (in 65% 
yield over the 2 steps from the methyl ester).264, 438-439 With the modified domino substrate 
373 in hand, the asymmetric domino process was again attempted, this time using 3-buten-2-
one with the previously identified domino conditions (Scheme 4.34). 
 
Scheme 4.34 The asymmetric domino Heck-aza-Michael reaction for the synthesis of C1-substituted 
tetrahydro-β-carbolines 
                                                        
§§ Previous studies (see Section 3.2.3) had discounted the use of stronger bases and more polar 
solvents for the domino process, as intermolecular aza-Michael addition occurred before Heck 
reaction. 
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Following a simple work up, the crude product was purified by column chromatography to 
afford the desired tetrahydro-β-carboline ketone derivative 374 in 81% yield as an 
inseparable mixture of diastereomers (Scheme 4.34). The diastereomeric ratio of the product 
was confirmed following analysis by chiral HPLC (60% de). The major product formed 
during this domino process was the cis-isomer, determined using Nuclear Overhauser effect 
(NOE) NMR experiments, with the through space interaction of both the C1- and C3-
protons with the aromatic proton of the tosyl group identified, an interaction which can only 
be conceived when the molecule is in the cis-conformation (Figure 4.12). 
 
Figure 4.12 The NOE NMR experiments confirmed the cis-isomer was the major diastereomer 
formed during the tetrahydro-β-carboline asymmetric domino process 
 
The reaction was repeated at a range of temperatures, however, degradation of the starting 
material occurred above 120 oC, and reducing the reaction temperature lead to formation of 
only the Heck adduct. Further attempts to expand the scope of this asymmetric domino 
process using additional alkenes (including butyl acrylate, methyl acrylate and acrylonitrile) 
for the synthesis of 1,3-disubstituted tetrahydro-β-carbolines proved unsuccessful, with only 
the Heck adduct identified following each reaction. These results once again confirm how 
subtle electronic differences this time in the alkene and sulfonamide substrates can play a 
role in determining the success of N-heterocycle formation. 
With an asymmetric domino Heck-aza-Michael process developed for the synthesis of the 
1,3-disubsituted tetrahydro-β-carboline, attention turned to the two other N-heterocyclic 
systems successfully accessed using domino Heck-aza-Michael processes during this 
research project, namely the tetrahydroisoquinolines and isoindolines. 
Tetrahydroisoquinolines 
 
As the requisite 2-halophenylalanine derivatives were relatively expensive and not readily 
available, the preparation of such compounds was investigated. The ortho-iodination of the 
L-phenylalanine has been reported by Barluenga to occur in good yield and excellent 
selectivity (>95% conversion, 10:1, ortho:para-iodinated product).440 However, as this 
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methodology cannot be applied to the synthesis of the ortho-halogenated phenylglycine 
derivative (to be used to investigate the asymmetric synthesis of isoindolines), a more 
general method to ortho-halogenate the amino acids required for this investigation was 
sought. 
Palladacycles have attracted a large amount of interest recently as they have shown great 
potential as both catalysts and medicinal chemistry agents.195, 441 The development of 
palladacycle catalysts (usually as a source of highly active Pd(0), for example the Herrmann-
Beller palladacycle) has facilitated the catalysis of a number of synthetic transformations.162, 
195, 442-443 Palladacycles have also found use as medicinal chemistry agents, showing activity 
as both cytotoxic agents and cathepsin B inhibitors, an enzyme thought to be involved with a 
number of cancer related events.444-447 *** 
 
Figure 4.13 The Herrmann-Beller palladacycle (A) and a palladacycle found to exhibit cytotoxic 
effects (B) 
 
Traditionally, palladacycles were only isolated when a tertiary amine was employed.448-449 
However, in recent years, the ortho-palladation of both primary and secondary amines has 
been reported.134, 450-458 This has allowed the development of several protocols for 
functionalising aryl-amines via palladacycle intermediates, including ortho-halogenation.134-
135, 246, 452, 454, 459 
The ortho-halogenation of phenethylamines, via a palladacycle intermediate was recently 
published by Vicente.452 In a similar fashion, the ortho-halogenation of phenylglycine 
derivatives has also been reported to occur, utilising palladacycle intermediates.460 As such, 
the domino substrates for the synthesis of tetrahydroisoquinolines and isoindolines could 
both be prepared following ortho-palladation of the necessary amino acid derivatives 
(Scheme 4.35). 
                                                        
*** For a comprehensive review of palladacycles refer to The potential of palladacycles: More than 
just precatalysts. (Chemical Reviews, 2005, 105, (6), 2527-2571)441 and Palladacycles: Synthesis, 
Characterisation and Applications (Dupont, J.; Pfeffer, M., Wiley-VCH Verlag GmbH & Co.: 
Weinheim, 2008).447 
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Scheme 4.35 The proposed synthesis of the domino precursors, with ortho-halogenation via a 
palladacycle intermediate 
 
The palladacycle methodology allows for both iodination and bromination of the ortho-
position of appropriate amino acids (375 and 378), however as the domino Heck-aza-
Michael process performed well previously for the 2-bromoarylamines, at this point of the 
investigation, bromination was favoured. 
In this study, the ortho-bromination of L-phenylalanine 375 was carried out in three steps 
using the protocol described by Vicente.452 The initial formation of the palladacycle was 
accomplished by reacting L-phenylalanine methyl ester hydrochloride (378) with one 
equivalent of palladium acetate in acetonitrile for 6 days (Scheme 4.36). Ortho-bromination 
of the L-phenylalanine was then readily accomplished in two steps by (i) reaction of the 
palladacycle 381 with bromine, and then (ii) reaction with 1,10-phenanthroline (which 
chelates to the palladium, resulting in the formation of the bright yellow PdBr2(Phen) 
complex).452 
 
Scheme 4.36 Ortho-bromination of L-phenylalanine methyl ester 
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After a simple work, up the L-2-bromophenylalanine methyl ester 376 was isolated in 50% 
yield over three steps (Scheme 4.36). The aryl-halide was fully characterised by NMR 
spectroscopy and mass spectrometry, with the presence of only four aromatic proton 
resonances in the 1H NMR spectrum confirming bromination and the presence of the free 
amine proton resonance confirming palladium decoordination. 
With the L-2-bromophenylalanine 376 in hand the free amine was protected with the tosyl 
group (found optimal for previous domino reactions) in 92% yield, and the domino substrate 
383 subjected to the previously identified domino conditions for tetrahydroisoquinoline 
synthesis (Scheme 4.37). 
 
Scheme 4.37Attempted stereoselective synthesis of 1,3-disubstituted tetrahydroisoquinolines 
 
Once again, the formation of the chiral tetrahydroisoquinoline scaffold 384 did not proceed 
in the presence of the methyl ester. Using the same approach applied to the tetrahydro-β-
carboline stereoselective synthesis, the domino substrate was modified with the methyl ester 
383 reduced to the corresponding alcohol using NaBH4, and was subsequently converted to 
the silyl ether 385 upon reaction with TBDMS-Cl (Scheme 4.38) 
 
Scheme 4.38 Modification of the domino precursor for the asymmetric synthesis of 
tetrahydroisoquinolines 
 
The stereoselective synthesis of tetrahydroisoquinolines was then investigated using a range 
of catalytic conditions and the major product in each attempt was determined by 1H NMR 
spectroscopy (Table 4.7). It was remarkable that during these optimisation studies, the major 
by-product identified was due to the intramolecular C-N cross-coupling to form the 5-
membered indoline scaffold 387.††† 
                                                        
††† Although always considered a possibility, the product formed due to C-N coupling had not been 
observed during previous investigations into the domino Heck-aza-Michael process. 
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Table 4.7 Optimisation of the asymmetric domino process for tetrahydroisoquinoline synthesis 
 
Entry Pd Catalyst a Base Solvent Major Products (% Conversion) 
1 Pd(OAc)2/PPh3 K2CO3 PhMe THIQ 386 (30%) 
2 Pd2(dba)3/DavePhos K2CO3 PhMe THIQ 386 (50%), Indoline 387 (50%) 
3 Pd2(dba)3/P(tBu)3 K2CO3 PhMe Indoline 387 (100%) 
4 Pd2(dba)3/PPh3 K2CO3 PhMe THIQ 386 (10%), Indoline 387 (90%) 
5 Pd(OAc)2/P(tBu)3 K2CO3 PhMe Indoline 387 (100%) b 
6 Pd(OAc)2/PPh3 Cy2NMe PhMe NR 
7 Pd(OAc)2/PPh3 Na2CO3 PhMe NR 
8 Pd(OAc)2/PPh3 K2CO3 c PhMe THIQ 386 (70%)d, Indoline 387 (30%) 
 
a Palladium catalyst loading 10 mol%. Pd:Ligand ratio was 1:1. 
b The C-N cross coupling adduct was isolated in a yield of 97% 
c 5.0 equivalents of K2CO3 and 2.0 equivalents of 3-buten-2-one were used 
d The domino adduct was isolated in a yield of 68% 
Reaction was performed in a sealed tube containing the aryl-halide (1.0 eq.), 3-buten-2-one (1.2 eq), palladium catalyst (10 
mol%), and base (3.0 eq.) in solvent (4 mL). The reaction mixture was then heated to 120 oC for 16 h. 
 
The first reaction was trialled using the conditions previously successful for the domino 
process for the synthesis of tetrahydroisoquinolines (Table 4.7, entry 1). The major product 
identified from this reaction was the Heck-aza-Michael adduct 386, however following 
several attempts, conversion above 30% was not realised. To increase the rate of the Heck 
reaction, several more active catalytic conditions were trialled (Table 4.7, entries 2-5) in the 
presence of K2CO3 and toluene. The conversion to the desired domino product was increased 
(up to 50%, entry 2), however the formation of the indoline 387 through an intramolecular 
C-N cross coupling reaction (Buchwald-Hartwig reaction) was favoured under these more 
active catalytic conditions. In fact, complete conversion to this indoline 387 was realised 
when the Fu salt was employed (isolated in 97% yield, entries 3 and 5). Further attempts 
using the Pd(OAc)2/PPh3 catalyst with a range of bases failed to product the domino adduct 
(Table 4.7, entries 6-7). Eventually it was determined that by increasing the equivalents of 
alkene (from 1.2 to 2.0 equivalents) and base (from 3.0 to 5.0 equivalents), the domino 
reaction produced tetrahydroisoquinoline 386 in 70% conversion (with 30% of the C-N 
adduct 387 also identified, Table 4.7 entry 8). Following column chromatography, the 
tetrahydroisoquinoline ketone 386 was isolated in a yield of 68%. The diastereomeric ratio, 
determined by NMR was approximately 19:1, with chiral HPLC confirming the asymmetric 
domino reaction had afforded the major diastereomer in 85% de. 
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To further investigate the asymmetric domino reaction, butyl acrylate was employed as the 
alkene substrate, affording the butyl ester tetrahydroisoquinoline 388 in 73% yield (92% de, 
Scheme 4.39). 
 
Scheme 4.39 The asymmetric domino Heck-aza-Michael reaction for the synthesis of chiral 1,3-
disubstituted tetrahydroisoquinolines 
 
The major isomer formed during this domino process was again confirmed to be the cis-
diastereomer, with both the C1- and C3-proton resonances exhibiting a through space NOE 
interaction with the aromatic protons of the tosyl protecting group closest to the sulfonyl 
motif, an interaction that can only be conceived if both of these protons are in the same 
configuration. 
 
Figure 4.14 The NOE NMR experiments confirmed the cis-isomer was the major diastereomer 
formed during the tetrahydroisoquinoline asymmetric domino process 
Isoindolines 
 
In a similar fashion to that employed for the preparation of the domino substrate for the 
asymmetric synthesis of tetrahydroisoquinolines, ortho-halogenation of (S)-(+)-
phenylglycine methyl ester 378 was carried out following ortho-palladation (Scheme 4.40).  
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Scheme 4.40 Ortho-iodination of the phenylglycine derivative 
 
Initial investigations involved ortho-bromination of the phenylglycine methyl ester 378, 
however for reasons unknown, following attempted tosylation of the free amine a clean 
product could not be obtained. Alternatively, the ortho-iodination was then investigated 
(Scheme 3.36). Formation of the palladacycle 389 was achieved by refluxing the 
phenylglycine methyl ester 378 with palladium acetate in acetone overnight. Following 
recrystallisation of the palladacycle 389, it was treated with iodine in dichloromethane to 
furnish the ortho-iodinated product 390. Once again, the addition of 1,10-phenanthroline 
monohydrate to the solution containing the aryl-halide facilitated the release of the 
palladium to afford the 2-iodoamine 391 in 30% over three steps. As previous attempts at 
the domino reaction with the methyl ester substrates were unsuccessful, following tosylation 
of the amine, the ester was again reduced with NaBH4 and readily converted to the silyl 
ether 392 in an unoptimised yield of 12% over three steps (Scheme 4.41) 
 
Scheme 4.41 Preparation of the domino precursor for the asymmetric synthesis of isoindolines. 
 
As previously reported, ortho-halogenation via the palladacycle intermediate results in slight 
racemisation of the phenylglycine.460 Indeed the enantiopurity of the 2-iodosulfonamide 392 
prepared during this project was confirmed by chiral HPLC as 86% ee. With the domino 
substrate in hand, the asymmetric domino Heck-aza-Michael reaction for the synthesis of 
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chiral 1,3-disubstituted isoindolines was attempted with butyl acrylate using the conditions 
previously identified for isoindoline formation (Scheme 4.42). 
 
Scheme 4.42 The asymmetric domino reaction for the synthesis of 1,3 disubstituted isoindolines 
 
The butyl ester isoindoline 393 was formed in 79% yield, in a diastereomeric ratio of 
approximately 19:1 (determined by 1H NMR spectroscopy). The stereoselectivity of this 
domino process was confirmed by chiral HPLC (revealing an 87% de). Further attempts 
employing 3-buten-2-one resulted in formation of the desired isoindoline, however this 
product could not be separated from the remaining starting material. This success also 
proved that the domino Heck-aza-Michael reaction was also plausible using aryl-iodides. 
In accordance with previous experiments, the major diastereomer from the isoindoline 
reaction sequence (Scheme 4.42) was again identified as the cis-isomer with NOE NMR 
experiments confirming the through space interactions of the C1- and C3- proton resonances 
with each other, as well as with the aromatic protons of the tosyl group. 
 
Figure 4.15 The NOE NMR experiments confirmed the cis-isomer was the major diastereomer 
formed during the isoindoline asymmetric domino process 
 
An asymmetric domino Heck-aza-Michael process was successfully developed for the 
synthesis of chiral 1,3-disubstituted tetrahydro-β-carbolines, tetrahydroisoquinolines and 
isoindolines in good yields and with moderate to excellent diastereoselectivity. These 
disubstituted N-heterocycles contain orthogonal functionality readily available for further 
functionalisation (an ester or ketone at C1 and a protected alcohol at C3). 
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To further illustrate how this methodology provides access to N-heterocycles that are useful 
as building blocks in the synthesis of more complex molecules, the silyl alcohol protecting 
group could be readily cleaved,264 and the alcohol oxidised to form the carboxylic acid. 
Following reaction of this carboxylic acid to form the activated Barton ester, this ester could 
be cleaved through a reductive decarboxylation process to produce the C1-monosubstituted 
N-heterocycle, or utilised in the formation of new carbon-carbon, carbon-halide and carbon-
heteroatom bonds.461 
4.4.4 Chiral Catalysis 
 
Asymmetric catalysis is an especially appealing method for realising asymmetric syntheses. 
Small amounts of a catalyst can often be used to control the stereochemical outcome of a 
reaction.462 The use of a catalyst often makes the isolation of the product easier, as there is 
less unwanted material to remove at the end of a reaction.416 A number of enantioselective 
palladium-catalysed transformations, in particular the Heck reaction, have been recently 
reported.201 
 
Scheme 4.43 The potential stereoselective synthesis of THBCs using chiral palladium catalysis 
 
One approach considered for the development of an asymmetric domino Heck-aza-Michael 
reaction was the use of chiral palladium catalysts containing chiral ligands (such as (R)-
BINAP) to potentially induce stereochemistry (Scheme 4.43). The mechanism of this N-
heterocycle formation would require the chiral Pd-catalyst to be in close proximity to one 
face of the double bond following Heck reaction, allowing aza-Michael addition to only 
occur from the opposite face of the double bond, resulting in the formation of one 
stereoisomer. As the palladium catalyst was not considered to play a major role in the 
stereodefining step during formation of the N-heterocycle, the use of chiral palladium 
catalysis at this point was not investigated. 
4.5 Conclusion 
 
The syntheses of tetrahydroisoquinolines and isoindolines using a domino Heck-aza-
Michael reaction were achieved in good yield, providing access to these N-heterocycles 
containing a variety of functional groups. The expansion of the domino methodology to 
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include these two additional heterocyclic systems resulted in a publication in Organic & 
Biomolecular Chemistry (see Appendix One).396 
The synthesis of benzofuran and benzothiophene-based N-heterocycles was also attempted 
using the domino Heck-aza-Michael methodology. The benzofuran domino precursor was 
able to be accessed in good yield from 2-hydroxyacetophenone, however the rate of the 
Heck reaction at the benzofuran-2-position was not sufficient enough that Heck reaction 
took place before intermolecular aza-Michael addition. The benzothiophene analogue of 
tryptamine was synthesised in good yield over several steps from thiophenol, but 
bromination of the benzothiophene-2-position was not readily achieved. A domino process 
attempted using the benzothiophene domino precursor did reveal that some of the desired N-
heterocycle had formed, however further investigation into both these systems is required. 
The domino Heck-aza-Michael reactions reported to date, including those investigated 
during this research project, had only proved successful using the limited range of 
commercially available electron-deficient terminal alkenes. To further expand the scope of 
this methodology, a three-component domino process for the synthesis of C1-acetamide 
tetrahydroisoquinolines was developed. The first reaction in the one-pot reaction sequence 
involved the coupling of acryloyl chloride to a primary or secondary amine. This acrylamide 
formation was followed by domino Heck-aza-Michael reaction to furnish a series of 16 
amide functionalised N-heterocycles. The expansion of the domino methodology to a three-
component protocol, allowing synthesis of the requisite alkene in the same pot as the 
domino process, resulted in a publication in European Journal of Organic Chemistry (see 
Appendix One).463 
To further explore the domino Heck-aza-Michael process an asymmetric version was 
investigated using a variety of approaches including chiral protecting groups, chiral alkenes 
and chiral amine substrates. This eventually lead to the development of an asymmetric 
domino reaction, using chiral amino acid starting materials, for the synthesis of 1,3-
disubstituted tetrahydro-β-carbolines, tetrahydroisoquinolines and isoindolines in good yield 
and with moderate to good diastereoselectivity. In comparison to existing techniques 
employing a similar approach to asymmetric N-heterocycle synthesis (see Scheme 4.29), 
both higher reaction yields, and greater diastereoselectivity were achieved using the 
methodology developed during this project (a publication presenting these results is 
currently in preparation). 
 
 Chapter Five 
Indole-Based PPARγ Agonists 
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5.1 Chapter Overview 
 
Following the development of novel palladium-catalysed methodology to access 
functionalised N-heterocycles, a new project involving the application of indole-based N-
heterocycles in the synthesis of PPARγ agonists was investigated. 
Focus turned to the indole-scaffold in an attempt to increase the insulin-sensitising activity 
of potential PPARγ agonists previously identified.2 Conformationally restricted analogues 
were designed by varying the size and functionality contained within the indole-based N-
heterocyclic scaffold. A number of indole-based scaffolds, synthesised from tryptamine, 
were functionalised as required as PPARγ agonists. 
5.2 PPARγ Agonists for Treating Type-2 Diabetes 
 
There are currently a range of pharmaceutical agents available for the treatment of type 2 
diabetes (T2D), acting at different biological targets within the body. Before the discussion 
of new treatments can take place, an understanding of type 2 diabetes is required and the role 
the PPARγ plays in mediating blood glucose levels. 
5.2.1 Type-2 Diabetes 
 
Diabetes Mellitus (DM) is a group of diseases characterised by the abnormally persistent 
elevation of blood-glucose levels within the body (hyperglycaemia).221, 464 Chronic 
hyperglycaemia can result in long term complications including kidney failure, coronary 
heart disease and stroke. More than half of those patients diagnosed with type 2 diabetes 
eventually die of cardiovascular related causes.221 
In 2005, over 1.1 million people worldwide died from diabetes.220 However, this number is 
more likely closer to 3 million, as many deaths where diabetes was a predominant factor 
were attributed to heart disease or kidney failure.220 Currently, over 180 million people 
worldwide have been diagnosed with diabetes. Alarmingly, the number of sufferers is 
expected to more than double by the year 2030, as this chronic disease reaches epidemic 
status.220 
Whereas type 1 (insulin dependent) diabetes is caused by a lack of insulin production, type 2 
(non-insulin dependent) diabetes is a result of impaired insulin action (or insulin 
resistance).465 Insulin resistance is a characteristic metabolic defect in a number of patients 
affected by diabetes.221 Symptoms of patients with type 2 diabetes often include excessive 
urination, thirst, constant hunger, weight loss and changes to vision and tiredness. 
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Insulin is predominantly produced by the β cells of the islets of Langerhans, with over one 
million islets contained in the pancreas.465 The hormone insulin stimulates glucose transport 
from blood into muscles and tissues, and is responsible for controlling the metabolism of 
proteins, fats and carbohydrates.465-466 The insulin produced is utilised by the body to 
maintain acceptable levels of glucose within the body (typically 700-1500 mg/L). The onset 
of type 2 diabetes generally occurs when glucose levels in the body move above this range 
for an extended period of time.221, 465 Furthermore, many of the symptoms of diabetes can be 
moderated by reducing the level of glucose in the blood.465, 467-468 
The term insulin resistance is defined by the failure of the β cells of the pancreas to keep up 
with the body’s requirements. This resistance to insulin results in the ineffective removal of 
glucose from the blood.221, 369, 465-466 ‡‡‡  
Treating Type 2 Diabetes 
 
For thousands of years, there were no treatments for diabetes.470 Children who developed 
diabetes often died within days, and older people were forced to live with the demoralising 
symptoms. A variety of remedies were employed ranging from the use of assorted herbs to 
more extreme methods, including “opening the veins”.470 
Although the management of diet and exercise is the front line treatment for type 2 diabetes, 
it is usually accompanied by one or more of the available pharmaceutical treatments, 
especially where lifestyle changes are difficult. Current pharmaceutical agents focus on 
either increasing the inadequate level of insulin production or increasing the sensitivity of 
target tissues to insulin.467 Unfortunately, associated with each of the current treatments are a 
number of side effects (Table 5.1). 
Table 5.1 Current therapeutic agents for the treatment of type 2 diabetes 471 
 
Drug Class Molecular Target Site(s) of Action Adverse Effects 
Insulin Insulin Receptor Liver, muscle, fat Hypoglycaemia, weight gain 
Sulfonylureas 
Sulfonylurea 
Receptor/ K+ ATP 
channel 
Pancreatic β-cell Hypoglycaemia, weight gain 
Metformin Unknown Liver (muscle) Gastrointestinal disturbances,  lactic acidosis 
Acarbose α-glucosidase Intestine Gastrointestinal disturbances 
Thiazolidinediones PPARγ Fat, muscle, liver Weight gain, oedema, anaemia 
 
                                                        
‡‡‡ For a more comprehensive discussion of insulin resistance refer to the book by Reaven and Laws 
(Insulin Resistance: The Metabolic Syndrome X; Humana Press Inc.: Totowa, New Jersey, 1999.)469 
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The thiazolidinediones (TZDs) and their target, the Peroxisome Proliferator-Activated 
Receptors (PPARs), are the particular focus of this project. Thiazolidinediones are insulin-
sensitising antidiabetic drugs.221 TZDs are used in the treatment of overweight patients 
whose diabetic condition cannot be adequately controlled by diet and exercise, and where 
metformin is inappropriate.472 There are currently only two TZDs available on the market; 
Pioglitazone 394 and Rosiglitazone 395 (Figure 5.1). The first available TZD (Troglitazone) 
was withdrawn after severe liver toxicity was observed.473  
 
Figure 5.1 The structure of the two commercially available thiazolidinediones. 
 
Thiazolidinediones are agonists of the Peroxisome Proliferator-Activated Receptor gamma 
(PPARγ) which is predominantly found in skeletal and muscle cells.221 Unfortunately, 
associated with the TZDs are a number of side effects including upper respiratory tract 
infection and weight gain, and they have also been linked with a number of cardiovascular 
problems.221 In fact, there has been so much controversy surrounding the safety profile of 
Rosiglitazone 395 (marketed as Avandia) that the European Medicines Agency (EMA) has 
decided to remove the troubled diabetes drug from the market, while the US Food and Drug 
Administration (FDA) will 'significantly restrict' it’s use.474 
Although a large range of antidiabetic drugs are currently available there is still no ideal 
treatment or cure for diabetes.221 As such, there is still a great need for the development of 
new or improved treatments with better safety profiles. Herein the focus is on the synthesis 
of new antidiabetic agents that act at the same biological target as the TZDs- the Peroxisome 
Proliferator-Activated Receptors. 
Peroxisome Proliferator-Activated Receptors (PPARs) 
 
The Peroxisome Proliferator-Activated Receptors (PPARs) are a subfamily of the nuclear 
receptor superfamily that control many metabolic and cellular processes 475-476 The PPARs 
are ligand-activated transcription factors that regulate target gene expression.477 They play 
an essential role in controlling glucose levels, acting as lipid sensors, and regulating the 
storage and catabolism of dietary fats.478-479  
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After the binding of an agonist (usually a small, lipophilic molecule)480 to a receptor, the 
conformation of the PPAR is altered to create a binding cleft and the recruitment of 
transcriptional coactivators is initiated.481 A process known as transactivation ensues that 
results in a greater expression level of mRNAs encoded by PPAR target genes, increasing 
the rate of transcription of these genes.481 The final result is an increased differentiation of 
adipocytes (fat cells).482 For a comprehensive review of PPAR action, refer to Willson et. al 
479 and Berger et. al.481 
There are three PPAR nuclear receptor isotypes; PPARα, PPARγ and PPARδ.481 PPARα is 
expressed predominantly in tissues that extract their energy requirements from lipids (the 
liver, heart and kidney) and holds an essential role in the regulation of fatty acid 
oxidation.478, 483 PPARδ is expressed in many tissues at a low level, but little is known 
regarding its mechanism of action and biological role.381, 478 
PPARγ is critical in the regulation of adipocyte expression and differentiation, and has been 
linked with several genes found to influence the action of insulin.479, 481 Activation of the 
PPARγ causes a reduction in insulin resistance by enhancing the sensitivity of insulin target 
tissues. This increases the removal of glucose from the blood, and therefore provides a 
valuable target for antidiabetic treatments.479 There is also strong evidence to suggest that 
PPARγ agonists may be employed therapeutically in the treatment of cancer and 
atherosclerosis (a chronic inflammatory response in the walls of arteries).479 
Natural Ligands of PPARγ 
 
Recent studies have revealed that several naturally occurring fatty acids, eicosinoids, 
prostaglandins and their metabolites weakly activate PPARγ at micromolar 
concentrations.389, 475 Additionally, several reports have recently emerged detailing a range 
of seed, herb and plant extracts that stimulate the PPARγ.484-489 Attempts to confirm the 
identity of these naturally occurring PPARγ agonists have identified several potential lead 
compounds for further development of pharmaceutical treatments for type 2 diabetes.490-492 
One specific example of this is psi-baptigenin 396 (Figure 5.2), which was shown to activate 
the PPARγ, inducing an insulin-sensitising effect, in addition to the well known anti-
inflammatory properties of such flavonoids and related compounds.491, 493 
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Figure 5.2 Psi-baptigenin was identified as a novel PPARγ agonist 
 
Synthetic Ligands of PPARγ 
 
Thiazolidinediones (TZDs) or “glitazones” were the first reported synthetic compounds 
demonstrating high-affinity as PPARγ agonists.479 TZDs have been shown to reduce insulin 
resistance by increasing the quantity of sugars absorbed by muscle tissues, while reducing 
the amount of sugar released by the liver.464 The thiazolidinediones bind to the PPARγ 
receptor, initiating transcription of insulin responsive genes.494 Certain effects of insulin are 
enhanced or partially mimicked, allowing the target tissues to once again become sensitive 
to the action of insulin.494-495 A large number of genes activated or suppressed by TZDs are 
involved in the metabolism of carbohydrates and lipids and are thus responsible for the 
desired antihyperglycaemic effect.473  
The large number of side effects associated with the TZDs (Section 5.2.1) has directed the 
research of several groups towards the search for new compounds, which, similarly to the 
thiazolidinediones, target the PPARγ, but minimises the associated side effects.475, 477, 480, 482, 
496-513 It is the aim of this project to also develop new compounds that act as PPARγ agonists. 
Selective PPARγ Modulators 
 
Recently, a number of compounds have been shown to bind to more than one isotype of the 
PPAR family. This class of compounds is known as dual-agonists or pan-agonists. It is 
proposed that dual agonists may provide an improved safety profile for PPAR agonists.514 
Evidence also exists that a number of the side effects associated with the current TZDs for 
treating type 2 diabetes can be minimised by only partially activating the PPARγ 
(compounds that allow this are called selective PPARγ modulators or SPPARMs). These 
SPPARMs operate by a different mode of action, binding different residues in the receptor 
than the full PPARγ agonists. This leads to a less dramatic conformational change in the 
receptor and therefore the recruitment of a different combination of coactivators, resulting in 
a different outcome and an improved safety profile.515-517 
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5.2.2 Design of Indole-Based PPARγ Agonists 
 
From the literature, a general molecular template has been identified for those compounds 
reported to show a degree of selectivity for the PPARγ (Figure 5.3).499, 508, 510 The template 
for the design of a successful PPARγ agonist consists of an acidic head, attached to an 
aromatic scaffold, which is then linked to a hydrophobic hetero-aromatic tail (Acid-Ar-
Linker-Ar). 499, 508, 510 Whilst the template allows for diversity in the Ar-Linker-Ar moieties 
employed, compounds without an acidic head were found to be biologically inactive in 
binding and functional assays.508 In the commercially available TZDs for treating type 2 
diabetes, the thiazolidinedione moiety functions as the acidic head group. 
 
Figure 5.3 The molecular template of a PPARγ agonist 
 
As outlined in chapter one, the indole scaffold has been utilised in pharmaceuticals for the 
treatment of numerous medical conditions.1, 5, 505 The indole scaffold allows for further 
derivatisation at numerous positions, making it ideal for drug development and 
optimisation.9, 505 Furthermore, several of the more effective compounds in activating the 
PPARγ are also built around an indole scaffold (Figure 5.4).496, 499-500, 502, 505, 507-508, 510, 518-520 
Evidence exists that the indole scaffold interacts with a number of amino acid residues of the 
PPARγ binding cleft,508-510 and as such the indole moiety was also chosen as the aromatic 
scaffold for the work herein. 
 
Figure 5.4 Several indole-based PPARγ agonists have been reported499, 509, 521 
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In previous studies, two indole-based compounds synthesised from tryptamine (109 and 110, 
Figure 5.5) exhibited a moderate insulin-sensitising effect, when compared to rosiglitazone 
395.2-3 These compounds were identified as lead compounds in the development of new 
potential PPARγ agonists for the treatment of type 2 diabetes 
 
Figure 5.5 Two lead compounds that exhibited a moderate insulin-sensitising ability 
 
It was considered that modification of these lead compounds could increase their insulin-
sensitising ability. Furthermore, the introduction of key characteristics identified from 
naturally occurring PPARγ agonists, for example the multiple fused heterocyclic groups 
observed in the flavonoids, could both improve biological activity and the safety profile of 
the potential PPARγ agonists. 
A simple modification to the indole-based aromatic scaffold was proposed through the 
introduction of a second N-heterocycle (Scheme 5.1), whilst keeping the acidic head group 
and aromatic tail group relatively similar to those previously used. 
 
Scheme 5.1 The proposed modification to improve the biological activity of the PPARγ agonists 
 
By introducing a second N-heterocycle onto the requisite aromatic scaffold 401, a higher 
level of preorganisation would be achieved. For tryptamine derivatives 400 (Figure 5.5), 
there is a large amount of flexibility in the linker group between the indole scaffold and the 
aromatic group. However, if a tetrahydro-β-carboline is employed, the conformational 
restriction, and therefore the direction of the tethered aromatic tail group, can be altered. 
Through the introduction of a N-heterocycle of differing size (e.g. 5, 6, 7, or 8-membered 
heterocycles), the degree of conformational restriction could ultimately be tuned to target 
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different amino acid residues within the large PPARγ binding cleft. In the case of the 
tetrahydro-β-carboline scaffold, the 6-membered N-heterocyclic ring lies almost planar to 
the indole ring. However, for the indoloazocine scaffold, the 8-membered N-heterocyclic 
ring is much more likely to adopt a distorted, non-planar conformation, allowing the 
aromatic tail group to be tethered at a much different angle than for the THβC scaffold. The 
possibility of introducing additional groups during the cyclisation process to improve 
solubility or participate in the binding process also exists. 
There are currently a range of methodologies available for accessing indole-based N-
heterocyclic scaffolds from tryptamine (2) (see Chapter One). Following synthesis of the 
selected polycyclic indole-based scaffold 402, the introduction of both the aromatic tail and 
the carboxylic acid head group would complete the functionalisation of the PPARγ agonists 
404 (Scheme 5.2) and a number of established methods exist for this purpose. 
 
Scheme 5.2 The proposed synthetic pathway to PPARγ agonists from tryptamine 
 
Once complete, the potential PPARγ agonists 404 were to be submitted for biochemical 
evaluation using a glucose uptake assay and adipocyte differentiation assay. If this initial 
analysis proved successful, further evaluation of these compounds employing more specific 
assays including the PPARγ transcription factor assay and mRNA analysis were planned.493, 
522 
 
 
 
 
  Chapter 5 
- 143 - 
5.3 Synthesis of Indole-Based PPARγ Agonists 
 
Several methods for the formation of indole-based N-heterocycles from tryptamine were 
selected. Initial investigations were carried out using the Pictet-Spengler reaction to access 
the tetrahydro-β-carboline scaffold. The Bischler-Napieralski and the gold-catalysed 
cyclisation of indolyl-alkynes to access ring systems of differing size and functionality were 
also trialled. 
5.3.1 The Pictet-Spengler Reaction 
 
The Pictet-Spengler reaction takes place between tryptamine (2) and an appropriate carbonyl 
compound (typically an aldehyde) under acid-catalysed conditions (usually TFA). In recent 
years, a number of modified protocols have been developed, including microwave heating,48-
49 the use of H2O as a solvent,523  non-acid catalysts43-44, 46, 524 and modified aldehyde 
reagents (for example nitriles and alkynes).22-23, 25, 47  
Herein, tryptamine was employed in the Pictet-Spengler reaction with an appropriate 
aldehyde partner using a range of conditions (Table 5.2). While asymmetric variants of the 
Pictet-Spengler reaction have been widely reported,51 the β-carboline scaffolds synthesised 
during this project were obtained as racemic mixtures. 
Table 5.2 Investigations into the Pictet-Spengler reaction 
 
Entry Aldehyde Conditions R Yield (%) 
1 butyraldehyde 10% TFA/H2O -(CH)2CH3 (405) 79 
2 butyraldehyde 10% TFA/CH2Cl2 -(CH)2CH3 (405) 99 
3 benzaldehyde 10% TFA/H2O -Ph (406) 88 
4 cinnamaldehyde 10% TFA/H2O -CH=CHPh (407) 0a 
5 4-pyridinecarboxaldehyde 10% TFA/H2O -4-Pyridine (408) NR 
6 4-pyridinecarboxaldehyde 1% I2 in Ethanol -4-Pyridine (408) NR 
7 formaldehyde 10% TFA/H2O -H (409) NR 
8 propionaldehyde 10% TFA/H2O -CH2CH3 (410) 0a 
9 propionaldehyde 10% TFA/CH2Cl2 -CH2CH3 (410) 0a 
10 methyl 4-formylbenzoate 10% TFA/CH2Cl2 -4-methylbenzoate (411) 69 
11 methyl 3-formylbenzoate 10% TFA/ CH2Cl2 -3-methylbenzoate (412) 87 
 
a The desired product could not be separated from the excess aldehyde using column chromatography 
 
The Pictet-Spengler reaction using 10% TFA in H2O was successful for the synthesis of the 
C1-substituted tetrahydro-β-carbolines using butyraldehyde and benzaldehyde (Table 5.2, 
entries 1, 3). The use of 10% TFA in CH2Cl2 also furnished the butyraldehyde derivative 
405 in a greater yield (99%), due to the increased solubility of both the starting materials and 
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products (Table 5.2, entry 2). Using these same conditions (10% TFA/CH2Cl2), access to 
several other functionalised indole scaffolds was realised (Table 5.2, entries 10-11). 
Unfortunately the desired product was not isolated following reaction with propionaldehyde, 
cinnamaldehyde, 4-pyridinecarboxaldehyde and formaldehyde (Table 5.2, entries 4-9). The 
modified Pictet-Spengler reaction using iodine as a catalyst in ethanol did not provide access 
to the pyridine derivative 408 (Table 5.2 entry 6).524 
The success of each reaction was readily determined by NMR spectroscopy and mass 
spectrometry. In the 1H NMR spectrum, the characteristic proton from the C1-position is 
observed between δ 4.0-5.5 ppm as a singlet or triplet depending on the substrate. In 
addition to this, the loss of the indole-C2-proton resonance, and the downfield shift and 
additional splitting patterns of the tryptamine ethylene CH2 proton resonances, confirm 
cyclisation.  
To further investigate the range of scaffolds available using this methodology, the Pictet-
Spengler reaction with ketones was trialled (Table 5.3). Traditionally, when using ketones, 
the Pictet-Spengler reaction does not occur as readily as it does for aldehydes, and often 
higher temperatures and longer reaction times are required.49 The advent of microwave 
irradiation as an effective way of reducing reaction times now means that the Pictet-Spengler 
reaction with ketones can be readily accomplished in a matter of minutes.525 
Table 5.3 The Pictet-Spengler reaction between tryptamine and a ketone  
 
Entry Ketone Conditions R Yield (%) 
1 methyl pyruvate 10% TFA/methanol, 70 oC for 4 days CO2Me (413) 99 
2 acetone CHCl3 62 oC for 3 days CH3 (415) 58 
3 acetone CHCl3 60 oC MW for 20 mins. CH3 (415) 96 
 
The reaction with methyl pyruvate (Table 5.3, entry 1) afforded the C1-disubstituted 
tetrahydro-β-carboline 413 in exceptional yield (99%), however a long reaction time was 
required (typically 4 days).526 The first reaction attempted  with acetone (Table 5.3, entry 2) 
to access the dimethyl-derivative 415 was performed under conventional heating methods 
(for 3 days) and produced the requisite tetrahydro-β-carboline in yield of 58%.527 The yield 
of this reaction was significantly enhanced (96% - Table 5.3, entry 3) when microwave 
heating was employed, allowing the reaction to take place in only 20 minutes, confirming 
the advantages of microwave irradiation. 
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The Pictet-Spengler reactions trialled so far had taken place with a primary amine at the N10-
position of tryptamine. To investigate whether the Pictet-Spengler was also possible using a 
functionalised tryptamine, reductive amination with benzaldehyde afforded the N10-benzyl 
tryptamine 178,528 which was then subject to reaction with methyl pyruvate (Scheme 5.3). 
 
Scheme 5.3 The Pictet-Spengler reaction using a functionalised tryptamine derivative 
 
Although successful, the yield for this reaction was significantly lower than that observed 
for the unfunctionalised tryptamine (Table 5.3, entry 1). This may be explained by that fact 
that with the N10-amine functionalised, the Pictet-Spengler reaction is hindered by the steric 
properties associated with the formation of the congested tetrasubstituted tetrahydro-β-
carboline. 
Functionalisation of the Tetrahydro-β-carboline Scaffolds 
 
A number of the scaffolds synthesised using Pictet-Spengler reactions were to be 
functionalised at both available nitrogens to afford potential PPARγ agonists. As the 
secondary amine is more reactive than the indole nitrogen this amine was functionalised 
first. The reactivity of this secondary amine was investigated using a range of approaches 
including amide-bond formation, acylation, alkylation and aza-Michael addition (Table 
5.4).529 
When the secondary amine of the THβC scaffold was coupled with a carboxylic acid to form 
an amide bond, the reaction was carried out in the presence of the dehydrating reagents 
EDCI and HOBt in dichloromethane.530-534 When reacting with an acid chloride, the reaction 
was performed under basic conditions in the presence of a catalytic amount of DMAP.535-536 
When functionalisation of the carboline with an alkyl halide was required, the reaction was 
performed under neutral conditions in dichloromethane.   
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Table 5.4. Investigations into the functionalisation of theC1-substituted tetrahydro-β-carbolines 
 
Entry R1 R2 Reagent (Method) Product Yield (%) 
1 Ph H acetyl chloride (A) 
 
100 
2 Ph H benzyl bromide (B) 
 
69 
3 (CH2)2CH3 H 
5-methyl-2-pyrazine 
carboxylic acid (C) 
 
34 
4 (CH2)2CH3 H hexanoyl chloride (A) 
 
60 
5 CH3 CO2Me 
5-methyl-2-pyrazine 
carboxylic acid (C) 
 
44 
Method A: Tetrahydro-β-carboline (1.0 eq), acid chloride (1.2 eq), Net3 (1.2 eq), DMAP (0.5 eq) in CH2Cl2 or DMF, 16 h. 
Method B: Tetrahydro-β-carboline (1.0 eq), benzyl bromide (1.2 eq), CH2Cl2, 16 h. 
Method C: Tetrahydro-β-carboline (1.0 eq), carboxylic acid (1.5 eq), EDCI (1.2 eq), HOBt (0.3 eq) in CH2Cl2, 16 h. 
 
Following investigation into the reactivity of selected tetrahydro-β-carboline scaffolds, it 
was determined that the secondary amine was readily functionalised in moderate to excellent 
yields using acid chlorides (Table 5.4, entries 1 and 4), carboxylic acids (Table 5.4, entries 3 
and 5) and alkyl halides (Table 5.4, entry 2). Typically, the reactions with the acid chlorides 
and alkyl halides performed better than those using carboxylic acids.  
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This reaction sequence allowed access to a series of highly functionalised tetrahydro-β-
carbolines (417 – 422) in two steps from tryptamine (2). To access a second series of 
analogues, an alternate approach to functionalising the secondary amine of the tetrahydro-β-
carbolines was envisaged, employing aza-Michael addition. To investigate this approach, a 
number of suitable conjugated Michael acceptors were prepared through reaction of acryloyl 
chloride with the requisite nitrogenous aromatic amines (Scheme 5.5). 
 
Scheme 5.4 Preparation of the acrylamide Michael acceptors 
 
With both the pyrazine (Scheme 5.4, X = N) and 2-pyridine (Scheme 5.4, X = CH) 
acrylamides in hand, the investigation into aza-Michael addition for the functionalisation of 
the carboline scaffold was carried out (Table 5.5). 
Table 5.5 Optimisation of aza-Michael addition of the tetrahydro-β-carboline 
 
Entry R1 R2 R3 Conditions Yield (%) 
1 Me Me pyrazine (425) MeOH, 25 oC, 60 h. NR 
2 Me Me pyrazine (425) NaHCO3, MeOH, 25 oC, 16 h. NR 
3 Me Me pyrazine (425) K2CO3, CHCl3 NR 
4 Me Me OMe (426) NaHCO3, CHCl3 NR 
5 Me Me OMe (426) Methanol NR 
6 Me Me 2-pyridine (427) K2CO3, DMF NR 
7 Me Me 2-pyridine (427) MeOH, THF 18 
8 (CH2)2CH3 H 2-pyridine (428) MeOH, THF 44 
 
NR = No reaction 
 
The initial reactions in this series were carried out using the C1-dimethylcarboline derivative 
415 obtained from reaction of tryptamine with acetone. Reaction of this carboline with the 
pyrazine acrylamide 424 under a range of conditions known to promote aza-Michael 
addition (Table 5.5, entries 1-3) proved unsuccessful.537-540 It was considered that the visible 
lack of solubility of the acrylamide 424 was impeding the progress of the reaction. As such, 
four more reactions using either methyl acrylate or 2-pyrazine acrylamide 423, were carried 
out (Table 5.5, entries 4-7). When using methyl acrylate the additional attempts failed to 
afford the functionalised carboline. However, when the 2-pyridine acrylamide was reacted 
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with the carboline 415 in MeOH/THF at 60 oC for 16 hours (Table 5.5, entry 7), the desired 
2-pyridinylcarboline 427 was isolated in a modest yield (18%). The identity of the isolated 
product was readily confirmed by NMR spectroscopy, with the addition of the two extra 
alkyl CH2 proton resonances and the downfield shift of the amide proton resonance 
following Michael addition (δ 9.13 ppm to δ 10.69 ppm). Thus, aza-Michael addition was a 
plausible approach for tethering the requisite aromatic tail group. 
The propyl-carboline derivative 405 was also subjected to reaction with 2-pyridine 
acrylamide 423 (Table 5.5, entry 8), using the same conditions previously successful for the 
aza-Michael addition step. Following purification of the crude material by column 
chromatography the desired product 428 from this reaction was isolated in yield of 44%. 
Once again, the dramatic downfield movement of the amide NH (δ 9.13 ppm to δ 10.91 
ppm) confirmed aza-Michael addition had taken place. Although, not occurring in 
exceptional yields, aza-Michael addition was seen as an appropriate method for installing 
the aromatic tail group on the tetrahydro-β-carboline, and as such, was used for the 
remainder of the project. 
Synthesis of the PPARγ agonist 
 
With the “Aryl-Linker-Aryl” portion of the tetrahydro-β-carboline PPARγ agonists accessed 
in two steps from tryptamine, the synthesis of the PPARγ agonist could be completed 
through introduction of the carboxylic acid group. To install the acidic head group onto the 
aromatic scaffold, a masked carboxylic acid (as an ester) would be introduced onto the 
indole-nitrogen followed by deprotection to reveal the free carboxylic acid. A number of 
approaches were considered, for example alkylation using ethyl bromoacetate. However, 
aza-Michael addition from the indole nitrogen using butyl or methyl acrylate, followed by 
saponification to reveal the carboxylic acid head, was considered the most efficient and as 
such, was investigated first. 
 
  Chapter 5 
- 149 - 
 
Scheme 5.5 Synthesis of the propyl THβC PPARγ agonist from tryptamine 
 
A number of literature methods have been reported for functionalisation of the indole-
nitrogen through aza-Michael addition.541-550 In our hands, the ester 429 was furnished in 
highest yield (46%, Scheme 5.5) when heating the propyl THβC 428 with methyl acrylate in 
K2CO3 and DMF at 100 oC for 16 hours. Saponification of the methyl ester using aqueous 
lithium hydroxide in THF264, 551-553 afforded the PPARγ agonist 430 in 68% yield (DLPR-
314). The synthesis was accomplished in only four steps from tryptamine (Scheme 5.5).  
5.3.2 The Bischler-Napieralski Reaction 
 
An alternative synthesis to the related methyl THβC was envisaged employing a Bischler-
Napieralski reaction. To install the methyl group at the C1-position of the THβC scaffold 
using a Bischler-Napieralski reaction, tryptamine (2) was first reacted with acetic anhydride 
to afford the N10-acetyl tryptamine 431 in 97% yield (Scheme 5.6). Cyclisation to form the 
new 6-membered N-heterocycle was then performed using phosphorous oxychloride in 
refluxing acetonitrile. Following a simple work, up the β-carboline 432 was isolated in 91% 
yield, with loss of the indole-C2-proton resonance and the slight downfield shift of the 
ethylene CH2 proton resonances confirming that cyclisation had taken place.  
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Following reduction of the imine 432 to free up the secondary amine, the aromatic tail group 
was installed by aza-Michael reaction, affording the functionalised methyl-THβC 434 in 
50% over two steps. The success of the aza-Michael addition step was once again confirmed 
by the downfield shift of the amide proton resonance following Michael addition (Scheme 
5.6). 
 
Scheme 5.6 Synthesis of the methyl THβC PPARγ agonist from tryptamine 
 
To install the necessary carboxylic acid functionality at the indole-nitrogen, Michael 
addition of an acrylate was again employed. Initial attempts were carried out using methyl 
acrylate; however, the desired product was inseparable from the starting material. 
Subsequent reactions were performed using the less polar butyl acrylate, and the desired 
THβC ester 435 was isolated in 66% yield (Scheme 5.6). The final step in the reaction 
sequence was saponification of the butyl ester to afford the carboxylic acid 436 using 
aqueous lithium hydroxide in THF (71 %).264, 554 
5.3.3 Gold-Catalysed Cyclisations 
 
With the synthesis of two tetrahydro-β-carboline based PPARγ agonists complete, attention 
turned to the increasing the size of the N-heterocycle to include 7- and 8-membered rings. 
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Gold-catalysed cyclisation of indoles with alkynes was chosen as an efficient route to access 
7- and 8-membered indole-based N-heterocycles (see Section 1.2.5).99-100  
 
Scheme 5.7 The gold-catalysed synthesis of indole-based N-heterocycles 
AuI = (Acetonitrile)[(2-biphenyl)di-tert-butylphosphine]gold(I) hexafluoroantimonate DNBS = Dinitrobenzenesulfonyl 
 
The size of the ring formed depends on the catalyst used with the cationic gold(I) catalyst 
forming the 7-membered ring 42 and the more electrophilic gold(III) catalyst predominantly 
resulting in the formation of the 8-membered ring 41 (Scheme 5.7). 
Au(III) cyclisation to form the 8-membered N-heterocycle 
 
The first system pursued was the 8-membered ring (Scheme 5.8). The cyclisation precursor 
was prepared from nosyl-tryptamine 140. The requisite alkyne tether was installed in 
quantitative yield by reaction of the N10-sulfonamide with propargyl bromide, in the 
presence of K2CO3 in DMF (Scheme 4.10). The successful reaction was confirmed by NMR 
spectroscopy and mass spectrometry, with the 1H NMR spectrum revealing the absence of 
the sulfonamide proton resonance, as well as the addition of the resonances attributed to the 
alkyne tether (CH2 δ 4.28 ppm, CH δ 2.24 ppm). 
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Scheme 5.8 The attempted synthesis of the indoloazocine PPARγ agonist 
 
To facilitate cyclisation to form the new 8-membered heterocycle, the indole-alkyne 437 was 
reacted with AuCl3 in dichloromethane for 16 hours.99-100 After this time, analysis of the 
crude reaction mixture confirmed that the 8-membered ring had formed (due to the alkene 
proton resonances now present) and the indoloazocine scaffold 438 was isolated in a modest 
yield of 51% (Scheme 5.8).  
Deprotection of the nosyl group was carried out using thiophenol under basic conditions to 
afford the secondary amine.555-557 Reaction of the deprotected indoloazocine with 2-pyridine 
acrylamide 423 afforded the desired aza-Michael adduct 439 in 67% yield over two steps. 
To install the carboxylic acid head group, the indoloazocine was again subject to reaction 
with methyl acrylate and K2CO3 in DMF (Scheme 5.8). The successful aza-Michael addition 
of the indole-nitrogen (in 88% yield) was confirmed through the absence of the indole-NH 
proton in the 1H NMR spectrum in addition to the new proton resonances attributed to the 
alkyl-ester now present. 
Saponification of the methyl ester 440 was attempted using aqueous sodium hydroxide, in 
ethanol.264 A trace amount of the desired product 441 was identified; however a pure sample 
could not be produced. Further attempts to scale up this reaction sequence to allow access to 
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synthetically useful amounts of the desired indoloazocine PPARγ agonist 441 (DLPR-320) 
were unsuccessful, with the aza-Michael addition of the acrylamide not performing as well 
as previously. As access to the expensive gold-catalysts at this point was limited, the 
successful synthesis of the carboxylic acid was not realised. 
Au(I) cyclisation to form the 7-membered N-heterocycle 
 
The synthesis of an azepinoindole PPARγ agonist was envisaged employing a gold-
catalysed reaction between the indole and an appropriately tethered alkyne to form the new 
7-membered N-heterocycle. The nosyl-tryptamine alkyne 437 was subjected to reaction with 
the Au(I) catalyst (acetonitrile)[(2-biphenyl)di-tert-butylphosphine]gold(I) 
hexafluoroantimonate in CH2Cl2 to afford the 7-membered heterocycle 442 in good yield of 
68% (Scheme 5.9).94, 99-100, 558-559 The identity of this product was confirmed by mass 
spectrometry and NMR spectroscopy, with the absence of the indole-C2-proton resonance 
and the addition of the terminal alkene proton resonances integrating for 2 protons. As 
observed in previous studies, once the new N-heterocycle has formed, a slight downfield 
shift and altered splitting pattern of the ethylene CH2 proton resonances was noted. 
 
Scheme 5.9 The attempted synthesis of the azepinoindole PPARγ agonist 
 
Following isolation of the azepinoindole 442, the 2-nitrobenzenesulfonyl protecting group 
was cleaved using thiophenol under basic conditions.555-557 Aza-Michael addition with 2-
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pyridine acrylamide was again used to tether the requisite aromatic tail from the secondary 
amine of the indole scaffold (in 31% yield over 2 steps). To install the masked carboxylic 
acid, the indole-nitrogen was subject to aza-Michael addition with methyl acrylate. Although 
the NMR analysis of the crude reaction mixture indicated the reaction was successful, the 
desired product 444 was inseparable from the unreacted starting material (Scheme 5.9). The 
reaction sequence was scaled up, so that the functionalisation of the indole-nitrogen could be 
attempted with the less polar butyl acrylate to allow efficient separation. However, as in the 
case of the indoloazocine PPARγ agonist (Scheme 5.8), aza-Michael addition did not 
provide a synthetically useful yield of the amide 443, and as access to the expensive gold-
catalysts at this point was limited, the successful synthesis of the carboxylic acid 445 was 
not accomplished. 
5.4 Conclusion 
 
A number of current methodologies to access tricyclic indole-based scaffolds from 
tryptamine were investigated during the synthesis of PPARγ agonists. Each of these 
methodologies had advantages in terms of the size and functionality that could be introduced 
during the formation of the new C-N heterocycle.  
The Pictet-Spengler reaction provided access to 6-membered heterocycles where a variety of 
substituents were able to be installed at the C1-position of the tetrahydro-β-carboline 
(including alkyl, aryl and ester functional groups). The secondary amine of the tetrahydro-β-
carboline was then shown to be readily functionalised using acylation, alkylation and aza-
Michael addition. The synthesis of propyl-THβC PPARγ agonist 430 (DLPR-314) was 
completed in four steps from tryptamine. 
A second method for accessing the tetrahydro-β-carboline scaffold, a Bischler-Napieralski 
reaction to synthesise the C1-methyl derivative was also used successfully. Further 
functionalisation of this indole-based scaffold afforded the methyl-THβC PPARγ agonist 
436 (DLPR-413) in good yield over 6 steps from tryptamine. 
Construction of 7- and 8-membered indole-based N-heterocyclic scaffolds as PPARγ 
agonists was also pursued. A reaction pathway involving a gold-catalysed cyclisation step 
was identified for the synthesis of these functionalised indoles. However, low yielding aza-
Michael addition steps, difficulties encountered during purification and limited access to the 
expensive gold-catalysts required means that to date, the reaction sequence has not been 
successfully completed to furnish both the azepinoindole 445 (DLPR-417) and the 
indoloazocine 441 (DLPR-320) PPARγ agonists. 
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The THβC PPARγ agonists (DLPR-314 and DLPR-413) were submitted for biochemical 
evaluation using glucose uptake and adipocyte differentiation assays to determine their 
potential as insulin-sensitising agents for the treatment of type 2 diabetes. Results from this 
analysis are still pending. 
 
 Chapter Six 
Conclusion 
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6.1 New Methodology for the Synthesis of Indole-Based N-Heterocycles 
 
To complement existing methodology, two strategies were identified for the synthesis of 
indole-based N-heterocycles from tryptamine employing a Heck reaction at the indole-2-
position. The first approach involved the tethering of a suitable olefinic cross-coupling 
partner from the N10-amine of tryptamine 113 followed by intramolecular Heck reaction at 
the indole-2-position to form the N-heterocycle 116 (Scheme 6.1). 
 
Scheme 6.1 The attempted synthesis of indole-based N-heterocycles using an intramolecular Heck 
reaction 
 
Following the investigation into both single-step and domino processes for a number of 
these substrates, a range of olefin tethers were installed in good yields, however the 
intramolecular Heck reaction failed in each case to produce the new N-heterocycle in 
synthetically useful amounts. 
The second approach investigated for the synthesis of indole-based N-heterocycles utilised 
an intermolecular Heck reaction at the indole-2-position followed by nucleophilic amine 
addition. This ultimately lead to the development of a domino Heck-aza-Michael process for 
the synthesis of a series C1-substituted tetrahydro-β-carbolines (Scheme 6.2). 
 
Scheme 6.2 The domino Heck-aza-Michael reaction for the synthesis of THβCs 
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6.2 Domino Heck-aza-Michael Reactions 
 
To further expand the scope of the domino Heck-aza-Michael reaction, the preparation of 
several additional N-heterocycles using this methodology was investigated (Schemes 6.3-
6.6). This domino process allowed access to a range of heterocyclic ring systems where the 
C1-subsituent could be readily varied through appropriate alkene selection. 
For the synthesis of benzofuran based N-heterocycles, the domino substrate 254 was 
prepared in good yield over 7 steps from 2-hydroxyacetophenone. Unfortunately, following 
the screening of several reaction conditions, only trace amounts of the domino adduct 250 
were produced (Scheme 6.3) 
 
Scheme 6.3 The attempted synthesis of benzofuran based N-heterocycles using the domino Heck-aza-
Michael methodology 
 
In a similar fashion to investigations into the benzofuran system, the benzothiophene 
domino substrate 267 was prepared in 6 steps from thiophenol. Unfortunately, the 
bromination of the benzothiophene could not be optimised above 27%, and as such 
investigation into the domino Heck-aza-Michael process was not synthetically viable 
(Scheme 6.4). 
 
Scheme 6.4 The proposed synthesis of benzothiophene based N-heterocycles 
 
The domino Heck-aza-Michael reaction sequence was next used for the synthesis of C1-
substituted tetrahydroisoquinolines (Scheme 6.5). Optimisation studies using butyl acrylate 
identified high yielding conditions for the domino process that was then applied to a range 
of electron deficient terminal alkenes to afford a series of functionalised 
tetrahydroisoquinolines. 
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Scheme 6.5 The synthesis of a series of C1-subsituted tetrahydroisoquinolines 
 
The final heterocyclic system constructed using the domino Heck-aza-Michael process was 
the isoindoline. A series of six isoindolines were successfully prepared using this 
methodology in high yields containing a variety of substituents at the C1-position (Scheme 
6.6). 
 
Scheme 6.6 The domino Heck-aza-Michael reaction developed for the synthesis of isoindolines 
 
Only commercially available electron-deficient alkenes had been employed for the domino 
Heck-aza-Michael reactions. To allow greater variation in the substituent introduced at the 
C1-position of the newly formed tetrahydroisoquinolines, a three-component process was 
developed where both acrylamide formation and the domino reaction took place in one-pot. 
A series of sixteen C1-substituted tetrahydroisoquinolines were prepared using primary 
amines, secondary amines and amino acids (Scheme 6.7). 
 
Scheme 6.7 The three-component, one-pot approach to functionalised tetrahydroisoquinolines 
 
To further extend the scope of this domino Heck-aza-Michael methodology, an asymmetric 
variant of this reaction was developed. Initial investigations were performed using chiral 
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protecting groups (up to 50% de) and chiral alkenes (up to 40% de). However the best 
results for this domino process were obtained when chiral amine substrates were employed 
(up to 92% de, Scheme 6.8). The synthesis of chiral 1,3-disubstituted tetrahydro-β-
carbolines, tetrahydroisoquinolines and isoindolines from naturally occurring amino acids 
was completed in good to excellent yields and moderate to good diastereoselectivity (with 
the major isomer determined as the cis-diastereomer by NOE NMR experiments).  
 
Scheme 6.8 The asymmetric domino Heck-aza-Michael reaction 
 
6.3 Synthesis of Indole-Based PPARγ Agonists 
 
Following investigations into the new methods for the preparation of indole-based N-
heterocycles from tryptamine, the design and synthesis of conformationally restricted 
PPARγ agonists for the treatment of type 2 diabetes was carried out. These PPARγ agonists 
were constructed around the indole-based N-heterocyclic scaffold, where, during heterocycle 
formation, the size and functionality of the new ring system formed could be readily varied. 
Two tetrahydro-β-carboline PPARγ agonists were constructed employing the Pictet-
Spengler reaction (DLPR-314 – four steps from tryptamine) or the related Bischler-
Napieralski methodology (DLPR-413 – six steps from tryptamine), and these have been 
submitted for biochemical evaluation. 
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Figure 6.1 The synthesis of two THβC PPARγ agonists from tryptamine was completed 
 
To further investigate these PPARγ agonists, the synthesis of both 7- and 8-membered 
heterocyclic systems was achieved using a gold-catalysed cyclisation process. The further 
elaboration of these indole scaffolds to afford the fully functionalised PPARγ agonists was 
only partially completed. 
 
Figure 6.2 The synthesis of PPARγ agonists containing a 7- or 8-membered N-heterocycle was 
partially completed 
 
6.4 Future Work 
 
A number of additional ideas stemming from this research project are presented in the 
following section. 
6.4.1 New Methodology for the Synthesis of Indole-Based N-Heterocycles 
 
Further to the new methods investigated during this work for the synthesis of indole-based 
N-heterocycles, two additional approaches were identified. The first would involve a 
palladium-mediated cross-coupling/hydroamination pathway for the synthesis of β-
carbolines (Scheme 6.9). 
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Scheme 6.9 The proposed cross-coupling/hydroamination reaction to access β-carbolines 
 
Following either the Heck reaction or Sonogashira reaction at the indole-2-position to install 
an alkene or alkyne respectively,235, 560 hydroamination of the N10-amine would form the new 
N-heterocycle. A range of appropriately functionalised alkenes and alkynes would lead to a 
series of C1-substituted β-carbolines 447. A similar reaction sequence for the synthesis of 
benzofused sultams was reported by Hanson et al.261 Hydroamination of both alkenes and 
alkynes is reported using palladium catalysis, in addition to a range of other conditions.439, 
561-570 Ideally, the reaction conditions could be tuned to facilitate a domino cross-
coupling/hydroamination pathway. 
New methodology for the synthesis of azepinoindoles could be accomplished employing 
allenes. One reaction sequence would involve a palladium-mediated C-C cross coupling 
reaction at the indole-2-position followed by the addition of the N10-amine, providing access 
to a series of functionalised azepinoindoles 448 or 449 (Scheme 6.10).571 Similarly, by first 
tethering an allene to the N10-amine of tryptamine,572-574 followed by the palladium-catalysed 
cross coupling at the indole-2-position, functionalised 7-membered heterocycles 451 would 
be produced (Scheme 6.10). A similar strategy, using these allenamide intermediates was 
employed in the synthesis of functionalised indoles.575 
 
Scheme 6.10 Allenes could also be used in the synthesis of azepinoindoles 
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6.4.2 Further applications of the Domino Heck-aza-Michael reaction 
 
To further explore the potential of the domino Heck-aza-Michael methodology, there are 
several additional factors that could be investigated (Scheme 6.11). These include the use of 
aryl-iodides to increase the rate of the Heck reaction, the use of more highly functionalised 
aryl-halides 452 (with both electron-withdrawing and electron-donating groups) and further 
investigations into the synthesis of ring systems of greater size (for example benzazepines 
455). 
 
Scheme 6.11 Further application of the domino Heck-aza-Michael methodology 
 
It was also considered that the use of an alternative amine protecting group (for example 
trifluoromethansulfonyl instead of the tosyl group) would allow aza-Michael addition to 
proceed for those instances where only the Heck adduct was produced. The particular 
systems where this may apply include the multicomponent approach to the tetrahydro-β-
carboline and isoindoline heterocycles, as well as for the asymmetric variant with the methyl 
ester intact. 
Further optimisation of substrate preparation and the domino reaction itself is also required 
for the asymmetric variant, to expand the scope of this process to allow the use of additional 
alkene coupling partners. The further development of a stereoselective three-component 
domino process also warrants investigation. Initial reactions employing the chiral 
phenethylamine substrate 385 resulted in 50% conversion to the domino adduct 456, 
however this was inseparable from the other major product produced, the Heck adduct 
(Scheme 6.12).  
 
  Chapter 6 
- 164 - 
 
Scheme 6.12 The asymmetric three-component domino process 
 
The application of the domino Heck-aza-Michael methodology in total synthesis could also 
be investigated. Utilising the asymmetric variant, it was envisaged that access to 
intermediates in a proposed total synthesis of both Elaeocarpidine and Ajmalicine 8 would 
be available (Scheme 6.13).22-23, 576 
 
Scheme 6.13 The domino Heck-aza-Michael reaction potentially employed in the total synthesis of 
natural products 
 
6.4.3 Indole-Based PPARγ Agonists 
 
The synthesis of both the indoloazocine and azepinoindole PPARγ agonists would need to 
be completed, and biochemical evaluation would confirm the role the size and functionality 
contained with the N-heterocyclic scaffold has on conformational restriction and therefore 
binding within the PPARγ. To further investigate the role of indole-based N-heterocycles, 
there are several other synthetic strategies available to access these scaffolds, each allowing 
for variation in the ring size and functionality introduced during N-heterocycle formation. 
 Chapter Seven 
Experimental 
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7.1 General Experimental 
 
All compounds synthesised were analysed by high resolution TOFMS, 1H NMR 
spectroscopy, and 13C NMR spectroscopy. In addition, melting points (mp) were collected 
where possible. 
Instrumentation 
 
NMR spectra were collected on either a JEOL JNM-GX 270 MHz FT-NMR spectrometer 
(Tokyo, Japan), a JEOL JNM-ECP 400 MHz FT-NMR spectrometer (Tokyo, Japan), or a 
Varian Unity + 300 MHz FT-NMR spectrometer (Palo Alto, USA) where indicated. 
Samples were dissolved in CDCl3, d3-MeOH, d6-acetone or d6-DMSO (~1 mL) and 
referenced against TMS = 0.00 ppm. Proton spectra are reported as: chemical shift (ppm) δ 
(multiplicity, coupling constant (Hz), integral, assignment). Carbon spectra are reported as 
the corresponding δ.  
High resolution TOFMS spectra were collected on an Agilent 6210 LC/MSDTOF 
spectrometer (California, USA). Analyte solutions (concentration ~ 1 mM) were prepared in 
HPLC grade MeCN and recorded in the positive or negative ion mode with a mobile phase 
(MeCN) flow rate of 5 μl min-1. HRMS spectra are reported as: molecular formula, 
calculated parent ion (m/z), observed parent ion (m/z). 
Chiral HPLC traces were collected on an Agilent 1200 series HPLC spectrometer 
(California, USA) using a UV detector. The column used was a Chiralpak AD-H column, 
and samples were run at a flow rate of 1.0 mL/min, injection volume 20 μL, at 25 oC. 
Analyte solutions (concentration ~ 1 mM) were prepared in HPLC grade 10% 
isopropanol/n-hexane. 
Reactions employing microwave irradiation were completed in a 10 mL capped vial using a 
CEM Discover microwave.  
All melting points were obtained using Stuart Scientific SMP3 melting point apparatus and 
are uncorrected. 
Chromatography 
 
Thin layer chromatography was achieved using Merck 60 F254 silica plates backed with 
aluminium. Visualisation employed a UVP Mineralight 254 nm UV lamp or an oxidising dip 
containing KMnO4 (1.0 g), K2CO3 (1.0 g) and H2O (100 mL). Heating of the ‘dipped‘ TLC 
plate with a heat-gun ensured all oxidisable compounds became visible.  
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Column chromatography was performed using Merck Kieselgel 60 (70 – 230 mesh). 
Columns were generally prepared from a slurry in a mixture of ethyl acetate/petroleum 
spirit. Products were eluted (gradient) with mixtures of EtOAc/Pet Sp and MeOH. All 
solvents were of AR grade. 
Dry Solvents 
 
THF, CHCl3 and DMF were dried using the Pure Solv (Innovative Technologies) solvent 
drying system. Solvents are degassed, and passed through two drying chambers of alumina 
and stored and collected under a positive pressure of nitrogen gas. 
Reagents 
 
All general reagents were analytical grade and used as supplied unless otherwise stated. 
Purification and/or drying of general reagents was performed according to Perrin.577 
Specialist reagents such as peptide coupling reagents and isothiocyanates were supplied by 
Aldrich Chemical Co.578 or A.K Scientific Inc.579 and used as supplied. Palladium 
tetrakis(triphenylphosphine) was prepared according to a literature procedure.580 
7.2 Specific Experimental 
 
The following sections detail the specific experimental conditions for each of the 
compounds successfully synthesised during this research project. The compounds are listed 
in chronological order according to the chapter in which they first appear. 
7.2.1 Chapter Two 
 
N-(2-(1H-indol-3-yl)ethyl)-trifluoroacetamide (459) 
To a stirring solution of tryptamine (4.0 g, 25.0 mmol) in CH2Cl2 
(40 mL) at 0 oC, was added trifluoroacetic anhydride (5.24 g, 25.0 
mmol). After 30 mins. a solution of NaHCO3 (saturated aqueous, 
20 mL) was added and stirring continued for an additional 15 
mins. After this time, the aqueous phase was extracted (CH2Cl2, 3 
× 10 mL). The combined organic phases were dried over MgSO4 and concentrated to afford 
the title compound as a light brown amorphous solid (5.444 g, 21.2 mmol, 85%). 1H NMR 
(270 MHz, CDCl3, δ) 8.05 (brs, 1H, indole-NH), 7.60 (d, J = 8.0 Hz, 1H, ArH), 7.40 (d, J = 
7.9 Hz, 1H, ArH), 7.11-7.23 (m, 2H, ArH), 7.05 (d, J = 2.5 Hz, 1H, indole-C2- ArH), 6.29 
(brs, 1H, NHCOCF3), 3.70 (q, J = 6.5 Hz, 2H, CH2CH2NH), 3.05 (t, J = 7.0 Hz, 2H, 
CH2CH2NH); 13C NMR (100 MHz, CDCl3, δ) 159.7 (q, J = 35 Hz), 137.4, 128.5, 127.2, 
121.3, 120.9, 117.9, 116.1 (q, J = 279 Hz), 112.1, 111.6, 41.4, 24.1; HRMS-ESI (m/z) 
[C12H11F3N2O + H]+ calcd 257.0896, found 257.0907. 
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N-(2-(2-bromo-1H-indol-3-yl)ethyl)-trifluoroacetamide (460) 
To a solution of trifluoroacetamide-indole 459 (542 mg, 2.12 
mmol) in CH2Cl2 (40 mL) at 0 oC was added N-bromosuccinimide 
(377 mg, 2.33 mmol) and the reaction stirred at room temperature 
for 30 mins. After this time the reaction mixture was concentrated 
and purified by column chromatography (1:9 EtOAc:Pet Sp.) to 
afford the title compound as a yellow oil that solidified on standing (587 mg, 1.75 mmol, 
83%). M.p. 101–103 °C. 1H NMR (270 MHz, CDCl3, δ): 8.13 (brs, 1H, indole-NH), 7.51 (d, 
J = 8.0 Hz, 1H, ArH), 7.30 (d, J = 7.9 Hz, 1H, ArH), 7.12-7.20 (m, 2H, ArH), 6.32 (brs, 1H, 
NHCOCF3), 3.66 (q, J = 6.4 Hz, 2H, CH2CH2NH), 3.02 (t, J = 6.6 Hz, 2H. CH2CH2NH). 13C 
NMR (125.8 MHz, d6-acetone, δ): 157.7 (q, J = 36 Hz), 137.5, 128.5, 122.8, 120.5, 118.6, 
117.1 (q, J = 288 Hz), 112.1, 111.6, 109.6, 40.4, 24.9. HRMS-ESI (m/z) [C12H10BrF3N2O + 
H]+ calcd 335.0001, found 334.9989.  
tert-butyl 2-bromo-3-(2-(trifluoroacetamido)ethyl)-1H-indole-1-carboxylate (60) 
To a stirred solution of trifluoroacetate-2-bromoindole 460 (1218 
mg, 3.63 mmol) and DMAP (45 mg, 0.36 mmol) in THF (30 mL) 
was added di-tert-butyl dicarbonate (873 mg, 4.0 mmol) in one 
portion. The resulting solution was heated to 40 °C for 30 mins. 
The reaction mixture was cooled to room temperature and 
concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (15 mL), and 
water (10 mL) was added. The phases were separated, and the aqueous phase was extracted 
with CH2Cl2 (2 × 15 mL). The combined organic phases were dried over MgSO4 and 
concentrated. Purification by column chromatography (1:9 EtOAc:Pet Sp.) afforded the title 
compound as as a white solid (1000 mg, 2.30 mmol, 63%) M.p. 115-116 °C. 1H NMR (270 
MHz, CDCl3, δ): 8.09 (d, J = 8.4 Hz, 1H, ArH), 7.46 (d, J = 7.6 Hz, 1H, ArH), 7.24-7.32 (m, 
2H, ArH), 6.43 (brs, 1H, NHCOCF3), 3.62 (q, J = 6.4 Hz, 2H, CH2CH2NH), 3.05 (t, J = 6.7 
Hz, 2H, CH2CH2NH), 1.71 (s, 9H, Boc-tBu); 13C NMR (125.8 MHz, CDCl3 δ): 157.5 (q, J = 
37.1 Hz), 149.1, 136.7, 128.6, 125.0, 123.4, 119.2, 117.8, 115.8 (q, J = 287.9 Hz), 115.6, 
110.0, 85.4, 39.3, 28.3, 24.8; HRMS-ESI (m/z) [C17H18BrF3N2O3 + H]+ calc. 435.0526; 
found 435.0535. 
3-(2-(p-toluenesulfonamido)ethyl)indole (131) 
To a cooled solution (0 oC) of tryptamine (1.0 g, 6.2 mmol) and 
triethylamine (695 mg, 6.9 mmol) in CH2Cl2 (10 mL) was added p-
toluenesulfonyl chloride (1.43 g, 7.5 mmol) in one portion. The 
reaction mixture was stirred for 2 h. at ambient temperature before 
being treated with HCl (1M, 2 × 10 mL), NaOH (Aq 5% w/w, 2 × 10 mL) and brine (10 
mL). The organic layer was separated, dried over MgSO4 and concentrated to afford the title 
compound as a pale orange solid (1.94 g, 6.2 mmol, 99%). FT-IR (ν, cm-1, KBr) 3406, 3282, 
1316, 1154, 744; 1H NMR (400 MHz, CDCl3, δ) 8.11 (brs, 1H, indole-NH), 7.63 (d, J = 8.4 
Hz, 2H, ArH), 7.40 (d, J = 8.0 Hz, 1H, ArH), 7.34 (d, J = 8.0 Hz, 1H, ArH), 7.21 (d, J = 8.0 
Hz, 1H, ArH), 7.17 (d, J = 8.0 Hz, 1H, ArH), 7.05 (t, J = 8.0 Hz, 2H, ArH), 6.97 (d, J = 2.4 
Hz, 1H, indole-C2- ArH), 4.45 (brt, J = 6.4 Hz, 1H, NHTs), 3.26 (q, J = 6.4 Hz, 2H, 
CH2CH2NH), 2.93 (t, J = 6.4 Hz, 2H, CH2CH2NH), 2.39 (s, 3H, Ts-CH3); 13C NMR (100 
MHz, CDCl3, δ) 142.1, 135.5, 135.2, 128.4, 125.8, 125.7, 121.4, 121.0, 118.2, 117.2, 110.3, 
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110.1, 41.8, 24.3, 20.3; HRMS-ESI (m/z) [C17H18N2O2S + H]+ calcd 315.1162, found 
315.1160. 
2-bromo-3-(2-(p-toluenesulfonamido)ethyl)indole (132) 
A solution of tosyl-indole 131 (600 mg, 1.9 mmol) in THF:CHCl3 
(1:1, 100 mL) was stirred at 0 oC for 15 mins. Pyridinium tribromide 
(671 mg, 2.1 mmol) was then added portion-wise over 1 h. Saturated 
aqueous sodium sulphite (10 mL) was added, and following a colour 
change to orange, saturated aqueous NaHCO3 (10 mL) was also added. The aqueous phase 
was extracted with CHCl3 (2 × 5 mL), the combined organic fractions were dried over 
MgSO4 and concentrated under reduced pressure. The crude oil was subjected to column 
chromatography (1:3 EtOAc:Pet Spirits) to afford the title compound as a clear colourless 
oil (673 mg, 90%). FT-IR (ν, cm-1, KBr) 3385, 1701, 1620, 1472, 1323, 1156, 754; 1H NMR 
(400 MHz, CDCl3, δ) 8.52 (brs, 1H, indole-NH), 7.64 (d, J = 8.2 Hz, 2H, ArH), 7.34 (d, J = 
7.9 Hz, 1H, ArH), 7.24 (m, 1H, ArH), 7.17 (d, J = 8.5 Hz, 1H, ArH), 7.17 (m, 1H, ArH), 
7.04 (m, 2H, ArH), 4.72 (brt, J = 6.1 Hz, 1H, NHTs), 3.25 (q, J = 6.7 Hz, 2H, CH2CH2NH), 
2.88 (t, J = 7.0 Hz, 2H, CH2CH2NH), 2.36 (s, 3H, TsCH3); 13C NMR (100 MHz, CDCl3, δ) 
142.1, 135.4, 134.9, 128.4, 126.0, 125.7, 121.1, 118.9, 116.5, 109.8, 109.6, 107.7, 41.5, 
24.1, 20.3; HRMS-ESI (m/z) [C17H17BrN2O2S + H]+ calcd 393.0278, found 393.0289. 
tert-butyl 2-bromo-3-(2-(p-toluenesulfonamido)ethyl)-1H-indole-1-carboxylate (133) 
To a solution containing tosyl-2-bromoindole 132 (940 mg, 2.39 
mmol) and DMAP (15 mg, 0.120 mmol) in CH2Cl2 (50 mL) was 
added di-tert-butyl dicarbonate (574 mg, 2.63 mmol). After stirring for 
2 h. at ambient temperature, water (10 mL) was added. The organic 
layer was separated, dried over MgSO4 and concentrated under reduced pressure. 
Purification by column chromatography (1:4 EtOAc:Pet Spirits) afforded the title compound 
as a clear colourless oil (633 mg, 1.28 mmol, 56%). FT-IR (ν, cm-1, KBr) 2980, 1732vs, 
1450, 1353, 1155, 1100; 1H NMR (400 MHz, CDCl3, δ) 8.01 (d, J = 8.4 Hz, 1H, ArH), 7.61 
(d, J = 8.3 Hz, 2H, ArH), 7.35 (d, J = 7.8 Hz, 1H, ArH), 7.12-7.25 (m, 4H, ArH), 4.91 (brt, 
1H, NHTs), 3.23 (q, J = 6.8 Hz, 2H, CH2CH2NH), 2.89 (t, J = 7.0 Hz, 2H, CH2CH2NH), 
2.35 (s, 3H, TsCH3), 1.69 (s, 9H, Boc-tBu); 13C NMR (100 MHz, CDCl3, δ) 147.7, 142.0, 
135.6, 135.2, 128.3, 127.2, 125.7, 123.3, 121.9, 118.0, 116.7, 114.1, 108.5, 83.9, 40.8, 27.0, 
24.7, 20.3; HRMS-ESI (m/z) [C22H25BrN2O4S + H]+ calcd 493.0791, found 493.0810. 
tert-butyl 2-bromo-3-(2-(N-(tert-butoxycarbonyl)-p-toluenesulfonamido)ethyl)-1H-
indole-1-carboxylate (134) 
To a solution containing tosyl-2-bromoindole 132 (650 mg, 1.65 mmol) 
and DMAP (10 mg, 0.08 mmol) in THF (20 mL) was added di-tert-
butyl dicarbonate (397 mg, 1.81 mmol). After stirring for 2 h. at 40 oC, 
water (10 mL) was added. The organic layer was separated, dried over 
MgSO4 and concentrated under reduced pressure. The resulting crude product was purified 
by column chromatography (1:4 EtOAc:Pet Spirits) to afford the title compound as a clear 
colourless oil (426 mg, 0.72 mmol, 44%). 1H NMR (400 MHz, CDCl3, δ) 8.07 (dd, J = 1.9 
and 7.0 Hz, 1H, ArH), 7.74 (d, J = 8.3 Hz, 2H, ArH), 7.67 (dd, J = 2.2 and 6.7 Hz, 1H, 
ArH), 7.24-7.30 (m, 4H, ArH), 3.99 (t, J = 7.8 Hz, 2H, CH2CH2NH), 3.19 (t, J = 8.1 Hz, 2H, 
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CH2CH2NH), 2.41 (s, 3H, TsCH3), 1.69 (s, 9H, Indole-NBoc), 1.36 (s, 9H, TsNBoc); 13C 
NMR (100 MHz, CDCl3, δ) 151.0, 149.2, 144.2, 137.3, 136.6, 129.3, 128.9, 128.0, 124.6, 
123.2, 119.7, 118.6, 115.3, 109.9, 85.5, 84.4, 45.7, 28.3, 28.0, 26.5, 21.7; HRMS-ESI (m/z) 
[C27H33BrN2O6S + H]+ calcd 593.1315, found 593.1306. 
N-(2-(1H-indol-3-yl)ethyl)-2-nitrobenzenesulfonamide (140) 
To a solution of tryptamine (500 mg, 3.12 mmol) and 
triethylamine (473 mg, 4.68 mmol) in CH2Cl2 (10 mL) at 0 oC 
was added 2-nitrobenzenesulfonyl chloride (761 mg, 3.43 
mmol). The reaction mixture was stirred for 2 h. at ambient 
temperature before being treated with HCl (1M, 2 × 10 mL), 
NaOH (Aq 5% w/w, 2 × 10 mL) and brine (10 mL). The 
organic layer was separated, dried over MgSO4 and concentrated to afford the title 
compound as a pale orange solid (1.017 g, 2.94 mmol, 94%). M.p. 131.5-133.6 oC 1H NMR 
(270 MHz, CDCl3, δ) 8.01 (m, 1H, ArH), 7.97 (brs, 1H, indole-NH), 7.57-7.67 (m, 3H, 
ArH), 7.30 (t, J = 7.9 Hz, 2H, ArH), 7.13 (ddd, J = 1.1 and 7.0 and 8.2 Hz, 1H, ArH), 7.01 
(d, J = 2.2 Hz, 1H, ArH), 6.95 (ddd, J = 1.1 and 7.0 and 8.0 Hz, 1H, ArH), 5.32 (t, J = 5.9 
Hz, 1H, NsNH), 3.45 (q, J = 6.5 Hz, 2H, CH2CH2NH), 2.99 (t, J = 6.6 Hz, 2H, CH2CH2NH); 
13C NMR (100 MHz, CDCl3, δ) 136.5, 135.2, 133.4, 132.7, 130.9, 126.7, 125.4, 124.4, 
122.9, 122.3, 119.6, 118.3, 111.4, 111.3, 43.8, 25.5; HRMS-ESI (m/z) [C16H15N3O4S + Na]+ 
calcd 368.0675, found 368.0683. (NB: 2-nitrobenzenesulfonyl is abbreviated as nosyl or Ns). 
N-(2-(2-bromo-1H-indol-3-yl)ethyl)-2-nitrobenzenesulfonamide (141) 
To a solution of N-nosyltryptamine 140 (500 mg, 1.45 mmol) 
in THF/CHCl3 (1:1, 100 mL) kept at 0 oC was added 
pyridinium tribromide (509 mg, 1.60 mmol) portionwise over 
1 h. After stirring for an additional 15 mins. the reaction was 
quenched by the addition of saturated aqueous Na2SO4 (10 
mL) and following a colour change saturated aqueous 
NaHCO3 (10 mL). After stirring for 15 minutes the reaction mixture was exctracted (2 × 10 
mL) and the combined organic phases were dried over MgSO4 and concentrated. The crude 
was purified by column chromatography (20% EtOAc/Pet. Sp.) to afford the title compound 
as a yellow oil (560 mg, 1.32 mmol, 91%). 1H NMR (270 MHz, CDCl3, δ) 8.09 (brs, 1H, 
indole-NH), 7.96 (m, 1H, ArH), 7.64 (m, 1H, ArH), 7.56 (m, 2H, ArH), 7.29 (d, J = 7.9 Hz, 
1H, ArH), 7.17 (dt, J = 1.0 and 8.1 Hz, 1H, ArH), 7.10 (dt, J = 1.2 and 7.0 Hz, 1H, ArH), 
6.98 (ddd, J = 1.2 and 7.0 and 8.0 Hz, 1H, ArH), 5.36 (t, J = 5.5 Hz, 1H, NsNH), 3.46 (q, J = 
6.8 Hz, 2H, CH2CH2NH), 2.95 (t, J = 6.9 Hz, 2H, CH2CH2NH); 13C NMR (100 MHz, 
CDCl3, δ) 147.5, 136.1, 133.6, 133.3, 132.7, 130.7, 127.2, 125.4, 122.6, 120.4, 117.7, 111.0, 
110.7, 109.3, 43.4, 25.4; HRMS-ESI (m/z) [C16H14N3O4BrS + H]+ calcd 423.9961, found 
423.9947. 
N-allyl-N-(2-(2-bromo-1H-indol-3-yl)ethyl)-2-nitrobenzenesulfonamide (142) 
A solution of nosyl-2-bromotryptamine 141 (173 mg, 0.41 
mmol), allyl bromide (54 mg, 0.45 mmol) and K2CO3 (85 mg, 
0.61 mmol) in acetonitrile (5 mL) was heated to 50 oC for 16h. 
The solvent was removed and the reaction mixture purified by 
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column chromatography (1:2 EtOAc:Pet Sp.) to afford the title compound as a pale orange 
oil (176 mg, 0.38 mmol, 93%). 1H NMR (270 MHz, CDCl3, δ) 8.14 (brs, 1H, indole-NH), 
7.95 (d, J = 7.6 Hz, 1H, ArH), 7.56 (m, 3H, ArH), 7.46 (d, J = 7.7 Hz, 1H, ArH), 7.22 (d, J = 
7.9 Hz, 1H, ArH), 7.12 (m, 2H, ArH), 5.79 (m, 1H, CH2CH=CH2) 5.29 (dd, J = 17.1 and 
24.1 Hz, 2H, CH2CH=CH2), 4.08 (d, J = 6.4 Hz, 2H, CH2CH=CH2), 3.49 (m, 2H, 
CH2CH2NH), 2.96 (m, 2H, CH2CH2NH); 13C NMR (67.5 MHz, CDCl3, δ) 136.3, 133.8, 
133.4, 133.1, 132.5, 131.7, 131.0, 127.2, 124.3, 122.2, 120.1, 119.8, 117.1, 113.2, 111.2, 
109.8, 50.6, 46.3, 24.7; HRMS-ESI (m/z) [C19H18N3O4SBr + H]+ calcd 464.0274, found 
464.0279. 
(E)-methyl 4-(N-(2-(2-bromo-1H-indol-3-yl)ethyl)-2-nitrophenylsulfonamido)but-2-
enoate (143) 
A solution containing nosyl-2-bromotryptamine 141 (238 
mg, 0.56 mmol), methyl-4-bromocrotonate (110 mg, 0.62 
mmol) and K2CO3 (116 mg, 0.84 mmol) in acetonitrile (5 
mL) was stirred at 60 oC for 4 h. After this time the 
solvent was evaporated. The reaction mixture was diluted with EtOAC (5 mL) and washed 
with H2O (10 mL) then brine. The organic phase was separated and dried over MgSO4. 
Purification by column chromatography (1:3 EtOAc:Pet Sp.) afforded the title compound as 
a pale yellow oil (258 mg, 0.49 mmol, 88%). 1H NMR (300 MHz, CDCl3, δ) 8.24 (brs, 1H, 
indole-NH), 7.96 (dd, J = 0.6 and 7.5 Hz, 1H, ArH), 7.58 (m, 3H, ArH), 7.40 (d, J = 7.5 Hz, 
1H, ArH), 7.21 (d, J = 14.0 Hz, 1H, ArH), 7.06-7.16 (m, 2H, ArH), 6.85 (dt, J= 6.0 and 15.7 
Hz, 1H, CH2CH=CH), 6.02 (d, J = 15.7 Hz, 1H, CH2CH=CH), 4.23 (dd, J = 1.2 and 6.0 Hz, 
2H, CH2CH=CH), 3.73 (s, 3H, CO2Me), 3.51 (t, J= 7.4 Hz, 2H, CH2CH2NH), 2.94 (dd, J = 
5.9 and 8.0 Hz, 2H, CH2CH2NH); 13C NMR (67.5 MHz, CDCl3, δ) 166.2, 147.6, 142.8, 
136.1, 133.8, 133.2, 131.9, 130.9, 127.3, 124.4, 124.2, 122.5, 120.3, 117.9, 111.2, 110.8, 
108.9, 52.0, 48.6, 47.0, 24.1; HRMS-ESI (m/z) [C21H20N3O6SBr + H]+ calcd 522.0329, 
found 522.0322. 
(E)-tert-butyl 2-bromo-3-(2-(N-(4-methoxy-4-oxobut-2-en-1-yl)-2-
nitrophenylsulfonamido)ethyl)-1H-indole-1-carboxylate (146) 
A solution containing 2-bromoindole crotonate 143 (186 
mg, 0.36 mmol), di-tert-butyl dicarbonate (94 mg, 0.43 
mmol) and DMAP (4 mg, 0.04 mmol) in CH2Cl2 (10 mL) 
was stirred at room temperature for 16 h. After this time 
H2O (10 mL) was added to quench the reaction and the aqueous phase extracted with 
CH2Cl2 (3 × 5mL). The combined organic phases were dried over MgSO4, filtered and 
concentrated. Purification by column chromatography afforded the title compound as a pale 
yellow oil (152 mg, 0.24 mmol, 69%). 1H NMR (270 MHz, CDCl3, δ) 7.99 (m, 1H, ArH), 
7.96 (dd, J = 1.3 and 1.8 Hz, 1H, ArH), 7.91 (dd, J = 1.0 and 7.8 Hz, 1H, ArH) 7.48-7.59 
(m, 2H, ArH), 7.41 (m, 1H, ArH), 7.22 (m, 2H, ArH), 6.86 (dt, J = 6.0 and 15.7 Hz, 1H, 
CH2CH=CH), 6.00 (dt, J = 1.4 and 15.7 Hz, 1H, CH2CH=CH), 4.26 (dd, J = 1.4 and 6.0 Hz, 
2H, CH2CH=CH), 3.71 (s, 3H, CO2Me), 3.48 (m, 2H, CH2CH2NH), 2.95 (m, 2H, 
CH2CH2NH), 1.67 (s, 9H, Boc-tBu); 13C NMR (67.5 MHz, CDCl3, δ) 166.0, 148.9, 147.6, 
142.5, 133.7, 133.3, 131.8, 131.0, 128.3, 124.8, 124.6, 124.4, 123.3, 119.1, 118.0, 115.5, 
109.8, 103.0, 85.3, 51.9, 48.7, 46.2, 28.3, 24.6; HRMS-ESI (m/z) [C26H28N3O8SBr +  H]+ 
calcd 622.0853, found 622.0838. 
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(E)-N-(2-(2-bromo-1H-indol-3-yl)ethyl)-N-(but-2-en-1-yl)-2-nitrobenzenesulfonamide 
(144) 
A solution containing nosyl-2-bromotryptamine 141 (295 mg, 
0.70 mmol), crotyl bromide (103 mg, 0.76 mmol), and K2CO3 
(145 mg, 1.05 mmol) in acetonitrile (5 mL) was stirred at 60 oC 
for 3 h. After this time the solvent was removed and the crude 
dissolved in EtOAC (10 mL) and washed with H2O (10 mL) 
then brine. The organic phase was dried over MgSO4 and concentrated to afford the title 
compound as a pale yellow oil (281 mg, 0.59 mmol, 84%). 1H NMR (270 MHz, CDCl3, δ) 
8.14 (brs, 1H, indole-NH), 7.94 (m, 1H, ArH), 7.53-7.59 (m, 3H, ArH), 7.44 (dd, J = 1.2 and 
6.9 Hz, 1H, ArH), 7.21 (m, 1H, ArH), 7.10 (dquin, J = 1.4 and 7.0 Hz, 2H, ArH), 5.72 (m, 
1H, CH2CH=CHCH3), 5.40 (m, 1H, CH2CH=CHCH3), 3.99 (d, J = 6.9 Hz, 2H, 
CH2CH=CHCH3), 3.46 (m, 2H, CH2CH2NH), 2.95 (m, 2H, CH2CH2NH), 1.70 (dd, J = 1.3 
and 6.4 Hz, 3H, CH2CH=CHCH3); 13C NMR (67.5 MHz, CDCl3, δ) 136.2, 133.2, 131.6, 
130.9, 128.7, 127.2, 125.6, 125.5, 124.2, 122.0, 120.0, 118.2, 115.4, 113.0, 111.1, 109.8, 
50.0, 46.7, 24.7, 17.7; HRMS-ESI (m/z) [C20H20N3O4SBr + H]+ calcd 478.0431, found 
478.0429. 
(E)-tert-butyl 2-bromo-3-(2-(N-(but-2-en-1-yl)-2-nitrophenylsulfonamido)ethyl)-1H-
indole-1-carboxylate (147) 
A solution containing crotyl-2-bromotryptamine 144 (280 mg, 
0.59 mmol), di-tert-butyl dicarbonate (192 mg, 0.88 mmol), and 
DMAP (14 mg, 0.12 mmol) in CH2Cl2 (10 mL) was heated to 
40 oC for 3 h. The reaction was quenched by addition of H2O 
(10 mL) and the reaction mixture extracted with CH2Cl2 (3 × 
5mL). The combined organic phases were dried over MgSO4 and concentrated. Purification 
by column chromatography (1:4 EtOAc:Pet Sp.) afforded the title compound as a pale 
yellow oil (149 mg, 0.26 mmol, 44%). 1H NMR (270 MHz, CDCl3, δ) 7.99 (m, 1H, ArH), 
7.92 (ddd, J = 1.1 and 1.5 and 7.3 Hz, 1H, ArH), 7.44-7.57 (m, 4H, ArH), 7.18-7.29 (m, 2H, 
ArH), 5.72 (m, 1H, CH2CH=CHCH3), 5.41 (m, 1H, CH2CH=CHCH3), 3.99 (d, J = 6.9 Hz, 
2H, CH2CH=CHCH3), 3.43 (m, 2H, CH2CH2NH), 2.99 (m, 2H, CH2CH2NH), 1.67 (s, 12H, 
CH2CH=CHCH3 and Boc-tBu); 13C NMR (67.5MHz, CDCl3, δ) 149.1, 136.5, 134.0, 133.7, 
133.4, 131.7, 131.6, 130.8, 128.6, 125.5, 124.7, 124.2, 123.2, 119.7, 118.2, 115.4, 109.6, 
85.1, 50.1, 45.1, 28.3, 24.8, 17.9; HRMS-ESI (m/z) [C25H28N3O6SBr +  H]+ calcd 578.0955, 
found 578.0967. 
N-(2-(2-bromo-1H-indol-3-yl)ethyl)-N-(3-methylbut-2-en-1-yl)-2-
nitrobenzenesulfonamide (145) 
A solution containing nosyl-2-bromotryptamine 141 (295 mg, 
0.70 mmol), dimethylallyl bromide (115 mg, 0.76 mmol), and 
K2CO3 (145 mg, 1.05 mmol) in acetonitrile (5 mL) was stirred 
at 60 oC for 3 h. After this time the solvent was removed and 
the crude dissolved in EtOAC (10 mL) and washed with H2O 
(10 mL) then brine. The organic phase was dried over MgSO4 and concentrated to afford the 
title compound as a pale yellow oil (302 mg, 0.61 mmol, 88%). 1H NMR (270 MHz, CDCl3, 
δ) 8.13 (brs, 1H, indole-NH), 7.92 (m, 1H, ArH), 7.44-7.58 (m, 4H, ArH), 7.22 (m, 1H, 
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ArH), 7.11 (dquin, J = 1.4 and 7.0 Hz, 2H, ArH), 5.14 (tt, J = 1.4 and 7.3 Hz, 1H, 
CH2CH=C(CH3)2), 4.05 (d, J = 7.2 Hz, 2H, CH2CH=C(CH3)2), 3.45 (m, 2H, CH2CH2NH), 
2.97 (m, 2H, CH2CH2NH), 1.71 (d, J = 0.9 Hz, 3H, CH2CH=C(CH3)2), 1.67 (d, J = 0.8 Hz, 
3H, CH2CH=C(CH3)2); 13C NMR (67.5MHz, CDCl3, δ) 138.0, 136.1, 133.8, 131.6, 130.7, 
129.5, 127.5, 124.2, 122.5, 120.3, 119.2, 118.1, 112.0, 110.6, 108.6, 46.5, 45.7, 26.0, 24.7, 
18.0; HRMS-ESI (m/z) [C21H22N3O4SBr - H]- calcd 490.0442, found 490.0429. 
tert-butyl 2-bromo-3-(2-(N-(3-methylbut-2-en-1-yl)-2-nitrophenylsulfonamido)ethyl)-
1H-indole-1-carboxylate (148) 
A solution containing dimethylallyl-2-bromotryptamine 145 
(300 mg, 0.61 mmol), di-tert-butyl dicarbonate (199 mg, 0.92 
mmol), and DMAP (15 mg, 0.12 mmol) in CH2Cl2 (10 mL) was 
heated to 40 oC for 3 h. The reaction was quenched by addition 
of H2O (10 mL) and the reaction mixture extracted with CH2Cl2 
(3 × 5mL). The combined organic phases were dried over MgSO4 and concentrated. 
Purification by column chromatography (1:2 EtOAc:Pet Sp.) afforded the title compound as 
a pale yellow oil (173 mg, 0.29 mmol, 48%). 1H NMR (270 MHz, CDCl3, δ) 7.99 (m, 1H, 
ArH), 7.92 (m, 1H, ArH), 7.53-7.59 (m, 3H, ArH), 7.46-7.49 (m, 1H, ArH), 7.19-7.29 (m, 
2H, ArH), 5.14 (tt, J = 2.8 and 7.3 Hz, 1H, CH2CH=C(CH3)2), 4.04 (d, J = 7.3 Hz, 2H, 
CH2CH=C(CH3)2), 3.42 (m, 2H, CH2CH2NH), 3.00 (m, 2H, CH2CH2NH), 1.71 (d, J = 0.9 
Hz, 3H, CH2CH=C(CH3)2), 1.67 (s, 12H, CH2CH=C(CH3)2 and Boc-tBu); 13C NMR (67.5 
MHz, CDCl3, δ) 149.1, 138.0, 136.5, 133.7, 133.3, 131.5, 130.8, 128.6, 124.7, 124.2, 123.2, 
119.7, 119.2, 118.2, 115.4, 109.5, 85.1, 45.9, 45.7, 28.3, 26.0, 25.3, 14.2; HRMS-ESI (m/z) 
[C26H30N3O6SBr +  H]+ calcd 592.1111, found 592.1107. 
N-(2-(2-bromo-1H-indol-3-yl)ethyl)-N-(but-3-en-1-yl)-2-nitrobenzenesulfonamide (163) 
To a cooled (0 oC) solution of nosyl-2-bromotryptamine 141 
(214 mg, 0.50 mmol), 3-buten-1-ol (40 mg, 0.55 mmol) and 
triphenylphosphine (262 mg, 1.0 mmol) in toluene (10 mL) was 
added diethylazodicarboxylate (139 mg, 0.80 mmol). The 
reaction was stirred at room temperature for 16 h. The solvent was removed and purification 
by column chromatography (1:3 EtOAc:Pet Sp.) afforded the title compound as a yellow oil 
(136 mg, 0.28 mmol, 57%). 1H NMR (300 MHz, CDCl3, δ) 8.03 (brs, 1H, indole-NH), 7.96 
(m, 1H, ArH), 7.57-7.65 (m, 3H, ArH), 7.47 (d, J = 8.4 Hz, 1H, ArH), 7.24 (m, 1H, ArH), 
7.14 (dtd, J = 1.4 and 7.0 and 16.7 Hz, 2H, ArH), 5.75 (m, 1H, CH2CH2CH=CH2), 5.07 (t, J 
= 17.2 Hz, 2H, CH2CH2CH=CH2), 3.53 (t, J = 7.7 Hz, 4H, CH2CH2CH=CH2 and 
CH2CH2NH), 2.99 (m, 2H, CH2CH2NH), 2.40 (q, J = 7.7 Hz, 2H, CH2CH2CH=CH2); 13C 
NMR (75 MHz, CDCl3, δ) 136.0, 134.3, 133.7, 133.3, 133.2, 131.5, 130.7, 127.3, 124.1, 
122.5, 120.4, 118.0, 117.5, 111.8, 110.5, 108.5, 47.1, 46.7, 32.8, 24.3; HRMS-ESI (m/z) 
[C20H20N3O4SBr -  H]- calcd 476.0285, found 476.0299. 
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tert-butyl 2-bromo-3-(2-(N-(but-3-en-1-yl)-2-nitrophenylsulfonamido)ethyl)-1H-indole-
1-carboxylate (164) 
A solution containing butene-2-bromotryptamine 163 (169 mg, 
0.35 mmol), di-tert-butyl dicarbonate (116 mg, 0.53 mmol) and 
DMAP (9 mg, 0.07 mmol) in CH2Cl2 (10 mL) was stirred at 40 
oC for 2 h. The reaction was quenched by the addition of H2O 
(10 mL) and extracted with CH2Cl2 (3 × 5 mL). The combined organic phases were dried 
over MgSO4 and concentrated. Purification by column chromatography (1:1 EtOAc:Pet Sp.) 
afforded the title compound as a pale yellow oil (179 mg, 0.31 mmol, 88%). 1H NMR (300 
MHz, CDCl3, δ) 8.04 (d, J = 8.1 Hz, 1H, ArH), 7.95 (d, J = 7.7 Hz, 1H, ArH), 7.59 (m, 3H, 
ArH), 7.46 (d, J = 8.2 Hz, 1H, ArH), 7.26 (m, 2H, ArH), 5.75 (m, 1H, CH2CH2CH=CH2), 
5.08 (t, J = 11.2 Hz, 2H, CH2CH2CH=CH2), 3.53 (m, 4H, CH2CH2CH=CH2 and 
CH2CH2NH), 3.02 (t, J = 7.2 Hz, 2H, CH2CH2NH), 2.44 (q, J = 7.2 Hz, 2H, 
CH2CH2CH=CH2), 1.68 (s, 9H, Boc-tBu); 13C NMR (75 MHz, CDCl3, δ) 149.3, 136.2, 
134.4, 133.7, 133.3, 133.1, 132.5, 130.5, 127.3, 124.1, 122.6, 120.3, 118.0, 117.8, 111.8, 
110.5, 108.5, 84.8, 47.3, 46.8, 33.1, 28.3, 24.1; HRMS-ESI (m/z) [C25H28N3O6SBr +  H]+ 
calcd 578.0955, found 578.0953. 
(E)-tert-butyl 2-bromo-3-(2-(N-(3-methoxy-3-oxoprop-1-en-1-yl)-2-nitrophenyl 
sulfonamido)ethyl)-1H-indole-1-carboxylate (175) 
To a solution containing nosyl-2-bromotryptamine 141 (373 
mg, 0.88 mmol) and methyl propiolate (96 mg, 1.1 mmol) in 
acetonitrile (10 mL) at 0 oC was added N,N-
dicyclohexylmethylamine (223 mg, 1.1 mmol) dropwise 
over 10 mins. After stirring at 0 oC for 2 h. the solvent was 
removed. The reaction mixture was dissolved in EtOAc and washed with HCl (0.1 M, 4 × 10 
mL). The organic phase was dried over MgSO4 and concentrated to afford the title 
compound as a pale yellow oil (383 mg, 0.75 mmol, 86%). 1H NMR (270 MHz, CDCl3, δ) 
8.55 (brs, 1H, indole-NH), 8.10 (d, J = 14.1 Hz, 1H, CH=CHCO2Me), 7.97 (d, J = 7.4 Hz, 
1H, ArH), 7.64 (m, 3H, ArH), 7.46 (m, 1H, ArH), 7.22 (m, 1H, ArH), 7.10-7.17 (m, 2H, 
ArH), 5.52 (d, J = 14.1 Hz, 1H, CH=CHCO2Me), 3.78 (s, 3H, CO2Me), 3.70 (m, 2H, 
CH2CH2NH), 3.05 (m, 2H, CH2CH2NH); 13C NMR (75 MHz, CDCl3, δ) 163.7, 141.2, 137.6, 
134.5, 133.7, 133.5, 132.8, 131.0, 128.4, 125.5, 124.0, 122.9, 121.0, 118.0, 113.6, 110.4, 
110.3, 53.0, 43.1, 25.8; HRMS-ESI (m/z) [C20H18N3O6SBr +  H]+ calcd 508.0172, found 
508.0183. 
(E)-tert-butyl 2-bromo-3-(2-(N-(3-methoxy-3-oxoprop-1-en-1-yl)-2-nitrophenyl 
sulfonamido)ethyl)-1H-indole-1-carboxylate (176) 
A solution containing acrylate-2-bromotryptamine 175 (383 
mg, 0.75 mmol), di-tert-butyl dicarbonate (247 mg, 1.13 
mmol) and DMAP (18 mg, 0.15 mmol) in CH2Cl2 (10 mL) 
was stirred at room temperature for 2 h. The reaction was 
quenched by the addition of H2O (10 mL) and the reaction 
mixture extracted with CH2Cl2 (3 × 5 mL). The combined organic phases were dried over 
MgSO4 and concentrated. Purification by column chromatography (1:2 EtOAc:Pet Sp.) 
afforded the title compound as a pale yellow oil (304 mg, 0.50 mmol, 66%). 1H NMR (270 
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MHz, CDCl3, δ) 8.09 (d, J = 14.1 Hz, 1H, CH=CHCO2Me), 8.00 (m, 1H, ArH), 7.94 (m, 1H, 
ArH), 7.62-7.69 (m, 3H, ArH), 7.48 (m, 1H, ArH), 7.26 (m, 2H, ArH), 5.55 (d, J = 14.1 Hz, 
1H, CH=CHCO2Me), 3.77 (s, 3H, CO2Me), 3.71 (m, 2H, CH2CH2NH), 3.10 (m, 2H, 
CH2CH2NH), 1.68 (s, 9H, Boc-tBu); 13C NMR (270 MHz, CDCl3, δ) 167.2, 148.9, 147.8, 
141.2, 136.5, 134.9, 132.3, 131.3, 131.2, 128.3, 125.1, 124.9, 123.4, 118.6, 117.9, 115.5, 
110.0, 98.9, 85.4, 51.7, 45.1, 28.3, 23.1; HRMS-ESI (m/z) [C25H26N3O8SBr +  H]+ calcd 
608.0697, found 608.0711. 
7.2.2 Chapter Three 
 
(E)-butyl 3-(3-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-indol-2-yl)acrylate (207) 
A sealed tube containing N10-Boc-2-bromotryptamine 206 (200 
mg, 0.59 mmol), potassium carbonate (246 mg, 1.77 mmol), butyl 
acrylate (226 mg, 1.77 mmol), tetrakis(triphenylphosphine) 
palladium (136.0 mg, 10 mol%) and toluene (2 ml) was heated to 
120 oC for 16 h.. The solvent was concentrated, then the crude 
reaction mixture taken up in EtOAc (5 ml) and enough silica added so that a dry powder was 
formed when the solvent was concentrated. Purification by column chromatography (1:7 
EtOAc/Pet Sp.) afforded the title compound as a pale yellow oil (143 mg, 0.37 mmol, 63%). 
1H NMR (400 MHz, CDCl3, δ) 8.46 (brs, 1H, indole-NH). 7.74 (d, J = 15.7 Hz, 1H, 
CH=CHCO2nBu), 7.61 (d, J = 8.0 Hz, 1H, ArH), 7.31 (d, J = 8.0 Hz, 1H, ArH), 7.26 (dt, J = 
1.1 and 8.0 Hz, 1H, ArH), 7.09 (dt, J = 1.1 and 8.0 Hz, 1H, ArH), 6.20 (d, J = 15.7 Hz, 1H, 
CH=CHCO2nBu), 4.56 (t, J = 5.8 Hz, 1H, NHBoc), 4.21 (m, 2H, CO2nBu), 3.39 (q, J = 6.2 
Hz, 2H, CH2CH2NH), 3.07 (t, J = 6.6 Hz, 2H, CH2CH2NH), 1.70 (m, 2H, CO2nBu), 1.45 (m, 
2H, CO2nBu), 1.42 (s, 9H, Boc-tBu), 0.96 (m, 3H, CO2nBu); 13C NMR (100 MHz, CDCl3 δ) 
167.1, 155.9, 137.5, 131.7, 130.6, 128.5, 125.2, 120.3, 120.1, 119.8, 114.9, 111.1, 79.3, 
64.6, 41.5, 30.9, 28.5, 25.0, 19.3, 13.9; HRMS-ESI (m/z) [C22H30N2O4 +  H]+ calcd 
387.2278, found 387.2275. 
(R,S)-methyl 2,3,4-tetrahydro-1H-carbolin-1-yl)acetate (210) 
To a solution of N10-Boc-2-acrylatetryptamine 207 (140 mg, 
0.36 mmol) in CH2Cl2 (9 mL) was added TFA (1 mL). After 
stirring at room temperature for 1 h. additional TFA (1 mL) was 
added and stirring continued for 1 h. After this time the solvent 
was removed and the reaction mixture dissolved in methanol (5 
mL) and sodium methoxide added (158 mg, 2.92 mmol). The resultant mixture was stirred at 
room temperature for 16 h. after which time the reaction mixture was concentrated and 
purified by column chromatography (1:8 MeOH:EtOAc) to afford the title compound as a 
clear oil (24 mg, 0.10 mmol, 27% over 2 steps). 1H NMR (270 MHz, CDCl3, δ) 8.57 (brs, 
1H, NH9), 7.49 (d, J = 7.5 Hz, 1H, ArH), 7.32 (d, J = 7.8 Hz, 1H, ArH), 7.15 (dt, J = 1.1 
and 7.1 Hz, 1H, ArH) 7.07 (dt, J = 1.3 and 7.6 Hz, 1H, ArH), 4.50 (t, J = 6.6 Hz, 1H, H1), 
3.75 (s, 3H, CO2Me), 3.23 (m, 1H, H3a), 3.10 (m, 1H, H3b), 2.86 (d, J = 6.8 Hz, 2H, H4), 
2.74 (t, J = 5.6 Hz, 2H, H1’), 2.53 (brs, 1H, NH2); 13C NMR (67.5 MHz, CDCl3 δ) 173.7, 
135.6, 134.7, 127.2, 121.9, 119.4, 118.2, 111.1, 109.1, 52.2, 48.8, 41.9, 40.5, 22.5; HRMS-
ESI (m/z) [C14H16N2O2 + H]+ calcd 245.1285, found 245.1292. 
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(E)-tert-butyl 2-(3-butoxy-3-oxoprop-1-en-1-yl)-3-(2-(trifluoroacetamido)ethyl)-1H-
indole-1-carboxylate (211) 
A sealed tube containing trifluoroacetate-2-bromoindole 60 (170 
mg, 0.39 mmol), Pd(PPh3)4 (45 mg, 10 mol%), Na2CO3 (124 mg, 
1.17 mmol) and butyl acrylate (75 mg, 0.59 mmol) in toluene (2 
mL) was heated at 120 oC for 16 hrs. The resulting mixture was 
cooled to room temperature, and concentrated under reduced 
pressure. The crude product was purified by column chromatography (1:9 EtOAc:Pet Sp) to 
afford the title compound as a clear oil (110 mg, 0.23 mmol, 58%). 1H NMR (400 MHz, 
CDCl3, δ) 8.17 (d, J = 8.4 Hz, 1H, ArH), 7.94 (d, J = 16.2 Hz, 1H, CH=CHCO2nBu), 7.62 
(d, J = 7.8 Hz, 1H, ArH), 7.37 (t, J = 8.0 Hz, 1H, ArH), 7.27 (t, J = 7.8 Hz, 1H, ArH), 6.56 
(brs, 1H, NH), 6.11 (d, J = 16.2 Hz, 1H, CH=CHCO2nBu), 4.21 (t, J = 6.7 Hz, 2H, 
CO2nBu), 3.65 (q, J = 6.7 Hz, 2H, CH2CH2NH), 3.12 (t, J = 7.6 Hz, 2H, CH2CH2NH), 1.69 
(m, 2H, CO2nBu), 1.65 (s, 9H, Boc-tBu), 1.43 (m, 2H, CO2nBu), 0.96 (t, J = 7.5 Hz, 3H, 
CO2nBu); HRMS-ESI (m/z) [C24H29N2O5F3 + H]+ calcd 483.2101, found 483.2107. 
(R,S)-methyl 2-(9-tert-butoxycarbonyl)-2,3,4-tetrahydro-1H-carbolin-1-yl)acetate (213) 
A solution containing 2-acrylatetryptamine 211 (122 mg, 0.25 
mmol) and K2CO3 (70 mg, 0.51 mmol) in methanol/H2O (7:3, 
10 mL) was heated at 60 oC for 2 h. The volatiles were removed, 
and EtOAc (30 mL) was added and the reaction mixture washed 
with H2O (10 mL) then brine. The organic phase was separated, 
dried over MgSO4 and concentrated. Purification by column 
chromatography (1:1 EtOAc: Pet Sp.) afforded the title compound as a pale yellow oil (50 
mg, 0.15 mmol, 57%). 1H NMR (300 MHz, CDCl3, δ) 8.12 (d, J = 7.6 Hz, 1H, ArH), 7.42 
(dd, J = 1.5 and 6.7 Hz, 1H, ArH), 7.20-7.32 (m, 2H, ArH), 5.06 (d, J = 9.1, 1H, H1), 3.75 
(s, 3H, CO2Me), 3.20 (m, 2H, H3), 3.00 (dd, J = 2.8 and 16.1 Hz, 1H, H4a), 2.74 (m, 3H, 
H4b and H1’), 2.15 (brs, 1H, NH2), 1.67 (s, 9H, Boc-tBu); 13C NMR (75 MHz, CDCl3 δ) 
172.3, 150.1, 135.9, 135.2, 129.2, 124.4, 122.8, 118.0, 116.2, 115.8, 84.3, 51.8, 49.7, 38.0, 
37.4, 28.2, 22.0; HRMS-ESI (m/z) [C19H24N2O4 + H]+ calcd 345.1809, found 345.1802. 
3-(2-(benzenesulfonamido)ethyl)indole (461) 
To a solution of tryptamine (500 mg, 3.12 mmol) and 
triethylamine (474 mg, 4.68 mmol) in CH2Cl2 (20 mL) was added 
benzenesulfonyl chloride (606 mg, 3.43 mmol). After stirring at 
room temperature for 16 h. the reaction mixture was washed with 
HCl (1M, 2 × 10 mL), NaOH (Aq 5% w/w, 2 × 10 mL) and brine 
(10 mL). The organic layer was separated, dried over MgSO4 and concentrated under 
reduced pressure to afford the title compound as a pale orange oil (865 mg, 2.88 mmol, 
93%). 1H NMR (270 MHz, CDCl3, δ) 8.29 (brs, 1H, indole-NH), 7.78 (d, J = 7.5 Hz, 2H, 
ArH), 7.31-7.53 (m, 5H, ArH), 7.18 (t, J = 6.9 Hz, 1H, ArH), 7.07 (t, J = 7.3 Hz, 1H, ArH), 
6.87 (s, 1H, indole-C2-ArH), 4.94 (brt, 1H, CH2CH2NH), 3.27 (q, J = 6.1 Hz, 2H, 
CH2CH2NH), 2.89 (t, J = 6.3 Hz, 2H, CH2CH2NH); 13C NMR (67.5 MHz, CDCl3, δ) 139.8, 
136.5, 132.8, 129.2, 127.1, 127.0, 123.0, 122.2, 119.5, 118.6, 111.7, 111.5, 43.4, 25.6; 
HRMS-ESI (m/z) [C16H16N2O2S + H]+ calcd 393.0279, found 393.0289. 
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2-bromo-3-(2-(benzenesulfonamido)ethyl)indole (462) 
To a cooled solution of benzenesulfonyltryptamine 461 (1683 mg, 
5.60 mmol) in THF:CHCl3 (1:1, 100 mL) was added pyridinium 
tribromide (1970 mg, 6.16 mmol) portionwise over 90 mins. 
Saturated aqueous sodium sulphite (10 mL) was added, and 
following a colour change, saturated aqueous NaHCO3 (10 mL) 
was also added. The aqueous phase was extracted with CHCl3 (3 × 5 mL), the combined 
organic fractions were dried over MgSO4 and concentrated under reduced pressure. The 
crude oil was subjected to column chromatography (1:4 EtOAc:Pet Spirits) to afford the title 
compound as a clear colourless oil (1753 mg, 4.62 mmol, 83%). 1H NMR (270 MHz, 
CDCl3, δ) 8.40 (brs, 1H, indole-NH), 7.77 (d, J = 7.5 Hz, 2H, ArH), 7.33-7.49 (m, 4H, ArH), 
7.23 (d, J = 7.9 Hz, 1H, ArH), 7.13 (t, J = 7.1 Hz, 1H, ArH), 7.04 (t, J = 7.7 Hz, 1H, ArH), 
4.71 (t, J = 5.9 Hz, 1H, CH2CH2NH), 3.24 (q, J = 6.5 Hz, 2H, CH2CH2NH), 2.87 (t, J = 6.8 
Hz, 2H, CH2CH2NH); 13C NMR – due to rapid degradation of the compound a clean 
spectrum was not obtained. HRMS-ESI (m/z) [C16H15N2O2SBr + H]+ calcd 379.0110, found 
379.0093.  
(E)-butyl 3-(3-(2-(2-nitrophenylsulfonamido)ethyl)-1H-indol-2-yl)acrylate (220) 
A sealed tube containing nosyl-2-bromotryptamine 141 (550 mg, 
1.3 mmol), Pd(PPh3)4 (150 mg, 10 mol%), K2CO3 (540 mg, 3.9 
mmol) and butyl acrylate (183 mg, 1.43 mmol) in toluene (5 mL) 
was heated at 120 oC for 16 hrs. The resulting mixture was cooled 
to room temperature, and concentrated under reduced pressure. 
The crude product was purified by column chromatography (1:2 EtOAc:Pet Sp) to afford the 
title compound as a clear oil (306 mg, 0.65 mmol, 50%). 1H NMR (270 MHz, CDCl3, δ) 
8.53 (brs, 1H, indole-NH), 7.96 (m, 1H, CH=CHCO2nBu), 7.70 (m, 2H, ArH), 7.58 (m, 2H, 
ArH), 7.44 (d, J = 7.9 Hz, 1H, ArH), 7.20-7.27 (m, 2H, ArH), 6.97-7.03 (m, 1H, ArH), 6.19 
(d, J = 15.9 Hz, 1H, CH=CHCO2nBu), 5.46 (t, J = 5.8 Hz, 1H, CH, NsNH), 4.18 (t, J = 6.7 
Hz, 2H, CO2nBu), 3.43 (q, J = 6.0 Hz, 2H, CH2CH2NH), 3.09 (t, J = 6.8 Hz, 2H, 
CH2CH2NH), 1.68 (m, 2H, CO2nBu), 1.43 (m, 2H, CO2nBu), 0.95 (t, J = 7.3 Hz, 3H, 
CO2nBu); 13C NMR (67.5 MHz, CDCl3, δ) 166.0, 146.1, 136.2, 132.3, 132.1, 131.5, 130.0, 
129.7, 129.2, 126.5, 124.1, 123.8, 119.0, 118.0, 116.1, 114.1, 110.2, 63.4, 43.1, 29.5, 23.5, 
179, 12.5; HRMS-ESI (m/z) [C23H25N3O6S + Na]+ calcd 494.1356, found 494.1372. 
N1-Benzyl-2-bromo-3-(2-(p-toluenesulfonylamido)ethyl)indole (222) 
A solution containing 2-bromoindole 132 (230 mg, 0.58 mmol), and 
NaH (42 mg, 1.7 mmol) in THF (10 mL) was stirred at 0 oC for 30 
mins. After this time, benzyl bromide (110 mg, 0.64 mmol) was added 
and the reaction mixture stirred at ambient temperature for 16 hrs. The 
reaction was treated with water (10 mL) and the aqueous phase extracted with EtOAc (3 × 
10 mL). The combined organic fractions were dried (MgSO4) and concentrated under 
reduced pressure. The crude product was purified by column chromatography (1:4 
EtOAc/Pet Sp) to afford the title compound as a clear colourless oil (110 mg, 0.23 mmol, 
39%). FT-IR (ν, cm-1, KBr) 1598, 1454, 1327, 1157, 1092, 813, 739; 1H NMR (300 MHz, 
CDCl3, δ) 7.68 (d, J = 8.2 Hz, 2H, ArH), 7.43 (d, J = 7.9 Hz, 1H, ArH), 7.06-7.29 (m, 10H, 
ArH), 5.37 (s, 2H, CH2Ph), 4.58 (brt, 1H, TsNH2), 3.29 (q, J = 6.5 Hz, 2H, CH2CH2NH), 
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2.98 (t, J = 6.9 Hz, 2H, CH2CH2NH), 2.40 (s, 3H, TsCH3); 13C NMR (75 MHz, CDCl3, δ) 
143.2, 136.9, 136.6, 129.6, 128.8, 127.6, 127.2, 127.0, 126.4, 122.4, 120.2, 118.0, 113.7, 
111.0, 110.0, 48.3, 42.8, 26.0, 21.5; HRMS-ESI (m/z) [C24H23BrN2O2S + H]+ calcd 
483.0747, found 483.0752. 
N1-(p-toluenesulfonyl)-2-bromo-3-(2-(p-toluenesulfonylamido)ethyl)indole (224) 
A solution containing 2-bromoindole 132 (218 mg, 0.55 mmol), 
DMAP (14 mg, 0.11 mmol), DIPEA (86 mg, 0.66 mmol) and tosyl 
chloride (116 mg, 0.61 mmol) in CH2Cl2 (10 mL) was stirred at 
ambient temperature for 4 hrs. The ensuing mixture was treated with 
water (10 mL) and the reaction mixture was extracted with CH2Cl2 (3 × 5 mL). The 
combined organic phases were dried (MgSO4) and concentrated under reduced pressure. The 
crude mixture was purified by column chromatography (1:4 EtOAc/Pet Sp) to afford the title 
compound as a clear colourless oil (97 mg, 0.18 mmol, 32%). FT-IR (ν, cm-1, KBr) 1596, 
1444, 1379, 1326, 1156, 1088, 813, 748, 670, 571; 1H NMR (300 MHz, CDCl3, δ) 8.23 (d, J 
= 9.0 Hz, 1H, ArH), 7.72 (d, J = 9.0 Hz, 2H, ArH), 7.55 (d, J = 9.0 Hz, 2H, ArH), 7.16-7.33 
(m, 7H, ArH), 4.47 (brs, 1H, TsNH), 3.17 (q, J = 6.0 Hz, 2H, CH2CH2NH), 2.82 (t, J = 6.0 
Hz, 2H, CH2CH2NH), 2.39 (s, 3H, TsCH3), 2.34 (s, 3H, TsCH3); 13C NMR (75 MHz, CDCl3, 
δ) 145.4, 143.4, 137.3, 136.6, 135.1, 129.8, 129.6, 129.1, 127.0, 126.8, 125.2, 124.0, 121.3, 
118.2, 115.4, 109.9, 41.7, 26.0, 21.6, 21.5; HRMS-ESI (m/z) [C24H23BrN2O4S2 + H]+ calcd 
547.0355, found 547.0338. 
N-(2-(2-bromo-1H-indol-3-yl)ethyl)-N-tosylacetamide (229) 
To a solution of tosyl-2-bromotryptamine 132 (801 mg, 2.04 mmol) 
in THF (40 mL) at 0 oC was added sodium hydride (49 mg, 2.04 
mmol). After 30 mins. acetyl chloride (160 mg, 2.04 mmol) was 
added and the resultant mixture stirred at room temperature for 16 h. 
To reaction was quenched by addition of H2O (10 mL) and extracted 
EtOAc (2 × 10 mL). The combined organic phases were washed with brine, dried over 
MgSO4 and concentrated to afford the title compound as a pale pink amorphous solid (779 
mg, 1.79 mmol, 88%). 1H NMR (270 MHz, CDCl3, δ) 8.20 (brs, 1H, indole-NH), 7.78 (d, J 
= 8.3 Hz, 2H, ArH), 7.68 (m, 1H, ArH), 7.30 (d, J = 8.1 Hz, 2H, ArH), 7.26 (m, 1H, ArH), 
7.12-7.19 (m, 2H, ArH), 3.94 (m, 2H, CH2CH2NH), 3.12 (m, 2H, CH2CH2NH), 2.41 (s, 3H, 
TsCH3), 2.37 (s, 3H, COMe); 13C NMR (67.5 MHz, CDCl3, δ) 170.3, 145.0, 136.8, 136.2, 
130.1, 130.0, 127.7, 127.6, 127.4, 122.6, 120.5, 118.5, 112.0, 110.5, 108.8, 46.6, 25.4, 25.2, 
21.7; HRMS-ESI (m/z) [C19H19BrN2O3S + H]+ calcd 435.0373, found 435.0382. 
tert-butyl 2-bromo-3-(2-(N-tosylacetamido)ethyl)-1H-indole-1-
carboxylate (230) 
To a solution of tosyl-2-bromotryptamine 132 (564 mg, 1.43 mmol) 
in THF (20 mL) at 0 oC was added sodium hydride (52 mg, 2.15 
mmol). After 20 mins. acetyl chloride (124 mg, 1.58 mmol) was 
added and the resultant mixture stirred at room temperature for 1 h. 
To this solution was then added DMAP (18 mg, 0.14 mmol) and di-tert-butyl dicarbonate 
(344 mg, 1.58 mmol) and reaction mixture heated at 40 oC for 30 mins. After cooling to 
room temperature, H2O (10 mL) was added and extracted with EtOAc (2 × 10 mL). The 
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combined organic phases were dried over MgSO4 and concentrated. Purification by column 
chromatography (1:4 EtOAc:Pet Sp.) afforded the title compound as a clear oil (503 mg, 
0.94 mmol, 66%). 1H NMR (270 MHz, CDCl3, δ) 8.05 (m, 1H, ArH), 7.72 (d, J = 8.4 Hz, 
2H, ArH), 7.68 (m, 1H, ArH), 7.25-7.30 (m, 4H, ArH), 3.91 (m, 2H, CH2CH2NH), 3.14 (m, 
2H, CH2CH2NH), 2.42 (s, 3H, TsCH3), 2.35 (s, 3H, COMe), 1.69 (s, 9H, Boc-tBu); 13C 
NMR (75 MHz, CDCl3, δ) 170.2, 149.1, 145.0, 136.7, 136.4, 129.9, 128.6, 127.6, 127.4, 
124.6, 123.2, 119.5, 118.4, 115.3, 109.8, 85.0, 45.5, 28.2, 25.7, 25.2, 21.6; HRMS-ESI (m/z) 
[C24H27BrN2O5S + H]+ calcd 535.0897, found 535.0888. 
tert-butyl 2-bromo-3-(2-(p-toluenesulfonamido)ethyl)-1H-indole-1-carboxylate (133) 
To a solution of N-tosylacetamido-2-bromotryptamine 230 (503 mg, 
0.94 mmol) in THF (10 mL) was added hydrazine monohydrate (79 
mg, 1.58 mmol) and the reaction mixture stirred for 3 h. at room 
temperature. The reaction was quenched by the addition of H2O (10 
mL) and extracted with EtOAc (2 × 10 mL). The combined organic phases were washed 
with brine, dried over MgSO4 and concentrated to afford the title compound as a clear oil 
(343 mg, 0.70 mmol, 74%). The characterisation data obtained for this compound was 
identical to that previously reported in Section 7.2.1. 
(E)-butyl 3-(3-(2-(p-toluenesulfonylamido)ethyl)-1H-indol-2-yl)acrylate (216) 
A sealed tube containing 2-bromoindole 132 (92 mg, 0.23 mmol), 
Pd(PPh3)4 (27 mg, 0.023 mmol), Na2CO3 (74 mg, 0.70 mmol) and 
butyl acrylate (33 mg, 0.26 mmol) in toluene (2 mL) was heated 
at 120 oC for 16 hrs. The resulting mixture was cooled to room 
temperature, and concentrated under reduced pressure. The crude 
product purified by column chromatography (1:4 EtOAc:Pet Sp) to afford the title 
compound as an orange oil (102 mg, 99%). FT-IR (ν, cm-1, KBr) 3345, 1692s, 1623, 1454, 
1321, 1181, 1156, 744; 1H NMR (400 MHz, CDCl3, δ) 8.58 (brs, 1H, indole-NH), 7.69 (d, J 
= 16.0 Hz, 1H, CH=CHCO2nBu), 7.65 (d, J = 8.2 Hz, 2H, ArH), 7.46 (d, J = 8.0 Hz, 1H, 
ArH), 7.30 (d, J = 8.2 Hz, 1H, ArH), 7.22 (d, J = 8.0 Hz, 2H, ArH), 7.06 (t, J = 8.0 Hz, 2H, 
ArH), 6.20 (d, J = 16.0 Hz, 1H, CH=CHCO2nBu), 4.70 (t, J = 6.0 Hz, 1H, TsNH), 4.11 (t, J 
= 6.8 Hz, 2H, CO2nBu), 3.23 (q, J = 6.6 Hz, 2H, CH2CH2NH), 3.05 (t, J = 6.8 Hz, 2H, 
CH2CH2NH), 2.38 (s, 3H, TsCH3), 1.63 (m, J = 8.0 Hz, 2H, CO2nBu), 1.42 (m, J = 7.5 Hz, 
2H, CO2nBu), 0.95 (t, J = 7.5 Hz, 3H, CO2nBu); 13C NMR (100 MHz, CDCl3, δ) 165.8, 
142.1, 136.1, 135.6, 130.1, 129.5, 128.4, 126.7, 125.7, 123.9, 119.1, 118.3, 116.7, 114.0, 
110.0, 63.3, 42.4, 29.5, 23.7, 20.2, 17.9, 12.5; HRMS-ESI (m/z) [C24H28N2O4S + H]+ calcd 
441.1843, found 441.1827. 
General procedure A for the synthesis of tetrahydro-β-carbolines: 
A sealed tube containing a 2-bromoindole (1.0 eq), Pd(PPh3)4 (10 mol%), K2CO3 (3.0 eq) 
and butyl acrylate (1.1 eq) in toluene was heated at 120 oC for 16 hrs. The reaction mixture 
was cooled to room temperature, the solvent removed in vacuo and the crude product 
purified by column chromatography using the solvent system specified. 
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(R,S)-butyl 2-(2-(p-toluenesulfonyl)-3,4,9-tetrahydro-1H-carbolin-1-yl)acetate (215) 
General procedure A was followed using 2-bromoindole 
132 (92 mg, 0.23 mmol), Pd(PPh3)4  (27 mg, 10 mol%), 
K2CO3 (97 mg, 0.70 mmol) and butyl acrylate (33 mg, 
0.26 mmol) in toluene (2 mL). Purification by column 
chromatography (1:4 EtOAc:Pet Sp) afforded the title 
compound as a pale yellow oil (31 mg, 0.07 mmol, 
30%). FT-IR (ν, cm-1, KBr) 3395, 1726s, 1455, 1337, 1158, 743; 1H NMR (400 MHz, 
CDCl3, δ) 8.77 (brs, 1H, NH9), 7.65 (d, J = 8.3 Hz, 2H, ArH), 7.33 (d, J = 8.0 Hz, 1H, ArH), 
7.29 (d, J = 8.1 Hz, 1H, ArH), 7.12-7.16 (m, 3H, ArH), 7.04 (dt, J = 1.0 and 7.0 Hz, 1H, 
ArH), 5.49 (dd, J = 3.0 and 10.6 Hz, 1H, H1), 4.19 (m, 3H, H5’ and H3a), 3.34 (m, 1H, 
H3b), 3.15 (dd, J = 3.3 and 17.3 Hz, 1H, H4a), 3.00 (dd, J = 10.7 and 17.3 Hz, 1H, H4b), 
2.50 (m, 2H, H1’), 2.28 (s, 3H, TsCH3), 1.63 (m, J = 7.9 Hz, 2H, H6’), 1.37 (m, J = 7.6 Hz, 
2H, H7’), 0.93 (t, J = 7.4 Hz, 3H, H8’); 13C NMR (100 MHz, CDCl3, δ) 171.9, 142.2, 136.6, 
134.3, 130.8, 128.5, 125.4, 125.0, 121.0, 118.1, 116.9, 109.9, 106.4, 64.0, 47.6, 40.0, 39.1, 
29.3, 20.2, 19.0, 17.8, 12.4; HRMS-ESI (m/z) [C24H28N2O4S + H]+ calcd 441.1843, found 
441.1832. 
(R,S)-butyl 2-(9-tert-butoxycarbonyl-2-(p-toluenesulfonyl)-3,4-tetrahydro-1H-carbolin-
1-yl)acetate (214) 
General procedure A was followed using 2-bromoindole 
133 (100 mg, 0.20 mmol), Pd(PPh3)4 (23 mg, 10 mol%), 
K2CO3 (84 mg, 0.61 mmol) and butyl acrylate (29 mg, 
0.22 mmol) in toluene (4 mL). Purification by column 
chromatography (1:4 EtOAc:Pet Sp) afforded the title 
compound as a pale yellow oil (91 mg, 0.17 mmol, 
83%). FT-IR (ν, cm-1, KBr) 1730vs, 1457, 1374, 1324, 1159, 747; 1H NMR (400 MHz, 
CDCl3, δ) 8.10 (d, J = 8.2 Hz, 1H, ArH), 7.62 (d, J = 8.3 Hz, 2H, ArH), 7.14-7.28 (m, 4H, 
ArH), 7.03 (d, J = 8.6 Hz, 1H, ArH), 6.12 (dd, J = 3.6 and 10.6 Hz, 1H, H1), 4.05 (m, 3H, 
H5’ and H3a), 3.50 (m, 1H, H3b), 3.00 (dd, J = 3.7 and 14.3 Hz, 1H, H4a), 2.70 (dd, J = 
10.6 and 14.3 Hz, 1H, H4b), 2.39-2.60 (m, 2H, H1’), 2.18 (s, 3H, TsCH3), 1.75 (s, 9H, Boc-
tBu), 1.60 (m, J = 7.8 Hz, 2H, H6’), 1.34 (m, J = 7.6 Hz, 2H, H7’), 0.92 (t, J = 7.5 Hz, 3H, 
H8’); 13C NMR (67.5 MHz, CDCl3, δ) 169.8, 149.9, 143.4, 137.5, 135.9, 133.0, 129.2, 
128.6, 127.1, 124.8, 122.9, 118.0, 115.7, 114.9, 85.0, 64.9, 51.1, 40.3, 37.9, 30.6, 28.4, 21.4, 
19.7, 19.2, 13.8; HRMS-ESI (m/z) [C29H36N2O6S - H]- calcd 539.2221, found 539.2219. 
(R,S)-butyl 2-(9-benzyl-2-(p-toluenesulfonyl)-3,4-tetrahydro-1H-carbolin-1-yl)acetate 
(234) 
General procedure A was followed using 2-bromoindole 222 (190 
mg, 0.39 mmol), Pd(PPh3)4 (45 mg, 10 mol%), K2CO3 (163 mg, 
1.2 mmol) and butyl acrylate (55 mg, 0.43 mmol) in toluene (5 
mL). Purification by column chromatography (1:4 EtOAc:Pet Sp) 
afforded the title compound as a pale yellow oil (113 mg, 0.21 
mmol, 54%). FT-IR (ν, cm-1, KBr) 1733s, 1458, 1342, 1158, 741, 721; 1H NMR (270 MHz, 
CDCl3, δ) 6.99-7.43 (m, 13H, ArH), 5.60 (d, J = 7.1 Hz, 1H, CH), 5.33 (q, J = 16.8 Hz, 2H, 
CH2Ph), 4.11 (m, 3H), 3.48 (m, 1H), 2.60-2.80 (m, 4H), 2.26 (s, 3H), 1.61 (m, J = 8.0 Hz, 
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2H), 1.36 (m, J = 7.5 Hz, 2H), 0.94 (t, J = 7.3 Hz, 3H); 13C NMR (67.5 MHz, CDCl3, δ) 
170.0, 143.2, 137.8, 137.29, 137.27, 133.1, 129.4, 129.0, 127.8, 127.0, 126.6, 126.4, 122.4, 
119.7, 118.5, 109.9, 108.4, 65.2, 49.6, 46.9, 41.1, 39.0, 30.6, 21.5, 20.0, 19.2, 13.8; HRMS-
ESI (m/z) [C31H34N2O4S + H]+ calcd 531.2312, found 531.2314. 
(R,S)-butyl 2-(9-(p-toluenesulfonyl)-2-(p-toluenesulfonyl)-3,4-tetrahydro-1H-carbolin-
1-yl)acetate (235) 
General procedure A was followed using 2-bromoindole 224 (200 
mg, 0.36 mmol), Pd(PPh3)4 (42 mg, 10 mol%), K2CO3 (151 mg, 
1.1 mmol) and butyl acrylate (52 mg, 0.40 mmol) in toluene (5 
mL). Purification by column chromatography (1:4 EtOAc:Pet Sp) 
afforded the title compound as a pale orange oil (118 mg, 0.20 
mmol, 54%). FT-IR (ν, cm-1, KBr) 1732s, 1598, 1452, 1375, 1335, 1174, 750, 666, 582, 
545; 1H NMR (270 MHz, CDCl3, δ) 8.15 (d, J = 8.3 Hz, 1H), 7.82 (d, J = 8.3 Hz, 2H), 7.54 
(d, J = 8.3 Hz, 2H), 7.18-7.30 (m, 5H), 7.10 (d, J = 8.2 Hz, 2H), 6.27 (d, J = 7.9 Hz, 1H, 
CH), 3.94 (m, 3H), 3.32 (dd, J = 2.9 and 15.2 Hz, 2H), 2.70 (m, 2H), 2.50 (dd, J = 2.8 and 
18.2 Hz, 1H), 2.33 (s, 3H), 2.28 (s, 3H), 1.54 (m, J = 7.0 Hz, 2H), 1.37 (m, J = 7.4 Hz, 2H), 
0.90 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3, δ) 169.7, 145.1, 143.3, 137.6, 136.3, 
134.6, 133.4, 129.9, 129.6, 129.3, 127.3, 127.0, 125.2, 123.9, 118.6, 118.4, 115.0, 64.7, 
50.7, 40.6, 37.6, 30.5, 21.5, 21.4, 20.5, 19.0, 13.7; HRMS-ESI (m/z) [C31H34N2O6S2 + H]+ 
calcd 595.1931, found 595.1919. 
(R,S)-methyl 2-(9-tert-butoxycarbonyl-2-(p-toluenesulfonyl)-3,4-tetrahydro-1H-
carbolin-1-yl)acetate (236) 
General procedure A was followed using 2-bromoindole 133 (250 
mg, 0.51 mmol), Pd(PPh3)4 (59 mg, 10 mol%), K2CO3 (210 mg, 
1.5 mmol) and methyl acrylate (73 mg, 0.56 mmol) in toluene (5 
mL). Purification by column chromatography (1:19 
acetone:toluene) afforded the title compound as a pale yellow oil 
(200 mg, 0.40 mmol, 79%). FT-IR (ν, cm-1, KBr) 1731vs, 1456, 
1373, 1323, 1159, 720; 1H NMR (270 MHz, CDCl3, δ) 8.06 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 
8.3 Hz, 2H), 7.16-7.25 (m, 3H), 7.03 (d, J = 8.0 Hz, 2H), 6.10 (dd, J = 3.6 and 10.7 Hz, 1H, 
CH), 4.12 (dd, J = 6.5 and 15.1 Hz, 1H), 3.65 (s, 3H, CO2Me), 3.46 (m, 1H), 3.03 (dd, J = 
3.7 and 14.4 Hz, 1H), 2.68 (dd, J = 10.7 and 14.3Hz, 1H), 2.46-2.59 (m, 2H), 2.19 (s, 3H), 
1.74 (s, 9H); 13C NMR (67.5 MHz, CDCl3, δ) 170.0, 149.8, 143.3, 137.4, 135.8, 132.8, 
129.2, 128.5, 127.0, 124.7, 122.8, 117.9, 115.7, 114.9, 85.0, 51.9, 51.0, 39.9, 37.8, 28.2, 
21.3, 19.6; HRMS-ESI (m/z) [C26H30N2O6S + H]+ calcd 499.1897, found 499.1915. 
(R,S)-(2-hydroxyethyl) 2-(9-tert-butoxycarbonyl-2-(p-toluenesulfonyl)-3,4-tetrahydro-
1H-carbolin-1-yl)acetate (237) 
General procedure A was followed using 2-bromoindole 
133 (280 mg, 0.57 mmol), Pd(PPh3)4 (66 mg, 10 mol%), 
K2CO3 (235 mg, 1.7 mmol) and 2-hydroxyethyl acrylate 
(73 mg, 0.62 mmol) in toluene (6 mL). Purification by 
column chromatography (1:4 EtOAc:Pet Sp) afforded the 
title compound as a pale yellow oil (192 mg, 0.36 mmol, 64%). FT-IR (ν, cm-1, KBr) 3524, 
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1738vs, 1457, 1377, 1325, 1245, 1157, 716; 1H NMR (400 MHz, CDCl3, δ) 8.05 (d, J = 8.3 
Hz, 1H), 7.54 (d, J = 8.3 Hz, 2H), 7.13-7.25 (m, 3H), 6.93 (d, J = 7.9 Hz, 2H), 6.18 (dd, J = 
3.6 and 10.8 Hz, 1H, CH), 4.50 (m, 1H, OH), 4.12 (m, 2H), 3.87 (t, J = 4.3 Hz, 2H), 3.56 
(m, 1H), 3.12 (dd, J = 3.7 and 14.8 Hz, 1H), 2.74 (dd, J = 10.8 and 14.7 Hz, 1H), 2.36 (m, 
2H), 2.10 (s, 3H), 1.76 (s, 9H); 13C NMR (67.5 MHz, CDCl3, δ) 169.5, 149.9, 143.9, 136.6, 
135.8, 132.5, 129.3, 128.4, 126.9, 124.9, 123.0, 118.0, 115.7, 114.7, 85.3, 67.4, 60.9, 51.2, 
40.5, 37.8, 28.4, 21.3, 18.9; HRMS-ESI (m/z) [C27H32N2O7S - H]- calcd 527.1857, found 
527.1846. 
(R,S)-2-(9-tert-butoxycarbonyl-2-(p-toluenesulfonyl)-3,4-tetrahydro-1H-carbolin-1-
yl)acetaldehyde (238) 
General procedure A was followed using 2-bromoindole 133 (200 
mg, 0.40 mmol), Pd(PPh3)4 (47 mg, 10 mol%), K2CO3 (168 mg, 1.2 
mmol) and acrolein (25 mg, 0.45 mmol) in toluene (5 mL). 
Purification by column chromatography (1:4 EtOAc:Pet Sp) 
afforded the title compound as a pale orange oil (122 mg, 0.26 
mmol, 64%). FT-IR (ν, cm-1, KBr) 2977, 1727vs, 1456, 1373, 1320, 1160, 749; 1H NMR 
(400 MHz, CDCl3, δ) 9.81 (dd, J = 1.2 and 4.2 Hz, 1H, CHO), 8.00 (d, J = 8.4 Hz, 1H), 7.64 
(d, J = 8.3 Hz, 2H), 7.16-7.29 (m, 3H), 7.07 (d, J = 7.9 Hz, 2H), 6.29 (d, J = 10.1 Hz, 1H, 
CH), 4.16 (dd, J = 6.4 and 16.0 Hz, 1H), 3.35 (m, 1H), 2.98 (d, J = 4.6 Hz, 1H), 2.39-2.69 
(m, 3H), 2.21 (s, 3H), 1.72 (s, 9H); 13C NMR (100 MHz, CDCl3, δ) 199.2, 148.8, 142.5, 
135.7, 134.2, 131.3, 128.2, 127.2, 125.7, 123.5, 121.6, 116.8, 114.4, 113.7, 83.7, 48.0, 46.2, 
36.6, 27.0, 20.0, 18.2; HRMS-ESI (m/z) [C25H28N2O5S + H]+ calcd 469.1792, found 
469.1773. 
(R,S)-2-(9-tert-butoxycarbonyl-2-(p-toluenesulfonyl)-3,4-tetrahydro-1H-carbolin-1-
yl)acrylonitrile (240) 
General procedure A was followed using 2-bromoindole 133 (100 
mg, 0.20 mmol), Pd(PPh3)4 (24 mg, 10 mol%), K2CO3 (84 mg, 0.61 
mmol) and acrylonitrile (12 mg, 0.22 mmol) in toluene (4 mL). 
Purification by column chromatography (1:4 EtOAc:Pet Sp) 
afforded the title compound as a pale yellow oil (63 mg, 0.14 mmol, 67%). FT-IR (ν, cm-1, 
KBr) 2251, 1727, 1456, 1374, 1320, 1160, 913, 750, 561; 1H NMR (400 MHz, CDCl3, δ) 
8.02 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.17-7.33 (m, 5H), 5.99 (m, 1H, CH), 4.10 
(m, 1H), 3.65 (m, 1H), 3.06 (m, 2H), 2.66 (m, 2H), 2.30 (s, 3H), 1.73 (s, 9H); 13C NMR (75 
MHz, CDCl3, δ) 150.1, 143.9, 136.7, 135.7, 130.6, 129.6, 128.3, 127.3, 125.2, 123.1, 118.4, 
117.3, 116.7, 115.9, 85.3, 49.7, 38.4, 28.3, 24.3, 21.4, 19.9; HRMS-ESI (m/z) [C25H27N3O4S 
+ H]+ calcd 466.1795, found 466.1775. 
(R,S)-2-(9-tert-butoxycarbonyl-2-(p-toluenesulfonyl)-3,4-tetrahydro-1H-carbolin-1-
yl)propan-2-one (241) 
 General procedure A was followed using 2-bromoindole 133 (300 
mg, 0.61 mmol,), Pd(PPh3)4 (70 mg, 10 mol%), K2CO3 (252 mg, 1.82 
mmol) and 3-buten-2-one (51 mg, 0.73 mmol) in toluene (3 mL) 
Purification by column chromatography (1:4 EtOAc:Pet Sp) afforded 
tetrahydro-β-carboline 17 as a pale yellow oil (228 mg, 0.47 mmol, 
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78%) FT-IR (ν, cm-1, KBr) 1716vs, 1465, 1386, 1327, 1159, 698; 1H NMR (270 MHz, 
CDCl3, δ) 7.96 (dt, J = 0.9, 8.3 Hz, 1H), 7.61 (d, J = 8.3 Hz, 2H), 7.12-7.27 (m, 3H), 7.00 
(dd, J = 0.6, 8.6 Hz, 2H), 6.23 (dd, J = 3.3, 10.6 Hz, 1H, CH), 4.05 (dd, J = 6.5, 15.3 Hz, 
1H), 3.38-3.50 (m, 1H), 3.08 (dd, J = 3.5, 14.2 Hz, 1H), 2.70 (dd, J = 10.6, 14.2 Hz, 1H), 
2.41-2.58 (m, 2H), 2.35 (s, 3H), 2.14 (s, 3H, COCH3), 1.73 (s, 9H); 13C NMR (75 MHz, 
CDCl3, δ) 206.0, 150.1, 143.5, 136.8, 135.2, 133.5, 129.1, 128.5, 127.0, 124.5, 122.8, 117.9, 
115.6, 114.5, 84.8, 50.5, 48.8, 37.7, 29.2, 28.3, 21.2, 19.2; HRMS-ESI (m/z) [C26H30N2O5S + 
Na]+ calcd 505.1768, found 505.1789. 
(R,S)-2-(9-tert-butoxycarbonyl-2-(p-toluenesulfonyl)-3,4-tetrahydro-1H-carbolin-1-
yl)acetamide (239) 
General procedure A was followed using 2-bromoindole 133 (180 
mg, 0.36 mmol), Pd(PPh3)4 (42 mg, 10 mol%), K2CO3 (151 mg, 
1.1 mmol) and acrylamide (29 mg, 0.40 mmol) in toluene (5 mL). 
Purification by column chromatography (1:4 EtOAc:Pet Sp) 
afforded a pale yellow oil. Partial indole deprotection during the 
domino procedure resulted in an inseparable mixture of indole protected tetrahydro-β-
carboline and indole deprotected tetrahydro-β-carboline (142 mg, approx 80%). Indole-N-
Boc = HRMS-ESI (m/z) [C25H29N3O5S + H]+ calcd 484.1901, found 484.1905. Indole-NH = 
HRMS-ESI (m/z) [C20H21N3O3S + H]+ calcd 384.1376, found 384.1379. 
7.2.3 Chapter Four 
 
benzofuran-3(2H)-one (261) 
A solution of 2-hydroxyacetophenone (1.0 g, 7.35 mmol) in CHCl3 (7 mL) was 
added to a refluxing solution of CuBr2 (3.28 g, 14.7 mmol) in EtOAc (15 mL) 
and the resultant mixture refluxed for 16 h. The reaction mixture was cooled to 
room temperature, washed with H2O (4 x 10 mL) then brine. The organic 
phase was dried over MgSO4, and concentrated. The crude mixture was dissolved in 
acetonitrile (10 mL) and triethylamine (3.0 mL, 21.5 mmol) was added and the reaction 
mixture stirred at 60oC for 2 hours. The solvent was concentrated and the crude mixture 
taken up in EtOAc, washed with HCl (1M, 2 × 20 mL), NaHCO3 (saturated aqueous, 20 mL) 
and brine. The organic layer was separated, dried over MgSO4 and concentrated. The crude 
was purified by column chromatography to afford the title compound as a bright orange oil 
(857 mg, 6.39 mmol, 87% over 2 steps). 1H NMR (270 MHz, CDCl3, δ) 7.69 (dd, J = 0.7, 
1.5 Hz, 1H, ArH), 7.66 (dd, J = 0.7, 1.5 Hz, 1H, ArH), 7.64 (d, J = 1.5 Hz, 1H, ArH), 7.61 
(d, J = 1.3 Hz, 1H, ArH), 7.58 (d, J = 1.5 Hz, 1H, ArH), 4.62 (s, 2H, CH2); 13C NMR (75 
MHz, CDCl3, δ) 199.9, 173.9, 137.9, 124.0, 122.0, 121.1, 113.6, 74.7; HRMS-ESI (m/z) 
[C8H6O2 + H]+ calcd 135.0441, found 135.0438. 
ethyl 2-(benzo[b]furan-3-yl)acetate (259) 
A solution containing benzofuranone 261 (300 mg, 2.24 mmol) and 
(carboxymethylene)triphenylphosphorane (1.169 mg, 3.36 mmol) in 
toluene (5 mL) was refluxed at 120 oC for 48 h. The reaction mixture 
was allowed to cool to room temperature, concentrated and the crude 
purified by column chromatography (1:49 EtOAc:Pet. Sp.) to afford the 
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title compound as a bright yellow oil (353 mg, 1.73 mmol, 77%). 1H NMR (270 MHz, 
CDCl3, δ) 7.63 (s, 1H, benzofuran-C2-ArH), 7.59 (m, 1H, ArH), 7.49 (m, 1H, ArH), 7.28 
(dquin, J = 1.6, 7.3 Hz, 2H, ArH), 4.20 (q, J = 7.2 Hz, 2H, CO2Et), 3.69 (s, 2H, CH2CO2Et), 
1.26 (t, J = 7.1 Hz, 3H, CO2Et); 13C NMR (75 MHz, CDCl3, δ) 170.7, 155.2, 142.8, 127.6, 
124.4, 122.6, 119.7, 113.2, 111.5, 61.1, 29.8, 14.2; HRMS-ESI (m/z) [C12H12O3 + H]+ calcd 
205.0859, found 205.0845. 
2-(benzo[b]furan-3-yl)ethanol (262) 
To a solution of LiAlH4 (195 mg, 5.13 mmol) in THF (5 mL) at 0oC was 
added dropwise benzofuran methyl ester 259 (350 mg, 1.71 mmoL) in 
THF (5 mL). After stirring at room temperature for 16 h. the reaction 
mixture was cooled to 0oC and quenched by the careful addition of H2O. 
After dilution with EtOAC (20 mL) the reaction mixture was washed with H2O (2 × 10 mL) 
and brine. The organic phase was separated, dried over MgSO4 and concentrated to afford 
the title compound as a pale yellow oil (250 mg, 1.54 mmol, 90%). 1H NMR (270 MHz, 
CDCl3, δ) 7.53-7.57 (m, 1H, ArH), 7.49 (m, 1H, ArH), 7.46 (m, 1H, ArH), 7.20-7.32 (m, 
2H, ArH), 3.88 (t, J = 6.4 Hz, 2H, CH2CH2OH), 2.90 (dt, J = 1.0, 6.4 Hz, 2H, CH2CH2OH), 
2.03 (brs, 1H, CH2CH2OH); 13C NMR (75 MHz, CDCl3, δ) 155.4, 142.1, 128.0, 124.4, 
122.5, 119.5, 116.8, 111.6, 61.7, 27.1; HRMS-ESI (m/z) [C10H10O2 + H]+ calcd 163.0754, 
found 163.0749. 
N-(2-(benzo[b]furan-3-yl)ethyl)-p-toluenesulfonamide (263) 
To a solution of benzofuran alcohol 262 (869 mg, 5.36 mmol) and 
triethylamine (1.12 mL, 8.04 mmol) in CH2Cl2 (10 mL) at 0 oC was 
added p-toluenesulfonyl chloride (1.532 g, 8.04 mmol) in one portion. 
After stirring for 3 hrs, the reaction mixture was diluted with CH2Cl2, 
washed 1M HCl (2 x 10 mL), 5% Aqueous NaOH (2 x 10 mL), and brine. The organic layer 
was separated, dried over MgSO4 and concentrated. The crude was then taken up in 
acetonitrile (20 mL). p-toluenesulfonamide and potassium carbonate were added and the 
resultant mixture was refluxed at 85 oC for 16 hrs. After cooling to room temperature the 
solvent was concentrated. The crude was then taken up in ethyl acetate and washed 1M HCl 
(2 x 10 mL), 5% Aqueous NaOH (2 x 10 mL), and brine. The organic layer was separated, 
dried over MgSO4 and concentrated to afford the title compound (939 mg, 2.98 mmol, 56% 
over 2 steps) 1H NMR (270 MHz, CDCl3, δ) 7.67 (d, J = 8.3 Hz, 2H, ArH), 7.40-7.44 (m, 
2H, ArH), 7.37 (s, 1H, benzofuran-C2-ArH), 7.14-7.29 (m, 4H, ArH), 4.89 (t, J = 6.2 Hz, 
1H, NHTs), 3.25 (q, J = 6.5 Hz, 2H, CH2CH2NH), 2.83 (t, J = 7.2 Hz, 2H, CH2CH2NH), 
2.37 (s, 3H, TsCH3); 13C NMR (75 MHz, CDCl3, δ) 155.4, 143.6, 142.3, 136.8, 129.8, 127.5, 
127.1, 124.5, 122.6, 119.4, 116.3, 111.7, 42.4, 24.2, 21.6; HRMS-ESI (m/z) [C17H17NO3S + 
Na]+ calcd 338.0821, found 338.0807. 
N-(2-(2-bromobenzo[b]furan-3-yl)ethyl)-p-toluenesulfonamide (264) 
A solution of N-bromosuccinimide (81 mg, 0.45 mmol) in acetonitrile 
(5 mL) was added dropwise to a stirred solution of benzofuran 
sulfonamide 263 (130 mg, 0.41 mmol) in chloroform (5 mL) at 0 oC. 
After stirring at room temperature for 1 h. the reaction mixture was 
poured into water and extracted with chloroform (3 × 10 mL). The combined organic phases 
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were dried over MgSO4 and concentrated. The crude product was purified by column 
chromatography to afford the title compound as a pale yellow oil (154 mg, 0.39 mmol, 
95%). 1H NMR (270 MHz, CDCl3, δ) 7.64 (d, J = 8.4 Hz, 2H, ArH), 7.34-7.37 (m, 2H, 
ArH), 7.22-7.25 (m, 1H, ArH), 7.14-7.20 (m, 3H, ArH), 4.84 (t, J = 6.2 Hz, 1H, NHTs), 3.25 
(q, J = 6.9 Hz, 2H, CH2CH2NH), 2.80 (t, J = 6.9 Hz, 2H, CH2CH2NH), 2.36 (s, 3H, TsCH3); 
13C NMR (75 MHz, CDCl3, δ) 155.2, 143.4, 136.7, 129.6, 128.1, 127.4, 126.9, 124.4, 123.3, 
118.6, 115.7, 111.0, 41.9, 25.0, 21.5; HRMS-ESI (m/z) [C17H16BrNO3S + H]+ calcd 
394.0107, found 394.0094. 
(E)-butyl 3-(3-(2-(p-toluenylsulfonamido)ethyl)benzo[b]furan-2-yl)acrylate (265) 
To a sealed tube containing toluene (3 mL) was added 
sequentially 2-bromobenzofuran sulfonamide 264 (100 mg, 0.25 
mmol), Na2CO3 (81 mg, 0.76 mmol), Pd(PPh3)4 (29 mg, 10 
mol%) and butyl acrylate (39 mg, 0.30 mmol). The resultant 
mixture was heated to 120 oC for 16 h. After cooling to room temperature the reaction 
mixture was filtered, concentrated and the crude purified by column chromatography (1:4 
EtOAc: Pet. Sp.) to afford the title compound as a pale yellow oil (68 mg, 0.15 mmol, 61%). 
1H NMR (270 MHz, CDCl3, δ) 7.63 (d, J = 8.5 Hz, 2H, ArH), 7.50 (d, J = 15.5 Hz, 1H, 
CH=CHCO2nBu), 7.30-7.44 (m, 3H, ArH), 7.15-7.21 (m, 3H, ArH), 6.54 (d, J = 15.5 Hz, 
1H, CH=CHCO2nBu), 4.95 (t, J = 6.4 Hz, 1H, NHTs), 4.16 (t, J = 6.6 Hz, 2H, CO2nBu), 
3.28 (q, J = 7.0 Hz, 2H, CH2CH2NH), 2.96 (t, J = 6.8 Hz, 2H, CH2CH2NH), 2.37 (s, 3H, 
TsCH3), 1.61-1.73 (m, 2H, CO2nBu), 1.32-1.48 (m, 2H, CO2nBu), 0.94 (t, J = 7.3 Hz, 3H, 
CO2nBu); 13C NMR (75 MHz, CDCl3, δ) 167.1, 154.9, 149.3, 143.5, 136.8, 129.7, 128.7, 
128.6, 127.1, 126.9, 123.3, 120.6, 120.2, 118.7, 111.5, 64.7, 42.9, 30.8, 24.6, 21.6, 19.3, 
13.8; HRMS-ESI (m/z) [C24H27NO5S + H]+ calcd 442.1683, found 442.1662. 
ethyl 3-oxo-4-(phenylthio)butanoate (271) 
To a stirred solution of thiophenol (5.00 g, 45.4 mmol) and 
triethylamine (5.51 g, 54.5 mmol) in CH2Cl2 (100 mL) at 0 oC 
was added ethyl-4-chloroacetoacetate (8.17 g, 49.6 mmol). After 
stirring for 4 h. at ambient temperature, the reaction mixture was 
washed with NaOH (5%. Aq w/w, 2 × 20 mL), HCl (1M. aq. 2 × 20 mL) and brine. The 
organic phase was separated, dried over MgSO4 and concentrated to afford the title 
compound as an orange oil (10.23 g, 42.9 mmol, 95%) 1H NMR (270 MHz, CDCl3, δ) 7.20-
7.34 (m, 5H, ArH), 4.16 (q, J = 7.2 Hz, 2H, CO2Et), 3.79 (s, 2H, CH2CO2Et), 3.61 (s, 2H, 
SCH2), 1.23 (t, J = 7.2 Hz, 3H, CO2Et); 13C NMR (75 MHz, CDCl3, δ) 198.0, 167.0, 134.1, 
129.7, 129.2, 127.1, 61.5, 46.6, 43.9, 14.1; HRMS-ESI (m/z) [C12H14O3S + H]+ calcd 
253.0767, found 253.0779. 
ethyl 2-(benzo[b]thiophen-3-yl)acetate (272) 
A solution containing polyphosphoric acid (20 g), Celite (10 g) and  
phosphorous pentoxide (1.80 g, 12.6 mmol) in toluene (150 mL) was 
refluxed for 1 h. After this time phenylthiobutanoate 271 (3.80 g, 15.95 
mmol) was added and refluxing continued for 16 h. After cooling to 
room temperature the reaction mixture was filtered, washed with K2CO3 
(Sat. Aq. 3 × 20 mL) and brine. The organic phase was dried over MgSO4and concentrated. 
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Purification by column chromatography (1:9 EtOAc:Pet Sp.) afforded the title compound as 
a yellow oil (2834 mg, 12.87 mmol, 81%). 1H NMR (300 MHz, CDCl3, δ) 7.89 (d, J = 7.05, 
1H, ArH), 7.78 (d, J = 7.0 Hz, 1H, ArH), 7.38 (m, 3H, ArH), 4.21 (q, J = 6.4 Hz, 2H, 
CO2Et), 3.88 (s, 2H, CH2CO2Et), 1.27 (t, J = 6.4 Hz, 3H, CO2Et); 13C NMR (75 MHz, 
CDCl3, δ) 170.7, 140.2, 138.6, 128.4, 124.5, 124.4, 124.2, 122.8, 121.8, 61.1, 34.6, 14.2; 
HRMS-ESI (m/z) [C12H12O2S + H]+ calcd 221.0631, found 221.0628. 
2-(benzo[b]thiophen-3-yl)ethanol (273) 
To a cooled solution (0 oC) of lithium aluminium hydride (639 mg, 
16.83 mmol) in THF (30 mL) was added dropwise 
benzothiopheneacetate 272 (1236 mg, 5.61 mmol) and the reaction 
mixture stirred at room temperature for 16 h. After cooling to 0 oC, the 
reaction was quenched by the careful addition of H2O (10 mL). The reaction mixture was 
filtered, diluted with EtOAc (20 mL) and washed with H2O (2 × 10 mL) then brine. The 
organic phase was dried over MgSO4 and concentrated to afford the title compound as a pale 
yellow oil (876 mg, 4.91 mmol, 88%). 1H NMR (300 MHz, CDCl3, δ) 7.89 (d, J = 7.7, 1H, 
ArH), 7.78 (d, J = 7.0 Hz, 1H, ArH), 7.38 (quin, J = 6.5 Hz, 2H, ArH), 7.23 (s, 1H, ArH), 
3.99 (q, J = 6.2 Hz, 2H, CH2CH2OH), 3.14 (t, J = 6.4 Hz, 2H, CH2CH2OH), 1.45 (t, J = 5.7 
Hz, 1H, CH2CH2OH); 13C NMR (75 MHz, CDCl3, δ) 139.9, 138.5, 128.4, 124.3, 124.0, 
123.0, 122.9, 121.6, 61.9, 31.9; HRMS-ESI (m/z) [C10H10OS + Na]+ calcd 201.0345, found 
201.0349. 
N-(2-(benzo[b]thiophen-3-yl)ethyl)-p-toluenesulfonamide (274) 
To a solution containing benzothiophene ethanol 273 (330 mg, 1.85 
mmol) and triethylamine (282 mg, 2.79 mmol) in CH2Cl2 was added p-
toluenesulfonyl chloride (532 mg, 2.79 mmol). After stirring for 3 h. 
the reaction mixture was diluted with CH2Cl2, washed 1M HCl (2 x 10 
mL), 5% Aqueous NaOH (2 x 10 mL), and brine. The organic layer was separated, dried 
over MgSO4 and concentrated. The crude was then taken up in acetonitrile (20 mL) and p-
toluenesulfonamide (288 mg, 1.68 mmol) and K2CO3 (232 mg, 1.68 mmol) were added and 
the resultant mixture was refluxed at 90 oC for 16 h. After cooling to room temperature the 
solvent was concentrated. Purification by column chromatography (1:4 EtOAc:Pet Sp.) 
afforded the title compound as a pale oil (185 mg, 0.56 mmol, 30% over 2 steps). 1H NMR 
(300 MHz, CDCl3, δ) 7.85 (m, 1H, ArH), 7.68 (d, J = 8.2 Hz, 2H, ArH), 7.60 (m, 2H, ArH), 
7.35 (m, 2H, ArH), 7.25 (d, J = 8.1 Hz, 1H, ArH), 7.10 (s, 1H, benzothiophene-C2- ArH), 
4.46 (t, J = 7.1 Hz, 1H, NHTs), 3.34 (q, J = 6.5 Hz, 2H, CH2CH2NH), 3.04 (t, J = 6.7 Hz, 
2H, CH2CH2OH), 2.40 (s, 3H, TsCH3); 13C NMR (67.5 MHz, CDCl3, δ) 143.6, 140.7, 138.3, 
136.8, 132.2, 129.8, 127.1, 124.5, 124.2, 123.3, 123.1, 121.4, 42.5, 29.0, 21.6; HRMS-ESI 
(m/z) [C17H17NO2S2 + H]+ calcd 332.0773 found 332.0783. 
N-(2-(2-bromobenzo[b]thiophen-3-yl)ethyl)-p-toluenesulfonamide (275) 
To a solution of benzothiophene sulfonamide 274 (180 mg, 0.54 
mmol) in CH2Cl2 at 0 oC was added N-bromosuccinimide (106 mg, 
0.60 mmol). After stirring at this temperature for 1 h. the reaction 
mixture was concentrated and purification by column 
chromatography afforded the title compound as a clear oil (60 mg, 0.15 mmol, 27%). 1H 
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NMR (270 MHz, CDCl3, δ) 7.77 (m, 1H, ArH), 7.66 (d, J = 7.5 Hz, 2H, ArH), 7.56 (m, 2H, 
ArH), 7.31 (m, 2H, ArH), 7.19 (d, J = 7.9 Hz, 1H, ArH), 4.60 (brs, 1H, NHTs), 3.23 (q, J = 
5.9 Hz, 2H, CH2CH2NH), 3.04 (t, J = 7.3 Hz, 2H, CH2CH2NH), 2.36 (s, 3H, TsCH3); 13C 
NMR – due to rapid degradation of the compound a clean spectrum was not obtained.; 
HRMS-ESI (m/z) [C17H16NO2S2Br + H]+ calcd 409.9879 found 409.9885. 
N-(2-bromophenethyl)-p-toluenesulfonamide (279) 
To a cooled solution (0 oC) of 2-bromophenethylamine (400mg, 2.0 
mmol) and triethylamine (242 mg, 2.4 mmol) in CH2Cl2 (10 mL) was 
added p-toluenesulfonyl chloride (420 mg, 2.2 mmol) in one portion. 
The reaction mixture was stirred for 2 h. at ambient temperature. The reaction mixture was 
then washed with HCl (1M, 2 × 10 mL), NaOH (Aq 5% w/w, 2 × 10 mL) and brine (10 mL). 
The organic layer was separated, dried over MgSO4 and concentrated under reduced 
pressure to afford the title compound as a colourless oil (624 mg, 1.76 mmol, 88%). 1H 
NMR (270 MHz, CDCl3, δ) 7.69 (d, J = 8.4 Hz, 2H, ArH), 7.47 (dd, J = 1.2, 7.9 Hz, 1H, 
ArH), 7.26 (d, J = 8.1 Hz, 2H, ArH) 7.03-7.20 (m, 3H, ArH), 4.57 (brt, J = 6.2 Hz, 1H, 
NHTs), 3.21 (q, J = 6.9 Hz, 2H, CH2CH2NH), 2.90 (t, J = 7.2 Hz, 2H, CH2CH2NH), 2.40 (s, 
3H, TsCH3); 13C NMR (75 MHz, CDCl3, δ); 143.4, 137.1, 133.0, 131.1, 129.7, 129.0, 128.2, 
127.7, 127.1, 124.4, 42.5, 36.3, 21.5; HRMS-ESI (m/z) [C15H16BrNO2S + Na]+ calcd 
375.9977, found 375.9979. 
General Procedure B for Tetrahydroisoquinoline Formation: 
A sealed tube containing a 2-bromophenethylamine 279 (1.0 eq), Pd(OAc)2 (10 mol%), PPh3 
(10 mol%), K2CO3 (3.0 eq) and alkene (1.2 eq) in toluene (3 mL) was flushed with argon, 
then heated at 120 oC for 16 hrs. The reaction mixture was cooled to room temperature, 
filtered, the solvent removed in vacuo and the crude product purified by column 
chromatography using the solvent system specified. 
(R,S)-butyl 2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetate (280) 
General procedure B was followed using 2-
bromophenethylamine 279 (100 mg, 0.28 mmol), butyl 
acrylate (44 mg, 0.34 mmol), Pd(OAc)2 (6 mg, 10 mol%), PPh3 
(7mg, 10 mol%), potassium carbonate (116 mg, 0.84 mmol) 
and toluene (3 mL). Purification by column chromatography 
(1:4 EtOAc:Pet Sp) afforded the title compound as a pale 
yellow oil (90 mg, 0.22 mmol, 80%). 1H NMR (270 MHz, CDCl3, δ) 7.63 (d, J = 8.4 Hz, 
2H, ArH), 7.14 (d, J = 7.9 Hz, 2H, ArH), 7.08-7.10 (m, 3H, ArH), 6.95 (m, 1H, ArH), 5.46 
(t, J = 6.9 Hz, 1H, H1), 4.04 (dt, J = 3.5, 6.7 Hz, 2H, H5’), 3.71-3.80 (m, 1H, H2a), 3.47-
3.58 (m, 1H, H2b), 2.88 (dd, J = 7.2, 14.6 Hz, 1H, H3a), 2.63-2.74 (m, 3H, H3b and H1’), 
2.32 (s, 3H, TsCH3), 1.58 (m, 2H, H6’), 1.32 (m, 2H, H7’), 0.90 (t, J = 7.4 Hz, 3H, H8’); 13C 
NMR (67.5 MHz, CDCl3, δ); 170.4, 143.3, 137.2, 135.5, 133.1, 129.5, 129.0, 127.3, 127.2, 
126.7, 126.5, 64.8, 53.4, 43.6, 39.7, 30.6, 27.0, 21.5, 19.1, 13.8; HRMS-ESI (m/z) 
[C22H27NO4S + H]+ calcd 402.1734, found 402.1734. 
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(R,S)-methyl 2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetate (283) 
General procedure B was followed using 2-bromophenethylamine 279 
(200 mg, 0.56 mmol), methyl acrylate (58 mg, 0.67 mmol), Pd(OAc)2 
(12 mg, 10 mol%), PPh3 (14 mg, 10 mol%), potassium carbonate (232 
mg, 1.68 mmol) and toluene (3 mL). Purification by column 
chromatography (1:9 EtOAc:Pet Sp) afforded the title compound as a 
pale yellow oil (168 mg, 0.47 mmol, 83%). 1H NMR (270 MHz, CDCl3, 
δ) 7.64 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 7.9 Hz, 2H), 7.08-7.10 (m, 3H), 6.95 (m, 1H), 5.47 
(t, J = 7.2 Hz, 1H, CH), 3.77 (m, 1H), 3.65 (s, 3H, CO2Me), 3.53 (m, 1H), 2.90 (dd, J = 7.6 
and 14.6 Hz, 1H), 2.62-2.75 (m, 3H), 2.32 (s, 3H); 13C NMR (67.5 MHz, CDCl3, δ); 170.7, 
143.3, 137.2, 135.3, 133.1, 129.5, 129.1, 127.3, 127.2, 126.6, 126.5, 53.5, 52.0, 43.4, 39.7, 
26.9, 21.5; HRMS-ESI (m/z) [C19H21NO4S + Na]+ calcd 382.1084, found 382.1081. 
(R,S)-2-hydroxyethyl 2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetate (284) 
General procedure B was followed using 2-
bromophenethylamine 279 (100 mg, 0.28 mmol), 2-hydroxyethyl 
acrylate (39 mg, 0.34 mmol), Pd(OAc)2 (6 mg, 10 mol%), PPh3 
(7mg, 10 mol%), potassium carbonate (116 mg, 0.84 mmol) and 
toluene (3 mL). Purification by column chromatography (2:3 
EtOAc:Pet Sp) afforded the title compound as a pale yellow oil (83 mg, 0.21 mmol, 76%). 
1H NMR (270 MHz, CDCl3, δ) 7.61 (d, J = 8.4 Hz, 2H), 7.06-7.15 (m, 5H), 6.91 (m, 1H), 
5.47 (t, J = 5.9 Hz, 1H, CH), 4.21-4.31 (m, 2H), 3.71-3.78 (m, 2H), 3.50-3.59 (m, 2H), 2.91 
(ddd, J = 1.5 and 8.2 and 14.8 Hz, 1H), 2.78 (dd, J = 5.7 and 14.8 Hz, 1H), 2.60-2.65 (m, 
2H), 2.31 (s, 3H); 13C NMR (75 MHz, CDCl3, δ); 170.0, 143.2, 137.1, 135.2, 133.0, 129.5, 
129.0, 127.2, 127.1, 126.7, 126.6, 126.4, 62.5, 53.4, 43.3, 39.6, 26.7, 21.4; HRMS-ESI (m/z) 
[C20H23NO5S + Na]+ calcd 412.1189, found 412.1178. 
(R,S)-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetonitrile (285) 
General procedure B was followed using 2-bromophenethylamine 279 
(100 mg, 0.28 mmol), acrylonitrile (18 mg, 0.34 mmol), Pd(OAc)2 (6 mg, 
10 mol%), PPh3 (7mg, 10 mol%), potassium carbonate (116 mg, 0.84 
mmol) and toluene (3 mL). Purification by column chromatography (1:9 
EtOAc:Pet Sp) afforded the title compound as a pale yellow oil (75 mg, 
0.23 mmol, 82%). 1H NMR (270 MHz, CDCl3, δ) 7.69 (d, J = 8.4 Hz, 2H), 7.13-7.22 (m, 
5H), 7.07 (m, 1H), 5.17 (t, J = 5.7 Hz, 1H, CH), 3.64-3.74 (m, 1H), 3.48-3.57 (m, 1H), 2.98 
(dd, J = 4.0 and 5.9 Hz, 2H), 2.64-2.92 (m, 2H), 2.37 (s, 3H); 13C NMR (75 MHz, CDCl3, 
δ); 144.1, 135.8, 134.1, 132.7, 130.0, 129.2, 128.2, 127.4, 127.1, 126.9, 117.3, 52.8, 41.1, 
28.0, 27.7, 21.6; HRMS-ESI (m/z) [C18H18N2O2S - H]- calcd 325.1016, found 325.1009. 
(R,S)-1-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propan-2-one (286) 
General procedure B was followed using 2-bromophenethylamine 279 (100 
mg, 0.28 mmol), 3-buten-2-one (24 mg, 0.34 mmol), Pd(OAc)2 (6 mg, 10 
mol%), PPh3 (7 mg, 10 mol%), potassium carbonate (116 mg, 0.84 mmol) 
and toluene (3 mL). Purification by column chromatography (1:9 
EtOAc:Pet Sp) afforded the title compound as a pale yellow oil (76 mg, 
0.22 mmol, 79%). 1H NMR (270 MHz, CDCl3, δ) 7.63 (d, J = 8.2 Hz, 2H), 7.14 (d, J = 8.2 
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Hz, 2H), 7.07-7.09 (m, 3H), 6.94 (m, 1H), 5.50 (t, J = 6.2 Hz, 1H, CH), 3.67-3.74 (m, 1H), 
3.46-3.56 (m, 1H), 3.05 (dd, J = 5.9 and 16 Hz, 1H), 2.82 (dd, J = 6.4 and 16 Hz, 1H), 2.64-
2.69 (m, 2H), 2.32 (s, 3H), 2.15 (s, 3H, COMe); 13C NMR (75 MHz, CDCl3, δ); 205.4, 
143.4, 136.7, 136.2, 132.8, 129.5, 128.8, 127.2, 127.0, 126.7, 126.6, 52.7, 52.1, 40.1, 30.4, 
27.2, 21.5; HRMS-ESI (m/z) [C19H21NO3S + Na]+ calcd 366.1134, found 366.1135. 
N-(2-bromobenzyl)-p-toluenesulfonamide (199) 
To a cooled solution (0 oC) of 2-bromobenzylamine hydrochloride (400 
mg, 1.80 mmol) and triethylamine (401 mg, 3.96 mmol) in CH2Cl2 (10 
mL) was added p-toluenesulfonyl chloride (378 mg, 1.98 mmol) in one 
portion. The reaction mixture was stirred for 2 h. at ambient temperature. The reaction 
mixture was then washed with HCl (1M, 2 × 10 mL), NaOH (Aq 5% w/w, 2 × 10 mL) and 
brine (10 mL). The organic layer was separated, dried (MgSO4) and concentrated under 
reduced pressure to afford the title compound as a colourless oil (610 mg, 1.79 mmol, 99%). 
1H NMR (270 MHz, CDCl3, δ) 7.69 (d, J = 8.4 Hz, 2H, ArH), 7.43 (dd, J = 1.2, 7.9 Hz, 1H, 
ArH), 7.19-7.30 (m, 4H, ArH), 7.07 (dt, J = 1.7 and 7.7 Hz, 1H, ArH), 5.11 (brt, J = 5.9 Hz, 
1H, NHTs), 4.21 (d, J = 6.2 Hz, 2H, CH2NH), 2.39 (s, 3H, TsCH3); 13C NMR (75 MHz, 
CDCl3, δ); 143.5, 136.9, 135.5, 132.8, 130.5, 129.6, 129.5, 127.7, 127.1, 123.5, 47.5, 21.5; 
HRMS-ESI (m/z) [C14H14BrNO2S - H]- calcd 337.9856, found 337.9862. 
General Procedure C for Isoindoline Formation: 
A sealed tube containing 2-bromobenzylamine 199 (1.0 eq), Pd(OAc)2 (10 mol%), PPh3 (10 
mol%), triethylamine (3.0 eq) and alkene (1.2 eq) in DMF was flushed with argon, then 
heated at 120 oC for 16 hrs. The reaction mixture was cooled to room temperature, filtered, 
the solvent removed in vacuo and the crude product purified by column chromatography 
using the solvent system specified. 
(R,S)-butyl 2-(2-tosylisoindolin-1-yl)acetate (292) 
General procedure C was followed using 2-
bromobenzylamine 199 (100 mg, 0.29 mmol), butyl acrylate 
(45 mg, 0.35 mmol), Pd(OAc)2 (7 mg, 10 mol%), PPh3 (8 mg, 
10 mol%), triethylamine (88 mg, 0.87 mmol) and DMF (3 
mL). Purification by column chromatography (1:9 EtOAc:Pet 
Sp) afforded the title compound as a pale yellow oil (86 mg, 
0.22 mmol, 77%). 1H NMR (270 MHz, CDCl3, δ) 7.75 (d, J = 8.2 Hz, 2H, ArH), 7.18-7.27 
(m, 5H, ArH), 7.10-7.13 (m, 1H, ArH), 5.27 (m, J = 3.0 and 3.7 Hz, 1H, H1), 4.73 (dd, J = 
2.5 and 13.8 Hz, 1H, H3a), 4.53 (d, J = 13.8 Hz, 1H, H3a), 4.09 (t, J = 6.7 Hz, 2H, H5’), 
3.30 (dd, J = 3.9 and 16.5 Hz, 1H, H1a’), 2.86 (dd, J = 7.9 and 16.5 Hz, 1H, H1a’), 2.36 (s, 
3H, TsCH3), 1.53-1.63 (m, 2H), 1.23-1.40 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H); 13C NMR (75 
MHz, CDCl3, δ); 171.0, 143.7, 139.6, 135.5, 134.0, 129.8, 128.1, 127.9, 127.6, 122.7, 122.4, 
64.6, 62.1, 53.9, 42.8, 30.6, 21.5, 19.1, 13.7; HRMS-ESI (m/z) [C21H25NO4S + Na]+ calcd 
410.1396, found 410.1380. 
 
 
  Chapter 7 
- 190 - 
(R,S)-2-hydroxyethyl 2-(2-tosylisoindolin-1-yl)acetate (296) 
General procedure C was followed using 2-bromobenzylamine 
199 (100 mg, 0.29 mmol), 2-hydroxyethyl acrylate (40 mg, 
0.35 mmol), Pd(OAc)2 (7 mg, 10 mol%), PPh3 (8 mg, 10 
mol%), triethylamine (88 mg, 0.87 mmol) and DMF (3 mL). 
Purification by column chromatography (2:3 EtOAc:Pet Sp) afforded the title compound as 
a pale yellow oil (91 mg, 0.24 mmol, 84 %). 1H NMR (270 MHz, CDCl3, δ) 7.74 (d, J = 8.2 
Hz, 2H), 7.19-7.28 (m, 5H), 7.09-7.16 (m, 1H), 5.31 (m, 1H, CH), 4.73 (dd, J = 2.5 and 14.1 
Hz, 1H), 4.50 (d, J = 13.8 Hz, 1H), 4.32 (m, 1H), 4.19 (m, 1H), 3.81 (m, 2H), 3.17 (dd, J = 
4.9 and 15.8 Hz, 1H), 2.99 (dd, J = 5.9 and 16.0 Hz, 1H), 2.36 (s, 3H), 2.33 (brt, 1H, OH); 
13C NMR (75 MHz, CDCl3, δ); 171.1, 144.0, 139.3, 135.5, 133.8, 129.9, 128.3, 128.0, 127.6, 
122.6, 122.5, 66.6, 62.3, 61.0, 53.9, 43.0, 21.5; HRMS-ESI (m/z) [C19H21NO5S + Na]+ calcd 
398.1032, found 398.1024. 
(R,S)-2-(2-tosylisoindolin-1-yl)acetamide (297) 
General procedure C was followed using 2-bromobenzylamine 199 
(100 mg, 0.29 mmol), acrylamide (25 mg, 0.35 mmol), Pd(OAc)2 (7 
mg, 10 mol%), PPh3 (8 mg, 10 mol%), triethylamine (88 mg, 0.87 
mmol) and DMF (3 mL). Purification by column chromatography (1:1 
EtOAc:Pet Sp) afforded the title compound as a pale yellow oil (68 mg, 
0.21 mmol, 71%). 1H NMR (270 MHz, CDCl3, δ) 7.75 (d, J = 8.2 Hz, 2H), 7.18-7.29 (m, 
5H), 7.10-7.14 (m, 1H), 5.86 (brs, 1H, NHa), 5.40 (brs, 1H, NHb), 5.18 (m, J = 3.2 and 3.9 
Hz, 1H, CH), 4.73(dd, J = 2.0 and 13.8 Hz, 1H), 4.53 (d, J = 13.8 Hz, 1H), 3.15 (dd, J = 3.7 
and 15.0 Hz, 1H), 2.90 (dd, J = 7.1 and 15.0 Hz, 1H), 2.36 (s, 3H); 13C NMR (75 MHz, 
CDCl3, δ); 172.0, 144.2, 139.2, 135.0, 133.2, 130.1, 128.3, 128.2, 127.8, 123.3, 122.4, 62.6, 
54.2, 43.7, 21.6; HRMS-ESI (m/z) [C17H18N2O3S + H]+ calcd 331.1111, found 331.1126. 
(R,S)-2-(2-tosylisoindolin-1-yl)acetonitrile (298) 
General procedure C was followed using 2-bromobenzylamine 199 (100 
mg, 0.29 mmol), acrylonitrile (18 mg, 0.35 mmol), Pd(OAc)2 (7 mg, 10 
mol%), PPh3 (8 mg, 10 mol%), triethylamine (88 mg, 0.87 mmol) and 
DMF (3 mL). Purification by column chromatography (1:6 EtOAc:Pet 
Sp) afforded the title compound as a pale yellow oil (62 mg, 0.20 mmol, 68%). 1H NMR 
(270 MHz, CDCl3, δ) 7.76 (d, J = 8.2 Hz, 2H), 7.18-7.33 (m, 6H), 5.11 (m, 1H, CH), 4.80 
(dd, J = 2.7 and 13.8 Hz, 1H), 4.55 (d, J = 13.8 Hz, 1H), 3.16 (s, 1H), 3.14 (d, J = 1.0 Hz, 
1H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3, δ); 144.4, 136.7, 135.8, 133.8, 130.1, 129.1, 
128.4, 127.5, 122.9, 122.6, 116.7, 61.5, 53.9, 26.9, 21.5; HRMS-ESI (m/z) [C17H16N2O2S + 
H]+ calcd 313.1005, found 313.1013.  
(R,S)-2-(2-tosylisoindolin-1-yl)acetic acid (299) 
General procedure C was followed using 2-bromobenzylamine 199 (100 
mg. 0.29 mmol), acrylic acid (25 mg, 0.35 mmol), Pd(OAc)2 (7 mg, 10 
mol%), PPh3 (8 mg, 10 mol%), triethylamine (88 mg, 0.87 mmol) and 
DMF (3 mL). Purification by column chromatography (3:1 EtOAc:Pet 
Sp) afforded the title compound as a pale yellow oil (82 mg, 0.25 mmol, 
85%). H NMR (270 MHz, CDCl3, δ) 7.75 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 7.18-
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7.22 (m, 3H), 7.10-7.13 (m, 1H), 5.28 (m, 1H, CH), 4.73 (dd, J = 2.2 and 13.9 Hz, 1H), 4.53 
(d, J = 13.9 Hz, 1H), 3.39 (dd, J = 3.9 and 16.5 Hz, 1H), 2.91 (dd, J = 7.9 and 16.5 Hz, 1H), 
2.36 (s, 3H); 13C NMR (75 MHz, CDCl3, δ); 176.5, 143.9, 139.2, 135.4, 133.8, 129.9, 128.3, 
128.1, 127.6, 122.7, 122.5, 61.8, 53.9, 42.7, 21.5; HRMS-ESI (m/z) [C17H17NO4S + Na]+ 
calcd 354.0771, found 354.0759. 
(R,S)-1-(2-tosylisoindolin-1-yl)propan-2-one (300) 
General procedure C was followed using 2-bromobenzylamine 199 (100 
mg, 0.29 mmol), 3-buten-2-one (24 mg, 0.35 mmol), Pd(OAc)2 (7 mg, 10 
mol%), PPh3 (8 mg, 10 mol%), triethylamine (88 mg, 0.87 mmol) and 
DMF (3 mL). Purification by column chromatography (1:4 EtOAc:Pet Sp) 
afforded the title compound as a pale yellow oil (82 mg, 0.25 mmol, 
86%). 1H NMR (270 MHz, CDCl3, δ) 7.74 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 7.9 Hz, 2H), 
7.16-7.20 (m, 3H), 7.07-7.12 (m, 1H), 5.30 (m, 1H, CH), 4.75 (dd, J = 2.4 and 13.9 Hz, 1H), 
4.50 (d, J = 13.9 Hz, 1H), 3.50 (dd, J = 3.4 and 17.8 Hz, 1H), 2.99 (dd, J = 7.7 and 18.0 Hz, 
1H), 2.36 (s, 3H), 2.22 (s, 3H, COMe); 13C NMR (75 MHz, CDCl3, δ) 206.5, 143.8, 140.2, 
135.1, 133.5, 129.9, 128.7, 128.0, 127.7, 122.9, 122.3, 61.1, 53.9, 52.2, 30.8, 21.5; HRMS-
ESI (m/z) [C18H19NO3S + Na]+ calcd 352.0978, found 352.0993.  
(E)-tert-butyl 2-(3-(benzylamino)-3-oxoprop-1-en-1-yl)-3-(2-(p-
toluenesulfonamido)ethyl)-1H-indole-1-carboxylate (309) 
To a solution containing benzylamine (32 mg, 0.36 mmol), and 
triethylamine (39 mg, 0.39 mmol) in toluene (3 mL) was added 
acryloyl chloride (38 mg, 0.36 mmol) and the resultant mixture 
stirred at room temperature for 1 h. After this time, Pd(PPh3)4 (37 
mg, 10 mol%), potassium carbonate (134 mg, 0.97 mmol) and 2-
bromoindolesulfonamide 133 (160 mg, 0.32 mmol, in 1 mL toluene) were added. The 
pressure vessel was purged with nitrogen, sealed and then heated to 120 oC for 16 hrs. After 
cooling to room temperature, the reaction mixture was filtered, and the solvent concentrated. 
Purification by flash chromatography (EtOAc:Pet Sp 1:1) afforded the title compound as a 
pale yellow oil (149 mg, 0.26 mmol, 80%). 1H NMR (270 MHz, CDCl3, δ) 8.16 (d, J = 8.3 
Hz, 1H, ArH), 7.93 (d, J = 15.8 Hz, 1H, CH=CHCONHBn), 7.61 (d, J = 8.3 Hz, 2H, ArH), 
7.15-7.38 (m, 10H, ArH), 6.80 (t, J = 5.8 Hz, 1H, NHBn), 6.50 (d, J = 15.8 Hz, 1H, 
CH=CHCONHBn), 5.00 (t, J = 6.6 Hz, 1H, NHTs), 4.58 (d, J = 5.8 Hz, 2H, CH2Ph), 3.29 
(m, 2H, CH2CH2NH), 3.05 (m, 2H, CH2CH2NH), 2.36 (s, 3H, TsCH3), 1.65 (s, 9H, Boc-
tBu); 13C NMR (75 MHz, CDCl3, δ) 165.5, 150.0, 143.6, 138.4, 137.0, 136.3, 133.4, 131.8, 
129.7, 129.2, 128.6, 127.8, 127.3, 126.7, 125.5, 123.5, 122.9, 118.6, 118.2, 115.7, 84.8, 
43.6, 43.0, 31.0, 28.2, 26.8, 21.5; HRMS-ESI (m/z) [C32H35N3O5S + H]+ calcd 574.2370, 
found 574.2372. 
General Procedure D for the three-component domino Heck-aza-Michael reaction 
To a pressure vessel containing a solution of potassium carbonate (116 mg, 0.84 mmol), 
amine (0.34 mmol) and toluene (2 mL + a few drops of DMF when necessary) was added 
acryloyl chloride (30 mg, 0.34 mmol) and the resultant mixture stirred for 1 hour at room 
temperature. After this time, Pd(OAc)2 (6 mg, 10 mol%), PPh3 (7 mg, 10 mol%) and 2-
bromophenethylsulfonamide 279 (100 mg, 0.28 mmol, in 1 mL toluene) were added. The 
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pressure vessel was purged with nitrogen, sealed and then heated to 120 oC for 16 hrs. After 
cooling to room temperature, the reaction mixture was filtered, and the solvent concentrated. 
Purification by flash chromatography (EtOAc:Pet Sp 2:3) afforded the desired 
tetrahydroisoquinoline. 
(R,S)-N-benzyl-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide (314) 
General procedure D was followed using benzylamine (36 
mg, 0.34 mmol). The title compound was isolated as a pale 
yellow oil (118 mg,  0.27 mmol, 97%). 1H NMR (270 MHz, 
CDCl3, δ) 7.62 (d, J = 8.3 Hz, 2H, ArH), 7.25-7.34 (m, 5H, 
ArH), 7.03-7.13 (m, 5H, ArH), 6.87-6.90 (m, 1H, ArH), 6.25 
(brs, 1H, NH4’), 5.40 (t, J = 6.4 Hz, 1H, H1), 4.42 (d, J = 5.7 
Hz, 2H, H5’), 3.76 (dt, J = 4.5 and 13.6 Hz, 1H, H3a), 3.43-
3.53 (m, 1H, H3b), 2.88 (dd, J = 7.3 and 14.9 Hz, 1H, H4a), 2.56-2.68 (m, 3H, H4b and 
H1’), 2.30 (s, 3H, TsCH3); 13C NMR (75 MHz, CDCl3, δ) 169.2, 143.5, 138.0, 136.6, 135.2, 
132.7, 129.5, 128.9, 128.6, 128.0, 127.4, 127.2, 127.1, 126.9, 126.5, 53.6, 45.4, 43.8, 39.8, 
26.7, 21.5; HRMS-ESI (m/z) [C25H26N2O3S + Na]+ calcd 457.1556, found 457.1568. 
(R,S)-N-(2-(1H-indol-3-yl)ethyl)-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide 
(315) 
General procedure D was followed using tryptamine (54 
mg, 0.34 mmol). The title compound was isolated as an 
orange oil (126 mg,  0.26 mmol, 92%). 1H NMR (270 MHz, 
CDCl3, δ) 8.31 (brs, 1H), 7.52-7.58 (m, 3H), 7.34 (d, J = 
8.0 Hz, 1H), 7.17 (dt, J = 1.2 and 7.0 Hz, 1H), 7.00-7.10 
(m, 7H), 6.84-6.87 (m, 1H), 6.02 (brt, J = 5.6 Hz, 1H, NH) 
5.36 (t, J = 6.5 Hz, 1H, CH), 3.76 (dt, J = 4.7 and 13.6 Hz, 
1H), 3.55 (q, J = 5.7 Hz, 2H), 3.36-3.46 (m, 1H), 2.94 (dt, J = 1.8 and 6.5 Hz, 2H), 2.71 (dd, 
J = 7.4 and 14.9 Hz, 1H), 2.46-2.59 (m, 3H), 2.28 (s, 3H); 13C NMR (75 MHz, CDCl3, δ) 
169.4, 143.5, 136.6, 136.4, 135.2, 132.7, 129.5, 128.8, 127.4, 127.1, 127.0, 126.9, 126.5, 
122.4, 122.0, 119.3, 118.7, 112.8, 111.3, 53.7, 45.4, 39.9, 39.7, 26.6, 25.1, 21.4; HRMS-ESI 
(m/z) [C28H29N3O3S + H]+ calcd 488.2002, found 488.1997. 
(R,S)-N-heptyl-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide (316) 
General procedure D was followed using heptylamine 
(39 mg, 0.34 mmol). The title compound was isolated 
as a pale yellow oil (110 mg,  0.25 mmol, 89%). 1H 
NMR (270 MHz, CDCl3, δ) 7.60 (d, J = 8.3 Hz, 2H), 
7.03-7.12 (m, 5H), 6.86-6.88 (d, J = 6.4 Hz,  1H), 6.10 
(brt, 1H), 5.37 (t, J = 6.9 Hz, 1H, CH), 3.78 (dt, J = 4.7 
and 13.6 Hz, 1H), 3.43-3.54 (m, 1H), 3.22 (q, J = 6.5 Hz, 2H), 2.82 (dd, J = 7.6 and 15.2 Hz, 
1H), 2.55-2.62 (m, 3H), 2.30 (s, 3H), 1.47 (m, 2H), 1.25 (m, 8H), 0.85 (t, J = 6.5 Hz, 3H); 
13C NMR (75 MHz, CDCl3, δ) 169.3, 143.5, 136.6, 135.2, 132.6, 129.5, 128.9, 127.2, 127.1, 
126.9, 126.5, 53.6, 46.2, 39.8, 39.6, 31.8, 29.3, 29.0, 26.9, 26.5, 22.6, 21.5, 14.1; HRMS-ESI 
(m/z) [C25H34N2O3S + H]+ calcd 443.2327, found 443.2341. 
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(R,S)-N-propyl-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide (317) 
General procedure D was followed using propylamine (20 mg, 
0.34 mmol). The title compound was isolated as a pale yellow oil 
(45 mg,  0.12 mmol, 42%). 1H NMR (270 MHz, CDCl3, δ) 7.60 (d, 
J = 8.3 Hz, 2H), 7.02-7.12 (m, 5H), 6.86-6.88 (d, J = 6.7 Hz, 1H), 
6.11 (brs, 1H), 5.37 (t, J = 5.9 Hz, 1H, CH), 3.76 (dtd, J = 0.9 and 
4.7 and 13.6 Hz, 1H), 3.44-3.55 (m, 1H), 3.17-3.24 (m, 2H), 2.82 (dd, J = 7.7 and 15.2 Hz, 
1H), 2.54-2.64 (m, 3H), 2.30 (s, 3H), 1.52 (t, J = 7.3 Hz, 2H), 0.90 (t, J = 7.3 Hz, 3H); 13C 
NMR (75 MHz, CDCl3, δ) 169.3, 143.5, 136.7, 135.2, 132.6, 129.5, 128.9, 127.2, 127.1, 
126.9, 126.5, 53.6, 45.2, 41.5, 39.5, 26.4, 22.6, 21.4, 11.4; HRMS-ESI (m/z) [C21H26N2O3S + 
Na]+ calcd 409.1556, found 409.1549. 
(R,S)-N-cyclohexyl-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide (318) 
General procedure D was followed using cyclohexylamine (33 mg, 
0.34 mmol). The title compound was isolated as a pale yellow oil 
(92 mg,  0.22 mmol, 77%). 1H NMR (270 MHz, CDCl3, δ) 7.60 (d, 
J = 8.3 Hz, 2H), 7.05-7.12 (m, 5H), 6.87 (d, J = 6.4 Hz,  1H), 5.95 
(d, J = 7.9 Hz, 1H), 5.37 (t, J = 6.4 Hz, 1H, CH), 3.67-3.83 (m, 
2H), 3.49 (dt, J = 8.1 and 16.4 Hz, 1H), 2.79 (dd, J = 7.6 and 15.1 
Hz, 1H), 2.52-2.62 (m, 3H), 2.30 (s, 3H), 1.86-1.90 (m, 2H), 1.55-1.70 (m, 4H), 1.05-1.40 
(m, 4H); 13C NMR (75 MHz, CDCl3, δ) 168.3, 143.5, 136.8, 135.2, 132.6, 129.5, 128.9, 
127.1, 127.0, 126.9, 126.4, 53.7, 48.5, 45.3, 39.5, 32.9, 26.4, 25.5, 24.9, 21.4; HRMS-ESI 
(m/z) [C24H30N2O3S - H]- calcd 425.1904, found 425.1898. 
(R,S)-N-(tert-butyl)-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide (319) 
General procedure D was followed using tert-butylamine (25 mg, 
0.34 mmol). The title compound was isolated as a pale yellow oil 
(104 mg,  0.26 mmol, 93%). 1H NMR (270 MHz, CDCl3, δ) 7.62 (d, J 
= 8.3 Hz, 2H), 7.02-7.12 (m, 5H), 6.87 (d, J = 6.4 Hz, 1H), 6.72 (brs, 
1H), 5.35 (t, J = 6.5 Hz, 1H, CH), 3.76 (dt, J = 4.7 and 14.2 Hz, 1H), 
3.45-3.56 (m, 1H), 2.76 (dd, J = 7.1 and 14.9 Hz, 1H), 2.46-2.58 (m, 
3H), 2.30 (s, 3H), 1.33 (s, 9H, tBu); 13C NMR (75 MHz, CDCl3, δ) 168.7, 143.5, 136.9, 
135.5, 132.7, 129.6, 128.9, 127.2, 127.1, 127.0, 126.5, 53.9, 51.5, 46.4, 39.7, 28.7, 26.6, 
21.5; HRMS-ESI (m/z) [C22H28N2O3S + H]+ calcd 401.1893, found 401.1903. 
 (R,S)-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide (320) 
General procedure D was followed using 2-nitrobenzylamine 
hydrochloride (63 mg, 0.34 mmol). The title compound was isolated as a 
pale yellow oil (31 mg, 0.09 mmol, 32%). 1H NMR (270 MHz, CDCl3, 
δ) 7.62 (d, J = 8.3 Hz, 2H), 7.03-7.12 (m, 5H), 6.87 (d, J = 7.0 Hz, 1H), 
6.25 (brs, 1H, NHa), 5.49 (brs, 1H, NHb), 5.39 (dd, J = 5.6 and 7.7 Hz, 
1H, CH), 3.82 (dtd, J = 0.7 and 4.7 and 14.2 Hz, 1H), 3.46-3.57 (m, 1H), 2.89 (dd, J = 8.0 
and 15.6 Hz, 1H), 2.69 (dd, J = 5.4 and 15.6 Hz, 1H), 2.56-2.61 (m, 2H), 2.30 (s, 3H); 13C 
NMR (75 MHz, CDCl3, δ) 171.8, 143.8, 136.6, 135.1, 132.6, 129.6, 129.0, 127.3, 127.2, 
126.9, 126.7, 53.6, 44.8, 39.6, 26.4, 21.5; HRMS-ESI (m/z) [C18H20N2O3S + H]+ calcd 
345.1267, found 345.1257. 
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(R,S)-N-phenyl-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide (325) 
General procedure D was followed using aniline (31 mg, 0.34 
mmol). The title compound was isolated as a pale yellow oil (98 
mg,  0.23 mmol, 83%). 1H NMR (270 MHz, CDCl3, δ) 8.02 (brs, 
1H), 7.64 (d, J = 8.3 Hz, 2H), 7.56 (d, J = 7.6 Hz, 2H), 7.31 (t, J = 
7.5 Hz, 2H), 7.07-7.13 (m, 6H), 6.90 (d, J = 6.4 Hz, 1H), 5.46 (dd, 
J = 5.1 and 7.5 Hz, 1H, CH), 3.82 (dt, J = 4.6 and 14.1 Hz, 1H), 
3.47-3.58 (m, 1H), 3.00 (dd, J = 7.7 and 15.5 Hz, 1H), 2.82 (dd, J = 5.2 and 15.6 Hz, 1H), 
2.59-2.65 (m, 2H), 2.29 (s, 3H); 13C NMR (75 MHz, CDCl3, δ) 167.8, 143.7, 138.0, 136.3, 
134.9, 132.7, 129.6, 129.0, 128.9, 127.2, 127.1, 126.8, 126.6, 124.3, 120.1, 53.5, 46.1, 39.6, 
26.5, 21.5; HRMS-ESI (m/z) [C24H24N2O3S + H]+ calcd 421.1580, found 421.1599. 
(R,S)-N-(4-methoxyphenyl)-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide 
(326) 
General procedure D was followed using p-anisidine (41 mg, 
0.34 mmol). The title compound was isolated as a pale 
yellow oil (100 mg,  0.22 mmol, 79%). 1H NMR (270 MHz, 
CDCl3, δ) 8.05 (brs, 1H), 7.62 (d, J = 8.3 Hz, 2H), 7.44 (d, J 
= 9.0 Hz, 2H) 7.05-7.10 (m, 5H), 6.89 (d, J = 5.7 Hz, 1H), 
6.82 (d, J = 9.0 Hz, 2H), 5.40 (dd, J = 5.5 and 7.7 Hz, 1H, 
CH), 3.78 (m, 1H), 3.76 (s, 3H, OMe), 3.43-3.56 (m, 1H), 2.97 (dd, J = 7.9 and 15.4 Hz, 
1H), 2.75 (dd, J = 5.3 and 15.4 Hz, 1H), 2.56-2.63 (m, 2H), 2.28 (s, 3H); 13C NMR (75 
MHz, CDCl3, δ) 167.6, 156.4, 143.8, 136.5, 135.1, 132.7, 131.2, 129.6, 129.1, 127.3, 127.2, 
127.0, 126.7, 122.0, 114.1, 55.5, 53.7, 46.0, 39.7, 26.5, 21.5; HRMS-ESI (m/z) 
[C25H26N2O4S + Na]+ calcd 473.1505, found 473.1484. 
(R,S)-N-(pyrazin-2-yl)-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide (327) 
General procedure D was followed using aminopyrazine (32 mg, 
0.34 mmol). The title compound was isolated as a pale yellow oil 
(33 mg,  0.08 mmol, 28%). 1H NMR (270 MHz, CDCl3, δ) 9.48 (s, 
1H), 8.33 (d, J = 2.5 Hz, 1H), 8.22-8.25 (m, 2H), 7.65 (d, J = 8.4 
Hz, 2H), 7.08-7.14 (m, 5H), 6.96 (d, J = 4.7 Hz, 1H), 5.50 (t, J = 
6.3 Hz, 1H, CH), 3.80 (dt, J = 5.1 and 13.6 Hz, 1H), 3.50-3.60 (m, 
1H), 3.04 (dd, J = 7.3, 14.9 Hz, 1H), 2.88 (dd, J = 5.6 and 15.0 Hz, 1H), 2.66-2.73 (m, 2H), 
2.29 (s, 3H); 13C NMR (75 MHz, CDCl3, δ) 168.1, 147.9, 143.7, 142.1, 140.3, 137.2, 136.4, 
134.9, 133.0, 129.6, 129.0, 127.4, 127.2, 127.1, 126.8, 53.5, 46.6, 40.1, 27.1, 21.5; HRMS-
ESI (m/z) [C22H22N4O3S + H]+ calcd 423.1485, found 423.1505. 
(R,S)-N,N-diethyl-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide (329) 
General procedure D was followed using diethylamine (25 mg, 0.34 
mmol). The title compound was isolated as a pale yellow oil (64 mg,  
0.16 mmol, 57%). 1H NMR (270 MHz, CDCl3, δ) 7.66 (d, J = 8.3 Hz, 
2H), 7.05-7.17 (m, 5H), 6.93-6.96 (m, 1H), 5.54 (dd, J = 5.1 and 7.4 
Hz, 1H, CH), 3.52-3.71 (m, 2H), 3.26-3.42 (m, 2H), 3.06-3.22 (m, 
2H), 2.88 (dd, J = 5.1 and 14.6 Hz, 1H), 2.67-2.75 (m, 3H), 2.32 (s, 
3H), 1.09 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3, δ) 168.8, 
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143.1, 136.8, 136.3, 133.0, 129.5, 128.5, 127.3, 127.2, 126.9, 126.4, 53.7, 42.4, 42.1, 40.8, 
40.4, 27.7, 21.4, 14.3, 13.0; HRMS-ESI (m/z) [C22H28N2O3S + H]+ calcd 401.1893, found 
401.1878. 
(R,S)-1-(piperidin-1-yl)-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)ethanone (333) 
General procedure D was followed using piperidine (29 mg, 0.34 
mmol). The title compound was isolated as a pale yellow oil (102 mg,  
0.25 mmol, 88%). 1H NMR (270 MHz, CDCl3, δ) 7.62 (d, J = 8.3 Hz, 
2H), 7.06-7.18 (m, 5H), 6.93-6.96 (m, 1H), 5.48 (dd, J = 5.9 and 6.9 
Hz, 1H, CH), 3.23-3.71 (m, 6H), 2.98 (dd, J = 7.9 and 16.7 Hz, 1H), 
2.67-2.80 (m, 3H), 2.32 (s, 3H), 1.40-1.59 (m, 6H); 13C NMR (75 
MHz, CDCl3, δ) 167.8, 143.2, 136.8, 136.1, 133.0, 129.5, 128.6, 127.2, 127.1, 127.0, 126.4, 
53.6, 47.0, 42.8, 42.4, 40.5, 27.4, 26.3, 25.4, 24.5, 21.4; HRMS-ESI (m/z) [C23H28N2O3S + 
H]+ calcd 413.1893, found 413.1914. 
(R,S)-1-morpholino-2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)ethanone (334) 
General procedure D was followed using morpoholine (29 mg, 0.34 
mmol). The title compound was isolated as a pale yellow oil (91 mg,  
0.22 mmol, 78%). 1H NMR (270 MHz, CDCl3, δ) 7.63 (d, J = 8.4 
Hz, 2H), 7.08-7.18 (m, 5H), 6.94-6.97 (m, 1H), 5.48 (t, J = 6.3 Hz, 
1H, CH), 3.28-3.68 (m, 8H), 3.00 (dd, J = 5.9 and 14.5 Hz, 1H), 2.76 
(dd, J = 7.3 and 14.5 Hz, 3H), 2.68 (t, J = 6.2 Hz, 2H), 2.32 (s, 3H); 13C NMR (75 MHz, 
CDCl3, δ) 168.5, 143.4, 136.7, 135.8, 133.1, 129.7, 128.8, 127.3, 127.2, 127.1, 126.6, 66.8, 
66.5, 53.8, 46.4, 42.2, 42.1, 40.7, 27.4, 21.5; HRMS-ESI (m/z) [C22H26N2O4S + H]+ calcd 
415.1686, found 415.1707. 
(R,S)-methyl 2-(2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamido)acetate (339) 
General procedure D was followed using glycine methyl ester 
hydrochloride (54 mg, 0.34 mmol). The title compound was 
isolated as an orange oil (84 mg,  0.20 mmol, 72%). 1H NMR 
(270 MHz, CDCl3, δ) 7.63 (d, J = 8.3 Hz, 2H), 7.05-7.14 (m, 
5H), 6.90 (d, J = 6.0 Hz, 1H), 6.54 (brt, 1H, NH) 5.41 (t, J = 6.5 
Hz, 1H, CH), 4.02 (t, J = 5.0 Hz, 2H), 3.76 (m, 1H), 3.74 (s, 3H, 
CO2Me), 3.55 (m, 1H), 2.89 (dd, J = 7.4 and 14.9 Hz, 1H), 2.59-2.71 (m, 3H), 2.31 (s, 3H); 
13C NMR (75 MHz, CDCl3, δ) 170.3, 169.7, 143.5, 136.7, 135.1, 132.7, 129.5, 128.9, 127.2, 
127.1, 126.9, 126.6, 53.6, 52.4, 45.2, 41.4, 39.8, 26.7, 21.5; HRMS-ESI (m/z) [C21H24N2O5S 
+ H]+ calcd 417.1479, found 417.1496. 
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(2R)-benzyl 3-(1H-indol-3-yl)-2-(2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-
yl)acetamido) propanoate (340) 
General procedure D was followed using L-tryptophan benzyl 
ester hydrochloride (99 mg, 0.34 mmol). The title compound 
was isolated as an orange oil (167 mg,  0.27 mmol, 96%). 1H 
NMR (270 MHz, CDCl3, δ) 8.23 (brs, 0.5H),  8.14 (brs, 0.5H), 
7.60 (dd, J = 1.5 and 8.2 Hz, 2H), 7.52 (d, J = 7.7 Hz, 0.5H), 
6.93-7.36 (m, 14H), 6.88 (d, J = 2.2 Hz, 0.5H), 6.84 (m, 0.5H), 
6.67 (d, J = 2.2 Hz, 0.5H), 6.29 (t, J = 10.0 Hz, 1H), 5.40 (t, J 
= 6.4 Hz, 1H, CH), 5.05 (d, J = 2.5 Hz, 2H), 4.97 (m, 1H), 
3.68 (m, 1H), 3.15-3.46 (m, 3H), 2.47-2.81 (m, 4H),  2.28 (s, 
3H); 13C NMR (75 MHz, CDCl3, δ) 171.7, 171.6, 169.2, 169.1, 143.4, 136.8, 136.5, 136.1, 
136.0, 135.4, 135.34, 135.32, 135.2, 132.9, 132.6, 129.5, 129.4, 128.8, 128.7, 128.56, 
128.55, 128.46, 128.41, 128.38, 128.35, 127.6, 127.5, 127.2, 127.0, 126.9, 126.49, 126.48, 
123.4, 123.3, 122.0, 119.6, 119.5, 118.5, 111.3, 111.2, 109.6, 109.5, 67.15, 67.11, 53.5, 
53.4, 53.1, 53.0, 45.3, 40.0, 39.7, 27.6, 27.5, 27.0, 26.6, 21.4; HRMS-ESI (m/z) 
[C36H35N3O5S - H]- calcd 620.2225, found 620.2197. (Diastereomeric ratio approx. 1:1 by 
1H and 13C NMR) 
(2R)-methyl 2-(2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamido)propanoate 
(341) 
General procedure D was followed using L-alanine methyl ester 
hydrochloride (47 mg, 0.34 mmol). The title compound was 
isolated as an orange oil (65 mg,  0.15 mmol, 54%). 1H NMR 
(300 MHz, CDCl3, δ) 7.61 (d, J = 8.3 Hz, 2H), 7.09-7.13 (m, 
5H), 6.89 (m, 1H), 6.59 (d, J = 7.0 Hz, 0.5H), 6.45 (d, J = 7.3 
Hz, 0.5H), 5.43 (dt, J = 2.4 and 7.0 Hz, 1H, CH), 4.57 (m, 1H), 
3.77 (m, 1H), 3.74 (s, 1.5H), 3.72 (s, 1.5H), 3.54 (m, 1H), 2.84 (m, 1H), 2.66 (m, 3H, 
CO2Me), 2.31 (s, 3H), 1.41 (d, J = 7.3 Hz, 1.5H), 1.39 (d, J = 7.3 Hz, 1.5H); 13C NMR (75 
MHz, CDCl3, δ) 173.4, 173.3, 169.0, 168.9, 143.45, 143.43, 136.8, 136.7, 135.2, 135.1, 
132.6, 129.5, 128.9, 128.8, 127.16, 127.14, 127.12 ,127.0, 126.9, 126.8, 126.5, 126.4, 53.6, 
53.5, 52.44, 52.40, 48.3, 48.2, 45.1, 39.7, 39.6, 26.6, 26.5, 21.5, 18.2, 18.1; HRMS-ESI 
(m/z) [C22H26N2O5S + H]+ calcd 431.1635, found 431.1619. (Diastereomeric ratio approx. 
1:1 by 1H and 13C NMR) 
(2R)-methyl 3-methyl-2-(2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-
yl)acetamido)butanoate (342) 
General procedure D was followed using L-valine methyl ester 
hydrochloride (56 mg, 0.34 mmol). The title compound was 
isolated as an orange oil (94 mg,  0.20 mmol, 73%). 1H NMR 
(300 MHz, CDCl3, δ) 7.66 (d, J = 5.9 Hz, 2H), 7.04-7.14 (m, 
5H), 6.92 (m, 1H), 6.45 (d, J = 8.4 Hz, 0.25H), 6.31 (d, J = 8.5 
Hz, 0.75H), 5.43 (t, J = 6.3 Hz, 1H, CH), 4.54 (dd, J = 5.0 and 
8.6 Hz, 1H), 3.82 (m, 1H), 3.72 (s, 3H), 3.57 (m, 1H), 2.89 (m, 1H), 2.61-2.70 (m, 3H), 2.32 
(s, 3H), 2.13 (m, 1H), 0.96 (m, 6H); 13C NMR (75 MHz, CDCl3, δ) 127.2, 169.4, 143.4, 
136.7, 135.3, 132.7, 129.5, 128.9, 127.2, 127.1, 127.0, 126.9, 126.5, 57.5, 53.6, 53.5, 52.1, 
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52.0, 45.6, 45.4, 40.0, 39.8, 31.1, 31.0, 26.9, 26.7, 21.5, 18.8, 18.0; HRMS-ESI (m/z) 
[C24H30N2O5S + H]+ calcd 459.1948, found 459.1931. HPLC: tr = 16.99 min [major], tr = 
27.35 min [minor] (Chiralpak AD column, flow rate 1.0 mL/min, n-hexane/iPrOH = 80:20, λ 
= 278 nm, 25 °C) de = 40%. 
(1R)-(-)-10-camphorsulfonyl chloride (347) 
A solution of (1R)-(-)-10-camphorsulfonic acid (1.0 g, 4.30 mmol) in 
SOCl2 (1534 mg, 12.9 mmol) was stirred at room temperature for 1 h., 
heated at 40 oC for 6 h. then stirred at ambient temperature for 16 h. The 
reaction mixture was diluted with ether (10 mL), quenched with H2O over 
ice then extracted with ether (2 × 5 mL). The combined organic phases 
were washed with H2O, and NaHCO3 (sat. aq., 4 × 10 mL), dried over MgSO4 then 
concentrated to afford the title compound as a clear oil (970 mg, 3.87 mmol, 90%)  1H NMR 
(270 MHz, CDCl3, δ) 4.31 (d, J = 14.6 Hz, 1H, CH), 3.73 (d, J = 14.6, 1H, CH), 2.36-2.44 
(m, 2H), 2.06-2.16 (m, 2H), 1.95 (d, J = 18.6 Hz, 1H), 1.70-1.80 (m, 1H), 1.45-1.51 (m, 1H), 
1.11 (s, 3H, CH3), 0.90 (m, 3H, CH3); 13C NMR (67.5 MHz, CDCl3, δ) 212.9, 64.4, 59.8, 
48.3, 42.9, 42.4, 27.0, 25.4, 19.8, 19.7; HRMS-ESI (m/z) [C10H15ClO3S + H]+ calcd 
251.0503, found 251.0496. 
N-(2-bromophenethyl)-1-((1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-
yl)methanesulfonamide (348) 
To a solution of 2-bromophenethylamine (262 mg, 1.31 mmol) 
and triethylamine (331 mg, 3.28 mmol) in CH2Cl2 (5 mL) at 0 
oC was added a solution of (1R)-(-)-10-camphorsulfonyl 
chloride 347 (330 g, 1.31 mmol) in CH2Cl2 (5 mL). After 
stirring at ambient temperature for 2 h. the reaction mixture 
was washed with HCl (1M, 2 × 10 mL), NaOH (Aq 5% w/w, 2 
× 10 mL) and brine (10 mL). The organic layer was separated, dried over MgSO4 and 
concentrated under reduced pressure to afford the title compound as a white amorphous 
solid (433 mg, 1.04 mmol, 80%). 1H NMR (270 MHz, CDCl3, δ) 7.50 (d, J = 0.9, 7.9 Hz, 
1H, ArH), 7.12-7.30 (m, 2H, ArH), 7.04-7.10 (m, 1H, ArH), 5.23 (brs, 1H, NHSO2), 3.40 (t, 
J = 6.9 Hz, 2H, CH2CH2NH), 3.36 (d, J = 15.0 Hz, 1H), 3.03 (dt, J = 1.5, 6.7 Hz, 2H, 
CH2CH2NH), 2.88 (d, J = 15.0 Hz, 1H), 2.29-2.38 (m, 1H), 1.81-2.21 (m, 5H), 1.41 (m, 1H), 
0.98 (s, 3H, CH3), 0.85 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3, δ) 216.7, 137.5, 133.0, 
131.3, 128.5, 127.7, 124.5, 59.1, 49.4, 48.7, 43.2, 42.9, 42.7, 36.9, 27.0, 26.5, 19.9, 19.5; 
HRMS-ESI (m/z) [C18H24BrNO3S + H]+ calcd 414.0733, found 414.0748. 
N-(2-bromobenzyl)-1-((1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-
yl)methanesulfonamide (350) 
To a solution of 2-bromobenzylamine hydrochloride (291 mg, 
1.31 mmol) and triethylamine (331 mg, 3.28 mmol) in CH2Cl2 
(5 mL) at 0 oC was added a solution of (1R)-(-)-10-
camphorsulfonyl chloride (330 g, 1.31 mmol) in CH2Cl2 (5 
mL). After stirring at ambient temperature for 2 h. the reaction 
mixture was washed with HCl (1M, 2 × 10 mL), NaOH (Aq 
5% w/w, 2 × 10 mL) and brine (10 mL). The organic layer was separated, dried over MgSO4 
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and concentrated under reduced pressure to afford the title compound as a white amorphous 
solid (436 mg, 1.09 mmol, 83%). 1H NMR (270 MHz, CDCl3, δ) 7.51 (dt, J = 1.2 and 7.9 
Hz, 2H, ArH), 7.29 (dt, J = 1.2 and 7.5 Hz, 1H, ArH), 7.14 (dt, J = 1.8 and 7.5 Hz, 1H, 
ArH), 5.93 (t, J = 6.6 Hz, 1H, NHSO2), 4.43 (dd, J = 3.1 and 6.6 Hz, 2H, CH2NH), 3.15 (d, J 
= 15.0 Hz, 1H), 2.83 (d, J = 15.6 Hz, 1H), 1.99-2.38 (m, 5H), 1.96 (d, J = 18.5 Hz, 1H), 1.39 
(m, 1H), 0.92 (s, 3H, CH3), 0.73 (s, 3H, CH3); 13C NMR (67.5 MHz, CDCl3, δ) 216.7, 136.5, 
133.0, 130.8, 129.7, 127.9, 123.9, 59.4, 51.3, 48.8, 47.9, 43.0, 42.8, 27.1, 27.0, 19.9, 19.5; 
HRMS-ESI (m/z) [C17H22BrNO3S + H]+ calcd 400.0577, found 400.0589. 
(R)-4,4-dimethyl-2-oxotetrahydrofuran-3-yl acrylate (357) 
To a cooled solution (0 oC) of (R)-(-)-pantolactone (100 mg, 0.77 mmol) in 
THF (5 mL) was sequentially added acryloyl chloride (70 mg, 0.77 mmol) 
then triethylamine (117 mg, 1.15 mmol). After stirring at room 
temperature for 3 h. the reaction mixture was concentrated, re-dissolved in 
EtOAc (10 mL) then washed with HCl (1M, 10 mL), NaHCO3 (Sat. Aq. 10 
mL) and brine. The organic phase was dried over MgSO4 and concentrated to afford the title 
compound as a white amorphous solid (116 mg, 0.63 mmol, 82%). 1H NMR (270 MHz, 
CDCl3, δ) 6.52 (dd, J = 1.3 and 17.3 Hz, 1H, CH2=CH), 6.20 (dd, J = 10.4 and 17.3 Hz, 1H, 
CH2=CH), 5.95 (dd, J = 1.3 and 10.4 Hz, 1H, CH2=CH), 5.40 (s, 1H, CH), 4.03 (s, 2H, 
CH2), 1.21 (s, 3H, CH3), 1.09 (s, 3H, CH3); 13C NMR (67.5 MHz, CDCl3, δ) 172.4, 164.9, 
133.0, 127.1, 76.3, 75.2, 40.4, 23.1, 20.0; HRMS-ESI (m/z) [C9H12O4 + H]+ calcd 185.0808, 
found 185.0806. 
(1S,2R,5S)-2-isopropyl-5-methylcyclohexyl acrylate (359) 
To a cooled solution (0 oC) of (+)-menthol (100 mg, 0.64 mmol) in THF 
(5 mL) was sequentially added acryloyl chloride (58 mg, 0.64 mmol) 
then triethylamine (97 mg, 0.96 mmol). After stirring at room 
temperature for 3 h. the reaction mixture was concentrated, re-dissolved 
in EtOAc (10 mL) then washed with HCl (1M, 10 mL), NaHCO3 (Sat. 
Aq. 10 mL) and brine. The organic phase was dried over MgSO4 and concentrated to afford 
the title compound as a white amorphous solid (104 mg, 0.49 mmol, 77%).  1H NMR (270 
MHz, CDCl3, δ) 6.38 (dd, J = 1.6 and 17.3 Hz, 1H, CH2=CH), 6.08 (dd, J = 10.3 and 17.3 
Hz, 1H, CH2=CH), 5.75 (dd, J = 1.6 and 10.3 Hz, 1H, CH2=CH), 4.73 (dt, J = 4.4 and 10.8 
Hz, 1H, CH), 1.99 (m, 1H, CH), 1.84 (m, 1H, CH), 1.66 (m, 2H, CH2), 1.43 (m, 2H, CH2), 
1.01 (m, 2H, CH2), 0.95 (m, 1H, CH), 0.88 (d, J = 6.5 Hz, 3H, CH3), 0.84 (d, J = 7.0 Hz, 
3H), 0.74 (d, J = 7.0 Hz, 3H, CH3); 13C NMR (67.5 MHz, CDCl3, δ) 165.9, 130.3, 129.1, 
74.4, 47.1, 40.9, 34.3, 31.4, 26.4, 23.6, 22.1, 20.8, 16.5; HRMS-ESI (m/z) [C13H22O2 + H]+ 
calcd 211.1693, found 211.1698. 
(S)-methyl 3-(1H-indol-3-yl)-2-(p-toluenylsulfonamido)propanoate (463) 
To a solution of L-tryptophan methyl ester hydrochloride (400 mg, 
1.57 mmol) and triethylamine (477 mg, 4.71 mmol) in CH2Cl2 (20 
mL) was added p-toluenesulfonyl chloride (449 mg, 2.36 mmol). After 
stirring at room temperature for 16 h. the reaction mixture was washed 
with HCl (1M, 2 × 10 mL), NaOH (Aq 5% w/w, 2 × 10 mL) and brine 
(10 mL). The organic layer was separated, dried over MgSO4 and concentrated under 
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reduced pressure to afford the title compound as a clear oil (514 mg, 1.38 mmol, 88%). 1H 
NMR (270 MHz, CDCl3, δ) 8.39 (brs, 1H, indole-NH), 7.56 (d, J = 8.3 Hz, 2H, ArH), 7.41 
(d, J = 7.9 Hz, 1H, ArH), 7.29 (d, J = 8.0 Hz, 1H, ArH), 7.13 (dt, J = 1.1 and 7.0 Hz, 1H, 
ArH), 7.09 (d, J = 8.3 Hz, 2H, ArH), 7.00 (m, 1H, ArH), 6.94 (d, J = 2.4 Hz, 1H, indole-C2- 
ArH), 5.49 (d, J = 8.7 Hz, 1H, NHTs), 4.23 (m, 1H, CH2CH), 3.43 (s, 3H, CO2Me), 3.19 
(dd, J = 2.8 and 5.3 Hz, 2H, CH2CH), 2.31 (s, 3H, TsCH3); 13C NMR (67.5 MHz, CDCl3, δ) 
172.0, 143.6, 136.4, 136.3, 129.6, 127.2, 127.1, 123.9, 122.0, 119.5, 118.4, 111.6, 108.7, 
56.2, 52.6, 29.2, 21.6; HRMS-ESI (m/z) [C19H20N2O4S + H]+ calcd 373.1217, found 
373.1228. 
(S)-methyl 3-(2-bromo-1H-indol-3-yl)-2-(p-toluenylsulfonamido)propanoate (464) 
A solution of tosyl-tryptophan 463 (850 mg, 2.28 mmol) in 
THF:CHCl3 (1:1, 300 mL) was stirred at 0 oC for 15 mins. Pyridinium 
tribromide (803 mg, 2.51 mmol) was then added portion-wise over 1 h. 
Saturated aqueous sodium sulphite (10 mL) was added, and following 
a colour change, saturated aqueous NaHCO3 (10 mL) was also added. 
The aqueous phase was extracted with CHCl3 (2 × 5 mL), the combined organic fractions 
were dried over MgSO4 and concentrated under reduced pressure. The crude oil was 
subjected to column chromatography (1:3 EtOAc:Pet Spirits) to afford the title compound as 
a clear colourless oil (710 mg, 1.57 mmol, 69%). 1H NMR (270 MHz, CDCl3, δ) 8.50 (brs, 
1H, indole-NH), 7.51 (d, J = 8.3 Hz, 2H, ArH), 7.38 (d, J = 7.5 Hz, 1H, ArH), 7.15 (m, 1H, 
ArH), 7.06-7.11 (m, 2H, ArH), 7.05 (d, J = 7.9 Hz, 2H, ArH), 5.30 (d, J = 9.5 Hz, 1H, 
NHTs), 4.20 (m, 1H, CH2CH), 3.49 (s, 3H, CO2Me), 3.12 (ddd, J = 6.1 and 14.5 and 26.9 
Hz, 2H, CH2CH), 2.29 (s, 3H, TsCH3); 13C NMR (67.5 MHz, CDCl3, δ) 171.9, 143.5, 136.4, 
136.1, 129.4, 127.4, 127.0, 122.5, 120.4, 117.9, 110.8, 109.8, 109.0, 55.9, 52.8, 29.3, 21.6; 
HRMS-ESI (m/z) [C19H19N2O4SBr + H]+ calcd 451.0322, found 451.0313. 
(S)-tert-butyl 2-bromo-3-(3-methoxy-2-(p-toluenylsulfonamido)-3-oxopropyl)-1H-
indole-1-carboxylate (371) 
To a solution (359 mg, 1.64 mmol) containing tosyl-2-
bromotryptophan 464 (742 mg, 1.64 mmol) and DMAP (10 mg, 0.08 
mmol) in CH2Cl2 (20 mL) was added di-tert-butyl dicarbonate. After 
stirring for 2 h. at ambient temperature, water (10 mL) was added. The 
organic layer was separated, dried over MgSO4 and concentrated under 
reduced pressure. The resulting crude product was purified by column chromatography (1:4 
EtOAc:Pet Spirits) to afford the title compound as a clear colourless oil (787 mg, 1.43 
mmol, 87%). 1H NMR (270 MHz, CDCl3, δ) 7.98 (d, J = 7.5 Hz, 1H, ArH), 7.40 (d, J = 8.4 
Hz, 2H, ArH), 7.33 (m, 1H, ArH), 7.16-7.23 (m, 2H, ArH), 6.95 (d, J = 8.4 Hz, 2H, ArH), 
5.36 (d, J = 9.6 Hz, 1H, NHTs), 4.22 (m, 1H, CH), 3.56 (s, 3H, CO2Me), 3.06 (ddd, J = 6.0 
and 14.3 and 22.9 Hz, 2H, CH2), 2.28 (s, 3H, TsCH3), 1.68 (s, 9H, Boc-tBu); 13C NMR (67.5 
MHz, CDCl3, δ) 171.8, 148.8, 143.3, 136.4, 129.2, 128.7, 128.3, 126.7, 124.6, 123.2, 117.9, 
117.3, 115.3, 110.7, 85.3, 55.2, 52.9, 29.6, 28.3, 21.6; HRMS-ESI (m/z) [C24H27N2O6SBr + 
Na]+ calcd 573.0665, found 573.0692. 
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(S)-tert-butyl 2-bromo-3-(3-((tert-butyldimethylsilyl)oxy)-2-(p-
toluenylsulfonamido)propyl)-1H-indole-1-carboxylate (373) 
To a cooled solution (0 oC) containing Boc 2-bromotryptophan 
371 (787 mg, 1.43mmol) in THF/EtOH (2:3, 20 mL) was added 
NaBH4 (162 mg, 4.28 mmol). After stirring at room temperature 
for 16 h. the reaction was quenched by the addition of H2O (10 
mL) and the volatiles removed in vacuo. Aqueous NaOH (25% 
w/w, 1 mL) was added and the reaction mixture extracted with 
CH2Cl2 (2 × 10 mL). The combined organic phases were washed with brine, dried over 
MgSO4 and concentrated. The crude product was then taken up in DMF (10 mL) and 
imidazole (183 mg, 2.69 mmol) and tert-butyldimethylsilyl chloride (194 mg, 1.29 mmol) 
were added and the resultant mixture stirred at room temperature for 16 h. The crude 
reaction mixture was concentrated, and following the addition of NH4Cl (saturated aqueous, 
10 mL) extracted with diethyl ether (2 × 10 mL). The combined organic phases were dried 
over MgSO4, concentrated and purified by column chromatography (1:9 EtOAc:Pet Sp.) to 
afford the title compound as a clear oil (590 mg, 0.93 mmol, 65%). 1H NMR (400 MHz, 
CDCl3, δ) 7.95 (d, J = 8.5 Hz, 1H, ArH), 7.36 (d, J = 8.2 Hz, 2H, ArH), 7.30 (d, J = 7.8 Hz, 
1H, ArH), 7.22 (m, 1H, ArH), 7.14 (m, 1H, ArH), 6.82 (d, J = 8.1 Hz, 2H, ArH), 4.83 (d, J = 
7.6 Hz, 1H, NHTs), 3.73 (dd, J = 2.9 and 9.7 Hz, 1H, CH), 3.59 (dd, J = 5.8 and 9.7 Hz, 1H, 
CH2-Si), 3.52 (m, 1H, CH2-Si), 2.94 (dd, J = 5.5 and 14.5 Hz, 1H, ArCH2), 2.79 (dd, J = 9.0 
and 14.5 Hz, 1H, ArCH2), 2.25 (s, 3H, TsCH3), 1.70 (s, 9H, Boc-tBu), 0.93 (s, 9H, Si-tBu), 
0.09 (s, 3H, Si-Me), 0.07 (s, 3H, Si-Me); 13C NMR (67.5 MHz, CDCl3, δ) 148.9, 142.9, 
136.7, 136.4, 129.0, 128.5, 126.4, 124.4, 123.0, 119.2, 117.9, 115.3, 109.8, 85.1, 65.4, 54.9, 
28.3, 26.0, 21.6, -5.2, -5.4 HRMS-ESI (m/z) [C29H41O5N2SSiBr + H]+ calcd 637.1762, found 
637.1743. 
(1S,3S)-tert-butyl 3-(((tert-butyldimethylsilyl)oxy)methyl)-1-(2-oxopropyl)-2-tosyl-3,4-
dihydro-1H-pyrido[3,4-b]indole-9(2H)-carboxylate (374) 
A sealed tube containing 2-bromoindole 373 (100 mg, 0.16 
mmol), Pd(PPh3)4 (18 mg, 0.016 mmol), K2CO3 (65 mg, 0.47 
mmol) and 3-buten-2-one (13 mg, 0.19 mmol) in toluene (3 
mL) was heated at 110 oC for 16 hrs. The resulting mixture 
was cooled to room temperature, and concentrated under 
reduced pressure. The crude product purified by column 
chromatography (1:7 EtOAc:Pet Sp) to afford the title 
compound as a yellow oil (81 mg, 0.13 mmol, 81%). 1H NMR (270 MHz, CDCl3, δ) 7.95 (d, 
J = 8.2 Hz, 1H, ArH), 7.64 (d, J = 8.3 Hz, 2H, ArH), 7.17-7.29 (m, 3H, ArH), 7.04 (d, J = 
8.1 Hz, 2H, ArH), 6.33 (dd, J = 3.2 and 9.5 Hz, 1H, H1), 4.24 (m, 1H, H3), 3.83 (dd, J = 4.9 
and 9.7 Hz, 1H, H1a”), 3.68 (t, J = 9.4 Hz, 1H, H1b”), 2.99 (dd, J = 3.9 Hz, 1H, H1a’), 2.59-
2.74 (m, 3H, H1b’ and H4), 2.40 (s, 3H, COMe), 2.22 (s, 3H, TsCH3), 1.71 (s, 9H, Boc-
tBu), 0.83 (s, 9H, Si-tBu), 0.00 (s, 6H, Si-(Me)2); 13C NMR (67.5 MHz, CDCl3, δ) 206.1, 
150.3, 143.5, 136.7, 135.8, 132.9, 129.5, 128.9, 128.7, 127.3, 127.2, 126.7, 124.6, 122.9, 
118.2, 115.7, 113.7, 84.8, 65.8, 53.1, 51.3, 50.0, 29.5, 28.3, 26.0, 21.4, 20.2, 18.3, -5.3; 
HRMS-ESI (m/z) [C33H46O6N2SSi + H]+ calcd 627.2919, found 627.2931. HPLC: tr = 4.98 
min [minor], tr = 5.30 min [major] (Chiralpak AD column, flow rate 1.0 mL/min, n-
hexane/iPrOH = 90:10, λ = 256 nm, 25 °C); de = 60%.  
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L-2-bromophenylalanine methyl ester (376) 
A solution containing L-phenylalanine methyl ester hydrochloride 
(100 mg, 4.64 mmol) and Pd(OAc)2 (1040 mg, 4.63 mmol) in 
acetonitrile (60 mL) was stirred at room temperature for 6 days. After 
this time the reaction mixture was filtered through a plug of MgSO4 and the filtrate 
concentrated. The residue was then dissolved in CH2Cl2 (5 mL) and Et2O (30 mL) added to 
precipitate an orange solid which was filtered, washed with Et2O (2 × 5 mL) and air dried 
(1255 mg, 1.96 mmol). The solid was taken up in CH2Cl2 (50 mL) and Br2 (627 mg, 3.92 
mmol) added and the solution stirred at room temperature for 16 h. After this time the 
reaction mixture was filtered through a plug of Celite and the filtrate concentrated. The 
residue was then dissolved in CH2Cl2 (20 mL) and following the addition of 1,10-
phenanthroline monohydrate (328 mg, 1.65 mmol), the solution was stirred at room 
temperature for 3 h. The yellow solid was filtered off, and the filtrate was concentrated. Et2O 
was added and the resulting suspension filtered through a plug of Celite. The filtrate was 
concentrated to afford the title compound as a yellow oil (594 mg, 2.30 mmol, 50% yield 
over 3 steps). 1H NMR (270 MHz, CDCl3, δ) 7.50 (d, J = 8.5 Hz, 1H, ArH), 7.15-7.19 (m, 
2H, ArH), 7.01-7.07 (m, 1H, ArH), 3.78 (dd, J = 5.7 and 8.6 Hz, 1H, CH), 3.63 (s, 3H, 
CO2Me), 3.17 (dd, J = 5.6 and 13.6 Hz, 1H, CH2), 2.85 (dd, J = 8.7 and 13.6 Hz, 1H, CH2), 
1.52 (brs, 2H, NH2); 13C NMR (67.5 MHz, CDCl3, δ) 175.4, 137.1, 133.1, 131.7, 128.6, 
127.5, 124.9, 54.5, 52.1, 41.6; HRMS-ESI (m/z) [C10H12O2NBr + H]+ calcd 258.0124, found 
258.0121. 
(S)-methyl 3-(2-bromophenyl)-2-(p-toluenylsulfonamido)propanoate (383) 
To a solution of 2-bromo-L-phenylalanine methyl ester 376 (1800 mg, 
6.97 mmol) and triethylamine (1058 mg, 10.46 mmol) in CH2Cl2 (50 
mL) was added p-toluenesulfonyl chloride (1462 mg, 7.67 mmol). 
After stirring at room temperature for 16 h. the reaction mixture was washed with HCl (1M, 
2 × 10 mL), NaOH (Aq 5% w/w, 2 × 10 mL) and brine (10 mL). The organic layer was 
separated, dried over MgSO4 and concentrated under reduced pressure to afford the title 
compound as a clear oil (2651 mg, 6.43 mmol, 92%). M.p. 103.1-104.8 oC 1H NMR (270 
MHz, CDCl3, δ) 7.92 (d, J = 8.4 Hz, 1H, ArH), 7.57 (d, J = 8.3 Hz, 2H, ArH), 7.44 (dd, J = 
1.2 and 7.9 Hz, 1H, ArH), 7.14 (d, J = 8.0 Hz, 2H, ArH), 7.08 (m, 1H, ArH), 7.02-7.06 (m, 
1H, ArH), 5.21 (d, J = 9.8 Hz, 1H, NHTs), 4.24 (m, 1H, CH), 3.49 (s, 3H, CO2Me), 2.98-
3.17 (m, 2H, CH2), 2.37 (s, 3H, TsCH3); 13C NMR (67.5 MHz, CDCl3, δ) 171.7, 143.6, 
135.0, 133.0, 131.8, 130.3, 129.6, 128.9, 127.6, 127.2, 124.8, 55.5, 52.6, 39.6, 21.6; HRMS-
ESI (m/z) [C17H18O4NSBr + Na]+ calcd 434.0032, found 434.0033. 
(S)-N-(1-(2-bromophenyl)-3-((tert-butyldimethylsilyl)oxy)propan-2-yl)-p-
toluenesulfonamide (385) 
To a cooled solution (0 oC) containing 2-bromophenylalanine 383 
(1131 mg, 2.74 mmol) in THF/EtOH (2:3, 20 mL) was added 
NaBH4 (311 mg, 8.22 mmol). After stirring at room temperature for 
16 h. the reaction was quenched by the addition of H2O (10 mL) and 
the volatiles removed in vacuo. Aqueous NaOH (25% w/w, 1 mL) was added and the 
aqueous phase extracted with CH2Cl2 (2 × 10 mL). The combined organic phases were 
washed with brine, dried over MgSO4 and concentrated. The crude product was then taken 
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up in DMF (10 mL) and imidazole (560 mg, 8.22 mmol) and tert-butyldimethylsilyl chloride 
(1239 mg, 8.22 mmol) were added and the resultant mixture stirred at room temperature for 
16 h. The crude reaction mixture was concentrated, and following the addition of NH4Cl 
(saturated aqueous, 10 mL) extracted with diethyl ether (2 × 10 mL). The combined organic 
phases were dried over MgSO4, concentrated and purified by column chromatography (1:19 
EtOAc:Pet Sp.) to afford the title compound as a clear oil (878 mg, 1.76 mmol, 64%). 1H 
NMR (270 MHz, CDCl3, δ) 7.54 (dt, J = 2.0 and 8.5 Hz, 2H, ArH), 7.37 (dd, J = 1.2 and 7.8 
Hz, 1H, ArH), 7.12 (m, 2H, ArH), 6.95-7.06 (m, 3H, ArH), 4.85 (d, J = 8.3 Hz, 1H, NHTs), 
3.59 (m, 1H, CH), 3.50 (m, 2H, CH2-Si), 2.89 (t, J = 7.7 Hz, 2H, ArCH2CH), 2.36 (s, 3H, 
TsCH3), 0.88 (s, 9H, Si-tBu), 0.02 (s, 3H, Si-Me), 0.01 (s, 3H, Si-Me); 13C NMR (67.5 MHz, 
CDCl3, δ) 143.0, 137.3, 133.0, 131.9, 129.5, 128.6, 128.2, 127.4, 127.0, 124.7, 64.5, 54.9, 
38.7, 26.1, 21.5, 18.2, -5.5; HRMS-ESI (m/z) [C22H32O3NSSiBr + H]+ calcd 498.1128, found 
498.1146. 
(S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-1-tosylindoline (387) 
A sealed tube containing 2-bromophenyl sulfonamide 385 (100 
mg, 0.20 mmol), Pd(OAc)2 (5 mg, 0.02 mmol), P(tBu)3.HBF4 (6 
mg, 0.02 mmol), K2CO3 (83 mg, 0.6 mmol) and 3-buten-2-one 
(42 mg, 0.60 mmol) in toluene (3 mL) was heated at 110 oC for 
16 hrs. The resulting mixture was cooled to room temperature, and concentrated under 
reduced pressure. The crude product purified by column chromatography (1:9 EtOAc:Pet 
Sp) to afford the title compound as a clear oil (81 mg, 0.19 mmol, 97%). 1H NMR (270 
MHz, CDCl3, δ) 7.63 (d, J = 8.1 Hz, 1H, ArH), 7.54 (d, J = 8.3 Hz, 2H, ArH), 7.19 (m, 1H, 
ArH), 7.16 (d, J = 8.2 Hz, 2H, ArH), 7.00 (m, 2H, ArH), 4.24 (m, 1H, H2), 3.90 (dd, J = 4.2 
and 10.0 Hz, 1H, H1a’), 3.62 (dd, J = 7.9 Hz, 1H, H1b’), 2.86 (dd, J = 2.6 and 16.4 Hz, 1H, 
H3a), 2.73 (dd, J = 9.4 and 16.3 Hz, 1H, H3b), 2.33 (s, 3H, TsCH3), 0.79 (s, 9H, Si-tBu), 
0.05 (s, 3H, Si-Me), 0.00 (s, 3H, Si-Me); 13C NMR (67.5 MHz, CDCl3, δ) 143.9, 141.9, 
135.2, 132.3, 129.6, 127.5, 127.1, 125.2, 124.6, 117.0, 65.7, 62.9, 31.1, 25.8, 21.6, 18.2, -
5.3, -5.4; HRMS-ESI (m/z) [C22H31O3NSSi + H]+ calcd 418.1867, found 418.1859. 
1-((1S,3S)-3-(((tert-butyldimethylsilyl)oxy)methyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinolin-1-yl)propan-2-one (386) 
A sealed tube containing 2-bromophenyl sulfonamide 385 (150 
mg, 0.30 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), PPh3 (8 mg, 0.03 
mmol), K2CO3 (207 mg, 1.5 mmol) and 3-buten-2-one (42 mg, 
0.60 mmol) in toluene (3 mL) was heated at 110 oC for 16 h. The 
resulting mixture was cooled to room temperature, and 
concentrated under reduced pressure. The crude product was 
purified by column chromatography (1:19 EtOAc:Pet Sp) to afford 
the title compound as a yellow oil (99 mg, 0.20 mmol, 68%). 1H NMR (400 MHz, CDCl3, δ) 
7.49 (d, J = 8.2 Hz, 2H, ArH), 7.04 (d, J = 8.5 Hz, 2H, ArH), 7.01 (m, 1H, ArH), 6.95 (m, 
3H, ArH), 5.38 (dd, J = 3.6 and 8.5 Hz, 1H, H1), 3.88 (m, 1H, H3), 3.81 (m, 2H, H1”), 3.19 
(dd, J = 3.8 and 17.6 Hz, 1H, H1a’), 2.90 (d, J = 8.4 Hz, 1H, H4a), 2.84 (dd, J = 3.2 and 8.6 
Hz, 1H, H4b), 2.75 (dd, J = 6.4 and 16.1 Hz, 1H, H1b’), 2.27 (s, 3H, TsCH3), 2.12 (s, 3H, 
H4’), 0.92 (s, 9H, Si-tBu), 0.098 (s, 3H, Si-Me), 0.096 (s, 3H, Si-Me); 13C NMR (67.5 MHz, 
CDCl3, δ) 205.4, 143.1, 136.7, 136.1, 132.4, 129.4, 128.2, 127.3, 127.2, 126.9, 126.3, 66.5, 
55.0, 53.2, 52.1, 30.4, 29.3, 26.0, 21.5, 18.4, -5.2, -5.3; HRMS-ESI (m/z) [C26H37O4NSSi + 
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H]+ calcd 488.2285, found 488.2287. HPLC: tr = 10.42 min [major], tr = 11.38 min [minor] 
(Chiralpak AD-H column, flow rate 1.0 mL/min, n-hexane/iPrOH = 98:2, λ = 256 nm, 25 
°C) de = 85%. 
butyl 2-((1S,3S)-3-(((tert-butyldimethylsilyl)oxy)methyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinolin-1-yl)acetate (388) 
A sealed tube containing 2-bromophenyl sulfonamide 385 (150 mg, 
0.30 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), PPh3 (8 mg, 0.03 mmol), 
K2CO3 (207 mg, 1.5 mmol) and butyl acrylate (77 mg, 0.60 mmol) 
in toluene (3 mL) was heated at 110 oC for 16 hrs. The resulting 
mixture was cooled to room temperature and concentrated. The 
crude product was purified by column chromatography (1:7 
EtOAc:Pet Sp) to afford the title compound as a clear oil (120 mg, 
0.22 mmol, 73%). 1H NMR (400 MHz, CDCl3, δ) 7.47 (d, J = 8.2 Hz, 2H, ArH), 6.91-7.04 
(m, 6H, ArH), 5.31 (dd, J = 5.4 and 8.8 Hz, 1H, ArC1H), 3.81-4.09 (m, 5H, C3H, CH2-Si 
and CO2nBu), 2.70-2.97 (m, 4H, ArCH2 and CH2CO2nBu), 2.26 (s, 3H, TsCH3), 1.56 (m, 
2H, CO2nBu), 1.31 (m, 2H, CO2nBu), 0.91 (s, 9H, Si-tBu), 0.88 (m, 3H, CO2nBu), 0.09 (s, 
6H, Si-(Me)2); 13C NMR (67.5 MHz, CDCl3, δ) 207.1, 170.7, 143.1, 136.1,, 132.8, 129.3, 
128.2, 127.5, 127.3, 126.8, 126.1, 67.2, 64.7, 55.4, 54.2, 43.3, 31.0, 30.6, 29.4, 26.0, 21.4, 
19.2, 13.8, -5.3; HRMS-ESI (m/z) [C29H43O5NSSi + H]+ calcd 546.2704, found 546.2698. 
HPLC: tr = 8.68 min [major], tr = 11.68 min [minor] (Chiralpak AD-H column, flow rate 1.0 
mL/min, n-hexane/iPrOH = 98:2, λ = 256 nm, 25 °C); de = 92%. 
(S)-methyl 2-amino-2-(2-iodophenyl)acetate (391) 
A solution containing (S)-(+)-2-phenylglycine methyl ester hydrochloride 
(1888 mg, 9.36 mmol) and Pd(OAc)2 (2000 mg, 8.91 mmol) in acetone was 
refluxed for 16 h. After cooling to room temperature the reaction mixture 
was filtered through a plug of MgSO4 and the filtrate concentrated. The 
residue was then dissolved in CH2Cl2 (5 mL) and Et2O (30 mL) added to precipitate an 
orange solid which was filtered, washed with Et2O (2 × 5 mL) and air dried (2.569 mg, 4.20 
mmol). The solid was taken up in CH2Cl2 (75 mL) and I2 (2072 mg, 8.16 mmol) added and 
the solution stirred at room temperature for 16 h. After this time the reaction mixture was 
filtered through a plug of Celite and the filtrate concentrated. The residue was then dissolved 
in CH2Cl2 (20 mL) and following the addition of 1,10-phenanthroline monohydrate (607 mg, 
3.06 mmol), the solution was stirred at room temperature for 3 h. The yellow solid was 
filtered off, and the filtrate was concentrated. Et2O (30 mL) was added and the resulting 
suspension filtered through a plug of Celite. The filtrate was concentrated to afford the title 
compound as a yellow oil (813 mg, 2.79 mmol, 30% over 3 steps). 1H NMR (270 MHz, 
CDCl3, δ) 7.86 (d, J = 7.8 Hz, 1H, ArH), 7.33-7.36 (m, 2H, ArH), 6.97 (m, 1H, ArH), 5.02 
(s, 1H, CH2), 3.73 (s, 3H, CO2Me); 13C NMR (67.5 MHz, CDCl3, δ) 174.2, 140.1, 130.2, 
129.8, 129.0, 127.6, 100.0, 62.7, 52.8; HRMS-ESI (m/z) [C9H10O2NI + H]+ calcd 291.9829, 
found 291.9826. 
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(S)-N-(2-((tert-butyldimethylsilyl)oxy)-1-(2-iodophenyl)ethyl)-p-toluenesulfonamide 
(392) 
To a solution of 2-iodophenylglycine methyl ester 391 (800 mg, 2.75 
mmol) and triethylamine (417 mg, 4.13 mmol) in CH2Cl2 (20 mL) was 
added p-toluenesulfonyl chloride (629 mg, 3.30 mmol). After stirring at 
room temperature for 16 h. the reaction mixture was washed with HCl 
(1M, 2 × 10 mL), NaOH (Aq 5% w/w, 2 × 10 mL) and brine (10 mL). 
The organic layer was separated, dried over MgSO4 and concentrated under reduced 
pressure to afford the title compound as a yellow oil (955 mg, 2.14 mmol, 78%). To a cooled 
solution (0 oC) containing 2-iodophenylglycine (950 mg, 2.13 mmol) in THF/EtOH (2:3, 30 
mL) was added NaBH4 (242 mg, 6.39 mmol). After stirring at room temperature for 16 h. 
the reaction was quenched by the addition of H2O (10 mL) and the volatiles removed in 
vacuo. Aqueous NaOH (25% w/w, 1 mL) was added and the aqueous phase extracted with 
CH2Cl2 (2 × 10 mL). The combined organic phases were washed with brine, dried over 
MgSO4 and concentrated. The crude product was then taken up in DMF (10 mL) and 
imidazole (435 mg, 6.39 mmol) and tert-butyldimethylsilyl chloride (963 mg, 6.39 mmol) 
were added and the resultant mixture stirred at room temperature for 16 h. The crude 
reaction mixture was concentrated, and following the addition of NH4Cl (saturated aqueous, 
10 mL) extracted with diethyl ether (2 × 10 mL). The combined organic phases were dried 
over MgSO4, concentrated and purified by column chromatography (1:9 EtOAc:Pet Sp.) to 
afford the title compound as a clear oil (132 mg, 0.25 mmol, 12%). 1H NMR (270 MHz, 
CDCl3, δ) 7.74 (dd, J = 1.24 and 7.9 Hz, 1H, ArH), 7.67 (d, J = 8.5 Hz, 2H, ArH), 7.36 (dd, 
J = 1.6 and 7.7 Hz, 1H, ArH), 7.18-7.24 (m, 3H, ArH), 6.90 (dt, J = 1.9 and 7.9 Hz, 1H, 
ArH), 5.37 (d, J = 3.9 Hz, 1H, NHTs), 4.52 (dt, J = 4.1 and 7.3 Hz, 1H, CH), 3.67 (dd, J = 
4.1 and 10.5 Hz, 1H, CH2), 3.37 (dd, J = 7.3 and 10.5 Hz, 1H, CH2), 2.37 (s, 3H, TsCH3), 
0.77 (s, 9H, Si-tBu), -0.12 (s, 3H, Si-Me), -0.15 (s, 3H, Si-Me); 13C NMR (67.5 MHz, 
CDCl3, δ) 143.5, 139.9, 139.4, 136.3, 129.6, 129.5, 129.3, 128.2, 127.6, 127.1, 98.3, 65.0, 
42.1, 25.8, 21.6, -5.50, -5.51; HRMS-ESI (m/z) [C21H30O3NSSiI + H]+ calcd 532.0833, 
found 532.0847. HPLC: tr = 5.41 min [major], tr = 5.81 min [minor] (Chiralpak AD-H 
column, flow rate 1.0 mL/min, n-hexane/iPrOH = 98:2, λ = 210 nm, 25 °C); de = 86%. 
butyl 2-((1S,3S)-3-(((tert-butyldimethylsilyl)oxy)methyl)-2-tosylisoindolin-1-yl)acetate 
(393) 
A sealed tube containing 2-iodophenylsulfonamide 392 (60 
mg, 0.11 mmol), Pd(OAc)2 (3 mg, 0.006 mmol), PPh3 (3 mg, 
0.006 mmol), triethylamine (33 mg, 0.33 mmol) and butyl 
acrylate (18 mg, 0.14 mmol) in DMF (2 mL) was heated at 
110 oC for 16 hrs. The resulting mixture was cooled to room 
temperature, and concentrated under reduced pressure. The 
crude product purified by column chromatography (1:19 
EtOAc:Pet Sp) to afford the title compound as a clear oil (47 mg, 0.09 mmol, 79%). 1H 
NMR (270 MHz, CDCl3, δ) 7.70 (d, J = 8.3 Hz, 2H, ArH), 7.11-7.23 (m, 6H, ArH), 5.25 
(dd, J = 4.1 and 8.9 Hz, 1H, H1), 4.78 (dd, J = 3.2 and 6.5 Hz, 1H, H3), 4.14 (m, 3H, H5’ 
and H1a’), 3.77 (dd, J = 6.8 and 9.9 Hz, 1H, H1b’), 3.23 (dd, J = 4.2 and 16.1 Hz, 1H, 
H1a”), 2.77 (dd, J = 9.0 and 16.1 Hz, 1H, H1b”), 2.33 (s, 3H, TsCH3), 1.64 (m, 2H, H6’), 
1.35 (m, 2H, H7’), 0.92 (t, J = 7.3 Hz, 3H, H8’), 0.82 (s, 9H, Si-tBu), 0.02 (s, 3H, Si-Me), -
0.01 (s, 3H, Si-Me); 13C NMR (67.5 MHz, CDCl3, δ) 171.3, 143.8, 139.8, 138.2, 134.5, 
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129.9, 128.1, 127.9, 127.5, 123.6, 122.7, 67.7, 66.6, 64.6, 62.1, 44.3, 31.0, 30.7, 25.9, 25.5, 
21.6, 19.2, 18.4, 13.8, -5.3, -5.5; HRMS-ESI (m/z) [C13H22O2 + H]+ calcd 211.1693, found 
211.1698. HRMS-ESI (m/z) [C28H41O5NSSi + H]+ calcd 532.2547, found 532.2561. HPLC: 
tr = 7.98 min [major], tr = 9.01 min [minor] (Chiralpak AD-H column, flow rate 1.0 mL/min, 
n-hexane/iPrOH = 98:2, λ = 256 nm, 25 °C); de = 87%.  
7.2.4 Chapter Five 
 
1-propyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (405) 
Method A: To a solution of tryptamine (1000 mg, 6.24 mmol) and 
butyraldehyde (450 mg, 6.24 mmol) in H2O (22.5 mL) at room 
temperature was added trifluoroacetic acid (2.5 mL). After stirring for 
16 h. at ambient temperature, NaHCO3 (5% aq. w/w, 10 mL) was 
added to quench the reaction. The reaction mixture was extracted with 
EtOAc (2 × 20 mL). The combined organic phases were dried over 
MgSO4 and concentrated to afford the title compound as an orange amorphous solid (1061 
mg, 4.95 mmol, 79%) Method B: To a solution of tryptamine (500 mg, 3.12 mmol) and 
butyraldehyde (247 mg, 3.43 mmol) in CH2Cl2 (9 mL) at room temperature was added 
trifluoroacetic acid (1 mL). After stirring for 16 h. at ambient temperature NaHCO3 (5% aq. 
w/w, 10 mL) was added to quench the reaction. The reaction mixture was extracted with 
CH2Cl2 (2 × 10 mL). The combined organic phases were dried over MgSO4 and 
concentrated to afford the title compound as an orange amorphous solid (664 mg, 3.10 
mmol, 99%). 1H NMR (270 MHz, CDCl3, δ) 7.88 (brs, 1H, indole-NH), 7.48 (dd, J = 1.6 
and 7.3 Hz, 1H, ArH), 7.27-7.31 (m, 1H, ArH), 7.11 (dqn, J = 1.5 and 7.1 Hz, 2H, ArH), 
4.06 (m, 1H, H1), 3.35 (dt, J = 4.5 and 12.6 Hz, 1H, H3a), 2.97-3.07 (m, 1H, H3b), 2.74 (m, 
2H, H4), 1.46-1.87 (m, 6H, H1’ and H2’), 0.99 (t, J = 7.5 Hz, 3H, H3’); 13C NMR (67.5 
MHz, CDCl3, δ) 136.5, 135.7, 127.7, 121.5, 119.4, 118.1, 110.8, 109.0, 52.6, 42.7, 37.4, 
22.9, 19.2, 14.3; HRMS-ESI (m/z) [C14H18N2 + H]+ calcd 215.1543, found 215.1539. 
1-phenyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (406) 
To a solution of tryptamine (100 mg, 0.62 mmol) and benzaldehyde 
(73 mg, 0.69 mmol) in H2O (4.5 mL) at room temperature was 
added trifluoroacetic acid (0.5 mL). After stirring for 16 h. the 
reaction was quenched by the addition of NaHCO3 (5% Aq, w/w). 
The reaction mixture was extracted with CH2Cl2 (2 × 10 mL). The 
combined organic phases were washed with H2O (2 × 20 mL) then brine. The organic layer 
was separated, dried over MgSO4 and concentrated. The crude was purified by column 
chromatography (1:8, MeOH:EtOAc) to afford the title compound as a pale yellow 
amorphous solid (137 mg, 0.55 mmol, 88%). 1H NMR (270 MHz, CDCl3, δ) 7.67 (brs, 1H), 
7.53 (m, 1H), 7.27-7.33 (m, 5H), 7.10-7.17 (m, 3H,), 5.17 (s, 1H, CH), 3.34 (dt, J = 4.3 and 
12.5 Hz, 1H), 3.07-3.16 (m, 1H), 2.78-2.99 (m, 2H); 13C NMR (100 MHz, CDCl3, δ) 141.5, 
136.0, 134.2, 129.0, 128.9, 128.7, 128.6, 128.4, 127.4, 121.9, 119.5, 118.3, 110.9, 110.3, 
58.2, 42.9, 22.4; HRMS-ESI (m/z) [C17H16N2 + H]+ calcd 249.1386, found 249.1398. 
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methyl 4-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)benzoate (411) 
To a solution of tryptamine (500 mg, 3.12 mmol) and methyl-4-
formylbenzoate (564 mg, 3.43 mmol) in CH2Cl2 (19 mL) at room 
temperature was added trifluoroacetic acid (1 mL). After stirring 
for 16 h. at ambient temperature the reaction mixture was 
concentrated. K2CO3 (5% aq. w/w, 30 mL) was added and the 
crude extracted with CH2Cl2. The organic phase was separated, 
dried over MgSO4 and concentrated. Purification by column 
chromatography (1:49 MeOH:CH2Cl2) afforded the title compound as a pale brown 
amorphous solid (655 mg, 2.14 mmol, 69%). 1H NMR (270 MHz, CDCl3, δ) 8.00 (d, J = 8.0 
Hz, 2H), 7.54 (m, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.08-7.24 (m, 3H), 5.20 (s, 1H, CH), 3.90 
(s, 3H, CO2Me), 3.35 (dt, J = 4.7 and 12.3 Hz, 1H), 3.09-3.19 (m, 1H), 2.78-2.96 (m, 2H), 
1.83 (brs, 1H); 13C NMR (75 MHz, CDCl3, δ) 166.7, 146.9, 135.9, 133.6, 130.1, 130.0, 
128.5, 127.3, 121.9, 119.5, 118.3, 110.9, 110.5, 57.8, 52.2, 42.7, 22.5; HRMS-ESI (m/z) 
[C19H18N2O2 + H]+ calcd. 307.1441, found 307.1427. 
methyl 3-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)benzoate (412) 
To a solution of tryptamine (500 mg, 3.12 mmol) and methyl-
3-formylbenzoate (564 mg, 3.43 mmol) in CH2Cl2 (19 mL) at 
room temperature was added trifluoroacetic acid (1 mL). After 
stirring for 16 h. at ambient temperature the reaction mixture 
was concentrated. K2CO3 (5% aq. w/w, 30 mL) was added and 
the crude extracted with CH2Cl2. The organic phase was 
separated, dried over MgSO4 and concentrated. Purification by column chromatography 
(1:49 MeOH:CH2Cl2) afforded the title compound as a pale brown amorphous solid (828 
mg, 2.70 mmol, 87%). 1H NMR (270 MHz, CDCl3, δ) 7.95-7.99 (m, 2H), 7.65 (brs, 1H), 
7.53 (m, 1H), 7.50 (dt, J = 1.5 and 7.7 Hz, 1H), 7.36-7.42 (m, 1H), 7.10-7.22 (m, 3H), 5.18 
(s, 1H, CH), 3.86 (s, 3H, CO2Me), 3.35 (dt, J = 4.0 and 12.3 Hz, 1H), 3.08-3.18 (m, 1H), 
2.78-2.94 (m, 2H), 1.85 (brs, 1H); 13C NMR (75 MHz, CDCl3, δ) 166.8, 142.4, 136.0, 133.9, 
133.1, 130.7, 130.5, 129.4, 128.9, 127.4, 121.8, 119.5, 118.3, 110.9, 110.4, 57.9, 52.2, 42.9, 
22.5; HRMS-ESI (m/z) [C19H18N2O2 + H]+ calcd. 307.1441, found 307.1448. 
methyl 1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-carboxylate (413) 
To a solution of tryptamine (200 mg, 1.25 mmol) and methyl 
pyruvate (153 mg, 1.49 mmol) in methanol (9.5 mL) at room 
temperature was added trifluoroacetic acid (0.5 mL). After refluxing 
at 67 oC for 72 h. the reaction mixture was cooled to room 
temperature and the volatiles removed. The crude was dissolved in EtOAc (10 mL) and 
washed with NaHCO3 (sat. aq. 20 mL) and brine. The organic phase was separated, dried 
over MgSO4 and concentrated to afford the title compound as a pale brown amorphous solid 
(303 mg, 1.24 mmol, 99%). 1H NMR (270 MHz, CDCl3, δ) 8.35 (brs, 1H), 7.48 (d, J = 7.7 
Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.08-7.21 (m, 2H), 3.78 (s, 3H, CO2Me), 3.21 (m, 2H), 
2.73 (m, 2H), 1.72 (s, 3H, CH3); 13C NMR (67.5 MHz, CDCl3, δ) 174.9, 136.3, 133.0, 126.9, 
122.3, 119.6, 118.7, 111.2, 110.3, 59.2, 53.0, 41.1, 27.1, 22.3; HRMS-ESI (m/z) 
[C14H16N2O2 + H]+ calcd 245.1285, found 245.1293. 
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1,1-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (415) 
To a solution of tryptamine (500 mg, 3.12 mmol) and acetone (2 mL)  
in toluene (4.5 mL) at room temperature was added trifluoroacetic acid 
(0.5 mL). The reaction mixture was heated using microwave irradiation 
(minimum power) at 60 oC for 20 mins. After this time, the mixture was 
diluted with K2CO3 (5% aq. w/w, 30 mL) was added and the crude extracted with CH2Cl2 (3 
× 15 mL). The combined organic phases were dried over MgSO4 and concentrated to afford 
the title compound as a pale brown amorphous solid (598 mg, 2.99 mmol, 96%). 1H NMR 
(270 MHz, CDCl3, δ) 7.85 (brs, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.31 (d, J = 8.2 Hz, 1H), 7.08-
7.19 (m, 1H), 3.55 (brs, 1H), 3.26 (t, J = 5.8 Hz, 2H), 2.77 (t, J = 5.7 Hz, 2H), 1.52 (s, 6H, 
C(CH3)2); 13C NMR (67.5 MHz, CDCl3, δ) 136.5, 135.6, 127.3, 121.8, 119.5, 118.3, 110.7, 
107.3, 51.0, 39.7, 28.7, 22.5, 14.3; HRMS-ESI (m/z) [C13H16N2 + H]+ calcd. 201.1386, found 
201.1379.  
N10-benzyltryptamine (178) 
A solution containing tryptamine (300 mg, 1.87 mmol), 
benzaldehyde (218 mg, 2.06 mmol) and MgSO4 (100 mg) in 
toluene (10 mL) was stirred at room temperature for 16 h. After 
this time, the MgSO4 was filtered off and the reaction mixture 
concentrated in vacuo. The crude was taken up in methanol (10 
mL) and NaBH4 (71 mg, 1.87 mmol) was added and the resultant mixture stirred at ambient 
temperature for 90 mins. The reaction was quenched by the addition H2O. Following 
removal of the volatiles, the reation mixture was diluted EtOAc and washed with NaHCO3 
(sat. aq., 20 mL) and brine. The organic phase was separated, dried over MgSO4 and 
concentrated to afford the title compound as a pale orange oil (437 mg, 1.75 mmol, 93%). 1H 
NMR (270 MHz, CDCl3, δ) 8.49 (brs, 1H, indole-NH), 7.65 (d, J = 7.6 Hz, 1H, ArH), 7.13-
7.40 (m, 8H, ArH), 6.94 (s, 1H, ArH), 3.86 (s, 2H, CH2Ph), 3.05 (s, 4H, CH2CH2NH), 2.02 
(brs, 1H, NHBn); 13C NMR (67.5 MHz, CDCl3, δ) 140.0, 136.7, 128.7, 128.5, 127.6, 127.3, 
122.6, 122.1, 119.3, 119.0, 113.4, 111.6, 53.9, 49.4, 25.8; HRMS-ESI (m/z) [C17H18N2 + H]+ 
calcd. 251.1543, found 251.1555. 
methyl 2-benzyl-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-carboxylate 
(416) 
To a solution of N-benzyltryptamine 178 (200 mg, 0.80 mmol) 
and methyl pyruvate (98 mg, 0.96 mmol) in methanol (9.5 mL) 
at room temperature was added trifluoroacetic acid (0.5 mL). 
After refluxing for 4 h. the reaction mixture was concentrated. 
The crude was then dissolved in ethyl acetate (10 mL) and 
washed with NaHCO3 (sat aq. 10 mL). The organic phase was separated, dried over MgSO4 
and concentrated. Purification by column chromatography (1:1 EtOAc:Pet. Sp.) afforded the 
title compound as an orange amorphous solid (90 mg, 0.27 mmol, 34%). 1H NMR (270 
MHz, CDCl3, δ) 8.13 (brs, 1H), 7.52 (d, J = 7.8 Hz, 4H), 7.11-7.39 (m, 5H), 3.92 (q, J = 
14.8 Hz, 2H, CH2Ph), 3.78 (s, 3H, CO2Me), 3.18 (m, 1H), 2.90 (m, 1H), 2.74 (m, 2H), 1.83 
(s, 3H, CH3); 13C NMR (67.5 MHz, CDCl3, δ) 174.7, 140.7, 136.4, 133.8, 128.4, 128.2, 
127.0, 122.2, 119.6, 118.7, 111.1, 110.2, 63.8, 55.1, 52.4, 44.9, 23.2, 21.8; HRMS-ESI (m/z) 
[C21H22N2O2 + H]+ calcd. 335.1754, found 335.1745. 
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(5-methylpyrazin-2-yl)(1-propyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-
yl)methanone (419) 
A solution containing propyl tetrahydro-β-carboline 405 (400 
mg, 1.87 mmol), 5-methyl-2-pyrazine carboxylic acid (387 
mg, 2.81 mmol), HOBt (63 mg, 0.47 mmol), EDCI (537 mg, 
2.80 mmol) in CH2Cl2 (10 mL) was stirred at ambient 
temperature for 16 h. The reaction mixture was then diluted 
with CH2Cl2 (30 mL) and washed with H2O (20 mL) then 
brine. The organic layer was separated, dried over MgSO4 and concentrated. The crude 
product was purified by column chromatography to afford the title compound as a pale 
yellow amorphous solid (215 mg, 0.64 mmol, 34%). 1H NMR (270 MHz, CDCl3, δ) 8.84 (s, 
1H, ArH), 8.45 (s, 1H, ArH), 8.13 (brs, 1H, indole-NH), 7.45 (d, J = 7.3 Hz, 1H, ArH), 7.32 
(d, J = 8.0 Hz, 1H, ArH), 7.05-7.17 (m, 2H, ArH), 5.89 (t, J = 7.0 Hz, 1H, CH), 4.15 (m, 
1H), 3.54 (ddd, J = 4.1 and 11.7 and 13.7 Hz, 1H), 2.98 (ddd, J = 4.9 and 13.1 and 15.9 Hz, 
1H), 2.72 (dd, J = 3.2 and 15.0 Hz, 1H), 2.63 (s, 3H, CH3), 1.95 (m, 2H), 1.60 (m, 2H), 0.99 
(t, J = 7.3 Hz, 3H); 13C NMR (67.5 MHz, CDCl3, δ) 166.5, 154.9, 147.1, 145.1, 144.2, 
142.6, 136.1, 133.9, 122.1, 119.8, 118.2, 111.0, 107.9, 50.0, 41.8, 37.1, 22.5, 21.8, 19.8, 
14.3; HRMS-ESI (m/z) [C20H22N4O + H]+ calcd 335.1866, found 335.1880. 
1-(1-phenyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)ethanone (417) 
To a solution of phenyl tetrahydro-β-carboline 406 (100 mg, 0.40 
mmol), triethylamine (49 mg, 0.48 mmol), and DMAP (25 mg, 0.20 
mmol) in DMF (5 mL) was added acetyl chloride (38 mg, 0.48 
mmol). After stirring at ambient temperature for 5 h. the reaction 
mixture was concentrated. The crude product was purified by 
column chromatography (1:8 MeOH:EtOAc) to afford the title 
compound as a white amorphous solid (118 mg, 0.40, 100%). 1H NMR (270 MHz, CDCl3, 
δ) 7.94 (brs, 1H), 7.54 (d, J = 7.0 Hz, 2H), 7.28 (m, 5H), 7.13 (quin, J = 7.0 Hz, 2H), 7.00 (s, 
1H, CH), 3.85 (m, 1H), 3.43 (m, 1H), 2.91 (m, 2H), 2.18 (s, 3H, COMe); 13C NMR (67.5 
MHz, CDCl3, δ) 169.1, 140.0, 136.4, 131.8, 128.9, 128.6, 128.2, 126.8, 122.3, 119.7, 118.2, 
111.2, 109.9, 51.7, 40.7, 22.2, 21.9; HRMS-ESI (m/z) [C19H18N2O + Na]+ calcd 313.1311, 
found 313.1313. 
2-benzyl-1-phenyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (418) 
To a solution of phenyl tetrahydro-β-carboline 406 (400 mg, 
1.61 mmol) in CH2Cl2 (10 mL) was added benzyl bromide 
(334 mg, 1.93 mmol). The resultant mixture was stirred at 
ambient temperature after which time the solvent was removed 
and the crude purified by column chromatography (1:3 
EtOAc:Pet Sp) to afford the title compound as a pale yellow 
solid (376 mg, 1.11 mmol, 69%). M.p. 150.1-151.7 oC 1H 
NMR (270 MHz, CDCl3, δ) 7.52 (m, 1H), 7.46 (m, 2H), 7.25-7.40 (m, 8H), 7.16 (m, 1H), 
7.10 (m, 2H), 4.65 (s, 1H, CH), 3.90 (d, J = 13.6 Hz, 1H, CH2Ph), 3.40 (d, J = 13.6 Hz, 1H, 
CH2Ph), 3.24 (dt, J = 5.0 and 11.7 Hz, 1H), 2.91 (m, 1H), 2.87 (m, 1H), 2.66 (ddd, J = 4.2 
and 9.6 and 11.6 Hz, 1H); 13C NMR (100 MHz, CDCl3, δ) 141.5, 139.6, 136.4, 135.0, 129.1, 
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128.8, 128.7, 128.3, 128.2, 127.3, 127.0, 121.6, 119.4, 118.4, 110.9, 109.0, 64.7, 58.4, 48.5, 
21.3; HRMS-ESI (m/z) [C24H22N2 + H]+ calcd 339.1856, found 339.1859. 
1-(1-propyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)hexan-1-one (420) 
To a solution of phenyl tetrahydro-β-carboline 405 (300 
mg, 1.40 mmol), triethylamine (170 mg, 1.68 mmol), and 
DMAP (86 mg, 0.70 mmol) in CH2Cl2 (10 mL) was 
added hexanoyl chloride (226 mg, 1.68 mmol). After 
stirring at ambient temperature for 16 h. the reaction 
mixture was concentrated. The crude product was purified by column chromatography (1:3 
EtOAc:Pet. Sp.) to afford the title compound as a brown oil (262 mg, 0.84 mmol, 60%). 1H 
NMR (270 MHz, CDCl3, δ) 8.48 (brs, 1H), 7.44 (d, J = 7.6 Hz, 1H), 7.29 (d, J = 8.0 Hz, 
1H), 7.09 (quin, J = 7.9 Hz, 2H), 5.81 (dd, J = 6.0 and 8.1 Hz, 1H, CH), 4.07 (d, J = 15.4 
Hz, 2H), 3.47 (m, 1H), 2.79 (m, 2H), 2.45 (m, 2H), 2.33 (t, J = 7.5 Hz, 2H), 1.63 (m, 4H), 
1.37 (m, 6H), 0.91 (6H); 13C NMR (67.5 MHz, CDCl3, δ) 172.4, 136.1, 135.1, 126.8, 121.7, 
119.5, 117.9, 111.0, 107.4, 49.0, 40.3, 36.9, 33.9, 31.8, 25.3, 22.6, 22.4, 19.7, 14.3, 14.1; 
HRMS-ESI (m/z) [C20H28N2O + H]+ calcd 313.2274, found 313.2268. 
methyl 1-methyl-2-(5-methylpyrazine-2-carbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-1-carboxylate (421) 
A solution containing tetrahydro-β-carboline methyl ester 
413 (300 mg, 1.23 mmol), 5-methyl-2-pyrazine carboxylic 
acid (187 ng, 1.35 mmol), EDCI (283 mg, 1.48 mmol) and 
HOBt (50 mg, 0.37 mmol) in CH2Cl2 (5 mL) was stirred at 
ambient temperature for 16 h. After this time the reaction 
mixture was diluted with CH2Cl2 and washed with NaHCO3 (sat. aq. 2 × 30 mL) and brine 
(30 mL). The organic layer was separated, dried over MgSO4 and concentrated. The crude 
was purified by column chromatography (1:1 EtOAc:Pet. Sp.) to afford the title compound 
as a clear oil (197 mg, 0.54 mmol, 44%). 1H NMR (270 MHz, CDCl3, δ) 9.15 (brs, 1H), 8.88 
(s, 1H), 8.51 (s, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.18 (t, J = 6.3, 1H), 
7.11 (t, J = 7.0 Hz, 1H), 4.32 (m, 1H), 3.65 (s, 3H, CO2Me), 3.50 (m, 1H), 3.11 (m, 1H), 
2.88 (dt, J = 2.9 and 15.0 Hz, 1H), 2.65 (s, 3H, ArCH3), 2.08 (s, 3H, CH3); 13C NMR (100 
MHz, CDCl3, δ) 172.2, 167.1, 155.5, 146.6, 144.6, 142.8, 136.3, 132.1, 126.4, 122.8, 120.0, 
118.6, 111.5, 109.5, 62.2, 53.2, 44.6, 21.8, 21.6, 14.1; HRMS-ESI (m/z) [C20H20N4O3 + H]+ 
calcd 387.1428, found 387.1435. 
N-(pyridin-2-yl)acrylamide (423) 
To a cooled solution of 2-aminopyridine (1000 mg, 10.6 mmol) and 
triethylamine (1162 mg, 11.5 mmol) in CH2Cl2 (10 mL) was added 
acryloyl chloride (1058 mg, 11.7 mmol). After stirring at room 
temperature for 4 h. the reaction was quenched by the addition of H2O. The organic layer 
was separate, washed with brine, dried over MgSO4 and concentrated to afford the title 
compound as an orange amorphous solid (1078 mg, 7.25 mmol, 68%). 1H NMR (270 MHz, 
CDCl3, δ) 9.13 (brs, 1H, NH), 8.32 (dt, J = 0.8 and 8.4 Hz, 1H, ArH), 8.26 (ddd, J = 0.9 and 
1.9 and 5.0 Hz, 1H, ArH), 7.71 (ddd, J = 1.9 and 7.4 and 9.3 Hz, 1H, ArH), 7.04 (ddd, J = 
1.0 and 4.9 and 7.3 Hz, 1H, ArH), 6.49 (dd, J = 1.5 and 16.9 Hz, 1H, CH2=CH), 6.29 (dd, J 
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= 10.0 and 16.9 Hz, 1H, CH2=CH), 5.75 (dd, J = 1.5 and 10.0 Hz, 1H, CH2=CH); 13C NMR 
(100 MHz, CDCl3, δ) 164.2, 152.0, 147.6, 138.7, 131.0, 128.6, 120.0, 115.1; HRMS-ESI 
(m/z) [C8H8N2O + H]+ calcd 149.0709, found 149.0702. 
N-(pyrazin-2-yl)acrylamide (424) 
To a cooled solution of aminopyrazine (920 mg, 9.7 mmol) and 
triethylamine (1174 mg, 11.6 mmol) in CH2Cl2 (10 ml) was added 
acryloyl chloride (963 mg, 10.6 mmol). After stirring at room 
temperature for 4 h. the reaction was quenched by the addition of H2O. 
The organic layer was separated, washed with brine, dried over MgSO4 and concentrated to 
afford the title compound as an orange amorphous solid (1360 mg, 9.1 mmol, 94%). 1H 
NMR (270 MHz, CDCl3, δ) 9.62 (s, 1H, NH), 8.36 (d, J = 2.6 Hz, 1H, ArH), 8.24 (dd, J = 
1.5 and 2.6 Hz, 1H, ArH), 7.99 (brs, 1H, ArH), 6.50 (dd, J = 1.1 and 11.2 Hz, 1H, 
CH2=CH), 6.30 (dd, J = 10.2 and 16.9 Hz, 1H, CH2=CH), 5.87 (dd, J = 1.1 and 10.2 Hz, 1H, 
CH2=CH); 13C NMR (100 MHz, CDCl3, δ) 167.7, 163.7, 142.1, 140.5, 137.3, 130.2, 129.7; 
HRMS-ESI (m/z) [C7H7N3O + H]+ calcd 150.0662, found 150.0669. 
3-(1,1-dimethyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-N-(pyridin-2-
yl)propanamide (427) 
A solution containing dimethyl tetrahydro-β-
carboline 415 (470 mg, 2.35 mmol), and N-(pyridin-
2-yl)acrylamide 423 (384 mg, 2.59 mmol) in 
methanol/THF (1:1, 10 mL) was heated to 60 oC for 
16 h. After this time the reaction mixture was concentrated. Purification by column 
chromatography (1:1 EtOAc:Pet. Sp. to 1:9 MeOH:EtOAc) afforded the title compound as a 
pale orange oil (146 mg, 0.42 mmol, 18%). 1H NMR (270 MHz, CDCl3, δ) 10.69 (brs, 1H, 
amide-NH), 8.12 (m, 2H), 7.72 (brs, 1H, indole-NH), 7.61 (dt, J = 1.5 and 7.4 Hz, 1H), 7.47 
(m, 1H), 7.34 (m, 1H), 7.07-7.19 (m, 2H), 6.88-6.93 (m, 1H), 3.03 (t, J = 5.7 Hz, 2H), 2.98 
(t, J = 5.6 Hz, 2H), 2.84 (t, J = 5.6 Hz, 2H), 2.63 (t, J = 5.5 Hz, 2H), 1.50 (s, 6H, C(CH3)2); 
13C NMR (75 MHz, CDCl3, δ) 171.3, 151.7, 148.1, 139.7, 137.8, 136.0, 127.1, 121.5, 119.4, 
119.2, 118.3, 114.0, 110.7, 107.6, 55.9, 44.3, 43.1, 34.7, 31.0, 24.1, 21.4; HRMS-ESI (m/z) 
[C21H24N4O + H]+ calcd. 349.2023, found 349.2035. 
3-(1-propyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-N-(pyridin-2-yl)propanamide 
(428) 
A solution containing propyl tetrahydro-β-carboline 
405 (200 mg, 0.93 mmol), and N-(pyridin-2-
yl)acrylamide (153 mg, 1.0 mmol) in methanol/THF 
(1:1, 10 mL) was heated to 60 oC for 48 h. After this 
time the reaction mixture was concentrated. 
Purification by column chromatography (1:2 EtOAc:Pet. Sp.) afforded the title compound as 
a pale orange oil (148 mg, 0.41 mmol, 44%). 1H NMR (270 MHz, CDCl3, δ) 10.91 (brs, 1H, 
amide-NH), 8.27 (ddd, J = 0.9 and 1.9 and 4.9 Hz, 1H), 8.22 (m, 1H), 7.96 (brs, 1H, indole-
NH), 7.66 (dt, J = 1.9 and 7.6 Hz, 1H), 7.50 (m, 1H), 7.29 (m, 1H), 7.06-7.18 (m, 2H), 6.98 
(ddd, J = 1.0, 4.9, 7.3 Hz, 1H), 3.74 (dd, J = 4.7 and 7.7 Hz, 1H, CH), 3.41 (m, 1H), 3.13 (m, 
1H), 2.88-2.99 (m, 3H), 2.50-2.60 (m, 3H), 1.94 (m, 1H), 1.74 (m, 2H), 1.53 (m, 1H), 0.93 
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(t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3, δ) 171.7, 152.0, 148.2, 138.1, 135.9, 134.6, 
127.2, 121.7, 119.5, 119.4, 118.2, 114.4, 110.9, 107.2, 57.2, 48.7, 43.8, 37.4, 34.4, 20.3, 
17.2, 14.3; HRMS-ESI (m/z) [C22H26N4O - H]- calcd. 361.2034, found 361.2044. 
methyl 3-(2-(3-oxo-3-(pyridin-2-ylamino)propyl)-1-propyl-3,4-dihydro-1H-pyrido[3,4-
b]indol-9(2H)-yl)propanoate (429) 
A solution containing propyl THβC pyridine 428 
(717 mg, 2.0 mmol), methyl acrylate (342 mg, 4.0 
mmol) and K2CO3 (821 mg, 5.9 mmol) in DMF (5 
mL) was heated to 100 oC for 16 h. After cooling to 
room temperature, the crude mixture was 
concentrated and purification by column 
chromatography (2:3 EtOAc:Pet Sp.) afforded the 
title compound as an orange oil (410 mg, 0.91 mmol, 46%). 1H NMR (300 MHz, CDCl3, δ) 
10.83 (brs, 1H, amide-NH), 8.30 (m, 1H), 8.20 (dt, J = 0.9 and 8.4 Hz, 1H), 7.70 (dt, J = 1.9 
and 7.6 Hz, 1H), 7.51 (d, J = 6.8 Hz, 1H), 7.22 (dt, J = 1.3 and 7.0 Hz, 1H), 7.11 (dt, J = 1.2 
and 7.7 Hz, 1H), 6.99 (ddd, J = 1.0, 4.9, 7.3 Hz, 1H), 4.35 (t, J = 7.0 Hz, 2H), 4.07 (d, J = 
8.1 Hz, 1H, CH), 3.63 (s, 3H, CO2Me), 3.48 (m, 1H), 3.16 (dd, J = 5.7 and 14.2 Hz, 1H), 
2.84-3.00 (m, 3H), 2.63-2.74 (m, 3H), 2.44-2.52 (m, 1H), 1.83-1.96 (m, 2H), 1.60-1.71 (m, 
4H), 0.99 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3, δ) 171.1, 171.6, 152.0, 148.0, 
137.9, 135.8, 135.7, 127.4, 121.4, 119.4, 119.3, 118.3, 114.2, 109.0, 106.2, 54.8, 52.0, 48.5, 
42.7, 38.8, 37.2, 34.4, 33.9, 20.4, 16.7, 14.0; HRMS-ESI (m/z) [C26H32N4O3 + H]+ calcd. 
449.2547, found 449.2568. 
3-(2-(3-oxo-3-(pyridin-2-ylamino)propyl)-1-propyl-3,4-dihydro-1H-pyrido[3,4-b]indol-
9(2H)-yl)propanoic acid (430) 
A solution containing propyl THβC methyl ester 429 
(300 mg, 0.45 mmol) and LiOH (1M, 9 mL) in THF 
(11 mL) was stirred at room temperature for 30 mins. 
After this time the volatiles were removed and NaOH 
(1M, 5 mL) was added. The reaction mixture was 
extracted with CH2Cl2 (2 × 5 mL). The aqueous 
phase was acidified to pH 5 using HCl (1M) then 
extracted with EtOAc (2 × 10 mL). The combined organic phases were dried over MgSO4 
and concentrated to afford the title compound as a beige solid (131 mg, 0.30 mmol, 68%). 
M.p. 147.1-149.4 oC 1H NMR (300 MHz, CDCl3, δ) 12.96 (brs, 1H, CO2H), 11.23 (brs, 1H, 
amide-NH), 8.26 (d, J = 8.5 Hz, 1H), 7.92 (ddd, J = 0.8 and 1.8 and 5.2 Hz, 1H), 7.71 (dt, J 
= 1.8 and 7.4 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.18 (dt, J = 1.3 and 6.9 Hz, 1H), 7.08 (dt, J 
= 1.2 and 7.8 Hz, 1H), 6.96 (ddd, J = 1.0 and  5.2 and 7.3 Hz, 1H), 4.67 (dd, J = 2.3 and 9.9 
Hz, 1H, CH), 4.50 (ddd, J = 2.2 and 12.3 and 14.6 Hz, 1H), 4.28 (dt, J = 3.2 and 14.9 Hz, 
1H), 3.40 (ddd, J = 5.4 and 12.0 and 14.0 Hz, 1H), 3.22 (ddd, J = 2.8 and 12.2 and 17.7 Hz, 
1H), 2.51-3.16 (m, 8H), 2.04 (s, 1H), 1.52-1.83 (m, 4H), 1.04 (t, J = 6.7 Hz, 3H); 13C NMR 
(75 MHz, CDCl3, δ) 177.6, 171.3, 152.0, 145.0, 140.3, 137.3, 135.3, 127.8, 121.2, 119.3, 
119.2, 118.5, 115.0, 109.2, 105.5, 52.7, 50.7, 45.2, 38.7, 38.4, 37.1, 33.3, 20.4, 17.3, 14.3; 
HRMS-ESI (m/z) [C25H30N4O3 - H]- calcd. 433.2245, found 433.2239. 
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N-(2-(1H-indol-3-yl)ethyl)acetamide (431) 
Acetic anhydride (701 mg, 6.24 mmol) was added to a solution of 
tryptamine (1000 mg, 6.24 mmol) in CH2Cl2 (20 mL) at 0 oC. After 
stirring for 1 h. saturated aqueous NaHCO3 (20 mL) was added and 
stirring continued for 30 mins. The aqueous phase was then extracted 
with CH2Cl2 (2 × 5 mL). The combined organic phases were dried 
over MgSO4 and concentrated to afford the title compound as an orange amorphous solid 
(1227 mg, 6.06 mmol, 97%). 1H NMR (270 MHz, CDCl3, δ) 8.37 (brs, 1H, indole-NH), 
7.56-7.60 (m, 1H, ArH), 7.36 (ddd, J = 0.8 and 1.2 and 8.0 Hz, 1H, ArH), 7.19 (dt, J = 1.2 
and 7.0 Hz, 1H, ArH), 7.08-7.14 (m, 1H, ArH), 7.00 (d, J = 2.4 Hz, 1H, ArH), 5.62 (brs, 1H, 
NHAc), 3.59 (q, J = 6.7 Hz, 2H, CH2CH2NH), 2.95 (dt, J = 0.7 and 6.7 Hz, 2H, 
CH2CH2NH), 1.90 (s, 3H, COMe); 13C NMR (75 MHz, CDCl3, δ) 170.3, 136.4, 127.3, 
122.1, 122.0, 119.4, 118.7, 112.8, 111.4, 39.9, 25.3, 23.4; HRMS-ESI (m/z) [C12H14N2O + 
H]+ calcd. 203.1179, found 203.1170. 
1-methyl-4,9-dihydro-3H-pyrido[3,4-b]indole (432) 
A solution of N10-acetyltryptamine 431 (4894 mg, 24.2 mmol) and 
POCl3 (4081 mg, 26.6 mmol) in acetonitrile (50 mL) was refluxed at 80 
oC for 48 h. After this time, the reaction was quenched by the addition of 
H2O (50 mL) and extracted with EtOAc (3 × 20 mL). The combined 
organic phases were dried over MgSO4 and concentrated to afford the title compound as a 
brown oil (4078 mg, 22.1 mmol, 91%). 1H NMR (270 MHz, CDCl3, δ) 9.86 (brs, 1H, 
indole-NH), 7.57 (dt, J = 1.0 and 7.9 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 7.27 (m, 1H), 7.12 
(ddd, J = 1.0 and 7.0 and 8.0 Hz, 1H), 3.81 (dt, J = 1.3 and 7.6 Hz, 2H), 2.87 (t, J = 8.7 Hz, 
2H), 2.44 (s, 3H, COMe); 13C NMR (75 MHz, CDCl3, δ) 195.0, 142.0, 129.4, 126.1, 124.2, 
123.9, 121.8, 120.9, 114.1, 42.7, 19.8, 19.2; HRMS-ESI (m/z) [C12H12N2 + H]+ calcd. 
185.1073, found 185.1073. 
3-(1-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-N-(pyridin-2-yl)propanamide 
(434) 
A solution containing methyl tetrahydro-β-carboline 
433 (610 mg, 3.28 mmol), and N-(pyridin-2-
yl)acrylamide 423 (273 mg, 6.56 mmol) in 
methanol/THF (1:1, 20 mL) was heated to 60 oC for 
24 h. After this time the reaction mixture was concentrated. Purification by column 
chromatography (1:2 EtOAc:Pet. Sp.) afforded the title compound as a pale orange oil (615 
mg, 1.84 mmol, 56%). 1H NMR (270 MHz, CDCl3, δ) 10.95 (brs, 1H, amide-NH), 8.22 
(ddd, J = 0.9, 1.9 and 4.9 Hz, 1H), 8.17 (dt, J = 0.9 and 8.4 Hz, 1H), 7.91 (brs, 1H, indole-
NH), 7.64 (ddd, J = 1.9 and 7.4 and 8.4 Hz, 1H), 7.47 (m, 1H), 7.32 (m, 1H), 7.12 (dt, J = 
1.4 and 7.1 and 15.9 Hz, 2H), 6.95 (ddd, J = 1.0 and 4.9 and 7.3 Hz, 1H), 3.98 (q, J = 6.7 
Hz, 1H, CH), 3.33 (m, 1H), 2.87-3.06 (m, 4H), 2.56-2.70 (m, 3H), 1.56 (d, J = 6.7 Hz, 3H, 
CH3); 13C NMR (75 MHz, CDCl3, δ) 171.3, 151.9, 148.1, 137.9, 136.0, 135.2, 127.0, 121.7, 
119.5, 119.3, 118.2, 114.2, 110.8, 107.5, 53.2, 48.7, 44.4, 34.0, 19.7, 18.6; HRMS-ESI (m/z) 
[C20H22N4O + H]+ calcd. 335.1866, found 335.1872. 
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butyl 3-(1-methyl-2-(3-oxo-3-(pyridin-2-ylamino)propyl)-3,4-dihydro-1H-pyrido[3,4-
b]indol-9(2H)-yl)propanoate (435) 
A solution containing methyl THβC pyridine 434 
(1253 mg, 3.75 mmol), butyl acrylate (1441 mg, 
11.24 mmol) and K2CO3 (1553 mg, 11.24 mmol) in 
DMF (10 mL) was heated to 100 oC for 16 h. After 
cooling to room temperature, the crude mixture was 
concentrated and purification by column 
chromatography (3:1 EtOAc:Pet Sp.) afforded the 
title compound as an pale orange oil (1137 mg, 2.46 mmol, 66%). 1H NMR (400 MHz, 
CDCl3, δ) 11.18 (brs, 1H, amide-NH), 8.24 (ddd, J = 0.6 and 1.3 and 3.3 Hz, 1H), 8.20 (d, J 
= 5.6 Hz, 1H), 7.65 (dt, J = 1.3 and 4.6 Hz, 1H), 7.50 (d, J = 5.2 Hz, 1H), 7.30 (d, J = 5.5 
Hz, 1H), 7.19 (dt, J = 0.8 and 4.7 Hz, 1H), 7.11 (dt, J = 0.5 and 5.2 Hz, 1H), 6.98 (ddd, J = 
0.6 and 3.3 and 4.9 Hz, 1H), 4.34 (t, J = 7.6 Hz, 2H), 4.27 (q, J = 6.5 Hz, 1H, CH), 4.01 (m, 
2H), 3.41 (ddd, J = 5.0 and 12.1 and 13.8 Hz, 1H), 3.17 (dd, J = 5.6 and 13.8 Hz, 1H), 3.02 
(m, 1H), 2.87-2.94 (m, 3H), 2.62 (m, 3H), 2.55 (m, 1H), 1.62 (d, J = 6.8 Hz, 3H, CHCH3), 
1.51 (m, 2H), 1.26 (m, 2H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3, δ) 171.7, 
171.4, 152.2, 148.2, 138.0, 136.6, 136.0, 127.5, 121.6, 119.5, 119.3, 118.5, 114.4, 109.2, 
106.4, 64.9, 51.2, 48.8, 41.8, 38.9, 34.3, 34.0, 30.6, 20.3, 19.1, 17.5, 13.8; HRMS-ESI (m/z) 
[C27H34N4O3 + H]+ calcd. 463.2704, found 463.2705. 
3-(1-methyl-2-(3-oxo-3-(pyridin-2-ylamino)propyl)-3,4-dihydro-1H-pyrido[3,4-b]indol-
9(2H)-yl)propanoic acid (436) 
A solution containing butyl ester tetrahydro-β-
carboline 435 (200 mg, 0.43 mmol) and LiOH (1M, 
1.08 mL) in THF/H2O (1:1, 10 mL) was stirred at 
room temperature for 2 h. After this time the 
volatiles were removed and the reaction mixture 
diluted with H2O (10 mL). Following extraction with 
CH2Cl2 (3 × 5 mL) the aqueous phase was acidified 
to pH 5 using HCl (1M). The reaction mixture was then extracted with EtOAc (2 × 5 mL). 
The combined organic phases were dried over MgSO4 and concentrated to afford the title 
compound as a pale yellow solid (125 mg, 0.31 mmol, 71%). M.p. 202.1-203.9 oC 1H NMR 
(270 MHz, CDCl3, δ) 11.21 (s, 1H, amide-NH), 8.25 (d, J = 8.5 Hz, 1H), 7.95 (dd, J = 1.8 
and 5.2 Hz, 1H), 7.73 (dt, J = 1.9 and 7.4 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.28 (d, J = 8.7 
Hz, 1H), 7.18 (dt, J = 1.0 and 7.1 Hz, 1H), 7.08 (dt, J = 0.7 and 7.8 Hz, 1H), 6.99 (ddd, J = 
0.7 and 5.1 and 7.0 Hz, 1H), 4.96 (brs, 1H, CO2H), 4.48 (ddd, J = 2.0 and 12.5 and 14.8 Hz, 
1H), 4.30 (dt, J = 3.1 and 14.9 Hz, 1H, CH), 3.43 (m, 1H), 3.23 (m, 1H), 3.08 (m, 1H), 2.63-
2.91 (m, 8H), 1.50 (d, J = 6.9 Hz, 3H, CH3); 13C NMR (67.5 MHz, CDCl3, δ) 177.5, 171.0, 
151.8, 145.0, 140.3, 135.4, 127.7, 121.3, 119.4, 118.5, 115.1, 109.2, 105.1, 50.6, 48.4, 45.0, 
38.6, 38.0, 33.4, 31.0, 29.8, 20.5, 17.6; HRMS-ESI (m/z) [C23H26N4O3 + H]+ calcd 407.2078, 
found 407.2071. 
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N-(2-(1H-indol-3-yl)ethyl)-2-nitro-N-(prop-2-yn-1-yl)benzenesulfonamide (437) 
A solution containing N10-nosyltryptamine 140 (700 mg, 2.03 
mmol), propargyl bromide (241 mg, 2.23 mmol) and K2CO3 (842 
mg, 6.09 mmol) in DMF was heated to 60 oC for 6 h. After this time 
the reaction mixture was diluted with HCl (1M, 100 mL) and 
extracted with CH2Cl2 (4 × 5 mL). The combined organic phases were dried over MgSO4 
and concentrated. Purification by column chromatography (1:3 EtOAc:Pet Sp.) afforded the 
title compound as a yellow oil (778 mg, 2.03 mmol, 100%). 1H NMR (300 MHz, CDCl3, δ) 
7.96 (brs, 1H, indole-NH), 7.94 (d, J = 8.1 Hz, 1H, ArH), 7.50-7.60 (m, 4H, ArH), 7.31 (d, J 
= 8.0 Hz, 1H, ArH), 7.18 (t, J = 7.0 Hz, 1H, ArH), 7.11 (t, J = 7.7 Hz, 1H, ArH), 7.05 (s, 
1H, ArH), 4.28 (d, J = 2.2 Hz, 2H, CH2C≡CH), 3.74 (t, J = 7.2 Hz, 2H, CH2CH2NH), 3.12 
(t, J = 7.3 Hz, 2H, CH2CH2NH), 2.24 (t, J = 2.4 Hz, 1H, CH2C≡CH); 13C NMR (75 MHz, 
CDCl3, δ) 195.1, 148.0, 136.1, 133.4, 132.8, 131.5, 130.6, 127.1, 124.1, 122.3, 122.1, 119.5, 
118.5, 111.8, 111.2, 73.9, 47.2, 36.7, 24.0; HRMS-ESI (m/z) [C19H17N3O4S + H]+ calcd. 
384.1013, found 384.0997. 
(Z)-3-((2-nitrophenyl)sulfonyl)-2,3,4,7-tetrahydro-1H-azocino[5,4-b]indole (438) 
A solution containing nosyltryptamine 437 (800 mg, 2.09 mmol) and 
AuCl3 (32 mg, 5 mol%) in CH2Cl2 was heated to 40 oC for 3 h. After 
cooling to room temperature the reaction mixture was filtered 
through a plug of Celite and concentrated. Purification by column 
chromatography (1:4 EtOAc:Pet Sp.) afforded the title compound as 
a pale yellow oil (410 mg, 1.07 mmol, 51%). 1H NMR (270 MHz, CDCl3, δ) 7.81 (d, J = 1.8 
Hz, 1H, ArH), 7.78 (d, J = 1.1 Hz, 1H, ArH), 7.74 (brs, 1H, indole-NH), 7.44-7.55 (m, 4H, 
ArH), 7.06-7.22 (m, 2H, ArH), 6.59 (d, J = 11.3 Hz, 1H, CH=CHCH2), 5.93 (dt, J = 6.6 and 
11.2 Hz, 1H, CH=CHCH2), 4.05 (dd, J = 0.8 and 6.6 Hz, 2H, CH=CHCH2), 3.65 (m, 2H, 
CH2CH2NH), 3.06 (m, 2H, CH2CH2NH); 13C NMR (67.5 MHz, CDCl3, δ) 147.9, 136.1, 
133.2, 131.6, 131.5, 130.6, 128.1, 127.5, 124.2, 123.9, 123.5, 122.8, 119.8, 118.4, 112.3, 
111.3, 110.8, 46.3, 24.8; HRMS-ESI (m/z) [C19H17N3O4S + Na]+ calcd 406.0832, found 
406.0846. 
(Z)-3-(1H-azocino[5,4-b]indol-3(2H,4H,7H)-yl)-N-(pyridin-2-yl)propanamide (439) 
A solution containing indoloazocine 438 (214 mg, 
0.56 mmol), thiophenol (136 mg, 1.23 mmol) and 
potassium carbonate (232 mg, 1.68 mmol) in DMF 
(10 mL) was heated to 40 oC for 4 h. After this time 
the reaction mixture was diluted with H2O (100 mL) 
and extracted with CH2Cl2 (4 × 5 mL). The combined 
organic phases were dried over MgSO4 and 
concentrated. The deprotected product was then taken up in MeOH/THF (1:1, 10 mL) and 
following the addition of N-(pyridin-2-yl)acrylamide 423 (163 mg, 1.1 mmol) was heated to 
60 oC for 48 h. The reaction mixture was concentrated and purification by column 
chromatography (1:2 EtOAc:Pet. Sp. to 2:3 EtOH:EtOAc) afforded the title compound as a 
yellow amorphous solid (130 mg, 0.38 mmol, 67% over 2 steps). 1H NMR (300 MHz, 
CDCl3, δ) 11.03 (s, 1H, amide-NH), 8.27 (d, J = 3.9 Hz, 1H), 8.17 (d, J = 8.3 Hz, 1H), 7.91 
(brs, 1H, indole-NH), 7.65 (t, J = 7.9 Hz, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.29 (d, J = 8.4 Hz, 
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1H), 7.19 (t, J = 7.0 Hz, 1H), 7.11 (t, J = 7.7 Hz, 1H), 6.99 (m, 1H), 6.71 (d, J = 10.9 Hz, 
1H, CH=CHCH2), 5.93 (m, 1H, CH=CHCH2), 3.61 (d, J = 7.7 Hz, 2H, CH=CHCH2), 3.19 
(m, 4H), 2.94 (t, J = 4.7 Hz, 2H), 2.57 (t, J = 6.0 Hz, 2H); 13C NMR (75 MHz, CDCl3, δ) 
171.4, 152.0, 148.0, 137.9, 130.4, 128.8, 125.9, 125.8, 122.6, 119.5, 119.3, 118.6, 114.4, 
112.3, 110.5, 51.0, 49.4, 49.3, 33.9, 29.7, 22.7; HRMS-ESI (m/z) [C21H22ON4 + H]+ calcd 
347.1866, found 347.1859. 
(Z)-methyl 3-(3-(3-oxo-3-(pyridin-2-ylamino)propyl)-3,4-dihydro-1H-azocino[5,4-
b]indol-7(2H)-yl)propanoate (440) 
A solution containing indoloazocine pyridine 439 
(113 mg, 0.33 mmol), methyl acrylate (56 mg, 0.65 
mmol) and K2CO3 (135 mg, 0.98 mmol) in DMF ( 5 
mL) was heated at 100 oC for 16 h. The reaction 
mixture was then diluted with H2O (100 mL) and 
extracted with CH2Cl2 (4 × 5 mL). The combined 
organic phases were dried over MgSO4 and 
concentrated to afford the title compound as an 
orange oil (124 mg, 0.29 mmol, 88%). 1H NMR 
(270 MHz, CDCl3, δ) 10.97 (s, 1H, amide-NH), 8.21 (m, 1H), 8.15 (m, 1H), 7.63 (m, 1H), 
7.54 (m, 1H), 7.19-7.30 (m, 2H), 7.11 (m, 1H), 6.96 (ddd, J = 1.0 and 4.9 and 7.3 Hz, 1H), 
6.83 (d, J = 11.0 Hz, 1H, CH=CHCH2), 6.06 (m, 1H, CH=CHCH2), 4.38 (t, J = 7.3 Hz, 2H, 
CH=CHCH2), 3.64 (s, 3H, CO2Me), 3.49 (d, J = 7.7 Hz, 2H), 3.08 (m, 4H), 2.95 (t, J = 6.2 
Hz, 2H), 2.68 (t, J = 7.6 Hz, 2H), 2.57 (t, J = 6.3 Hz, 2H); 13C NMR (67.5 MHz, CDCl3, δ) 
171.6, 171.5, 152.0, 148.1, 138.0, 136.4, 132.0, 128.5, 128.1, 123.5, 122.5, 119.5, 119.4, 
118.8, 114.4, 109.0, 52.0, 50.8, 50.0, 49.9, 39.3, 34.6, 33.9, 29.8, 22.7; HRMS-ESI (m/z) 
[C25H28O3N4 + Na]+ calcd 455.2054, found 455.2053. 
5-methylene-3-((2-nitrophenyl)sulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 
(442) 
A solution containing nosyl tryptamine 437 (3000 mg, 7.84 mmol) 
and (acetonitrile)[(2-biphenyl)di-tert-butylphosphine]gold(I) 
hexafluoroantimonate (303 mg, 5 mol%) in CH2Cl2 (40 mL) was 
stirred at room temperature for 16 h. After this time, the reaction 
mixture was filtered through a plug of Celite and concentrated. Purification by column 
chromatography (1:4 EtOAc:Pet Sp.) afforded the title compound as a pale yellow oil (2047 
mg, 5.34 mmol, 68%). 1H NMR (300 MHz, CDCl3, δ) 8.19 (s, 1H, indole-NH), 7.91 (dd, J = 
1.1 and 5.4 Hz, 1H, ArH), 7.42-7.57 (m, 5H, ArH), 7.18 (dt, J = 0.9 and 7.0 Hz, 1H, ArH), 
7.09 (t, J = 7.9 Hz, 1H, ArH), 5.27 (s, 1H, CH2=C), 5.20 (s, 1H, CH2=C), 4.34 (s, 2H, 
CCH2N), 3.75 (t, J = 5.7 Hz, 2H, CH2CH2NH), 3.12 (t, J = 5.9 Hz, 2H, CH2CH2NH); 13C 
NMR (75 MHz, CDCl3, δ) 148.0, 137.4, 135.9, 133.6, 133.0, 132.8, 131.7, 130.4, 128.4, 
124.0, 123.2, 119.7, 118.6, 112.8, 112.2, 110.9, 52.9, 49.1, 24.6; HRMS-ESI (m/z) 
[C19H17N3O4S + Na]+ calcd 406.0832, found 406.0824. 
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3-(5-methylene-1,2,4,5-tetrahydroazepino[4,5-b]indol-3(6H)-yl)-N-(pyridin-2-
yl)propanamide (443) 
A solution containing azepinoindole 442 (2047 mg, 
5.34 mmol), thiophenol (1369 mg, 12.43 mmol) and 
potassium carbonate (2214 mg, 16.02 mmol) in 
DMF (10 mL) was heated to 40 oC for 4 h. After this 
time the reaction mixture was diluted with H2O (100 mL) and extracted with CH2Cl2 (4 × 5 
mL). The combined organic phases were dried over MgSO4 and concentrated. The 
deprotected product was then taken up in MeOH/THF (1:1, 20 mL) and following the 
addition of N-(pyridin-2-yl)acrylamide 423 (1582 mg, 10.68 mmol) heated to 60 oC for 48 h. 
The reaction mixture was concentrated and purification by column chromatography (3:1 
EtOAc:Pet. Sp.) afforded the title compound as a yellow oil (573 mg, 1.65 mmol, 31% over 
2 steps). 1H NMR (270 MHz, CDCl3, δ) 10.80 (brs, 1H, amide-NH), 8.27 (m, 1H), 8.19 (d, J 
= 8.4 Hz, 1H), 8.00 (brs, 1H, indole-NH), 7.66 (ddd, J = 2.0 and 7.6 and 8.7 Hz, 1H), 7.50 
(d, J = 7.6 Hz, 1H), 7.31 (d, J = 7.9 Hz, 1H), 7.19 (dt, J = 1.0 and 6.9 Hz, 1H), 7.09 (dt, J = 
1.0 and 7.9 Hz, 1H), 6.99 (ddd, J = 0.8 and 5.0 and 7.3 Hz, 1H), 5.35 (s, 1H, CH2=C), 5.17 
(s, 1H, CH2=C), 4.09 (s, 2H, CCH2N), 3.42 (t, J = 5.4 Hz, 2H), 3.05 (m, 4H), 2.58 (t, J = 6.3 
Hz, 2H); 13C NMR (67.5 MHz, CDCl3, δ) 171.6, 152.1, 148.1, 139.0, 138.2, 135.9, 134.0, 
129.0, 123.3, 119.8, 119.5, 118.9, 114.5, 114.4, 112.9, 110.7, 59.1, 53.5, 45.9, 33.1, 22.4; 
HRMS-ESI (m/z) [C21H22N4O + H]+ calcd. 347.1866, found 347.1869. 
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A simple and efficient palladium-catalyzed domino reac-
tion for the synthesis of a series of C1-substituted tetra-
hydro-β-carbolines is described. This domino process
involves a Heck reaction at the indole 2-position of a
halogenated tryptamine precursor, followed by intramo-
lecular aza-Michael addition.
Tetrahydro-β-carbolines (THβCs or tryptolines) substi-
tuted at the 1-position are central to a number of pharma-
ceutical targets with potential for the treatment of medical
conditions including breast cancer, type-2 diabetes, and
bacterial infections.1 This ring system is prevalent in several
more structurally complex natural products, including the
secologanin-type terpenoid indole alkaloid ajmalicine (1)
(Figure 1) and the antihypertensive agent reserpine (2).1a,2
Biosynthetically, attaching a 3-(l-Δ0-pyrroliniumyl)propanal
to this carboline ring system accesses the alkaloid elaeo-
carpidine (3) containing an additional indolizidine ring
fragment.3
Domino reactions are an attractive proposition for the
modern synthetic chemist, generating a high level of mole-
cular complexity in one efficient step.4 A domino reaction is
defined as “the execution of two or more bond-forming
transformations under identical reaction conditions, in
which the latter transformations take place at the function-
alities formed by the preceding transformation.”4,5
These reactions are appealing to industry and research
laboratories because of their potential to minimize the use of
solvents, reagents, time, and energy.4 The more conceivable
domino reactions are those where all transformations occur
under similar reaction conditions, for example, where each of
the steps are palladium-catalyzed.5,6 The range of single-step
reactions involving palladium catalysis has grown to the
extent where palladium-mediated reactions are common-
place in most synthetic laboratories. Consequently, the
number of palladium-mediated domino reactions has also
increased over the past decade.7 In spite of this increase,
domino Heck-Michael methodology remains relatively
underutilized, with limited examples in the literature.8 Of
those reported, only one details a dominoHeck-aza-Michael
process, used in the synthesis of benzo-fused sultams.8c
Due to their biological relevance, it is important that
molecularly diverse THβCs are prepared containingmultiple
sites for further functionalization. Traditionally, C1-substi-
tuted THβCs are accessed through the acid-catalyzed Pictet-
Spengler reaction between tryptamine and an appropriate
aldehyde.9 Alternatively, a four-step process involving a
FIGURE 1. Natural products (1-3) containing the tetrahydro-β-
carboline heterocyclic core.
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Bischler-Napieralski reaction to afford the dihydro-β-carbo-
line and subsequent reduction is effective in producing specific
THβCs.10
More recently, due to difficulties in the preparation and
handling of the requisite aldehydes (for example, β-formyl
esters11), modified Pictet-Spengler reactions have been
developed using alternatives such as alkynoates2a and per-
hydro-1,3-heterocycles.2c To complement these existing
methodologies, a domino Heck-aza-Michael reaction of a
tryptamine derivative (such as compound 4, Scheme 1) was
foreseen as an efficient method for introducing molecular
diversity at C1 of the THβC scaffold. Using cheap and
readily available acrylates under mild conditions, an ortho-
gonally protected THβC scaffold containing multiple sites
for further functionalization would be readily accessible.
The indoleC2-position of tryptaminewas considered ideal
for further functionalization using a domino Heck-aza-
Michael reaction (Scheme 1). Palladium-catalyzed cross-
coupling of C2-halogenated indole compounds, namely,
the Heck, Sonogashira, and Suzuki reactions, has been
reported by our group and others.12 As the Heck reaction
regenerates the olefin functionality following syn-elimina-
tion and is reliably efficient with electron-deficient terminal
alkenes, the potential exists for a second nucleophilic addi-
tion reaction. In this case, a 1,4-Michael addition should be
suitable, depending on the nature of the tethered amine and if
it reacts before or after the Heck reaction (an intra- vs
intermolecular aza-Michael reaction; see Scheme 1).
As such, a dominoHeck-aza-Michael transformationwith
an appropriately functionalized tryptamine was considered
highly likely as both aza-Michael addition13 and the Heck
reaction14 take place under mildly basic conditions. In this
dominoprocess, a newC-CandC-Nbondwould be created
in sequence, at the same carbon atom.
Initially, severalprotectinggroups (atR1,Scheme1) including
tert-butoxycarbonyl, trifluoroacetate, tosyl, benzenesulfonyl,
and 2-nitrobenzenesulfonyl were trialed to influence the acidity
of the proton on the protected amine, tuning nucleophilicity at
the tryptamine N10 nitrogen. During these preliminary investi-
gations, the tosyl group was quickly identified as most suited to
our domino system.6b
The tosyl protectionof theprimaryaminewithin tryptamine
(8) proceeded in quantitative yields to afford sulfonamide 9.
Similarly, bromination of the C2 position proceeded readily to
give 2-bromoindole 10 in excellent yields (90%). Following
preliminary treatment of the precursor 10 with Pd(PPh3)4,
K2CO3 and butyl acrylate, the target tetrahydro-β-carboline
11 was isolated in a promising yield of 30% (Scheme 2).
The synthesis of carboline 11 from tryptamine (8) was
achieved in three steps in a moderate overall yield of 27%.
More importantly, this encouraging result confirmed that the
domino Heck-aza-Michael reaction was applicable to this
particular ring system. To improve the yield, three features of
the domino Heck-aza-Michael reaction were identified for
further optimization, namely, theHeck reaction, the nucleophi-
licity of the sulfonamide, and the degree of electrondeficiencyof
theMichael acceptor. The Heck reaction, the initial step of this
domino process, was optimized first, with the roles of the
palladium catalyst, base, and the solvent investigated (Table 1).
The results from this investigation were consistent with
previous reports of the Heck reaction at the indole 2-posi-
tion,12c,15 with Pd(PPh3)4 (10 mol %) providing the highest
yields. Interestingly, the use of Na2CO3 (Table 1, entry 5)
produced only the Heck adduct 12 in excellent yields,
whereas K2CO3 facilitated the formation of the desired
tetrahydro-β-carboline 11 (Scheme 2). Unfortunately, the
highly reactive catalytic system pioneered by Fu16 afforded
only amoderate yield for theHeck product (Table 1, entry 3).
SCHEME 1. Single Step versus a Domino Process To Access
THβCs
SCHEME 2. Initial Attempts of theDominoHeck-Aza-Michael
Reaction in the Synthesis of the Tetrahydro-β-carboline 11
(10) da Silva, W. A.; Rodrigues, M. T.; Shankaraiah, N.; Ferreira, R. B.;
Andrade, C. K. Z.; Pilli, R. A.; Santos, L. S. Org. Lett. 2009, 11, 3238–3241.
(11) Dinh, M. T.; Bouzbouz, S.; Peglion, J. L.; Cossy, J. Tetrahedron
2008, 64, 5703–5710.
(12) (a) Luo,S.; Zificsak,C.A.;Hsung,R.P.Org.Lett. 2003, 5, 4709–4712.
(b) Uno, T.; Beausoleil, E.; Goldsmith, R. A.; Levine, B. H.; Zuckermann,
R. N. Tetrahedron Lett. 1999, 40, 1475–1478. (c) Stewart, S. G.; Heath, C. H.;
Ghisalberti, E. L. Eur. J. Org. Chem. 2009, 1934-1943.
(13) (a) Chandrasekhar, S.; Ramakrishna Reddy, N.; Srinivasa Rao,
Y. Tetrahedron 2006, 62, 12098–12107. (b) Rayabarapu,D. K.; Zhou, A.; Jeon,
K. O.; Samarakoon, T.; Rolfe, A.; Siddiqui, H.; Hanson, P. R. Tetrahedron
2009, 65, 3180–3188. (c) Ihara, M.; Ishida, Y.; Tokunaga, Y.; Kabuto, C.;
Fukumoto, K. J. Chem. Soc., Chem Commun. 1995, 2085–2086.
(14) (a) Beletskaya, I. P.; Cheprakov, A. V. Chem. Rev. 2000, 100, 3009–
3066. (b) Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. Angew. Chem., Int. Ed.
2005, 44, 4442–4489.
(15) Jain, H. D.; Zhang, C.; Zhou, S.; Zhou, H.;Ma, J.; Liu, X.; Liao, X.;
Deveau, A.M.;Dieckhaus, C.M.; Johnson,M.A.; Smith,K. S.;Macdonald,
T. L.; Kakeya, H.; Osada, H.; Cook, J. M. Bioorg. Med. Chem. 2008, 16,
4626–4651.
(16) Littke, A. F.; Fu, G. C. J. Am. Chem. Soc. 2001, 123, 6989–7000.
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With the Heck reaction proceeding in excellent yields, the
second step in the domino sequence, the aza-Michael addi-
tion, was explored (Table 2).17 A range of organic amines
(i.e., NEt3,DBU) and inorganic bases (i.e., Na2CO3,K2CO3,
Cs2CO3) did not improve the domino transformation.
A range of solvents were also trialed to improve the Pd-
(PPh3)4,K2CO3 catalytic system; however, solventsmore polar
than toluene (MeCN,DMF,anddioxane,Table 2, entries 6-8)
failed to increase the yield of the domino process with many of
these increasing the propensity for the sulfonamide to undergo
an initial 1,4-addition (to compound 5, Scheme 1). In such
cases, the relatively slow rate of the Heck reaction is secondary
to the more reactive intermolecular aza-Michael addition.
The addition of the phase transfer agent TBAC to improve
the rate of key steps in the catalytic cycle (Table 2, entries 10
and 11) also failed to increase the yield of the domino process
beyond 30%.14,18 Alternatively, a change in the reactivity of
the R,β-unsaturated moiety in the initial Heck adduct was
envisaged through protection of the indole nitrogen. To our
delight, this approach proved successful and the domino
reaction usingN-Boc indole 13a produced the desired carbo-
line 14a in an excellent yield of 83% (Table 2, entry 14).
To further investigate the role of indoleN-substitution on
the domino process, two additional protecting groups were
trialed (Table 2, entries 18 and 19). These substrates were
reacted according to the previously identified conditions for
the domino process, and a marked improvement in the yield
of the desired tetrahydro-β-carbolines was observed.
The highest yields (up to 83%) for the domino process
were obtained following the additionofPd(PPh3)4 (10mol%),
alkene (1.1 equiv), and K2CO3 (3.0 equiv) to a sealed tube
containing 2-bromoindole (1.0 equiv) in toluene (5 mL)
that was subsequently stirred at 120 C for 16 h. A simple
purification protocol, including column chromatography,
furnished the desired tetrahydro-β-carbolines. Reproducible
yields for this domino process were obtained on various
scales (ranging from 0.1 to 1.1 mmol).
To illustrate the versatility of this methodology, the
domino Heck-aza-Michael reaction was repeated using a
number of terminal alkenes, each possessing a suitably
conjugated Michael-type acceptor (Table 3). This domino
process allowed access to a series of tetrahydro-β-carboline
scaffolds, containing a variety of sites available for further
functionalization.
The two-step domino process performed well for all
alkenes employed (except in the case of acrylic acid) with
isolated yields ranging from 64 to 83% (Table 3).
In conclusion, a novel domino Heck-aza-Michael reac-
tion has been developed. This methodology has been
applied to the synthesis of a series of C1-substituted tetra-
hydro-β-carbolines. Using mild conditions, this domino
process affords indole-based heterocyclic scaffolds, highly
amenable to larger total syntheses. Furthermore, the dom-
ino Heck-aza-Michael conditions reported by Hanson
et al. failed for those systems in which the sulfonyl moiety
was not contained within the heterocyclic ring formed.8c
The domino Heck-aza-Michael process reported herein
proved successful in the synthesis of tetrahydro-β-carbo-
lines with the sulfonyl group external to the newly con-
structed heterocycle. To the best of our knowledge, this
is the first example of a domino Heck-aza-Michael reac-
tion for the synthesis of a carbon-nitrogen heterocycle.
Complementing existingmethodology, this domino process
TABLE 1. Optimization of the Heck Transformation of Arylbromide 10
entry catalyst (10 mol %) base solvent yield (%)
1 Pd(OAc)2/PPh3
a NEt3 toluene 22
2 Pd2(dba)3/P(tBu)3
a NEt3 toluene 43
3 Pd2(dba)3/P(tBu)3
a Cy2NMe toluene 65
4 Pd(PPh3)4 NEt3 toluene 39
5 Pd(PPh3)4 Na2CO3 toluene 99
6 Pd(PPh3)4 K2CO3 DMF trace
b
7 Pd(PPh3)4 K2CO3 MeCN trace
b
8 Pd(PPh3)4 K2CO3 dioxane 32
9 Pd(PPh3)4 CH3CO2Na toluene 75
aCatalyst and ligand used in a 1:1 ratio. bTrace is <10% as deter-
mined by 1H NMR.
TABLE 2. Optimization of the Domino Heck-Aza-Michael Reaction
of Arylbromides
entry
substrate,
product
catalyst
(10 mol %) base solvent
yield
(%)
1 10, 11 Pd(PPh3)4 Cs2CO3 toluene 0
2 10, 11 Pd(PPh3)4 NEt3 toluene trace
a
3 10, 11 Pd(PPh3)4 DBU toluene trace
a
4 10, 11 Pd(PPh3)4 K2CO3 toluene 30
5 10, 11 Pd(PPh3)4 K2CO3 toluene 30
b
6 10, 11 Pd(PPh3)4 K2CO3 MeCN trace
a
7 10, 11 Pd(PPh3)4 K2CO3 DMF trace
a
8 10, 11 Pd(PPh3)4 K2CO3 dioxane 0
9 10, 11 Pd(PPh3)4 K2CO3 toluene 14
c
10 10, 11 Pd(PPh3)4 K2CO3 toluene trace
a,d
11 10, 11 Pd(PPh3)4 Na2CO3 toluene 17
d
12 10, 11 Pd2(dba)3/P(tBu)3
f NEt3 toluene trace
a
13 10, 11 Pd2(dba)3/P(tBu)3
f Cy2NMe toluene 0
14 13a, 14a Pd(PPh3)4 K2CO3 toluene 83
15 13a, 14a Pd(PPh3)4 K2CO3 MeCN trace
a
16 13a, 14a Pd(PPh3)4 Na2CO3 toluene 27
17 13a, 14a Pd(PPh3)4 Na2CO3 toluene 86
e
18 13b, 14b Pd(PPh3)4 K2CO3 toluene 54
19 13c, 14c Pd(PPh3)4 K2CO3 toluene 54
aTrace is <10% as determined by 1H NMR. bUsing 2 equiv of butyl
acrylate. cUsing 3 equiv of butyl acrylate also resulted in a large
formation of only the aza-Michael product 5. dTetra-n-butylammonium
chloride added to initial reaction mixture. eA one-pot process where
tetra-n-butylammonium chloride was added to reactionmixture after 12
h at 120 C,with stirring at 120 Ccontinued for 4 h. fCatalyst and ligand
used in a 1:1 ratio.
(17) Our attention turned to the optimal conditions to bring about a
simple 1,4-addition. In this case, the tosylamine tether was reactive enough
for aza-Michael addition to occur under mild basic conditions.
(18) The phase transfer agent used in an attempt to improve the solubility
of K2CO3 failed to significantly increase the yield.
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allows synthetic flexibility when access to a specific C1-sub-
stituted tetrahydro-β-carboline is required.
Current work within this group is focused on variations of
this domino process, including the use of more highly sub-
stituted alkenes and the introduction of chirality through the
use of tryptophan-derived starting materials.
Experimental Section
Typical Procedure for the Preparation of 1-Substituted THβCs
14a, 15-19 (Butyl Acetate THβC14a asExample).Asealed tube
containing a 2-bromoindole 13a (100 mg, 0.20 mmol), Pd(PPh3)4
(23 mg, 10 mol %), K2CO3 (84 mg, 0.61 mmol), and butyl
acrylate (29 mg, 0.22 mmol) in toluene (4 mL) was heated at
120 C for 16 h. The reaction mixture was cooled to room
temperature, the solvent removed invacuo, and the crudeproduct
purified by column chromatography (1:4 EtOAc/Pet Sp) to
afford the tetrahydro-β-carboline 14a (91 mg, 0.17 mmol, 83%)
as a pale yellow oil: FT-IR (ν, cm-1, KBr) 1730vs, 1457, 1374,
1324, 1159, 747; 1H NMR (400 MHz, CDCl3, δ) 8.10 (d,
J = 8.2 Hz, 1H), 7.62 (d, J = 8.3 Hz, 2H), 7.14-7.28 (m, 3H),
7.03 (d, J=8.6Hz, 1H), 6.12 (dd, J=3.6 and 10.6Hz, 1H), 4.05
(m, 3H), 3.50 (m, 1H), 3.00 (dd, J= 3.7 and 14.3 Hz, 1H), 2.70
(dd, J=10.6 and 14.3 Hz, 1H), 2.39-2.60 (m, 2H), 2.18 (s, 3H),
1.75 (s, 9H), 1.60 (m, J=7.8 Hz, 2H), 1.34 (m, J=7.6 Hz, 1H),
0.92 (t, J=7.5 Hz, 3H); 13C NMR (67.5MHz, CDCl3, δ) 169.8,
149.9, 143.4, 137.5, 135.9, 133.0, 129.2, 128.6, 127.1, 124.8, 122.9,
118.0, 115.7, 114.9, 85.0, 64.9, 51.1, 40.3, 37.9, 30.6, 28.4, 21.4,
19.7, 19.2, 13.8; HRMS-ESI (m/z) [C29H36N2O6S - H]- calcd
539.22213, found 539.22187.
Supporting Information Available: Experimental proce-
dures, characterization, copies of 1H and 13C NMR spectra for
all compounds. This material is available free of charge via the
Internet at http://pubs.acs.org.
TABLE 3. Preparation of Diverse 1-Substituted THβCs
entry alkene R product yield (%)
1 butyl acrylate CO2(CH2)3CH3 14a 83
2 methyl acrylate CO2CH3 15 79
3 2-hydroxyethyl acrylate CO2(CH)2OH 16 64
4 acrolein CHO 17 64
5 acrylamide CONH2 18 80
a
6 acrylonitrile CN 19 67
7 acrylic acid CO2H 20 0
aConversion calculated for desired product; however, partial Boc
deprotection during synthesis resulted in an inseparable mixture of
indole N-Boc and indole N-H tetrahydro-β-carbolines. See Supporting
Information.
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Palladium-catalyzed domino Heck–aza-Michael reactions for the synthesis of a series of C1-substituted
tetrahydro-b-carbolines, tetrahydroisoquinolines and isoindolines are described. The domino process
involves the initial intermolecular Heck reaction of an aryl bromide with an electron deﬁcient alkene,
followed by an intramolecular aza-Michael reaction to form the new N-heterocycle in high yield.
Introduction
In the ongoing pursuit of environmentally friendly reaction
processes, domino reactions have emerged as a powerful tool
for synthetic chemists.1,2 These domino processes generate a high
level of molecular complexity in one efﬁcient step, minimising
solvent use, reagents, time and energy.1 A domino reaction
is deﬁned as “the execution of two or more bond-forming
transformations under identical reaction conditions, in which the
latter transformations take place at the functionalities formed
by the preceding transformation”.1,2 The more feasible domino
reactions are those where all transformations occur under similar
reaction conditions, for example, where each of the reaction steps
is palladium-catalysed.2–5 Likewise, because of the reliance of base
in many Pd cross-coupling reactions, domino reactions involving
both a Pd-catalysed and a base-initiated synthetic step are also
plausible.
In spite of this possibility, the domino Heck–Michael method-
ology for the formation of heterocycles has not been widely
reported.6–8 Domino Heck–aza-Michael reactions have been ap-
plied to a series of unique benzo-fused sultams,7 and isoin-
dolinones using terminal alkene esters.8 However, attempts to
expand the scope of these methods to related substrates have
proved problematic. Recently, our group has reported a domino
Heck–aza-Michael reaction for the synthesis of a series of C1-
substituted tetrahydro-b-carbolines.9 Herein, we report that the
scope of this novel domino process has been successfully expanded
to include other N-heterocycles, namely tetrahydroisoquinolines
and isoindolines.
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The tetrahydro-b-carboline, tetrahydroisoquinoline and isoin-
doline scaffolds are all present in important biologically-active
compounds. Tetrahydro-b-carbolines (THbCs or tryptolines)
form the core of the antihypertensive agent reserpine (1)
(Fig. 1), along with a range of other biologically-active natural
products.10–17 Likewise, the tetrahydroisoquinoline ring system
forms the central part of a number of naturally-occurring
alkaloids,18–22 including the antitumor natural product quinocar-
cinol 2.23,24 In comparison, isoindoline-based natural products are
not as prevalent. Nevertheless, this scaffold is found in a range of
potential pharmaceutical agents,25–28 such as compound 3 (Fig. 1),
synthesized as a ligand for the melanocortin subtype-4 receptor
(MC4R).29
Fig. 1 Biologically-active compounds containing the tetrahydro-b-
carboline (1), tetrahydroisoquinoline (2) and isoindoline (3)N-heterocyclic
core.
As the importance of these classes of compounds grows in
a medicinal chemistry setting, so does the focus on a general
method for their synthetic preparation. Tetrahydro-b-carbolines
and tetrahydroisoquinolines have traditionally been prepared by
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reacting tryptamine or phenethylamine with a suitable aldehyde;
namely the Pictet–Spengler reaction.30–34 Similarly, the Bischler–
Napieralski reaction affords these ring systems through the
cyclodehydration of an appropriately substituted amide.32,35–39
Alternatives to the Pictet–Spengler or the Bischler–Napieralski
reactions are limited.One of themost recent, the Ferracioli synthe-
sis of tetrahydroisoquinolines, involves palladium-catalyzed ortho-
alkylation/vinylation followed by an aza-Michael reaction.40
Isoindolines substituted at theC1-position have also been accessed
using an aryl radical cyclization of N-benzylenaminone esters.41
More recently, 1,3-disubstituted isoindolines have been synthe-
sized using a Brønsted acid-catalyzed 1,2-addition followed by an
aza-Michael addition.42
A general approach to N-heterocycles using a domino Heck–
aza-Michael strategy would complement existing methods and in
some instances provide a more attractive option, for example,
when suitable aldehydes for the Pictet–Spengler reaction are
not readily available.14,17,43 In order to be applied to a range
of substrates, the domino process needs to occur under mild
conditions using a readily available catalyst, base and with
inexpensive electron deﬁcient alkenes. As a wide range of suitable
acrylates (such as acrolein, acrylonitrile, acrylic acid, etc.) are
commercially available, theC1 functionality of the newheterocycle
can be customised by appropriate alkene selection. To this end, we
herein describe our recent efforts to expand our domino Heck–
aza-Michael methodology from THbCs to include tetrahydroiso-
quinolines and isoindolines.
Results and discussion
In planning the Heck–aza-Michael domino process, a suitable
halogenated aryl ring system for a rapid Heck reaction with an
electron-withdrawn terminal alkene was sought. Aryl bromides 4
were selected due to the higher commercial cost of aryl iodides.
Initial C–H activation was also envisaged but deemed to be too
slow and less regioselective in the initial step of the domino
sequence.44
The ring size of the newly formedN-heterocycle (compounds 7–
9, Scheme 1) is governed by the length of the alkyl chain connecting
the amine to the aryl portion of starting material 4. Similarly, the
Scheme 1 Generic plan for the domino Heck–aza Michael reaction.
selection of a suitable protecting group for the tethered amine is
important when considering the Michael addition step. An ideal
protecting group would control the amine reactivity, avoiding the
likelihood of an intermolecular 1,4-addition, prior to the Heck
reaction.
As the Heck reaction at the C2 position of substituted
tryptamines is known from previous investigations within the
group,5 it was trialled ﬁrst. Readily available ortho-halogenated
benzylamines and phenethylamines were also identiﬁed as ideal
substrates for this investigation, as the ortho-tethered amine is
well positioned for the aza-Michael addition to form a new N-
heterocycle, following the initial Heck reaction.
Tetrahydro-b-carbolines
The detailed optimisation of a domino Heck–aza-Michael reac-
tion for the synthesis of tetrahydro-b-carbolines has previously
been described by our group.9 As the Heck reaction of 2-
bromoindoles has been reported,5,45,46 the limiting factor was the
aza-Michael reaction. A key ﬁnding of our THbC investigation
was that the tosyl protecting group of the tethered amine (superior
to Boc, Ac and triﬂuoroacetyl) allowed the aza-Michael reaction
to take place subsequent to the initial cross-coupling reaction.
Following optimisation, the highest yields for the domino process
between halogenated indole-N-Boc substrate 10 and butyl acrylate
were obtainedbyusing thePd(PPh3)4,K2CO3 and toluene catalytic
system.
The versatility of this domino Heck–aza-Michael reaction was
then investigated using a number of suitably conjugated terminal
alkenes (Scheme 2). The two-step domino process, forming a
new 6-membered N-heterocycle, performed well for the alkenes
employed, except in the case of acrylic acid, with isolated
yields ranging from 64–83% (compounds 11–16).‡ In addition
to these previously reported scaffolds,9 this domino process has
now been expanded to include 3-buten-2-one, which afforded
ketone-functionalised THbC 17 (78% yield). These tetrahydro-
b-carboline scaffolds contain a series of C1 functionalities that
allow for further synthetic manipulation and possible application
as part of total syntheses.9
Scheme 2 The synthesis of tetrahydro-b-carbolines using a domino
Heck–aza-Michael process.
Tetrahydroisoquinolines
Given the success of this initial series of domino reac-
tions to generate tetrahydro-b-carbolines 7, the synthesis of
‡ The unreactive nature of acrylic acid may be explained by the poor
solubility of the corresponding carboxylate ion.
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Table 1 Investigations into the domino reaction of aryl bromide 26
Entry Palladium catalysta (10 mol%) Base Solvent Major productb
1 Pd(PPh3)4 K2CO3 PhMe 22
2 Pd(PPh3)4 Na2CO3 PhMe 21
3 Pd2(dba)3/P(tBu)3 Cy2NMe PhMe 21
4 Pd(OAc)2/PPh3 NEt3 PhMe 21
5 Pd2(dba)3·CHCl3 K2CO3 PhMe NRd
6 Pd(OAc)2/PPh3 NEt3 DMF 21
7 Pd2(dba)3/DavePhos K2CO3 PhMe 20 (79)e
8 Pd(OAc)2/PPh3 K2CO3 PhMe 20 (80)e
9 Herrmann–Beller palladacyclef Cy2NMe DMF–MeCN–H2Oc 20 (67)e
a Palladium catalyst and ligand used in a 1 : 1 molar ratio. b As determined by 1H NMR analysis of the crude reaction mixture. For immediate identiﬁcation
of product ratios in the 1H NMR spectra d : 5.46 (red), 4.60 (green), 7.84 (blue) and 6.28 (purple). c DMF–MeCN–H2O (5 : 5 : 1). d NR = No reaction.
e Yield (%). f The Herrmann–Beller catalyst is [trans-di-(m-acetato)-bis[ortho-(di-ortho-tolylphosphino)benzyl]dipalladium(II)].
tetrahydroisoquinolines 9 using a domino Heck–aza-Michael re-
action was investigated. As in the case of the THbCs, the tosyl (Ts)
protecting group was employed to control amine nucleophilicity,9
and the desired domino substrate (sulfonamide 19) was prepared
in 86% yield. Using this substrate, a series of trial reactions were
carried out to determine if a domino Heck–aza-Michael process
was feasible. These reactions were initially performed by treating
aryl bromide 19 with butyl acrylate, a palladium catalyst, base and
solvent in a pressure vessel, and heating to 120 ◦C for 16 h. The
identiﬁcation of the products (20–22) was performed by means of
1H NMR spectroscopy of the crude reaction mixture (Table 1).
The ideal catalytic system for this domino process would rapidly
produce Heck product 21, with the base and solvent promoting
the aza-Michael addition to form desired tetrahydroisoquinoline
20, but not to an extent where intermolecular 1,4-nucleophilic
addition of the acrylate occurs prior to the Heck reaction.
In the ﬁrst attempt, the optimum conditions identiﬁed for the
synthesis of THbCs (Pd(PPh3)4, K2CO3, PhMe; Table 1, entry 1)
produced adduct 22 exclusively, i.e. the aza-Michael reaction is
favoured but the Heck reaction is slow.
A number of alternative Pd catalysts (Pd(PPh3)4,
Pd2(dba)3/P(tBu)3 and Pd(OAc)2/PPh3) combined with a
range of bases (Table 1, entries 2–4) were subsequently trialled;
however, only Heck adduct 21 was produced. It is apparent that
whilst the Heck reaction was proceeding, the base used (Na2CO3,
Cy2NMe and NEt3; Table 1, entries 2, 3 and 4, respectively)
in each of these trials was not strong enough to induce either
intra- or intermolecular aza-Michael addition, as only traces
of these products were observed. From the previous work on
THbCs, it is known that the aza-Michael process is sensitive to
subtle variations in the base used. Again, for the synthesis of
tetrahydroisoquinolines, slightly changing the base (e.g. from
K2CO3 to Na2CO3; Table 1, entries 1 and 2) either facilitates
or reduces the likelihood of the aza-Michael reaction. Of the
bases trialled to this point (Table 1, entries 1–6), only K2CO3 was
successful in enabling the aza-Michael reaction to occur (albeit
intermolecularly).
To ensure rapid formation of the Heck adduct, the highly
reactive and electron-rich Pd2(dba)3/DavePhos catalyst system,
developed by Buchwald and Hartwig, was used in combination
with K2CO3.47§ To our delight, this catalytic system furnished
desired tetrahydroisoquinoline 20 in high yield (Table 1, entry 7).
Following further trials, other catalytic systems (Table 1, entries
8 and 9) also resulted in clean conversion of domino precursor 19
to tetrahydroisoquinoline 20. These additional successes indicate
that a judicious choice of base and solvent is crucial for promoting
the desired aza-Michael cyclisation (compareTable 1, entries 4 and
8). In assessing each of these procedures, the Pd(OAc)2/PPh3 and
K2CO3 in toluene catalytic system was deemed the most attractive
due to its relatively low cost and commercial availability.
A range of acrylates were subject to this domino process
to afford a series of C1-substituted tetrahydroisoquinolines 9
(Table 2). The resulting products from this series of reactions
contain a range of functionalities, including ester, ketone and
nitrile (Table 2, entries 1–5). In each of these cases, there seems
to be no clear differentiation in the yield, suggesting that small
differences in the electronics of each of these acrylates does not
dramatically affect the domino process. Unfortunately, reactions
attempted with both acrolein and acrylic acid did not furnish the
desired tetrahydroisoquinolines, even though the reaction with
acrolein hadbeen successfully employed in aTHbCdominoHeck–
aza-Michael reaction (Scheme 2).9
Isoindolines
With the successful development of domino Heck–aza-Michael
reactions for the formation of two 6-membered N-heterocyclic
§ The possibility of a C–N cross-coupling was disregarded due to the
strained ring system that would be generated as part of this process.
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Table 2 Synthesis of a series of C1-substituted tetrahydroisoquinolines
Entry Alkene R Product Yield (%)
1 Butyl acrylate CO2nBu 20 80
2 Methyl acrylate CO2Me 23 83
3 2-Hydroxyethyl acrylate CO2(CH2)2OH 24 76
4 Acrylonitrile CN 25 82
5 3-Buten-2-one COCH3 26 79
6 Acrylamide CONH2 27 Tracea
7 Acrolein CHO 28 NRb
8 Acrylic acid CO2H 29 NRb
a Trace = less than 10%, as determined by 1H NMR. b NR = No reaction.
systems, our attention turned to a third scaffold. To expand the
scope of this methodology to include 5-memberedN-heterocycles,
an appropriately substituted benzylamine 30, was prepared in 99%
yield as a precursor to C1-substituted isoindolines 8.
As with both the THbCs and tetrahydroisoquinolines, a range
of conditions were evaluated for the preparation of the desired
isoindoline 31 (Table 3). Bromosulfonamide 30, butyl acrylate, a
palladium catalyst, base and solvent were combined in a pressure
vessel, and heated to 120 ◦C for 16 h. Following a simple work up,
the major product was identiﬁed by 1H NMR spectroscopy.
The ﬁrst trial with tetrakis(triphenylphosphine) palladium
(Pd(PPh3)4) afforded mixtures of the three predicted products,
31, 32 and 33 (Table 3, entry 1). Repeating the reaction with
Pd(PPh3)4 but changing the base and solvent (Table 3, entries 2–
4) also proved unsuccessful. The highly active catalytic system of
Pd2(dba)3/P(tBu)3 minimised the formation of aza-Michael–Heck
product 33; however, complete conversion of the Heck adduct to
the desired isoindoline was not realised (Table 3, entry 5).48
A high yield of desired isoindoline 31 was observed when
Pd(OAc)2/PPh3 and triethylamine were used in either toluene or
DMF (Table 3, entries 8 and 9). The use of other highly active
Pd catalysts also proved successful when teamed with an amine
base in DMF. Again, it was apparent that a suitable base (in this
case, an organic base rather than an inorganic base) was crucial to
effect the desired cyclisation following the Heck reaction.
Even though the Pd2dba3/DavePhos catalytic system (Table 3,
entry 10) provided isoindoline 31 in the highest yield, it was not
signiﬁcantly greater than that obtained when the Pd(OAc)2/PPh3
system was used (Table 3, entry 9). This latter system was
subsequently used for the remainder of this investigation due to
its low cost and commercial availability.
This optimized domino system was then used with a range of
acrylates to afford a series of C1-substituted isoindolines (Table 4).
The products synthesised contain a range of functionalities,
including carboxylic acid, ester, ketone, amide and nitrile. This
time, the use of acrylic acid resulted in the formation of isoindoline
acetic acid 38, presumably due to the increased solubility of
the carboxylate ion in the triethylamine/DMF solvent system.
Unfortunately, the use of acrolein49 once again did not yield the
desired isoindoline.
Conclusions
Following the successful development of a domino Heck–aza-
Michael reaction for the synthesis of the tetrahydro-b-carbolines,9
Table 3 Preliminary investigations into the formation of isoindolines
Entry Palladium catalysta (10 mol%) Base Solvent Major productb
1 Pd(PPh3)4 K2CO3 PhMe Mixture (31/32/33)
2 Pd(PPh3)4 Na2CO3 PhMe Mixture (31/32/33)
3 Pd(PPh3)4 Cs2CO3 PhMe NRd
4 Pd(PPh3)4 K2CO3 DMF NRd
5 Pd2(dba)3/P(tBu)3 Cy2NMe PhMe 31/32
6 Pd2(dba)3·CHCl3 NEt3 DMF NRd
7 Pd(OAc)2/PPh3 K2CO3 PhMe NRd
8 Pd(OAc)2/PPh3 NEt3 PhMe 31 (74)e
9 Pd(OAc)2/PPh3 NEt3 DMF 31 (77)e
10 Pd2(dba)3/DavePhos Cy2NMe DMF 31 (79)e
11 Pd2(dba)3/XPhos Cy2NMe DMF 31 (62)e
12 Pd2(dba)3/SPhos Cy2NMe DMF 31 (48)e
13 Herrmann–Beller palladacyclef Cy2NMe DMF–MeCN–H2Oc 31 (54)e
a Palladium and ligand used in a 1 : 1 molar ratio. b As determined by 1H NMR analysis of the crude reaction mixture. For immediate identiﬁcation of
product ratios in the 1H NMR spectra d : 5.28 (red), 5.10 (green), 7.62 (blue) and 6.38 (purple). c DMF–MeCN–H2O (5 : 5 : 1). d NR = No reaction. e Yield
(%). f The Herrmann–Beller catalyst is [trans-di-(m-acetato)-bis[ortho-(di-ortho-tolylphosphino)benzyl]-dipalladium(II)].
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Table 4 Synthesis of a series of C1-substituted isoindolines
Entry Alkene R Product Yield (%)
1 Butyl acrylate CO2nBu 31 77
2 Methyl acrylate CO2Me 34 Unknowna
3 2-Hydroxyethyl acrylate CO2(CH2)2OH 35 84
4 Acrylamide CONH2 36 71
5 Acrylonitrile CN 37 68
6 Acrylic acid CO2H 38 85
7 3-Buten-2-one COCH3 39 86
8 Acrolein CHO 40 NRb
a This domino process also performed well using methyl acrylate; however,
the isoindoline product could not be separated from the remaining starting
material by column chromatography. b NR = No reaction.
the scope of this new methodology has been expanded to include
the tetrahydroisoquinoline and isoindoline N-heterocyclic scaf-
folds. The key considerations of the domino Heck–aza-Michael
methodology were identiﬁed as (i) the relatively quick formation
of the Heck adduct (controlled through appropriate selection of
Pd catalyst) and (ii) the nucleophilicity of the tethered amine
(mediated through careful selection of the protecting group, base
and solvent).
In determining the appropriate conditions for the Heck reac-
tion, a palladium catalyst was required that facilitated a fast,
high-yielding reaction between the aryl halide and the alkene in
the presence of a mild base and a relatively non-polar solvent.
It is important that the acrylate is consumed rapidly by the
Heck process so that the intermolecular aza-Michael reaction
cannot take place. For the Heck reaction at the indole 2-position,
Pd(PPh3)4 afforded the highest yields. In the case of the benzyl- and
phenethylamine aryl halides, the use of Pd(OAc)2/PPh3 proved
optimal.
More importantly, an appropriate base is required; one that
is able to sufﬁciently promote aza-Michael reaction, but not
to the extent that it occurs before a high concentration of
the Heck adduct is realised. Indeed, the outcome of reactions
that were repeated, varying only the base used, ranged from a
rapid intermolecular Michael reaction prior to the Heck reaction
through to the desired domino Heck–aza-Michael process. For
the synthesis of both THbCs and tetrahydroisoquinolines, K2CO3
was required to effect the cyclisation; however, in the case of the
isoindolines, the new N-heterocycle formed in the presence of a
milder amine base (either NEt3 or Cy2NMe).
Other parameters that could limit reaction progress included
(i) the size of the N-heterocycle being formed, and (ii) the sterics
associated with the Heck reaction and subsequent Michael addi-
tion. If the steric bulk of the proximal sulfonamide (benzylamine
vs. phenethylamine) was a critical factor, the initial Heck reaction
would be faster for the formation of compounds 11 and 20 over
isoindoline 31. Furthermore, for 5-membered isoindoline series
8, a strained transition state in the Michael addition step may
also hinder the progress of the domino reaction. Nevertheless, as
little difference in the overall yields were observed for each of the
domino processes studied herein, the role of ring size and sterics
appears to be minor.
In conclusion, high yielding domino Heck–aza-Michael reac-
tions to access C1-substituted tetrahydro-b-carbolines, tetrahy-
droisoquinolines and isoindolines have been successfully devel-
oped as a general approach to N-heterocycles. These reactions
employ mild conditions, and readily available palladium catalysts
and acrylates. The mild conditions described suggest this domino
process may be applied to more complex substrates and key
transformations in total syntheses. As indicated, the use of other
highly active palladium catalysts may beneﬁt the scope of this
process and its functional group tolerance.
Experimental
General experimental
All proton (1H NMR) and carbon (13C NMR) spectra were
recorded on a 270 MHz FT-NMR, 400 MHz FT-NMR or
300 MHz FT-NMR spectrometer as indicated. Samples were
dissolved in deuterated chloroform (CDCl3). Proton peaks are
reported as follows: chemical shift d (ppm) (multiplicity (s =
singlet, d = doublet, t = triplet, q = quartet, m = multiplet),
integral, coupling constant J (Hz), assignment). Carbon peaks
are reported as chemical shift d (ppm). High resolution mass
spectra (HRMS) were recorded on a TOF mass spectrometer
with the following conditions: drying gas, nitrogen (7 mL min-1,
350 ◦C); nebulizer gas, nitrogen (16 psi); capillary voltage, 4.0 kV;
vaporizer temperature 350 ◦C; and cone voltage, 60V.HPLCgrade
methanol was used as the mobile phase. Samples were dissolved
in acetonitrile (less than 1 mg per mL). IR spectra were acquired
on an FT-IR instrument using KBr discs and are reported in wave
numbers (cm-1). Column chromatography was performed using
silica gel, 60 (70-230 mesh). Petroleum spirits (pet. sp) refers to
the fraction boiling at 40–60 ◦C. All solvents used were AR grade.
Pd(PPh3)4 was prepared according to a literature procedure.50
Full experimental details for the preparation of compounds 10–
16 are described in an earlier communication.9
Speciﬁc experimental
(R,S)-2-(9-tert-Butoxycarbonyl-2-(p-toluenesulfonyl)-3,4-tetra-
hydro-1H-carbolin-1-yl)propan-2-one (17). A sealed tube con-
taining 2-bromoindole 10 (300 mg, 0.61 mmol), Pd(PPh3)4 (70 mg,
10 mol%), K2CO3 (252 mg, 1.82 mmol) and 3-buten-2-one (51 mg,
0.73 mmol) in toluene (3 mL) was ﬂushed with argon, then
heated at 120 ◦C for 16 h. The reaction mixture was cooled to
room temperature, ﬁltered, and the solvent removed in vacuo.
Puriﬁcation by column chromatography (1 : 4 EtOAc : pet. sp.)
afforded tetrahydro-b-carboline 17 as a pale yellow oil (228 mg,
0.47 mmol, 78%). FT-IR (n, cm-1, KBr) 1716vs, 1465, 1386, 1327,
1159, 698; 1H NMR (270 MHz, CDCl3, d) 7.96 (dt, J = 0.9, 8.3 Hz,
1H), 7.61 (d, J = 8.3 Hz, 2H), 7.12–7.27 (m, 3H), 7.00 (dd, J =
0.6, 8.6 Hz, 2H), 6.23 (dd, J = 3.3, 10.6 Hz, 1H), 4.05 (dd, J = 6.5,
15.3 Hz, 1H), 3.38–3.50 (m, 1H), 3.08 (dd, J = 3.5, 14.2 Hz, 1H),
2.70 (dd, J = 10.6, 14.2 Hz, 1H), 2.41–2.58 (m, 2H), 2.35 (s, 3H),
2.14 (s, 3H), 1.73 (s, 9H); 13C NMR (75 MHz, CDCl3, d) 206.0,
150.1, 143.5, 136.8, 135.2, 133.5, 129.1, 128.5, 127.0, 124.5, 122.8,
117.9, 115.6, 114.5, 84.8, 50.5, 48.8, 37.7, 29.2, 28.3, 21.2, 19.2;
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HRMS-ESI (m/z) [C26H30N2O5S + Na]+ calc. 505.1768, found
505.1790.
N-(2-Bromophenethyl)-p-toluenesulfonamide (19). To a cooled
solution (0 ◦C) of 2-bromophenethylamine (400 mg, 2.0 mmol)
and triethylamine (242 mg, 2.4 mmol) in CH2Cl2 (10 mL) was
added p-toluenesulfonyl chloride (420 mg, 2.2 mmol) in one
portion. The reaction mixture was stirred for 2 h. at ambient
temperature. The reaction mixture was then washed with HCl
(1 M, 2 ¥ 10 mL), NaOH (Aq. 5% w/w, 2 ¥ 10 mL) and brine
(10 mL). The organic layer was separated, dried (MgSO4) and
concentrated under reduced pressure to afford phenethylamine 19
as a colorless oil (624 mg, 1.76 mmol, 88%). FT-IR (n, cm-1, KBr)
3152, 1598, 1233, 1059, 754, 647; 1H NMR (270 MHz, CDCl3, d)
7.69 (d, J = 8.4 Hz, 2H), 7.47 (dd, J = 1.2, 7.9 Hz, 1H), 7.26 (d,
J = 8.1 Hz, 2H) 7.03–7.20 (m, 3H), 4.57 (brt, J = 6.2 Hz, 1H),
3.21 (q, J = 6.9 Hz, 2H), 2.90 (t, J = 7.2 Hz, 2H), 2.40 (s, 3H);
13C NMR (75 MHz, CDCl3, d); 143.4, 137.1, 133.0, 131.1, 129.7,
129.0, 128.2, 127.7, 127.1, 124.4, 42.5, 36.3, 21.5; HRMS-ESI
(m/z) [C15H16BrNO2S + Na]+ calc. 375.9977, found 375.9979.
General procedure A for tetrahydroisoquinoline formation
A sealed tube containing a 2-bromophenethylamine 19 (1.0
equiv.), Pd(OAc)2 (10 mol%), PPh3 (10 mol%), K2CO3 (3.0 equiv.)
and alkene (1.2 equiv.) in toluene (3 mL) was ﬂushed with argon
and then heated at 120 ◦C for 16 h. The reaction mixture was
cooled to room temperature, ﬁltered, the solvent removed in vacuo
and the crude product puriﬁed by column chromatography using
the solvent system speciﬁed.
(R,S)-Butyl 2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)ace-
tate (20). General procedure A was followed using 2-
bromophenethylamine 19 (100 mg, 0.28 mmol), butyl acrylate
(44 mg, 0.34 mmol), Pd(OAc)2 (6 mg, 10 mol%), PPh3 (7 mg,
10 mol%), potassium carbonate (116 mg, 0.84 mmol) and toluene
(3 mL). Puriﬁcation by column chromatography (1 : 4 EtOAc : pet.
sp.) afforded tetrahydroisoquinoline 20 as a pale yellow oil (90 mg,
0.22 mmol, 80%). FT-IR (n, cm-1, KBr) 2959, 1732, 1338, 1161,
1091, 756, 660, 548; 1H NMR (270 MHz, CDCl3, d) 7.63 (d, J =
8.4 Hz, 2H), 7.14 (d, J = 7.9 Hz, 2H), 7.08–7.10 (m, 3H), 6.95
(m, 1H), 5.46 (t, J = 6.9 Hz, 1H), 4.04 (dt, J = 3.5, 6.7 Hz, 2H),
3.71–3.80 (m, 1H), 3.47–3.58 (m, 1H), 2.88 (dd, J = 7.2, 14.6 Hz,
1H), 2.63–2.74 (m, 3H), 2.32 (s, 3H), 1.58 (m, 2H), 1.32 (m, 2H),
0.90 (t, J = 7.4 Hz, 3H); 13C NMR (67.5 MHz, CDCl3, d); 170.4,
143.3, 137.2, 135.5, 133.1, 129.5, 129.0, 127.3, 127.2, 126.7, 126.5,
64.8, 53.4, 43.6, 39.7, 30.6, 27.0, 21.5, 19.1, 13.8;HRMS-ESI (m/z)
[C22H27NO4S + H]+ calc. 402.1734, found 402.1734.
(R,S)-Methyl 2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-
acetate (23). General procedure A was followed using 2-
bromophenethylamine 19 (200 mg, 0.56 mmol), methyl acrylate
(58 mg, 0.67 mmol), Pd(OAc)2 (12 mg, 10 mol%), PPh3 (14 mg,
10 mol%), potassium carbonate (232 mg, 1.68 mmol) and toluene
(3 mL). Puriﬁcation by column chromatography (1 : 9 EtOAc : pet.
sp.) afforded tetrahydroisoquinoline 23 as a pale yellow oil
(168 mg, 0.47 mmol, 83%). FT-IR (n, cm-1, KBr) 3464, 2924,
1744, 1333, 1158, 932, 750, 665, 546; 1H NMR (270 MHz, CDCl3,
d) 7.64 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 7.9 Hz, 2H), 7.08–7.10 (m,
3H), 6.95 (m, 1H), 5.47 (t, J = 7.2 Hz, 1H), 3.77 (m, 1H), 3.65 (s,
3H), 3.53 (m, 1H), 2.90 (dd, J = 7.6, 14.6 Hz, 1H), 2.62–2.75 (m,
3H), 2.32 (s, 3H); 13C NMR (67.5 MHz, CDCl3, d); 170.7, 143.3,
137.2, 135.3, 133.1, 129.5, 129.1, 127.3, 127.2, 126.6, 126.5, 53.5,
52.0, 43.4, 39.7, 26.9, 21.5; HRMS-ESI (m/z) [C19H21NO4S +Na]+
calc. 382.1084, found 382.1080.
(R,S)-2-Hydroxyethyl 2-(2-tosyl-1,2,3,4-tetrahydroisoquinolin-
1-yl)acetate (24). General procedure A was followed using 2-
bromophenethylamine 19 (100 mg, 0.28 mmol), 2-hydroxyethyl
acrylate (39 mg, 0.34 mmol), Pd(OAc)2 (6 mg, 10 mol%), PPh3
(7 mg, 10 mol%), potassium carbonate (116 mg, 0.84 mmol) and
toluene (3 mL). Puriﬁcation by column chromatography (2 : 3
EtOAc : pet. sp.) afforded tetrahydroisoquinoline 24 as a pale
yellow oil (83 mg, 0.21 mmol, 76%). FT-IR (n, cm-1, KBr) 2924,
1737, 1597, 1336, 1158, 1091, 756, 659, 547; 1H NMR (270 MHz,
CDCl3, d) 7.61 (d, J = 8.4 Hz, 2H), 7.06–7.15 (m, 5H), 6.91 (m,
1H), 5.47 (t, J = 5.9 Hz, 1H), 4.21–4.31 (m, 2H), 3.71–3.78 (m,
2H), 3.50–3.59 (m, 2H), 2.91 (ddd, J = 1.5, 8.2, 14.8 Hz, 1H),
2.78 (dd, J = 5.7, 14.8 Hz, 1H), 2.60–2.65 (m, 2H), 2.31 (s, 3H);
13C NMR (75 MHz, CDCl3, d); 170.0, 143.2, 137.1, 135.2, 133.0,
129.5, 129.0, 127.2, 127.1, 126.7, 126.6, 126.4, 62.5, 53.4, 43.3, 39.6,
26.7, 21.4; HRMS-ESI (m/z) [C20H23NO5S + Na]+ calc. 412.1189,
found 412.1178.
(R,S)-2-(2-Tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)acetonitrile
(25). General procedure A was followed using 2-
bromophenethylamine 19 (100 mg, 0.28 mmol), acrylonitrile
(18 mg, 0.34 mmol), Pd(OAc)2 (6 mg, 10 mol%), PPh3 (7 mg,
10 mol%), potassium carbonate (116 mg, 0.84 mmol) and toluene
(3 mL). Puriﬁcation by column chromatography (1 : 9 EtOAc : pet.
sp.) afforded tetrahydroisoquinoline 25 as a pale yellow oil (75 mg,
0.23 mmol, 82%). FT-IR (n, cm-1, KBr) 2249, 1652, 1401, 1162,
1006, 862, 702, 548; 1H NMR (270 MHz, CDCl3, d) 7.69 (d, J =
8.4 Hz, 2H), 7.13–7.22 (m, 5H), 7.07 (m, 1H), 5.17 (t, J = 5.7 Hz,
1H), 3.64–3.74 (m, 1H), 3.48–3.57 (m, 1H), 2.98 (dd, J = 4.0,
5.9 Hz, 2H), 2.64–2.92 (m, 2H), 2.37 (s, 3H); 13C NMR (75 MHz,
CDCl3, d); 144.1, 135.8, 134.1, 132.7, 130.0, 129.2, 128.2, 127.4,
127.1, 126.9, 117.3, 52.8, 41.1, 28.0, 27.7, 21.6; HRMS-ESI (m/z)
[C18H18N2O2S - H]- calc. 325.1016, found 325.1009.
(R,S)-1-(2-Tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propan-2-
one (26). General procedure A was followed using 2-
bromophenethylamine 19 (100 mg, 0.28 mmol), 3-buten-2-one
(24 mg, 0.34 mmol), Pd(OAc)2 (6 mg, 10 mol%), PPh3 (7 mg,
10 mol%), potassium carbonate (116 mg, 0.84 mmol) and toluene
(3 mL). Puriﬁcation by column chromatography (1 : 9 EtOAc : pet.
sp.) afforded tetrahydroisoquinoline 26 as a pale yellow oil (76 mg,
0.22 mmol, 79%). FT-IR (n, cm-1, KBr) 3412, 2924, 1713, 1597,
1335, 1159, 1091, 758, 663, 550; 1H NMR (270 MHz, CDCl3, d)
7.63 (d, J = 8.2 Hz, 2H), 7.14 (d, J = 8.2 Hz, 2H), 7.07–7.09 (m,
3H), 6.94 (m, 1H), 5.50 (t, J = 6.2 Hz, 1H), 3.67–3.74 (m, 1H),
3.46–3.56 (m, 1H), 3.05 (dd, J = 5.9, 16 Hz, 1H), 2.82 (dd, J =
6.4, 16 Hz, 1H), 2.64–2.69 (m, 2H), 2.32 (s, 3H), 2.15 (s, 3H);
13C NMR (75 MHz, CDCl3, d); 205.4, 143.4, 136.7, 136.2, 132.8,
129.5, 128.8, 127.2, 127.0, 126.7, 126.6, 52.7, 52.1, 40.1, 30.4, 27.2,
21.5;HRMS-ESI (m/z) [C19H21NO3S+Na]+ calc. 366.1134, found
366.1135.
N-(2-Bromobenzyl)-p-toluenesulfonamide (30). To a cooled
solution (0 ◦C) of 2-bromobenzylamine hydrochloride (400 mg,
1.80 mmol) and triethylamine (401 mg, 3.96 mmol) in CH2Cl2
(10mL)was added p-toluenesulfonyl chloride (378mg, 1.98mmol)
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in one portion. The reaction mixture was stirred for 2 h at ambient
temperature. The reaction mixture was then washed with HCl
(1 M, 2 ¥ 10 mL), NaOH (aq. 5% w/w, 2 ¥ 10 mL) and brine
(10 mL). The organic layer was separated, dried (MgSO4) and
concentrated under reduced pressure to afford benzylamine 30 as
a colorless oil (610 mg, 1.79 mmol, 99%). FT-IR (n, cm-1, KBr)
3087, 1622, 1159, 785, 667; 1H NMR (270 MHz, CDCl3, d) 7.69
(d, J = 8.4 Hz, 2H), 7.43 (dd, J = 1.2, 7.9 Hz, 1H), 7.19–7.30 (m,
4H), 7.07 (dt, J = 1.7, 7.7 Hz, 1H), 5.11 (brt, J = 5.9 Hz, 1H), 4.21
(d, J = 6.2 Hz, 2H), 2.39 (s, 3H); 13C NMR (75 MHz, CDCl3, d);
143.5, 136.9, 135.5, 132.8, 130.5, 129.6, 129.5, 127.7, 127.1, 123.5,
47.5, 21.5; HRMS-ESI (m/z) [C14H14BrNO2S - H]- calc. 337.9856,
found 337.9862.
General procedure B for isoindoline formation
A sealed tube containing a 2-bromobenzylamine 30 (1.0 equiv.),
Pd(OAc)2 (10 mol%), PPh3 (10 mol%), triethylamine (3.0 equiv.)
and alkene (1.2 equiv.) in DMF was ﬂushed with argon and then
heated at 120 ◦C for 16 h. The reactionmixturewas cooled to room
temperature, ﬁltered, the solvent removed in vacuo and the crude
product puriﬁed by column chromatography using the solvent
system speciﬁed.
(R,S)-Butyl 2-(2-tosylisoindolin-1-yl)acetate (31). General
procedure B was followed using 2-bromobenzylamine 30 (100 mg,
0.29 mmol), butyl acrylate (45 mg, 0.35 mmol), Pd(OAc)2 (7 mg,
10mol%), PPh3 (8mg, 10mol%), triethylamine (88mg, 0.87mmol)
and DMF (3 mL). Puriﬁcation by column chromatography (1 : 9
EtOAc : pet. sp.) afforded isoindoline 31 as a pale yellowoil (86mg,
0.22 mmol, 77%). FT-IR (n, cm-1, KBr) 3444, 2960, 1731, 1348,
1164, 1095, 666, 553; 1H NMR (270 MHz, CDCl3, d) 7.75 (d, J =
8.2Hz, 2H), 7.18–7.27 (m, 5H), 7.10–7.13 (m, 1H), 5.27 (m, J = 3.0,
3.7 Hz, 1H), 4.73(dd, J = 2.5, 13.8 Hz, 1H), 4.53 (d, J = 13.8 Hz,
1H), 4.09 (t, J = 6.7 Hz, 2H), 3.30 (dd, J = 3.9, 16.5 Hz, 1H), 2.86
(dd, J = 7.9, 16.5 Hz, 1H), 2.36 (s, 3H), 1.53–1.63 (m, 2H), 1.23–
1.40 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3,
d); 171.0, 143.7, 139.6, 135.5, 134.0, 129.8, 128.1, 127.9, 127.6,
122.7, 122.4, 64.6, 62.1, 53.9, 42.8, 30.6, 21.5, 19.1, 13.7; HRMS-
ESI (m/z) [C21H25NO4S + Na]+ calc. 410.1397, found 410.1380.
(R,S)-2-Hydroxyethyl 2-(2-tosylisoindolin-1-yl)acetate (35).
General procedure B was followed using 2-bromobenzylamine 30
(100 mg, 0.29 mmol), 2-hydroxyethyl acrylate (40 mg, 0.35 mmol),
Pd(OAc)2 (7 mg, 10 mol%), PPh3 (8 mg, 10 mol%), triethylamine
(88 mg, 0.87 mmol) and DMF (3 mL). Puriﬁcation by column
chromatography (2 : 3 EtOAc : pet. sp.) afforded isoindoline 35
as a pale yellow oil (91 mg, 0.24 mmol, 84%). FT-IR (n, cm-1,
KBr) 3523, 2924, 1732, 1343, 1162, 1094, 754, 666, 555; 1H NMR
(270 MHz, CDCl3, d) 7.74 (d, J = 8.2 Hz, 2H), 7.19–7.28 (m, 5H),
7.09–7.16 (m, 1H), 5.31 (m, 1H), 4.73 (dd, J = 2.5, 14.1 Hz, 1H),
4.50 (d, J = 13.8 Hz, 1H), 4.32 (m, 1H), 4.19 (m, 1H), 3.81 (m, 2H),
3.17 (dd, J = 4.9, 15.8 Hz, 1H), 2.99 (dd, J = 5.9, 16.0 Hz, 1H),
2.36 (s, 3H), 2.33 (brt, 1H); 13C NMR (75 MHz, CDCl3, d); 171.1,
144.0, 139.3, 135.5, 133.8, 129.9, 128.3, 128.0, 127.6, 122.6, 122.5,
66.6, 62.3, 61.0, 53.9, 43.0, 21.5; HRMS-ESI (m/z) [C19H21NO5S +
Na]+ calc. 398.1033, found 398.1024.
(R,S)-2-(2-Tosylisoindolin-1-yl)acetamide (36). General pro-
cedure B was followed using 2-bromobenzylamine 30 (100 mg,
0.29 mmol), acrylamide (25 mg, 0.35 mmol), Pd(OAc)2 (7 mg,
10 mol%), PPh3 (8 mg, 10 mol%), triethylamine (88 mg, 0.87
mmol) and DMF (3 mL). Puriﬁcation by column chromatography
(1 : 1 EtOAc : pet. sp.) afforded isoindoline 36 as a pale yellow oil
(68 mg, 0.21 mmol, 71%). FT-IR (n, cm-1, KBr) 3419, 2924, 1682,
1330, 1162, 1093, 667; 1H NMR (270 MHz, CDCl3, d) 7.75 (d, J =
8.2 Hz, 2H), 7.18–7.29 (m, 5H), 7.10–7.14 (m, 1H), 5.86 (brs, 1H),
5.40 (brs, 1H), 5.18 (m, J = 3.2, 3.9 Hz, 1H), 4.73 (dd, J = 2.0,
13.8 Hz, 1H), 4.53 (d, J = 13.8 Hz, 1H), 3.15 (dd, J = 3.7, 15.0 Hz,
1H), 2.90 (dd, J = 7.1, 15.0 Hz, 1H), 2.36 (s, 3H); 13C NMR
(75MHz,CDCl3, d); 172.0, 144.2, 139.2, 135.0, 133.2, 130.1, 128.3,
128.2, 127.8, 123.3, 122.4, 62.6, 54.2, 43.7, 21.6; HRMS-ESI (m/z)
[C17H18N2O3S + H]+ calc. 331.1111, found 331.1126.
(R,S)-2-(2-Tosylisoindolin-1-yl)acetonitrile (37). General pro-
cedure B was followed using 2-bromobenzylamine 30 (100 mg,
0.29 mmol), acrylonitrile (18 mg, 0.35 mmol), Pd(OAc)2 (7 mg,
10mol%), PPh3 (8mg, 10mol%), triethylamine (88mg, 0.87mmol)
and DMF (3 mL). Puriﬁcation by column chromatography (1 : 6
EtOAc : pet. sp.) afforded isoindoline 37 as a pale yellowoil (62mg,
0.20 mmol, 68%). FT-IR (n, cm-1, KBr) 3429, 2361, 2254, 1352,
1350, 1160, 756, 664, 559; 1H NMR (270 MHz, CDCl3, d) 7.76 (d,
J = 8.2 Hz, 2H), 7.18–7.33 (m, 6H), 5.11 (m, 1H), 4.80 (dd, J = 2.7,
13.8 Hz, 1H), 4.55 (d, J = 13.8 Hz, 1H), 3.16 (s, 1H), 3.14 (d, J =
1.0 Hz, 1H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3, d); 144.4,
136.7, 135.8, 133.8, 130.1, 129.1, 128.4, 127.5, 122.9, 122.6, 116.7,
61.5, 53.9, 26.9, 21.5; HRMS-ESI (m/z) [C17H16N2O2S + H]+ calc.
313.1005, found 313.1013.
(R,S)-2-(2-Tosylisoindolin-1-yl)acetic acid (38). General pro-
cedure B was followed using 2-bromobenzylamine 30 (100 mg.
0.29 mmol), acrylic acid (25 mg, 0.35 mmol), Pd(OAc)2 (7 mg,
10 mol%), PPh3 (8 mg, 10 mol%), triethylamine (88 mg, 0.87
mmol) and DMF (3 mL). Puriﬁcation by column chromatography
(3 : 1 EtOAc : pet. sp.) afforded isoindoline 38 as a pale yellow oil
(82 mg, 0.25 mmol, 85%). FT-IR (n, cm-1, KBr) 3435 (vs), 2923,
1697, 1574, 1397, 1339, 1162, 1094, 666, 555; 1H NMR (270 MHz,
CDCl3, d) 7.75 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H),
7.18–7.22 (m, 3H), 7.10–7.13 (m, 1H), 5.28 (m, 1H), 4.73 (dd,
J = 2.2, 13.9 Hz, 1H), 4.53 (d, J = 13.9 Hz, 1H), 3.39 (dd, J = 3.9,
16.5Hz, 1H), 2.91 (dd, J = 7.9, 16.5Hz, 1H), 2.36 (s, 3H); 13CNMR
(75MHz,CDCl3, d); 176.5, 143.9, 139.2, 135.4, 133.8, 129.9, 128.3,
128.1, 127.6, 122.7, 122.5, 61.8, 53.9, 42.7, 21.5; HRMS-ESI (m/z)
[C17H17NO4S + Na]+ calc. 354.0771, found 354.0759.
(R,S)-1-(2-Tosylisoindolin-1-yl)propan-2-one (39). General
procedure B was followed using 2-bromobenzylamine 30 (100 mg,
0.29 mmol), 3-buten-2-one (24 mg, 0.35 mmol), Pd(OAc)2 (7 mg,
10 mol%), PPh3 (8 mg, 10 mol%), triethylamine (88 mg, 0.87
mmol) and DMF (3 mL). Puriﬁcation by column chromatography
(1 : 4 EtOAc : pet. sp.) afforded isoindoline 39 as a pale yellow oil
(82 mg, 0.25 mmol, 86%). FT-IR (n, cm-1, KBr) 3448, 2923, 1714,
1342, 1161, 667, 559; 1H NMR (270 MHz, CDCl3, d) 7.74 (d, J =
8.2 Hz, 2H), 7.28 (d, J = 7.9 Hz, 2H), 7.16–7.20 (m, 3H), 7.07–7.12
(m, 1H), 5.30 (m, 1H), 4.75 (dd, J = 2.4, 13.9 Hz, 1H), 4.50 (d,
J = 13.9 Hz, 1H), 3.50 (dd, J = 3.4, 17.8 Hz, 1H), 2.99 (dd, J =
7.7, 18.0 Hz, 1H), 2.36 (s, 3H), 2.22 (s, 3H); 13C NMR (75 MHz,
CDCl3, d) 206.5, 143.8, 140.2, 135.1, 133.5, 129.9, 128.7, 128.0,
127.7, 122.9, 122.3, 61.1, 53.9, 52.2, 30.8, 21.5; HRMS-ESI (m/z)
[C18H19NO3S + Na]+ calc. 352.0978, found 352.0993.
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A One-Pot, Three-Component Approach to Functionalised
Tetrahydroisoquinolines Using Domino Heck–aza-Michael Reactions
Daniel L. Priebbenow,[a] Frederick M. Pfeffer,*[a] and Scott G. Stewart*[b]
Keywords: Tetrahydroisoquinoline / Multicomponent reactions / Domino reactions / Heck reaction / Aza-Michael
addition / Palladium
A one-pot, three-component method incorporating a domino
Heck–aza-Michael reaction has been developed for the rapid
synthesis of functionalised tetrahydroisoquinolines. Follow-
ing the in situ generation of an acrylamide, a domino process
Introduction
In recent years, palladium-catalysed domino Heck–aza-
Michael reactions have been developed for the synthesis of
a range of functionalised N-heterocycles including benzo-
fused sultams,[1] tetrahydro-β-carbolines,[2] tetrahydroiso-
quinolines,[2b,3] isoindolines[2b] and isoindolinones.[4] These
N-heterocyclic scaffolds have been prepared by treating aryl
halides with relatively cheap palladium catalysts and are
somewhat limited to the range of commercially available ac-
rylate-based starting materials. The ideal domino Heck–
aza-Michael process would allow for the use of function-
alised electron-deficient terminal alkenes. As such, the
scope of these reactions could be dramatically improved if,
in one pot, the alkene could be readily generated and then
undergo the domino Heck–aza-Michael reaction.
One-pot, multicomponent processes, like domino reac-
tions, are an efficient means of completing multiple syn-
thetic steps without the need for purification of intermedi-
ates. Three-component domino Heck–aza-Michael reac-
tions to date have involved variations in the domino precur-
sor, that is, the first step of the multicomponent reaction
was the preparation of the aryl halide.[1,3] However, the elec-
tron-deficient terminal alkenes employed for these three-
component domino reactions have been limited to commer-
cially available ester, carboxylic acid and ketone derivatives.
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involving intermolecular Heck reaction and subsequent
intramolecular aza-Michael addition affords tetrahydroiso-
quinolines bearing C1-acetamide functionality.
Attempted domino Heck–aza-Michael processes, where the
alkene employed has been generated in situ, have not been
successful.[1a]
The tetrahydroisoquinoline scaffold is central to a
number of naturally occurring alkaloids, some of which ex-
hibit interesting biological activity as antitumor and anti-
biotic agents.[5] The C1-acetamide tetrahydroisoquinoline
core (Figure 1) has also been employed in medicinal chem-
istry studies,[6] for example compound 1, which was devel-
oped as a ligand for the melanocortin subtype-4 receptor.[7]
Further examples include those generated as reversible in-
hibitors of cysteine proteases,[8] as well as bradykinin 1 an-
tagonists for treating pain and inflammation (compound 2,
Figure 1).[9]
Figure 1. C1-amide substituted tetrahydroisoquinoline medical
chemistry agents.
A range of synthetic strategies have been reported to
access C1-substituted tetrahydroisoquinoline scaffolds.[3,10]
Our group has recently discovered a palladium-catalysed
domino Heck–aza-Michael reaction for the synthesis
of a series of C1-substituted tetrahydroisoquinolines
(Scheme 1).[2b] The domino Heck–aza-Michael process re-
quires a catalytic system that facilitates fast Heck reaction
between the domino precursor and an electron-deficient ter-
minal alkene. Following this process aza-Michael cycli-
sation takes place to form the new N-heteroycle (Scheme 1).
Functionalised Tetrahydroisoquinolines
Scheme 1. Domino Heck–aza-Michael reaction to access C1-substituted tetrahydroisoquinolines.
Scheme 2. Proposed three-component domino Heck–aza-Michael reaction to access tetrahydroisoquinolines.
Using this method tetrahydroisoquinolines 4–8 were formed
by reaction of 2-bromophenethylamine (3) with commercial
acrylates using either the Pd(OAc)2/PPh3 or the Pd(OAc)2/
DavePhos in K2CO3 and toluene catalytic system.
This methodology allowed for the incorporation of vari-
ous functionalities at R including ester, nitrile and ketone;
however, neither the reaction with acrylic acid nor acryl-
amide was amenable (most likely due to deprotonation un-
der the reaction conditions). As the generation of tetra-
hydroisoquinolines bearing C1-acetamide functionality was
desirable, a modification of the original domino process was
sought. To this end, a three-component domino Heck–aza-
Michael process that would provide rapid and efficient ac-
cess to C1-functionalised tetrahydroisoquinolines was de-
vised (Scheme 2). Nucleophilic addition of primary or sec-
ondary amines 12 to acryloyl chloride (11), prior to the
aforementioned domino reaction would afford a vast array
of acrylamides. If acrylamide formation occurred under the
same mildly basic conditions required for both the Heck
and aza-Michael steps in this domino process, a sequential
one-pot three-component acylation and domino Heck–aza-
Michael reaction for the synthesis of tetrahydroisoquinol-
ines was plausible.
Herein we report the first three-component domino
Heck–aza-Michael reaction, for the synthesis of function-
alised tetrahydroisoquinolines, where in one pot, the elec-
tron-deficient alkene is generated, then subsequently un-
dergoes domino Heck–aza-Michael reaction.
Results and Discussion
To investigate this one-pot process, benzylamine was ini-
tially chosen as the amine nucleophile. This first reaction
involved the addition of acryloyl chloride (11) to a solution
of benzylamine, and potassium carbonate in toluene. After
stirring at room temperature for 1 h, Pd(OAc)2, PPh3 and
the 2-bromophenethylsulfonamide substrate 3 were added
sequentially and the resultant mixture heated to 120 °C for
16 h. To our delight, a simple workup followed by flash
chromatography afforded the desired N-benzylacet-
amidotetrahydroisoquinoline 13 in excellent yield (97%).
(As expected, no domino product or Heck adduct was ob-
Eur. J. Org. Chem. 2011, 1632–1635 © 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.eurjoc.org 1633
served when the reaction was repeated by using only acryl-
oyl chloride; attempts to also generate the tetrahydroiso-
quinolines in a multicomponent manner where all reagents
were present from the outset, also failed.) Following this
initial success, a range of amines, varying in nucleophilic
character were subsequently used in this one-pot process.
The amines, including alkyl primary amines (Table 1, En-
tries 1–7), arylamines (Table 1, Entries 8–10), acyclic sec-
ondary amines (Table 1, Entries 11), cyclic secondary
amines (Table 1, Entries 12–13), and amino acids (Table 1,
entries 14–16), were tested to explore the scope of this reac-
tion sequence.
The first attempt with tryptamine only resulted in trace
amounts of the desired tetrahydroisoquinoline. This lack of
reactivity appeared to be due to the insolubility of either
the initial amine or corresponding acrylamide in toluene.
To overcome this, a few drops of DMF were added to the
reaction mixture following addition of the amine nucleo-
phile. This approach quickly proved successful with the
second attempt using tryptamine to afford tetrahydroiso-
quinoline 14 in 92% yield (Entry 2, Table 1). During the
synthesis of a series of C1-acetamide substituted tetra-
hydroisoquinolines, a number of other amines also required
the addition of DMF to improve solubility.
The one-pot, three-component domino Heck–aza-
Michael process proved to be quite general, with high yields
(up to 97%) of the C1-acetamide tetrahydroisoquinolines
observed when alkylamines, arylamines, secondary amines
and amino acids were used. Several of the tetrahydroiso-
quinolines accessed by using this methodology (14, 26, 27)
resemble a number of the aforementioned medicinal chem-
istry agents (Figure 1). The only limiting factor in this pro-
cess appeared to be solubility of the amine and correspond-
ing acrylamide.
For the domino process employing 2-nitrobenzylamine
hydrochloride (Table 1, Entry 7), the in situ deprotection of
the 2-nitrobenzyl group occurred to afford tetrahydroiso-
quinoline 19. The 2-nitrobenzyl group is readily cleaved un-
der photolytic conditions in polar solvents (254–365 nm),[11]
As this reaction was carried out in toluene in a dark fume-
hood, deprotection of the 2-nitrobenzyl group under our
reaction conditions was unexpected. However, the basic
D. L. Priebbenow, F. M. Pfeffer, S. G. StewartSHORT COMMUNICATION
Table 1. Formation of functionalised tetrahydroisoquinolines by
using a three-component domino Heck–aza-Michael reaction.
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Table 1. (Continued).
[a] A few drops of DMF were added to aid in amine solubility. [b]
In situ deprotection of the 2-nitrobenzyl group occurred during
reaction, and the product isolated was the tetrahydroisoquinoline
acetamide in 32% yield. [c] When chiral amino acids were subject
to this domino process (Entries 14–15, Table 1) the resultant tetra-
hydroisoquinoline was isolated as a mixture of diastereomers in a
ratio of 1:1.
conditions and high temperatures employed in this reaction
sequence proved sufficient to cleave the 2-nitrobenzyl
group.
Multicomponent reactions using a chiral amino acid pre-
cursor (Table 1, Entries 14, 15) were carried out to identify
whether a stereoselective variant of this one-pot process was
achievable. The introduction of a stereogenic centre at the
C1-position of the newly formed tetrahydroisoquinoline
was monitored by NMR spectroscopy. Unfortunately, in
these particular cases where a chiral amino acid was used,
the products were determined to be present as a 1:1 mixture
of diastereomers, inseparable by standard column
chromatography. As such, the presence of a stereocentre in
the acrylamide R moiety had no significant induction ef-
fects on the stereochemistry at the C1-position of the tetra-
hydroisoquinoline heterocycle formed during the domino
process.
Functionalised Tetrahydroisoquinolines
Conclusions
A domino Heck–aza-Michael process has been devel-
oped where in one pot, the electron-deficient alkene gener-
ated by reaction between acryloyl chloride and an amine,
undergoes domino Heck–aza-Michael reaction to afford a
series of C1-acetamide tetrahydroisoquinolines. This is the
first example of a domino Heck–aza-Michael reaction that
allows the electron-deficient terminal alkene to be readily
varied in a one-pot process. This multicomponent domino
reaction proved to be quite general, by using a range of
primary and secondary amines to afford functionalised
tetrahydroisoquinolines, in moderate to excellent yields (28–
97%). This one-pot process, when employed in a medicinal
chemistry setting would facilitate the rapid generation of
compound libraries.
Supporting Information (see footnote on the first page of this arti-
cle): Detailed description of all experimental procedures and ana-
lytical data for all compounds.
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